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Abstract 
The overall purpose of this thesis was to examine the role of exercise in people with stable 
Peripheral Neuropathies (PN). A 12 week community based unsupervised exercise 
intervention in 16 people after Guillain-Barré syndrome (GBS) or with chronic inflammatory 
demyelinating polyradiculoneuropathy (CIDP) and ten healthy controls demonstrated that the 
exercise intervention was well tolerated and acceptable. After the intervention, PN participants 
had significantly reduced activity limitations, participation restrictions and fatigue; these 
improvements were maintained at six month follow up.  
Some outcome tools used in the exercise study, demonstrated limitations and so three studies 
to modify and evaluate tools for assessing mobility and activity limitations were conducted. The 
results showed that the Walk-12, a walking questionnaire, and the modified Physiological Cost 
Index, which measures the energy used whilst walking, were valid for use in people with PN. 
However, whilst the modification to the Overall Disability Sum Score to form the Overall 
Neuropathy Limitations Scale resulted in greater sensitivity and face validity, its 
responsiveness was somewhat reduced.  
The fatigue profile of 13 people with PN was described and compared to healthy people, to 
identify potential contributors to fatigue. Despite significantly greater experienced fatigue, PN 
participants did not have abnormal muscle fatigue. However, the experienced fatigue was 
significantly associated with greater activity limitations and poorer functioning in PN 
participants and they had significantly reduced cardiovascular fitness, were weaker and less 
active than healthy participants.  
Although there are several limitations of the studies in this thesis, they indicate that exercise 
was practical and may be helpful in reducing activity limitations and fatigue in people with PN. 
The results also identify outcome tools to evaluate functioning and provide data to inform the 
development of a controlled trial to evaluate the efficacy of exercise to manage activity 
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Chapter 1. Introduction 
1.1. Summary 
The overall purpose of the thesis was to examine the role of exercise in people with Peripheral 
Neuropathies (PN). Two aims were developed to meet this objective: (i) to evaluate the 
practicality and possible effects of a community based exercise intervention for people after 
Guillain-Barré syndrome (GBS) and with chronic inflammatory demyelinating 
polyradiculoneuropathy (CIDP) and (ii) to investigate and describe the nature of experienced 
and physiological fatigue in people with inflammatory PN. 
This chapter provides a background to the aims of this thesis by describing PN and discussing 
the common problems experienced by people with these conditions. The evidence evaluating 
the potential role of exercise to manage activity limitations is critically considered to place this 
thesis in a broader context and to outline the deficits of the current evidence base in PN. 
This chapter also describes the nature of fatigue experienced by many people with PN and 
defines experienced and physiological fatigue. A review of the literature which investigates 
fatigue in PN is undertaken and the need for further investigation of the contributors to fatigue 
is highlighted. The chapter closes with a critical discussion of the outcome tools that were used 




1.2. Brief Background 
Peripheral neuropathies (PN) encompass a range of disorders of the peripheral nerves. In the 
UK, PN affect approximately 2.4% of the population and commonly produce symptoms of 
altered sensation, pain and weakness (Martyn and Hughes 1997). There are many forms of 
PN, but the work in this thesis predominantly focuses upon inflammatory, immune mediated 
PN. Inflammatory PN have acute forms, including Guillain-Barré syndrome (GBS) and its 
variants, and chronic forms, including chronic inflammatory demyelinating 
polyradiculoneuropathy (CIDP) and paraproteinaemic demyelinating neuropathies (PDN). 
These neuropathies are described in Section 1.5. 
Immunomodulatory treatments are effective in GBS and can improve chronic PN but are not 
always curative (Hughes et al. 2006; van Schaik et al. 2002; van Schaik et al. 2005). At least a 
quarter of patients after GBS or with CIDP have significant sequelae many years after the 
onset of symptoms (Bernsen et al. 2002; Bernsen et al. 2005; Gorson et al. 1997; Kuwabara et 
al. 2006). Persistent residual problems, including increased feelings of fatigue, muscle 
weakness, reduced proprioception and altered sensation contribute to activity limitations and 
restricted participation in people with PN (de Jager and Minderhoud 1991; Erdmann et al. 
2005; Merkies et al. 2002a; Richardson et al. 2001; Teunissen et al. 2000). These activity 
limitations remain despite standard medical treatment, suggesting that rehabilitative 
interventions such as exercise warrant examination.  
1.3. Aims and Objective  
The overall objective of this thesis was to examine the role of exercise for treating people with 
PN. Therefore, the specific aims of this thesis were to: 
(i) Evaluate the practicality and possible effects of a community based exercise intervention for 
people at least 12 months after the nadir of Guillain-Barré syndrome (GBS) and people with 
chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) which has been stable for 
over six months. 
(ii) Investigate and describe the nature of experienced and physiological fatigue in people with 
inflammatory PN. 
1.4. Structure of this thesis 
This thesis is structured predominantly chronologically.  
This Chapter begins by describing the PN encountered in the studies in this thesis with their 
management and identifies the common activity limitations experienced by many people with 
PN. The current literature evaluating exercise in PN is critically considered and the nature of 
fatigue experienced by many people with PN is described. This chapter concludes with a 
critical review of the outcome tools that were used in the studies in the thesis. 
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The study in Chapter Two describes the practicality and possible effects of a 12 week 
community based exercise intervention for people with PN and evaluates the performance of 
the tools used. Several outcome tools that were used in this study did not perform as well as 
anticipated. The observed limitations of the primary outcome tool, the Overall Disability Sum 
Score (ODSS) were addressed by adapting it to produce a new tool, the Overall Neuropathy 
Limitations Scale (ONLS). The evaluation of the reliability, validity and responsiveness of the 
ONLS in comparison to the ODSS is presented in Chapter Three.  
The findings from Chapter Two also demonstrated that closer examination of tools which 
indicate aspects of mobility was warranted. Therefore, the properties of the Physiological Cost 
Index (PCI) and a mobility questionnaire, which had not previously been used in PN (Walk-12) 
were investigated in Chapter Four.  
In Chapters Five and Six, the nature of fatigue experienced by some people with PN is 
described and a range of potential contributors to fatigue in people with PN, such as strength, 
physiological fatigue and activity levels, are investigated.  
The key findings of the studies are summarised in Chapter Seven and the implications for 




1.5. Peripheral neuropathies 
Common symptoms of peripheral neuropathies include weakness, sensory changes and pain. 
Peripheral neuropathies can be hereditary or produced from toxin exposure, nutrient 
deficiencies, vasculitis, mechanical compression, neoplasms, metabolic disorders (e.g. 
diabetes), infection and inflammation (Goetz, 2007). They can also be classified depending 
upon the patterns of symptoms they produce. They can affect single nerves 
(mononeuropathy), several nerves (multiple mononeuropathy), a single nerve root 
(radiculopathy), several (polyradiculopathy), a nerve plexus (plexopathy) or can be generalised 
(symmetrical polyneuropathy) (Hughes 2002b; Thomas 1970). 
Community dwelling, population based studies have reported the prevalence of symmetrical 
polyneuropathies to be between 2400 and 7000 per 100,000 (Martyn and Hughes 1997). In 
Europe, diabetic neuropathy is the most common form of symmetrical polyneuropathy and 
affects over half of people with diabetes (Hughes 2002b; Vinik et al. 2000). Polyneuropathies 
are also reported in up to a quarter of people who abuse alcohol (Martyn and Hughes 1997; 
Vittadini et al. 2001).  
Some neuropathies are characterised by the presence of inflammation and have acute forms, 
notably GBS, and chronic variants such as CIDP (Hughes 2002b). Guillain-Barré syndrome is 
perhaps the most well recognised inflammatory symmetric neuropathy. Although its incidence 
is moderately low (one to two people per 100,000), it is the most common cause of flaccid 
paralysis in Western countries (Govoni and Granieri 2001; Hovi and Stenvik 2000; Martyn and 
Hughes 1997).  
Chronic inflammatory demyelinating polyradiculoneuropathy is one of several chronic 
symmetric peripheral neuropathies, which are characterised by a gradual development of 
weakness and altered sensation. It is estimated to affect three people per 100,000 (Martyn and 
Hughes 1997).  
People after GBS or with CIDP were chosen as the predominant patient groups to be studied 
in this thesis, as despite some clinical differences, both produce similar, significant and 
persistent activity limitations which appear refractory to medical treatment, but might be 
improved by rehabilitative interventions. The pathophysiology, management and outcome of 
these conditions are discussed in Sections 1.6 and 1.7.   
Despite the relatively low prevalence of inflammatory symmetric neuropathies, the host 
institution for this PhD had a special interest in these conditions, making recruitment of 
sufficient numbers of participants feasible and providing a unique opportunity for investigation.  
Diabetic PN was not included as although it is more common, the neuropathy is secondary to 
a primary metabolic disorder, predominantly affects sensory nerves and the benefits of 
exercise and activity are already relatively well researched in this patient group (Thomas et al. 
2006). Other chronic peripheral neuropathies including PDN, CMT and CIAP were included in 
some studies in this thesis and so are outlined in Sections 1.8.1, 1.8.2 and 1.8.3. Participants 
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with these conditions were included as they demonstrated similar activity limitations to people 
with inflammatory PN and increased the external validity of the results.  
1.6. Guillain-Barré syndrome  
Guillain-Barré syndrome is an immune mediated PN (Hughes and Cornblath 2005). It was 
named for two of a trio of French doctors, Guillain, Barré and Strohl, who, in 1916, reported 
two cases of acute weakness in infantrymen (Asbury 1990; Hughes 1990). They described 
features which today are considered typical of the disease, namely symmetrical sensory 
alterations, muscle weakness and loss of deep tendon reflexes, and increased protein in the 
cerebrospinal fluid (Hughes 1990). Other features include cranial nerve involvement and 
autonomic dysfunction including tachycardia, other potentially serious arrhythmias, hypo- or 
hypertension and vasomotor symptoms (Asbury and Cornblath 1990). 
Guillain-Barré syndrome is characterised by rapidly worsening symptoms which progress for 
up to four weeks, before plateau and eventual improvement (Asbury and Cornblath 1990). A 
typical plateau phase lasts from one to four weeks (Asbury and Cornblath 1990; Hughes 
1990), but recovery may not start for several months and is often incomplete (Hughes 1990; 
Nicholas et al. 2000). 
There appears to be a bimodal distribution for age of onset in younger patients and in the 
elderly, although this is controversial (Govoni and Granieri 2001). Approximately two thirds of 
patients with GBS report symptoms of an infection several weeks before the onset of 
weakness or sensory alterations (Asbury and Cornblath 1990; Hughes 1990; Jacobs et al. 
1998). These infections appear to initiate an aberrant immune response against peripheral 
nerves and result from cross reactivity between antibodies or T-cells to the infective agent and 
myelin or axonal antigens (molecular mimicry) (Ang et al. 2004; Gabriel et al. 2000; Hartung 
and Toyka 1990; Hughes and Cornblath 2005). Campylobacter jejuni (C. jejuni) infection, 
usually causing enteritis, is the most common antecedent infection, and was evident in 32% of 
patients (49 from 154) with GBS in one study (Jacobs et al. 1998). Despite this, only one in 
1000 cases of C. jejuni will lead to development of GBS which suggests that other factors, 
including genetics or previous exposure to an infective agent, determine who develops GBS 
(Quarles and Weiss 1999).  
1.6.1. Subtypes of Guillain-Barré syndrome  
Guillain-Barré syndrome has several widely recognised forms which are delineated by 
neurophysiological testing and the pattern of symptoms (Asbury et al. 1969; Hughes et al. 
1999). Those that produce limb weakness are considered in this thesis and so discussed here. 
Acute inflammatory demyelinating polyradiculoneuropathy (AIDP) is the most common form of 
GBS in the West and accounts for at least 85% of all cases (Rees et al. 1995). Symptoms 
include progressive weakness, often accompanied by sensory deficits and signs of autonomic 
dysfunction (Hartung 1998). Clinical tests demonstrate elevated protein in the cerebrospinal 
fluid, and nerve conduction studies show multifocal slowing of conduction velocity and partial 
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conduction block (Cornblath 1990; Hartung et al. 2002; Hughes et al. 1999). The pathogenesis 
of AIDP has not been fully elucidated. According to one hypothesis based upon an animal 
model of experimental autoimmune neuritis, a T-cell response against one of the myelin 
proteins P0, P2 or PMP22 (Gabriel et al. 2000) results in penetration of the peripheral nerve 
and spinal nerve roots by activated lymphocytes and macrophages which demyelinate 
segments of the nerve (Hadden et al. 2001; Pritchard and Hughes 2004). 
Acute motor axonal neuropathy (AMAN) is a much less common variant of GBS in Western 
countries (Hadden et al. 1998; Visser et al. 1995). These patients have only motor symptoms, 
with no sensory involvement (Hafer-Macko et al. 1996). A targeted attack against specific GM1 
gangliosides has been linked to the characteristic selective motor axon damage (Chowdhury 
and Arora 2001; Hadden et al. 1998). This form of GBS is more common in Asia, especially 
during the summer months, and accounts for over 70% of GBS cases in China (Ho et al. 
1997). However AMAN was only present in 27 of 147 European patients with GBS (18%) 
(Visser et al. 1995). 
A third variant of GBS is characterised by sensory and motor deficits caused by axonal 
damage to the sensory and motor nerves. This produces acute motor and sensory axonal 
neuropathy (AMSAN) (Chowdhury and Arora 2001; Feasby et al. 1986). Similarly to AMAN, it 
occurs in fewer people than AIDP in Europe and America and axonal damage is caused by a 
targeted immune attack on gangliosides, but in this case, present in both sensory and motor 
nerves (Chowdhury et al. 2001).  
1.6.2. Management of Guillain-Barré syndrome  
The aim of acute medical treatment in GBS is to limit the damage caused by the aberrant 
immune response and to provide supportive care (Hughes et al. 2005). Plasma exchange or 
intravenous immunoglobulin are used in over 65% of cases (Cheng et al. 2000; Chio et al. 
2003; Rees et al. 1998) and appear to accelerate recovery, reduce residual activity limitations 
and accelerate improvements in walking ability (Hughes et al. 2006; Raphael et al. 2002).  
Most natural recovery occurs within the first year after GBS for the majority of people 
(Forsberg et al. 2004). For those severely affected, clinical recovery can extend to two years 
(de Jager and Minderhoud 1991) but, in longer term studies, nearly all patients report no 
further change after three years (Bersano et al. 2005). Several factors predict a poor outcome 
at one or two years after the onset of GBS. These include increased age at onset, severe 
weakness at nadir, inexcitable nerves and diarrhoea preceding C. jejuni infection (Chio et al. 
2003; Fletcher et al. 2000; Rees et al. 1995; Van Koningsveld et al. 2007). 
Rehabilitation appears important during recovery after GBS but the components of 
rehabilitative treatment are likely to be highly individual and have not been detailed in many 
studies. Physiotherapeutic interventions for people with PN may include maintenance of joint 
range, timely management of secondary complications, re-education of movement and 
strength, provision of assistive devices to maximise function and improvement of overall 
fitness (Herbison et al. 1983; Hughes et al. 2005; Karni et al. 1984; Lennon et al. 1993; 
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Nicholas et al. 2000). Two small, uncontrolled studies have also described benefit from novel 
interventions using partial body weight support and mechanised balance training (Bulley 2003; 
Tukey and Greenwood 2004). Although the content of rehabilitation treatments was not 
described, a longer duration of rehabilitation was shown to be significantly associated with 
improved scores on functional outcome tools, including the Barthel index, in a longitudinal 
study of 24 people with GBS over three years (Nicholas et al. 2000). However, in a study of 
ten people 11 to 35 months after the onset of GBS, the duration of treatment varied 
enormously and five participants had their therapy withdrawn despite contractures and 
significant activity limitations (Lennon et al. 1993).  
1.6.3. Outcome after Guillain-Barré syndrome 
Despite timely treatment and rehabilitation, persistent symptoms of GBS may be present 
several years after nadir and are estimated to affect almost half of all patients (Cheng et al. 
2000; Dornonville de la Cour and Jakobsen 2005). This estimate increased to 65% (n= 37) in 
those who were most severely affected by GBS and required ventilation at nadir (de Jager and 
Minderhoud 1991). Residual problems after GBS include alterations in sensation and 
proprioception, decreased muscle strength, reduced walking ability and increased feelings of 
fatigue (Dornonville de la Cour and Jakobsen 2005; Merkies et al. 1999). Autonomic function is 
reported to return to normal in the majority of people after one year (Flachenecker et al. 1997), 
but reduced muscle strength is reported in over half and sensory deficits are evident in more 
than two thirds of people at least one year after GBS (Bernsen et al. 2001; Forsberg et al. 
2004; Hughes and Cornblath 2005). Persistent activity limitations caused significant alterations 
in the lives of people after GBS. A small number did not regain the ability to walk (4% of 79) 
whilst between seven (of 42) to 20% (of 53) required walking aids and 17% (of 79) were 
unable to run one to two years after nadir (Cheng et al. 2000; Dornonville de la Cour and 
Jakobsen 2005; Forsberg et al. 2004; Forsberg et al. 2005; Rees et al. 1998). Two years after 
GBS, 37% of 57 patients could not perform at their previous physical level (de Jager and 
Minderhoud 1991) and between 12% (of 42) and 27% (of 70) were dependent in some 
activities of daily living (Bernsen et al. 2002; Bersano et al. 2005; Forsberg et al. 2005). This 
necessitated retirement or changing jobs in 17% (of 42) to 38% (of 122) (Bernsen et al. 2002; 
Bernsen et al. 2005; Bersano et al. 2005; de Jager and Minderhoud 1991). Between 44% (of 
122) and 54% (of 90) reported altering hobbies as a direct result of their health two years after 
GBS, often reducing the intensity and frequency of physical and social activities (Bernsen et al. 
2002; Bernsen et al. 2005; Lennon et al. 1993). This suggests that return to or uptake of 
exercise cannot be assumed to be practical or achievable for some people with PN.  
Whilst decreased muscle strength, altered sensation and decreased proprioception contribute 
to persistent activity limitations, not all limitations have been adequately explained by these 
impairments (Bernsen et al. 2005; Lennon et al. 1993; Merkies et al. 2003b). Despite strength 
and sensation recovering to near normal values, many people have reported difficulty returning 
to pre morbid levels of functioning (Bersano et al. 2005; Burrows and Cuetter 1990; Lennon et 
al. 1993). This indicates that other factors must contribute to reduced functioning (Bernsen et 
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al. 1997; Dornonville de la Cour and Jakobsen 2005; Lennon et al. 1993). One of these factors 
could be severe experienced fatigue which has been significantly associated with poorer 
functioning and was reported by over 80% of 113 people with GBS or after CIDP several years 
after diagnosis (Merkies et al. 1999). However, the factors that contribute to the severity of 
experienced fatigue require investigation in order to increase understanding and to guide the 
development of treatments to reduce the negative effects associated with fatigue in people 
with PN.  
1.7. Chronic inflammatory demyelinating polyradiculoneuropathy  
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is presumed to be an 
acquired immune mediated disorder which causes demyelination of the peripheral nerves. 
Damage to the axon can also occur (Bouchard et al. 1999; Koller et al. 2005). It can start at 
any age and is slightly more common in those over 40 and in men (1.3:1) (Lunn et al. 1999; 
McLeod et al. 1999).  
A definitive diagnostic marker for CIDP has yet to be found (Koller et al. 2005). The typical 
clinical picture consists of an insidious onset of progressive or relapsing, symmetrical proximal 
and distal weakness, sensory loss, partial conduction block and reduced conduction velocity 
with reduced or absent reflexes (Ad Hoc Subcommittee of the American Academy of 
Neurology AIDS task force. 1991; Hughes et al. 2001; Joint task force of the EFNS and the 
PNS 2005; Saperstein et al. 2001). In a series of 92 patients, 80% experienced sensory 
changes and muscle weakness and 16% (of 100) to 24% (of 92) demonstrated involvement of 
the cranial nerves (Bouchard et al. 1999; McCombe et al. 1987). Crucially, the progression of 
symptoms of CIDP exceeds two months, distinguishing CIDP from subacute inflammatory 
demyelinating neuropathy and GBS (Hughes 2002a). Other, less frequent symptoms include 
sensory ataxia, tremor and autonomic involvement (Bouchard et al. 1999; Hughes 2002a; Lyu 
et al. 2002; McCombe et al. 1987).  
The inflammatory features characteristic of CIDP and its good response to treatments 
targeting the immune system support the hypothesis that CIDP is caused by an aberrant 
immune response (Mehndiratta et al. 2004a; van Schaik et al. 2002). A clear association with 
antecedent infection has not been reported, suggesting that the mechanisms of immune 
mediated nerve damage differ from GBS (McCombe et al. 1987; Melendez-Vasquez et al. 
1997). However, as the onset of CIDP is gradual and may be unnoticed for several months, 
recollection of antecedent illness can be inaccurate. 
Refinement of clinical diagnosis has identified other forms of chronic demyelinating 
neuropathies which differ from the typical presentation of CIDP, and which may represent 
distinct diseases (Koller et al. 2005). These forms account for around one tenth of all cases of 
CIDP (Hughes 2002a). Distal acquired demyelinating symmetric neuropathy (DADS) is 
distinguished from typical CIDP by the presence of distal sensory or sensorimotor symptoms 
with little proximal involvement (Katz et al. 2000). An asymmetrical presentation of sensory 
and motor symptoms is characteristic of another form of CIDP, called multifocal acquired 
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demyelinating sensory and motor asymmetrical neuropathy (MADSAM) (Saperstein et al. 
1999; Van den Berg-Vos RM et al. 2000).  
1.7.1. Management of chronic inflammatory demyelinating 
polyradiculoneuropathy  
In CIDP, treatment is directed to manage the immune and inflammatory processes and to limit 
secondary axonal damage (Joint task force of the EFNS and the PNS 2005; Koller et al. 2005). 
Corticosteroids are widely used in CIDP (Mehndiratta and Hughes 2001). However, they are 
not beneficial in pure motor forms of CIDP (Hughes 2002c; Umapathi et al. 2005) and their 
side effects have led to continued searches for other treatments (Hughes 2002a). Intravenous 
immunoglobulin and plasma exchange have also been used (Hughes 2002a; Mehndiratta et 
al. 2004a; van Schaik et al. 2002) but benefits of both are short lived and repeated treatment 
at regular intervals may be required (Joint task force of the EFNS and the PNS 2005; van 
Schaik et al. 2002). Other suggested treatments to manage CIDP include 
immunosuppressants, interferon and autologous stem cell transplantation (Good et al. 1998; 
Vermeulen and Van Oers 2002) but all these treatments require further investigation to 
determine their effectiveness. 
Supportive treatments for people with CIDP, including adequate pain relief, provision of 
assistive aids, maintenance of independence and psychological support are recommended 
(Joint task force of the EFNS and the PNS 2005). Although one study found improvements in 
functioning in four people with CIDP after they completed a supervised exercise intervention 
(Garssen et al. 2004; Garssen et al. 2005a), no studies have examined the effects or content 
of multidisciplinary rehabilitation upon the symptoms of CIDP, either during acute relapses or 
in the management of chronic activity limitations.  
1.7.2. Outcome in chronic inflammatory demyelinating 
polyradiculoneuropathy 
In a series of 46 and 92 patients with CIDP, 43 to 65% followed a relapsing-remitting course 
(Lunn et al. 1999; McCombe et al. 1987) whilst 13% of 46 patients had a monophasic illness 
(Lunn et al. 1999) . Conversely, a chronic progressive course with gradual worsening was 
reported in approximately 37% (of 46) (Lunn et al. 1999) and up to 40% (of 38) of patients 
required regular immunomodulatory treatment five years after their initial treatment began 
(Kuwabara et al. 2006). In one study, 11% of 83 patients had died within six years of onset as 
a result of complications associated with CIDP (Bouchard et al. 1999). Several factors predict 
a poorer outcome, these include advancing age, weakness in all four limbs and axonal 
damage (Bouchard et al. 1999; Koller et al. 2005; Sghirlanzoni et al. 2000).  
At least four years after the onset of CIDP, over 90% of a series of 67 patients exhibited some 
persistent symptoms (Gorson et al. 1997). These included muscle weakness, altered 
sensation and pain (Gorson et al. 1997). Many also reported moderate limitations in activities, 
suggesting that they struggled to return to hobbies and physical activities (Gorson et al. 1997; 
McCombe et al. 1987). In one study, only 56% (of 47) were independent in all activities of daily 
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living, six years after the onset of CIDP (Bouchard et al. 1999). In a cross sectional population 
investigation, based in the South East Thames region, Lunn et al. (1999) reported that a mean 
of 8.9 years after the onset of symptoms, 13% (of 46) of patients used an aid to walk and 
required help with activities of daily living. In a smaller study, ten of 12 people with CIDP 
reported difficulty walking or climbing stairs, although the time since diagnosis was not 
reported (Erdmann et al. 2005).  
The effect of CIDP on wider measures of health, participation and fatigue in this patient group 
has not been widely investigated. However, in a study of 113 people after GBS or with CIDP 
Merkies et al. (1999) reported that they had significantly more severe experienced fatigue than 
healthy participants. Although the severity of experienced fatigue in CIDP participants was not 
reported separately, this finding indicates that fatigue is likely to be problematic in this patient 
group. 
1.8. Other peripheral neuropathies 
1.8.1. Paraprotein associated demyelinating neuropathy associated with 
monoclonal gammopathy of undetermined significance 
Ten per cent of patients with chronic idiopathic neuropathies have an associated monoclonal 
gammopathy (PDN) (Kissel and Mendell 1995). The clinical picture of PDN is variable but the 
commonest form comprises slowly progressive, symmetrical distal weakness and sensory 
changes (Isoardo et al. 2005; Kissel and Mendell 1995). Painful paraesthesiae, ataxia, 
decreased balance and upper limb tremor are prominent, but autonomic and cranial nerve 
involvement are rare (Hartung 1998; Kissel and Mendell 1995; Mehndiratta et al. 2004b). 
Neurophysiological studies show mixed axonal degeneration and demyelination (Kissel and 
Mendell 1995; Mehndiratta et al. 2004b). After an average of eight years many people have 
only minor limitations in their activities of daily living (Nobile-Orazio et al. 2000) although no 
studies have considered quality of life or wider health in this patient group.   
1.8.2. Charcot-Marie-Tooth Disease 
Charcot-Marie-Tooth (CMT) disease is the most common of the hereditary neuropathies and 
can have demyelinating or axonal forms. It is estimated to affect from eight to 41 people per 
100 000 (Hughes 2002b; Kuhlenbaumer et al. 2002). Type 1 is the most common form, and 
accounts for approximately 80% of CMT cases. It causes demyelination which can result in a 
range of symptoms from none to severe sensory and motor loss (Hughes 2002b; 
Kuhlenbaumer et al. 2002). It is usually caused by duplication of the gene for peripheral nerve 
protein 22 on chromosome 17. 
1.8.3. Chronic idiopathic axonal polyneuropathy 
Up to 25% of neuropathies affecting the peripheral nerves have no causative diagnosis, 
despite detailed investigation (Notermans and Wokke 1996). These idiopathic neuropathies 
produce slowly progressive axonal damage (Hughes et al. 2004; Notermans and Wokke 1996) 
and are termed chronic idiopathic axonal polyneuropathies (CIAP). People with CIAP 
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experience a gradual and insidious onset of distal, predominantly sensory or sensorimotor 
symptoms, including pain, which tend to be worse in the feet than hands (Hughes et al. 2004; 
Notermans and Wokke 1996). The disease is more common in those over 50 and in men 
(Hughes et al. 2004). People with CIAP report reduced walking ability and decreased 
functioning, including limitations in physical functioning, poor mental health and decreased 
energy and vitality (Hughes et al. 2004; Teunissen et al. 2000).  
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1.9.  Exercise  
1.9.1. Clinical benefits of exercise 
Since the time of the ancient Greeks, physicians have advocated exercise to maintain and 
improve health and function (Berryman 1989). However, traditional medical care has often 
focussed predominantly upon the prevention and management of impairments in people with 
physical limitations, giving little attention to health promotion or management of secondary 
health conditions (Rimmer 2005a). Recent advances in health care have increased overall life 
expectancy including for those people with persistent activity limitations (Office for National 
Statistics 2005; Rimmer 2005a), although existing impairments are likely to be compounded by 
the natural aging process (McDonald 2002). People with impairments and activity limitations 
could be predisposed to a sedentary lifestyle that can increase their risk of developing 
secondary health complications such as heart disease, obesity and poor mental health 
(Gordon et al. 2004; Rimmer 2005a). As people with PN experience persistent activity 
limitations and restricted participation they may also be at risk of these health complications 
although this has not been studied (Gorson et al. 1997; Lennon et al. 1993; McDonald 2002). 
Physical activity is considered to be any bodily movement that is produced by voluntary 
muscles and consumes energy (Caspersen et al. 1985) and is associated with reductions in 
all-cause mortality and in the incidence of coronary heart disease and osteoporosis (Atlantis et 
al. 2004; Bean et al. 2004). Exercise is a subset of physical activity and has been defined as “a 
planned or structured activity which aims to improve or maintain physical fitness” (Caspersen 
et al. 1985, p126). There is strong and consistent research demonstrating that regular exercise 
has a protective effect against diseases associated with a sedentary lifestyle, reducing 
morbidity and mortality (Brach et al. 2004; Kesaniemi et al. 2001; Oguma et al. 2002; 
Villeneuve et al. 1998). Exercise can also improve daily functioning and has demonstrated 
beneficial effects beyond physiological parameters, including improvements in quality of life 
and feelings of well-being (Fox 1999; Rimmer et al. 2004). 
Potentially, these benefits could be replicated in people with PN if they were able to exercise 
regularly. However, difficulty accessing appropriate services, fear and lack of support mean 
that few people with restricted functioning engage in physical pursuits (Rimmer 1999; Rimmer 
et al. 2004; Rimmer 2005b).The location of exercise programmes may also affect the ability of 
people with activity limitations to participate (Rimmer et al. 2004). Whilst a centre based and 
medically supervised programme would provide support and motivation to exercise, potential 
volunteers who have difficulties travelling may not be able to participate and the cost of 
continual medical supervision may prove prohibitive for healthcare providers. Programmes 
based in the community or in the home are more practical, facilitate regular exercise and 
produce higher adherence (Ashworth et al. 2005; King et al. 1991; Rimmer et al. 2004), but 
medical supervision of exercise in this setting would be extremely difficult. Some people with 
PN may find exercising effectively difficult without supervision, could be unwilling to exercise in 
public (for instance in a gym) or be fearful of exercising alone, and are at risk of injuries 
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secondary to muscle weakness, loss of proprioception and balance deficits. However, they 
may be encouraged to participate in an exercise programme if it is shown to be practical and is 
prescribed and supported by health professionals. This highlights the need to investigate the 
practicality and acceptability of an unsupervised community based programme in people with 
inflammatory PN.  
In the following sections, the evidence evaluating exercise in neurological conditions is 
summarised, followed by detailed consideration of exercise in PN. 
1.9.2. Exercise interventions in neurological conditions  
Exercise interventions in neurological groups have been shown to be beneficial for reducing 
impairments such as muscle weakness (Duncan et al. 1998; Mostert and Kesselring 2002; 
Oken et al. 2004; Petajan et al. 1996; Teixeira-Salmela et al. 1999; White et al. 2004). They 
have also improved aspects of activities and participation (Petajan et al. 1996; Teixeira-
Salmela et al. 1999), although this has not been found in all studies and depends upon the 
type of exercise used (Meek et al. 2003).  
In neurological conditions affecting the central nervous system (CNS), including stroke and 
multiple sclerosis (MS), regular exercise has been reported to reduce impairments and 
minimise activity limitations in several studies (Kileff and Ashburn 2005; Leroux 2005; Liu et al. 
2003; Marigold et al. 2005; Oken et al. 2004; Surakka et al. 2004; Teixeira-Salmela et al. 1999; 
White et al. 2004). A systematic review of exercise for people after stroke identified 24 
randomised controlled trials (RCT) that met the inclusion criteria, comprising 1147 participants 
(Saunders et al. 2009). The synthesis of the results was limited by the lack of common 
outcome tools and the strength of several studies was reduced as they omitted details of 
assessor blinding (seven studies), were not blinded (five studies), had selection bias (five 
studies) or provided greater time and attention to the training group when compared to the 
control (nine studies). However, the review found that there was consistent evidence that 
physical training benefited aerobic capacity (peak oxygen consumption, three trials) and 
mobility (eight trials) although there was insufficient evidence to draw conclusions on the effect 
of training on activity limitations.  
A systematic review of nine controlled trials of exercise comprising a total of 260 patients with 
MS concluded that exercise therapy appeared to increase muscle power, exercise tolerance 
and mobility related activities of daily living (Rietberg et al. 2005). Pooling of data was not 
possible due to the range of outcome tools used so conclusions were based on a qualitative 
best evidence synthesis which considerably decreases their strength (Rietberg et al. 2005). 
Furthermore, there was a high risk of bias as only two studies stated that they blinded 
assessors and the sample sizes in each of included studies were small. However, exercise 
was based in the community and was not always supervised, which suggests that this form of 
exercise could also be practical and have some benefit for people with PN.  
Exercise interventions in neuromuscular conditions are also reported to improve functioning 
(Aitkens et al. 1993; Dean and Ross 1991; Wright et al. 1996). However, these studies are 
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generally of lower methodological quality than those in conditions affecting the CNS as they 
utilise smaller samples, lack blinding and are not adequately controlled. A systematic review 
including only two studies comprising 52 people with amytrophic lateral sclerosis or motor 
neuron disease reported that strength training benefited activities of daily living (ADL). 
However, this was based on the findings of two small studies so the strength of these 
conclusions is limited (bello-Haas et al. 2008). A review of strength training for people with 
muscle disease identified three studies of 121 people with either myotonic dystrophy, 
facioscapulohumeral muscular dystrophy or mitrochondrial myopathy. Although there was 
insufficient evidence of any benefit, the results showed that training did not appear harmful 
(Voet et al. 2009).  
Whilst the differences in pathophysiology, signs and symptoms of these conditions to PN 
mean that these findings cannot be extrapolated to PN, these studies provide background to, 
and some support for, the investigation of exercise in people with inflammatory PN. 
1.9.3. Exercise interventions in peripheral neuropathy 
A Cochrane systematic review of exercise for people with PN has been completed (White et al. 
2007a). Studies were selected for inclusion in the review if they were randomised or quasi 
randomised trials, and compared exercise in people with PN to no treatment or an alternative 
form of treatment. The review also aimed to select trials in which the primary outcome tool 
measured an aspect of functional ability at least eight weeks after the start of the intervention 
(White et al. 2007a). From 29 full text articles, only one trial of 29 people with CMT and 33 
people with myotonic dystrophy met all criteria for inclusion (Lindeman et al. 1995). Two 
additional studies were also included despite not measuring outcome beyond six weeks 
(Richardson et al. 2001; Ruhland 1997). These three studies included 82 participants with 
inflammatory (25 patients), hereditary (37 patients) or metabolic (20 patients) forms of PN, 
although only two studies published details of the criteria used to secure diagnoses (Lindeman 
et al. 1995; Richardson et al. 2001). Each study investigated the effect of different forms of 
exercise interventions so results could not be considered together. Lindeman et al.’s (1995) 
study examined the effects of 24 weeks of progressive strength training in 29 people with 
CMT, Ruhland et al. (1997) investigated the effect of combined aerobic and strengthening 
exercise over six weeks in 28 people with chronic PN and balance training was evaluated in 
ten diabetic participants in the study by Richardson et al. (2001).  
The methodological design, results and activity limitations of each of these studies are 
discussed in detail within the training modality sections (Pages 33 to 38). In brief, the findings 
of two studies which included progressive resistance training demonstrated significantly 
increased strength in trained muscles in people with CMT (Lindeman et al. 1995) and in those 
with CIDP and idiopathic neuropathy (Ruhland 1997). They also reported significant 
improvements in some aspects of physical and functional performance after training 
(Lindeman et al. 1995; Ruhland 1997). The third study found significant improvements in 
clinical balance measures in ten participants with diabetic PN who had undertaken three 
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weeks of balance and distal strength training when compared to an equal number of control 
participants who trained the upper limbs (Richardson et al. 2001).  
All included studies were judged to have inadequate allocation concealment and 
randomisation as two of the three studies matched participants in control and training groups, 
introducing a high risk of bias (White et al. 2007a). Lindeman et al. (1995) matched 
participants in control and training groups on knee extensor strength and performance on a 
stair climbing task, whilst Ruhland (1997) matched participants on age and gender. One study 
attempted to blind patients to treatment (Richardson et al. 2001) and one other study stated 
that they blinded the assessor (Lindeman et al. 1995). Two of the included studies 
demonstrated significant differences between control and training groups at baseline 
(Richardson et al. 2001; Ruhland 1997) despite matching control and training groups on age 
and gender in one (Richardson et al. 2001) and two studies were at risk of bias due to attrition 
during the study (Lindeman et al. 1995; Richardson et al. 2001).  
The results of the included studies indicated that progressive resistance training may benefit 
muscle strength. However data were not able to be pooled as differing outcome tools were 
utilised in each study, indicating that suitable and agreed outcome tools are yet to be 
established or widely used in this patient group. The systematic review concluded that there 
was insufficient evidence to evaluate the effect of exercise upon functional ability in people 
with PN and the high risk of bias in the included studies mean that the findings could not be 
confidently attributed to the effect of exercise (White et al. 2007a). The authors also concluded 
that a large, well designed controlled trial was needed to provide more evidence of the 
effectiveness of exercise in PN, but that supporting data was required to inform its design 
(White et al. 2007a).  
1.9.4. Training modalities 
Many exercise interventions in health and patient groups utilise strength training, aerobic 
training, or a combination of the two. Selection of the training modality is informed by the 
specific aims of exercise and determines the nature of any benefits (American College of 
Sports Medicine 1995). In the next section, the literature evaluating exercise in neurological 
conditions, with a specific focus on PN, is critically considered.  
 Strength training 
Many patients after GBS (48% of 40 patients between one and seven years after nadir) or with 
CIDP (over 90% of 67 patients over two years from the onset of symptoms) display muscle 
weakness in at least one muscle group (Dornonville de la Cour et al. 2005; Gorson et al. 
1997). This may result from incomplete reinnervation of muscle fibres which became 
denervated during the active neuropathic process (Dornonville de la Cour et al. 2005), but can 
be exacerbated by disuse (Duchateau and Hainaut 1998).  
Progressive resistance training is a common method of increasing muscle strength. It 
comprises near maximal muscular contraction against a high resistance. According to 
DeLorme (1945) multiple sets of resistance exercises should be performed in which individuals 
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lift a load which is equivalent to their ten-repetition maximum (RM). Each individual’s training 
load is determined by finding the maximal load that they can move ten times before temporary 
failure of the muscle (Fish et al. 2003). Participants begin training by completing sets at a 
percentage of this load (typically 50% to 75% of 10RM) and the last set of repetitions is 
performed at 100% of their 10RM. The Oxford system of progressive strength training utilises 
a similar approach but participants complete the first set of repetitions at 100% of 10RM, and 
subsequent sets at 75% and 50% (Fish et al. 2003). Both approaches increase the load or 
resistance as training progresses (Campos et al. 2002; De Lorme 1945; Khouw and Herbert 
1998) and have demonstrated similar strength gains (Fish et al. 2003). Strength training 
utilises the overload principle in which the muscle is subjected to greater loads than normal 
(Campos et al. 2002; De Lorme 1945; Khouw and Herbert 1998). Strength improvements after 
training are due to a combination of increased activation of the muscle, improved muscular 
metabolism, increased stiffness of connective tissues, hypertrophy and possibly hyperplasia of 
muscle fibres (Moritani 1992) and strength changes demonstrate specificity to the method of 
training (Baker et al. 1994; Roig et al. 2009). Changes in activation and muscle metabolism 
occur relatively quickly, but muscle fibre hypertrophy is reported to become apparent after at 
least four weeks of training in young participants, taking considerably longer in older people, 
and is dependent upon the training intensity and frequency (Kraemer et al. 2002; Moritani 
1992).  
Maintenance of muscle strength predicts better function in healthy adults as they age (Brill et 
al. 2000). In their systematic review of physical fitness training in stroke, Saunders et al. (2009) 
found only four trials of strength training (n=158) that met the criteria for inclusion but, despite 
significant strength gains, there was insufficient evidence to show benefits to function 
(Saunders et al. 2009). In MS, a systematic review of nine studies comprising 260 participants 
concluded that there was evidence in favour of exercise therapy on muscle power. However, 
the majority of included studies combined multiple training modalities so it is unclear of the 
effect of strength training alone and the limitations of this review (discussed on Page 31) 
means the results were at risk of bias (Rietberg et al. 2005).  
In hereditary PN, people with CMT have demonstrated significant increases in strength after 
training in several studies (Aitkens et al. 1993; Chetlin et al. 2004; Lindeman et al. 1995). In a 
prospective, double blinded controlled study, 20 people with CMT completed thrice weekly 
progressive strength training of the knee and elbow extensors and flexors for 12 weeks 
(Chetlin et al. 2004). Participants initially trained at 40% and 20% of one RM for the knee 
muscles and elbow muscles respectively increasing to 50% and 30% by 12 weeks. They also 
increased the number of repetitions from three sets of four repetitions to three sets of 10 
repetitions by the end of the programme. After training, they demonstrated significant 
improvements in timed activities of daily living (sit to stand, sitting up from supine, stair 
climbing, lift and reach) (Chetlin et al. 2004). Strength improved to become closer to normal 
population derived values but was not compared to baseline tests (Chetlin et al. 2004). 
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In another study, which comprised 24 weeks of progressive strength training of the knee 
extensors and flexors and hip abductors and extensors in 14 people with CMT and 15 
participants with myotonic dystrophy, a significantly greater mean strength increase (14%) in 
the knee extensors of CMT participants was shown compared to non-exercising controls 
(Lindeman et al. 1995). Participants trained three times a week, using free weights and 
resistance was increased from 60 to 80% of one RM during training whilst repetitions 
decreased from three sets of 25 to three sets of 10. After completing the programme, 
participants reported reduced activity limitations on the Western Ontario Mc Master University 
Arthritis (WOMAC) Index questionnaire which measures pain (five items) stiffness (two items) 
and functional limitations (17 items), but the validity of this finding is limited as the WOMAC 
was not designed to reflect activity limitations due to neurological problems. Analysis of the 
subgroup of CMT participants (n=14) demonstrated a significantly quicker preferred walking 
speed over six metres when compared to non-exercising controls and 46% (n=6) reported that 
they could undertake more activities than prior to the study. In another study, 27 people with 
progressive neuromuscular disease and 14 healthy controls trained thrice weekly for 12 weeks 
by undertaking moderate resistance upper limb, lower limb and hand grip exercises on one 
side of the body using free weights (Aitkens et al. 1993). Both groups demonstrated significant 
improvements in strength on both trained and untrained sides after the programme, and 
exercise appeared safe and practical, but the effects of these changes on function were not 
measured. The presence of significant strength gains in untrained limbs indicated that neural 
adaptations had occurred but the programme lacked clinical relevance as both sides would be 
trained in usual practice (American College of Sports Medicine 1995). These findings are also 
limited as the absence of a non-exercising patient control group and rater blinding mean that 
the observed changes cannot be attributed to the effect of the intervention. 
There are no studies which have examined strength training alone in people with inflammatory 
PN. It seems logical to include strength training in exercise programmes for people with 
inflammatory PN as it is clear that muscle strength is often reduced (Dornonville de la Cour et 
al. 2005; Gorson et al. 1997). However, strength training could also have adverse effects 
(discussed next) resulting in increased weakness which should be considered in the planning 
and monitoring of an exercise intervention. 
 Adverse effects of increased muscle activity and strength training 
Compensatory reinnervation after denervation results in enlarged motor units (Trojan and 
Cashman 2005). Enlarged motor units are common in people with after conditions such as 
polio (Trojan and Cashman 2005), but have also been found in 28 of 37 (76%) people with 
inflammatory PN by one study (Dornonville de la Cour et al. 2005; Trojan and Cashman 2005). 
Advice has traditionally warned against strenuous exercise, particularly strength training, in 
people after polio, suggesting it further reduced muscular strength and function (Johnson and 
Braddom 1971; Peach 1990). It is postulated that increasing the metabolic demands of 
enlarged motor units causes premature aging and death of the motor neuron, leading to further 
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depletion in motor unit numbers and thus increasing muscle weakness (McComas 1998). This 
could cause late onset of weakness which typifies post polio syndrome and is evident in 
muscles which were only minimally affected by polio, but have been overused to compensate 
for more severe weakness elsewhere (Perry et al. 1995). 
The effect of reinnervation and exercise on the motor unit has not been directly investigated in 
people with PN, and no advice regarding strength training in this patient group has been 
issued. Research in animal models of PN is not conclusive. Some observations in nerve 
injuries in rats suggest that intense and prolonged activity (such as eight hours of running or 
electrical stimulation) restricts progressive reinnervation of denervated end plates (Tam et al. 
2002; Tam and Gordon 2003). This prevents or reduces the enlargement of motor units after 
partial denervation and results in incomplete strength recovery (Tam et al. 2002; Tam and 
Gordon 2003). Conversely, other studies have reported that functional daily exercise was not 
detrimental to nerve sprouting and recovery immediately after partial denervation in rats 
(Gardiner and Faltus 1986; van Meeteren et al. 1998). However, this may depend on the type 
of exercise as 60 minutes of daily treadmill running appeared to retard motor recovery in rats 
with crushed sciatic nerves but 180 minutes of daily swimming did not (van Meeteren et al. 
1998). The translation of these results to humans with inflammatory PN is also difficult as 
chemical mediators and processes in inflammatory, immune mediated neuropathy may be 
different to those after an acute isolated injury to a single nerve root.  
A few studies in people with PN have reported that increased muscle activity is detrimental to 
muscle strength. One cross sectional study of 106 people with CMT attributed reduced 
strength in the dominant hand (a reversal of findings in healthy people) to over use during 
activities of daily living, although the data did not demonstrate cause and effect (Vinci et al. 
2003). Another report from a heterogeneous group of ten participants, including people with 
muscular dystrophy and CMT, observed a significant decrease in eccentric peak torque in the 
elbow flexors after 12 weeks of strength training (Kilmer et al. 1994). Participants increased 
the frequency of training from three to four days a week and increased repetitions from one set 
of 10 repetitions to five sets of 10 repetitions. The reduction in eccentric torque of the elbow 
flexors was attributed to damage produced by over work during resistance training, although 
this seems unlikely as significant increases in isometric and concentric strength in the same 
muscle group were evident, and there were significant improvements in the strength of the 
knee extensors which were trained identically. It is perhaps more likely that this finding was an 
artefact of the small sample and/or due to deterioration in a small number of participants with 
muscle disease which skewed results. 
In other studies, people with hereditary PN have demonstrated no evidence of overuse 
weakness after exercise and several have shown significant increases in strength after training 
at moderate and high intensities (Aitkens et al. 1993; Chetlin et al. 2004; Lindeman et al. 
1995). Therefore, it appears unlikely that over work weakness will affect muscle strength after 
exercise in people with PN. However, the absence of studies in inflammatory PN indicates that 
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any programme containing strengthening exercises should be monitored for signs of 
increasing muscle weakness. 
 Aerobic exercise 
Reduced cardiovascular fitness is common in people with neuromuscular disease (Kilmer 
2002; Nollet and Beelen 1999). Loss of aerobic fitness is attributed to, but may also 
exacerbate, reduced physical activity (Rimmer 1999) and is likely to increase the risk of heart 
disease and other medical problems (Bean et al. 2004). Aerobic training comprises raising 
heart rate above a percentage (usually 55% or 65%) of maximum heart rate (American 
College of Sports Medicine 1995). It is recommended that this is maintained for at least 20 
minutes, three to five times per week to produce changes in cardiovascular function and 
endurance which are evident after at least four weeks (Haskell et al. 2007; Pollock et al. 1998). 
Longer term health benefits associated with improved cardiovascular fitness including lowering 
the risk of stroke, diabetes and coronary heart disease which become evident with continued 
training (Bean et al. 2004). 
Participation in regular aerobic training has shown widespread benefits in healthy and ageing 
populations and in people with osteoarthritis, lung and circulatory problems (Bean et al. 2004; 
Brach et al. 2004). Studies in MS and after stroke have shown significantly increased exercise 
capacity, fitness and ADL after aerobic training (Petajan et al. 1996; Rietberg et al. 2005; 
Saunders et al. 2009). In a systematic review by Voet et al. (2009), aerobic training was 
concluded to be not harmful and possibly of benefit for people with muscle diseases although 
this was based on only one controlled, unblinded study of 20 participants that met the inclusion 
criteria.  
In a small study of seven people with post polio syndrome, the energy used when walking was 
significantly improved after six weeks of 30 minutes, thrice weekly aerobic treadmill training at 
55%-70% of age predicted maximal heart rate when compared to non-exercising controls, 
although this occurred in the absence of significant changes in aerobic fitness (Dean and Ross 
1991). One other uncontrolled study reported improved resting heart rates after 12 weeks of 
walking for 15 to 30 minutes three to four times per week at 50-60% of age predicted maximal 
heart rate in eight people with muscular dystrophy or CMT (n=3) (Wright et al. 1996). They 
concluded that participants had improved their cardiovascular fitness although changes in 
peak power and oxygen consumption were not significantly different when tested on a bicycle 
ergometer. However, the differences in testing and training modalities, the small number of 
participants and the absence of a non-exercising control reduces the strength of the results of 
both of these studies (Dean and Ross 1991; Wright et al. 1996).  
Two studies have examined aerobic training exercise programmes in people with inflammatory 
PN (Garssen et al. 2004; Pitetti et al. 1993). The first, a single case study, described the 
effects of aerobic training in a man three years after GBS, who undertook 30 minutes of thrice 
weekly, aerobic bicycle training at an intensity of 75-80% of his peak exercising heart rate 
(Pitetti et al. 1993). After 16 weeks, he demonstrated increased aerobic capacity, increased 
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peak workload and decreased resting heart rate during exercise testing on a cycle ergometer. 
The participant also reported reduced experienced fatigue and increased ability in activities of 
daily living but these were not assessed formally. Whilst these results imply improved 
cardiovascular fitness, their validity is limited due to the single case, unblinded and 
uncontrolled design.  
A second study examined changes in health related quality of life, experienced fatigue, 
participation and wider measures of health in people with inflammatory PN after aerobic 
training (Garssen et al. 2004). Twenty participants at least 12 months after GBS or with stable 
CIDP exercised for up to an hour thrice weekly in a hospital setting using a cycle ergometer, 
whilst medically supervised. Although two participants did not complete the programme (one 
was diagnosed with cardiovascular disease and one did not adhere to the programme), 
significant improvements in peak power output, oxygen consumption and peak heart rate were 
found after 12 weeks of training. Reported fatigue was also significantly improved, as were 
reports of physical functioning, mood and participation. Two years after completion of the 
programme, peak power, mood and experienced fatigue remained significantly improved from 
baseline (Garssen et al. 2005a).Ten participants (50%) reported continuing exercise, 
suggesting they perceived it to be beneficial, but their report was likely to be biased by a desire 
to please the rater and it is unclear why others chose not to continue exercising. Whilst 
promising, the strength of these results was limited by lack of blinding, the absence of a non-
exercising PN control group and biased by the expectations of participants and investigators. 
However, the reported changes indicate that aerobic exercise could be beneficial in people 
with inflammatory PN. They also show that wider measures of health which are associated 
with persistent activity limitations in this patient group, including fatigue, were improved after 
an intervention of this nature (Merkies et al. 1999).  
Although these findings provide some support for the inclusion of aerobic training in future 
exercise programmes in people with PN, greater benefits might have been apparent if strength 
training had been included in addition to aerobic exercise. This combined type of programme, 
discussed below, is more similar to that prescribed in clinical practice and to programmes 
recommended by exercise authorities (American College of Sports Medicine 1995). 
 Combined training 
Benefits from both strength and cardiovascular exercise can be produced by an exercise 
programme which combines both types of training and it is unlikely that this combination would 
significantly lessen the benefits of each component (McCarthy et al. 1994). Indeed, strength 
training could actually improve the ability to train aerobically, by increasing the strength of 
muscles used during aerobic exercise and so have a superior effect than one modality alone 
(Brill et al. 2000; Clark et al. 1996; Panton et al. 2004).  
A combination of strength and aerobic training produced significant improvements in strength, 
gait speed, activity, the ability to climb stairs and reported functioning in a RCT of six months 
of exercise in 96 people with MS (Romberg et al. 2004). In addition to strength and aerobic 
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training, combined programmes often include exercises targeted at specific functional 
difficulties experienced by the individual. Inclusion of such exercises, for example to improve 
balance and functional activities (e.g. rising from a chair), have been significantly associated 
with improved timed performances and reduced activity limitations in two uncontrolled 
prospective studies in 45 people after stroke (Eng et al. 2003; Leroux 2005).  
In their prospective controlled study, Ruhland (1997) included general exercises in addition to 
aerobic and strength training, but these were not targeted to improve specific functional 
problems (Ruhland 1997). Fourteen participants with CIDP, CIAP and hereditary neuropathies 
trained daily in their local community for six weeks, performing a combination of aerobic and 
strengthening exercise with general exercises (prone scapular retraction, back extension and 
abdominal curls) (Ruhland 1997). The exercise protocol comprised resisted upper limb 
exercises (using resistive band) and walking for 10 to 20 minutes at 60% to 70% of age 
predicted maximal heart rate. A control group (n=14) completed all outcome measurements 
but did not undertake exercise. One participant fell during training, but other practical issues 
related to community based exercise and adherence were not reported. After training, 
participants increased their average muscle score from baseline, becoming significantly 
stronger than non-exercising controls. Forced vital capacity (FVC), a measure of lung function, 
was not significantly changed from baseline. Although the authors concluded that this 
indicated that the participants’ cardiovascular fitness was unchanged after training, FVC is 
unlikely to be a sensitive measure of aerobic function. Significant changes in strength did not 
appear to be carried over to daily function and performance as only small improvements were 
reported which were similar to controls. The reason for this is unclear but larger changes may 
have been seen if the training had continued for longer, as some participants required several 
sessions before they could exercise at recommended intensities. Continuance of exercise 
beyond the intervention period was also not measured despite maintenance of health 
behaviours being necessary to promote long term health benefits (Dishman 1990). The 
limitations of this study include lack of assessor blinding and incomplete randomisation (as 
eight from 28 participants were not randomly assigned to control or training group). In addition, 
the relatively small sample, short training period, absence of follow up beyond the exercise 
intervention and lack of detail about the practicality of the community based programme 
reduce the usefulness of these findings.  
Whilst the evidence is limited, combined strength, aerobic and functional training is likely to be 
the most appropriate programme for people with PN. A programme of this nature, which is 
unsupervised and based in the community, could be maximally beneficial to facilitate regular 
exercise to reduce persistent disablement in people with inflammatory PN. A possible 
disadvantage of a combined programme is that it requires participants to undertake several 
different forms of exercise correctly and effectively, which may make it difficult or necessitate 
close supervision that is not available in the community. It is also unclear if participants would 
be willing to exercise regularly and independently. Therefore, the practicality and acceptability 
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of this type of intervention requires evaluation. This is the first aim of this thesis and is reported 
in Chapter Two. 
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1.10.  Experienced and physiological fatigue in people with 
peripheral neuropathies 
The second aim of this thesis was to investigate and describe the nature of fatigue in people 
with PN. In a series of 113 people after GBS, with CIDP or PDN, severe feelings of fatigue 
were reported by 80% (Merkies et al. 1999). These feelings of fatigue were significantly 
associated with poorer perceived health and functioning in people with PN but were not 
predicted by disease severity and little is known about factors that may contribute to them 
(Garssen et al. 2004; Merkies et al. 1999).  
1.10.1. Operational definitions of fatigue 
The meaning of the term fatigue is ambiguous. It is often used to describe feelings of 
tiredness, lassitude and lack of energy (Krupp and Pollina 1996). It can also represent 
physiological and chemical changes within the neuromuscular system, which result in a 
reduction in muscle performance (Gandevia 2001).   
For clarity different types of fatigue have been defined, producing three operational definitions 
which will be used throughout this thesis. These are: 
Experienced fatigue: “Feelings of fatigue, tiredness, lassitude and/or lack of energy” (Krupp 
and Pollina 1996; Piper et al. 1989). 
Physiological fatigue: “A reduction in the ability of a muscle to produce or maintain force due 
to changes within the neuromuscular system” (Gandevia, 2001). 
Some experienced fatigue is likely to be normal, therefore abnormal, severe experienced 
fatigue is also defined : 
Severe experienced fatigue: “An excessive, abnormal feeling of tiredness or lack of energy 
which is not relieved by rest” (Krupp and Pollina 1996; Piper et al. 1989).  
Few studies have investigated potential causes of severe experienced fatigue in people with 
PN. One cross sectional study reported reduced neuromuscular endurance
1
 in 29 people with 
hereditary PN, compared to healthy participants, during a sustained contraction of the knee 
extensors. A smaller study of 15 people with neurogenic weakness (including some PN) also 
found reduced neuromuscular endurance when the force decline during sustained contractions 
of the knee extensors and ankle dorsiflexors were compared to healthy controls (Lindeman et 
al. 1999; Milner-Brown and Miller 1989). Conversely, others found significantly greater 
muscular endurance in people with diabetic PN (n=44) and after GBS (n=40) when compared 
to healthy controls (Andersen 1998; Dornonville de la Cour and Jakobsen 2005). However, 
these studies tested force during repeated isokinetic contractions, rather than the sustained 
contractions used by Lindeman et al. (1999) and Milner Brown (1989), which could account for 
                                               
1
 Neuromuscular endurance was defined as the ability of the neuromuscular system to continue to work 
at a given intensity (Gandevia 2001). This is examined by measuring changes in the force output of the 
muscles under test. 
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the different findings of these studies. In addition, several of these studies included participants 
with metabolic or hereditary PN or a range of neuromuscular conditions, which means their 
findings cannot be directly transferred to inflammatory PN. 
Three studies have investigated the association between other factors, physiological and 
experienced fatigue in people with inflammatory PN. These are discussed in greater depth in 
Chapters Five and Six. In brief, Merkies et al. (1999) found that general strength, sensation, 
age and duration of symptoms were not significantly associated with experienced fatigue in 
113 people with inflammatory PN. Similar results were reported by Garssen et al. (2006) in 
100 people after GBS, although they found that more severe experienced fatigue was 
significantly associated with an age over 50 years and being female (Garssen et al. 2006c) . In 
a smaller study of 10 people several years after GBS, they also reported no associations 
between changes in the physiological muscular fatigue of the biceps brachii, nerve conduction 
velocity, functional limitations at nadir and experienced fatigue (Garssen et al. 2006a) .  
The absence of significant associations in these studies suggests that other factors which 
were not measured could contribute to more severe experienced fatigue. These factors, such 
as the physiological fatigue of functional, weight bearing muscles and cardiovascular fitness, 
should be investigated to aid understanding and develop targeted treatments.  
Although treatments to reduce experienced fatigue in people with PN appear elusive (Garssen 
et al. 2006), experienced fatigue has been significantly reduced after exercise interventions 
(Garssen et al. 2004; Garssen et al. 2005a; Pitetti et al. 1993). Whilst this suggests that 
exercise has a potential role in reducing fatigue, it also indicates that the factors improved by 
exercise may contribute to the severity of experienced fatigue.  
If possible contributors to experienced fatigue could be identified, targeted treatments could be 
developed to reduce its severity and reduce the activity limitations associated with it. This 




1.11.  Review of outcome tools  
1.11.1.  Background 
Outcome tools for the exercise study (Chapter Two) were pre-selected by a project steering 
group (Appendix One). 
In this section, although pre-selected, these tools are described and critically evaluated to 
allow the results they provide to be viewed in light of their properties. Tools that were used in 
other studies in this thesis are also critically considered.  
Where possible tools were appraised under the standard headings of impairments in body 
structure, activity limitations and participation restrictions (Salter et al. 2005b; Salter et al. 
2005a; Salter et al. 2005c; World Health Organisation 2001). However, whilst categorised 
under one International Classification of Functioning (ICF) descriptor, it is acknowledged that 
many tools assess more than one aspect of functioning and some contain items that are not 
explicitly included in ICF (Salter et al. 2005b; World Health Organisation 2001).  
1.11.2. Considerations when appraising an outcome tool 
Perhaps the most important and obvious consideration when appraising an outcome tool is 
that it provides the information that is wanted. Other important factors include its reliability, 
validity, floor and ceiling effects and responsiveness to ensure that the changes on the 
outcome tool are not caused by random error, that the tool measures what it purports to, and 
that it is sufficiently sensitive to reflect alterations in status (Lohr et al. 1996; Wade 1992b). 
Consideration of practical issues, for example the time taken to complete and the simplicity of 
the scale (burden), the acceptability to the patient, the usefulness, the interpretability and ease 
of communication of the information yielded by the tool, the ability to detect the predominant 
issues of the patient group of interest, and the clinical meaning of scores are also important. 
Consideration of these factors indicate if a tool is appropriate (suited to its application) and 
suitable (adapted for the characteristics of the patient group) (McHorney 1998; Wade 1992b). 
The recommendations of specialist bodies also informed the appraisal of the pre-selected 
outcome tools. The European Neuromuscular Centre group guidelines were used; this group 
comprises 23 international representatives including neurologists, neurophysiologists, 
pharmaceutical scientists with interests in PN, and a patient representative of the Guillain-
Barré Syndrome Foundation International (Merkies and Lauria 2006). The conclusions of the 
British Society of Rehabilitation Medicine were also used (British Society of Rehabilitation 
Medicine 2000). These recommendations were used cautiously alongside considerations 
discussed above in appraising each tool as it was recognised that they are likely to be 
influenced by personal opinion and bias.  
1.11.3. Considerations specific to people with PN 
As discussed in Sections 1.6, 1.7 and 1.8, common impairments in PN include altered 
sensation, experienced fatigue, altered mood and muscle weakness (Forsberg et al. 2004; 
Gorson et al. 1997; Hughes and Cornblath 2005). Activities such as walking and completing 
daily tasks are often affected (Erdmann et al. 2005; Forsberg et al. 2005; Gorson et al. 1997; 
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Lunn et al. 1999) and significant participation restrictions which necessitate changing jobs 
and/or hobbies are experienced by some (Bernsen et al. 2002; Bersano et al. 2005). The 
inclusion of these problems in an outcome tool adds to its suitability for people with PN and 
was considered when evaluating the selected tools.  
1.11.4. Limitations of outcome tools 
The majority of outcome tools share some limitations which are inherent to the type of data 
they generate. Whilst specific limitations are considered in context of each tool, to avoid 
repetition generic limitations are considered here. 
A common inadequacy of the data yielded by many outcome tools is that it is based solely 
upon participant report which can be biased or inaccurate (Rubenstein et al. 1984). The 
accuracy of self report is affected by a range of factors including gender, motivation, desire to 
please the rater and mental health (Goverover et al. 2005; Kempen et al. 1996; Rubenstein et 
al. 1984). A response shift, when respondents recalibrate their perception of their health often 
due to changes in health, influences self report and typically results in an underestimation of 
change by respondents (Schwartz et al. 2006; Schwartz and Spranger 1999). Although 
observation or proxy report might improve on some of the limitations of self report, they are still 
affected by bias and some constructs are impractical or impossible to measure by observation 
or from proxy report, for example experienced fatigue or the participant’s perception of their 
health (Ottenbacher et al. 1996).  
A further limitation is that many tools do not provide any information about why the participant 
is unable to complete activities or participate in life situations and cannot indicate the 
importance placed upon the activity by the individual. Although qualitative methods could 
provide these data, they do not facilitate direct comparison before or after intervention 
(Chapter Two) or between groups (Chapters Five and Six) and so were not appropriate for 
studies in this thesis. Finally, it is important to recognise that the properties of outcome tools 
are based upon the findings of others in published work which may be unavoidably biased by 
the opinions of the authors and publication bias (Cleophas and Cleophas 1999). Although 
these limitations are inherent to most published outcome tools, they are important to take into 
account when drawing conclusions from the data they yield. 
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1.12.  Body structure and function 
1.12.1. Muscle strength 
Muscle strength is a commonly used indicator of motor impairments in people with 
inflammatory PN (Merkies and Lauria 2006; Trigg and Wood 2003). Isometric muscle strength 
was measured using fixed dynamometry in the knee extensors in Chapter Two and by an 
isokinetic Kin Com dynamometer set in the isometric mode in the knee extensors in Chapter 
Six. Strength of muscles was graded in studies in Chapters Three and Four using the Medical 
Research Council (MRC) sum score (Medical Research Council 1976). A limitation of all these 
voluntary strength measures is that they assume that participants are making maximal effort. 
Submaximal efforts can be mistaken for weakness but this can be minimised by providing 
standardised verbal encouragement and adequate familiarisation (McNair et al. 1996).  
This chapter discusses the properties of fixed dynamometery (used in Chapter Two) and the 
MRC sum score measurements (used in Chapters Three and Four); the Kin Com 
dynamometer is considered separately in Chapter Six. 
 Fixed dynamometry 
Measurement using fixed dynamometry is considered to be the criterion standard of strength 
measurement (Aitkens et al. 1989). In Chapter Two, peak isometric knee extension force was 
measured using a fixed strain gauge. Lever arm length (between the centre of the knee joint 
and ankle cuff) was not incorporated in force calculation, therefore linear force was expressed 
in Newtons (N). The equipment used to measure knee extensor strength in these studies was 
reliable at forces up to 196 N as 20 repeated measurements, taken over three months using 
known weights up to 20 Kg were accurate and closely associated (r=0.99) (Appendix Two). 
However, it was not possible to assess reliability at higher forces.  
 Medical Research Council Sum Score 
The strength of muscles was graded using the Medical Research Council (MRC) sum score 
(Medical Research Council 1976). It was first used to grade strength after peripheral nerve 
injuries, and is now used in neurological practice around the world, being used in over 13 
published studies in inflammatory PN (Dyck et al. 2005). It is considered a valid measure of 
muscle strength in neuromuscular disease and is quick and easy to administer (Aitkens et al. 
1989). A MRC score ranging from zero (muscle paralysis) to five (normal strength) is assigned 
by the examiner who grades strength by resisting a maximal isometric contraction of the 
muscle group under test.  
The total sum score is calculated by summing the grades for the following muscle pairs, to give 
a total from 60: shoulder abductors, elbow flexors, wrist extensors, hip flexors, knee extensors 
and ankle dorsiflexors which are tested in standardised positions (Kleyweg et al. 1991; Medical 
Research Council 1976).  
The MRC sum score demonstrated good test re-test reliability when used in 102 people with 
neuromuscular disease (Florence et al. 1992), high overall inter-rater reliability (ICC= 0.96) 
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and was sensitive to change in clinical status in 113 people with GBS (Kleyweg et al. 1991; 
Merkies et al. 2003a). However, it may be insensitive to strength changes in muscles which 
display between 25% and 75% of full strength (Aitkens et al. 1989; Dyck et al. 2005). The 
relationship between MRC grades and fixed dynamometry has also not been established in 
neuromuscular disease and as MRC sum score grades are not linear, they are unlikely to be 
equivalent to dynamometry measurements which challenges the validity of the MRC sum 
score (Dyck et al. 2005). For these reasons, the MRC sum score was only used to indicate the 
strength of people with PN and was not used to judge change after an intervention. As the 
reliability of MRC scores was likely to be influenced by rater training and experience (Kleyweg 
et al. 1991) a single rater who was well practiced in using the sum score was used if 
consecutive measurements on the same patient were required. Standardised testing positions 
were also used to increase reliability (Kleyweg et al. 1991; Medical Research Council 1976). 
1.13.  Impairments 
1.13.1. Experienced fatigue 
There is no single criterion fatigue scale and at least 30 self report tools to measure 
experienced fatigue have been identified (Dittner et al. 2004; Friedberg and Jason 1998). 
Tools were not considered for use in the studies in this thesis if they only indicated a specific 
feature of fatigue e.g. cognitive fatigue, or if they could not describe the aspects of functioning 
most affected by fatigue e.g. a single visual analogue scale of fatigue severity. Tools that 
contained several items which reflected physical problems of fatigue, such as muscle 
weakness, were also excluded as they could erroneously attribute common physical 
impairments experienced by many people with PN to symptoms of more severe fatigue, 
confounding results. Respondent burden particularly influenced selection as long 
questionnaires are thought to further exacerbate symptoms in those who have fatigue, 
especially when part of a battery of other assessments (Dittner et al. 2004; Merkies et al. 
1999).  
The Fatigue Severity Scale (FSS) was pre-selected as the sole tool to measure fatigue in the 
study of exercise in Chapter Two. Two additional tools, which were also designed to reflect 
experienced fatigue, were also used in the investigation of fatigue in Chapters Five and Six: 
the fatigue impact scale and the revised Piper fatigue scale. A brief description of each of the 
three scales is provided and followed by a review of their advantages and limitations. 
 The fatigue severity scale 
The fatigue severity scale (FSS) is a unidimensional questionnaire and has nine items which 
measure the behavioural consequences and symptoms of fatigue (Krupp et al. 1989; Taylor et 
al. 2000). Each item on the FSS is answered by selecting one response from a seven point 
scale; a higher score indicates more severe fatigue. The overall score is found by calculating 




 The fatigue impact scale 
The fatigue impact scale (FIS) is a multi dimensional questionnaire which reflects the reported 
impact of fatigue upon a range of activities (Fisk et al. 1994). It allows delineation of the effects 
of fatigue in three areas: physical (ten items), cognitive (ten items) and psychosocial function 
(20 items). Each item is scored on a five point (0-4) Likert scale, to reflect how much difficulty 
this aspect of fatigue has caused in the last month. A higher score indicates greater fatigue. 
Subsection and total FIS scores are calculated by summing each item (total FIS score: 160). 
 The revised Piper Fatigue Scale 
The revised Piper Fatigue Scale (PFS) is a multidimensional questionnaire which assesses the 
perceived intensity of fatigue (Piper et al. 1998). Respondents are asked to rate the severity of 
specific aspects of their fatigue out of ten on 22 items; a higher score indicates greater 
experienced fatigue (Piper et al. 1998). In addition to a total score, dimension scores from 
behavioural severity (six items), affective meaning (five items), sensory (five items) and 
cognitive affect and mood (six items) are calculated. A score is generated by adding the 
numerical answers given in each dimension, and then dividing by the total number of items 
answered. A score of ten indicates most severe fatigue. Scores less than seven are reported 
to indicate moderate fatigue and below three, mild fatigue (Piper et al. 1998).  
 
1.13.2.  Evaluation of outcome tools measuring experienced fatigue  
 Advantages 
These tools have been used widely in other conditions, but only the reliability and validity of 
the FSS has been evaluated in PN. Merkies et al. (1999) reported significant differences in 
FSS scores between 113 people with inflammatory PN and healthy participants, indicating 
divergent validity and the concurrent validity of the FSS was supported as scores in the PN 
group were significantly associated with energy and vitality scores on the SF-36 questionnaire 
(Merkies et al. 1999). The FSS scores were also internally consistent (Cronbach’s α =0.93) 
and repeated measurements over several months were strongly associated (r= 0.86), inferring 
it was reliable (Merkies et al. 1999). In comparison to the other reviewed fatigue outcome 
tools, the FSS has the fewest items, and so has low respondent burden; it is also reported to 
have a high level of correct completion (95%, 57 from 60 participants with MS) (Chipchase et 
al. 2003; Friedberg and Jason 1998). These findings suggest that the FSS is suitable for 
people with PN and could yield important information about experienced fatigue in the studies 
in this thesis without adding considerably to respondent burden. 
The FIS, unlike the FSS, is a multidimensional fatigue scale and so could provide greater 
insight into the effect of experienced fatigue upon distinct aspects of functioning. It has 
demonstrated a relatively high correct completion rate in people with MS (88%) (Fisk et al. 
1994) but it contains 40 items and so has a greater burden than the FSS. The FIS has been 
used to measure perceived experienced fatigue in several conditions including chronic fatigue 
syndrome (CFS) and MS but has not been evaluated in PN (Fisk et al. 1994; Paul et al. 2000). 
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It has demonstrated internal consistency (Cronbach’s α >0.8) and discriminated between 145 
people with MS, 105 people with CFS and 34 people with heart disease, demonstrating 
divergent validity (Fisk et al. 1994; Paul et al. 2000). It has also shown responsiveness to 
changes in fatigue after targeted drug treatment in 218 people with MS (Metz et al. 2004), 
although an estimate of its responsiveness was not given and responsiveness in PN cannot be 
assumed. Although the reliability, validity and responsiveness of the FIS have not been 
evaluated in people with PN, it has been used to capture change, showing a 20% decrease in 
fatigue in 20 participants with PN after a 12 week supervised exercise intervention (Garssen et 
al. 2004). Its significant burden and the lack of evidence evaluating its properties in PN deter 
from using the FIS as a single indicator of fatigue or if detailed assessment of fatigue is not 
warranted. However, the performance of the FIS in other patient groups and its ability to reflect 
distinct aspects of fatigue supports its use alongside other tools to describe experienced 
fatigue in the investigations of fatigue in Chapters Five and Six.  
The PFS has not been used as widely as the FSS and FIS in neurological conditions and has 
not previously been used in PN. The PFS has a greater burden than the FSS as it has 22 
items but, unlike the FIS and FSS, it yields information regarding the intensity of experienced 
fatigue. Its properties have been investigated in 64 people with post polio syndrome 
(Strohschein et al. 2003). A strong association with scores on another fatigue scale, the 
Modified fatigue inventory (r=0.8) supported its validity, it also had face and content validity, 
excellent internal consistency (Cronbach’s α =0.98) and high test re-test reliability over short 
periods (ICC=0.98) in this patient group (Strohschein et al. 2003). 
The PFS was selected to be used alongside tools which indicate functional and affective 
components of experienced fatigue to provide information about the intensity of experienced 
fatigue in the investigations of fatigue in Chapters Five and Six.  
 Disadvantages 
All experienced fatigue outcome tools reviewed here have some similar disadvantages. In 
addition to the limitations of self report (discussed on Page 44), these questionnaires assume 
that fatigue reported by participants is similar to normal fatigue experienced by most people, 
but is of greater intensity or severity and consequently produces limitations (Taylor et al. 
2000). However, people with severe experienced fatigue could undergo a qualitatively very 
different and individual experience of fatigue, which would not be captured comprehensively by 
standardised outcome tools. Although qualitative investigation of the perception of fatigue 
overcomes this limitation, it would not allow comparison between groups or before and after an 
intervention in the same group, so would be inappropriate for the studies in this thesis.  
Whilst the FSS has been positively evaluated in people with PN, it has several limitations. 
Respondents completing the FSS may score highly on one specific item (“my motivation is 
lower when I am fatigued”), in the absence of experienced fatigue, as it could be argued that 
most people experience reduced motivation when fatigued. Similarly, some items on the PFS 
are also dependent upon the respondent’s perception of their fatigue, (e.g. “the fatigue I am 
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experiencing is pleasant or unpleasant”), rather than simple fatigue intensity. This could be 
overcome by comparing results from the FSS and PFS to those from healthy respondents to 
determine if totals could be judged to be abnormal. The validity of the PFS may be reduced if 
respondents have difficulty completing a numerical rating scale; this has been reported on 
other tools which use similar scales (Friedberg and Jason 1998; Strohschein et al. 2003). A 
ceiling effect on the PFS has also been reported in healthy participants which indicates it has 
decreased sensitivity to milder experienced fatigue which should be considered when 
reviewing the results in Chapter Five (Strohschein et al. 2003).  
1.13.3.  Mood 
The mood, mental health or well-being of people with PN has not been widely evaluated, 
possibly because it is not directly affected by the neuropathic process. However, low mood can 
be caused by, and contribute to, persistent activity limitations and reduced quality of life in 
people with PN, and thus warrants measurement (Bernsen et al. 2002; Lennon et al. 1993). 
The HADS and BDI were used to measure anxiety and depression in Chapter Two. Each tool 
is described separately and their advantages and disadvantages considered together.  
 Hospital anxiety and depression scale 
The hospital anxiety and depression scale (HADS) is a self completed 14 item questionnaire, 
which takes less than five minutes to answer (Snaith and Zigmond 1994). It measures 
generalised anxiety and loss of pleasure response on anxiety and depression subscales 
(seven items each). The anxiety and depression subscales are scored separately where a 
score less than seven is considered normal; scores below ten indicate mild levels of anxiety or 
depression and, below 14, moderate. If participants score above 15, they are considered 
severely anxious or depressed (Snaith and Zigmond 1994). 
 Beck depression inventory 
The Beck depression inventory (BDI, version 2, BDI-II) is a 21 item questionnaire which 
measures the severity of depression (Beck et al. 1996). It was developed by refining items 
from the original Beck scale in 1996 (Beck et al. 1996; Steer et al. 1999). Scores below 13 
indicate minimal or no depression, below 19 mild depression and scores over 28 severe 
depression (Beck et al. 1996).  
 
1.13.4. Evaluation of tools to measure mood 
 Advantages 
The HADS is a valid indicator of both anxiety and depression, and has been used in over 700 
reported studies with more than 10,000 participants (Bjelland et al. 2002; Snaith and Zigmond 
1994). It has been used in neurology and primary care settings, and in people with and without 
clinical levels of anxiety and depression (Bjelland et al. 2002; Snaith and Zigmond 1994). The 
BDI has also been used extremely widely in mental health and community settings (Beck et al. 
1996; Steer et al. 1999).  
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The HADS has been shown to be internally consistent (Cronbach’s α > 0.6) (Bjelland et al. 
2002) and reliable over at least six weeks (correlation between repeated scores exceeded 0.7) 
when re-tested in 900 people with and without clinical levels of anxiety and depression 
(Herrmann 1997). Similarly, the BDI is also reported to be internally consistent (Cronbach’s α 
=0.9) and its test re-test reliability excellent in a range of patient groups (overall r= 0.93) 
(Ambrosini et al. 1991; Beck et al. 1996).  
The HADS (depression scale) and BDI correlate significantly with each other suggesting they 
are valid (Bjelland et al. 2002). The HADS has also demonstrated significant associations with 
other measures of mood in healthy volunteers and psychiatric patients including visual 
analogue scales (r > 0.6) (Bjelland et al. 2002).  
In a review of 24 studies, the cut off value on the HADS after which anxiety and depression are 
considered abnormal was similar to that identified by its authors (>7) indicating it is able to 
detect low mood (Bjelland et al. 2002). Similarly, the cut off point of 13 on the BDI detected 
abnormal levels of depression with sensitivity of over 80% in 122 younger people in primary 
care (Ambrosini et al. 1991). The responsiveness of the BDI and HADS after exercise 
interventions has not been formally reported. However, the HADS was used to measure 
change after an exercise intervention in 20 people with PN, demonstrating significant changes 
(Garssen et al. 2004). The BDI also measured significant changes in depression after an 
exercise intervention in people with clinical depression, but it is not known if it would behave 
similarly in people with PN who are not clinically depressed (Lawlor and Hopker 2001).  
 Disadvantages 
The BDI and HADS have some drawbacks which should be considered when viewing the data 
they produce. Neither have been fully evaluated in PN and although both have been used in 
studies of exercise, it is unclear how responsive they would be to changes after an exercise 
intervention in people whose scores indicate normal levels of anxiety and depression (scores 
below seven and 13 on the HADS and BDI respectively). The validity of BDI scores is reduced 
in people with lower scores (Ambrosini et al. 1991) which implies its validity cannot be 
assumed in people with PN without depression. The BDI may also not be able to distinguish 
symptoms of depression from anxiety, reducing its validity to reflect depression alone (Richter 
et al. 1998). 
Although the HADS was developed to describe mental health in people with physical 
problems, some items describe physical symptoms which reduces its face validity e.g. “I feel 
as if I am slowed down...”. Similarly on the BDI, items indicate other impairments experienced 
by people with PN (e.g. fatigue), which would be erroneously be attributed to depression. This 
would artificially inflate scores. Furthermore, the cut off values after which anxiety and 
depression are considered abnormal on the HADS may be inaccurate for people with reduced 
functioning, as lower values were found in people after stroke (scores greater than five 
indicated anxiety, and greater than four indicated depression) (Bjelland et al. 2002). This 
suggests that normative cut off values should be used with caution in people with PN.  
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Whilst the HADS detects anxiety and depression, the BDI provides a greater insight into the 
severity and nature of depression and has been used to evaluate changes in mood after 
exercise. Both tools were used in the investigation of exercise (Chapter Two) and their 
performance was re-evaluated after their use. 
1.14.  Activity limitations 
Activity limitations refer to difficulties experienced by an individual when carrying out a task or 
action (World Health Organisation 2001). Changes at the level of activities are argued to be 
most important to the individual and so are the most suitable to evaluate rehabilitative 
interventions (Wade 1999). Therefore, changes in activities were selected to be the primary 
outcome of the exercise intervention (Chapter Two). This section reviews the properties of 
tools which measure activity and is subdivided into those which evaluate activities of daily 
living (ADL), extended activities of daily living (EADL) and specific activities of mobility and 
walking.  
1.14.1. Activities of Daily Living  
Activities of daily living (ADL) are stated to be tasks “...which everyone will need to accomplish 
every day, (or at least every week with some items).” (Wade, 1992d; p71). Activities which 
constitute activities of daily living are widely agreed to include: mobility, grooming, bathing, 
feeding and dressing (Dittmar and Gresham 1997).  
 Overall disability sum score 
The Overall disability sum score (ODSS) was designed to measure reported activity limitations 
in people with inflammatory PN (Merkies et al. 2002a). It was developed from a consensus of 
experts in order to address the perceived lack of suitable outcome tools in PN and consists of 
a checklist with five upper and lower limb items, including dressing, grooming and mobility. It is 
administered as an interview, taking less than two minutes to complete (Merkies et al. 2002a). 
Raters are instructed to calculate an overall score by summing upper and lower limb scores. A 
maximum score of 12 indicates inability to use the upper or lower limbs for purposeful 
movement, zero indicates no limitations.  




The Overall Disability Sum Score (ODSS) 
 
ARM DISABILITY SCALE – Function checklist  
                                                                                                    Not affected      Affected but not               Prevented 
                                                                                                                                Prevented 
Dressing upper part of body excluding buttons or zips       
 
Washing and brushing hair         
 
Turning a key in a lock          
 
Using a knife and fork (/spoon if patients never uses knife or fork)       
 
Doing or undoing buttons or zips         
 
Arm Grade  
0 = Normal 
1= Minor symptoms or signs in one or both arms but not affecting any of the functions listed 
2= Moderate symptoms or signs in one or both arms affecting but not preventing any of the functions listed 
3= Severe symptoms or signs in one or both arms preventing at least one but not all functions listed 
4= Severe symptoms or signs in both arms  preventing all functions listed but some  
purposeful movement still possible 
5= Severe symptoms or signs in both arms preventing all purposeful movements 
 
SCORE =  
LEG DISABILITY SCALE – Function checklist  
 
     No               Yes         Not Applicable 
Do you have any problem with your walking?      
 
Do you use a walking aid?       
  
How do you usually get around for about 10 metres? 
     Without aid        
     With one stick or crutch or holding to someone’s arm      
     With two sticks or crutches or one stick or  
     crutch holding onto someone’s arm      
     With a wheelchair       
 
If you use a wheelchair, can you stand and walk a few 
    steps with help?        
 
 If you are restricted to bed most of the time are you able to 
 make some purposeful movements?        
 
Leg grade 
0= Walking is not affected 
1= Walking is affected but does not look abnormal 
2= Walks independently but gait looks abnormal 
3= Usually uses unilateral support to walk 10 metres (25 feet) (stick, single crutch, one arm) 
4= Usually uses bilateral support to walk 10 metres (25 feet) (sticks, crutches, two arms) 
5= Usually uses wheelchair to travel 10 metres (25 feet) 
6= Restricted to wheelchair, unable to stand and walk few steps with help, 
 but able to make some purposeful leg movements 
7= Restricted to wheelchair or bed most of the day, preventing all purposeful 




Overall disability sum score = arm disability scale (range 0-5) + leg disability scale (range 0-7); 
Overall Range: 0 (no signs of disability), 12 (maximum disability).  
For the arm scale: allocate one arm grade only by completing the function checklist,  
indicate whether each function is “not affected”, “affected but not prevented” or “prevented”. 




 Evaluation of the overall disability sum score 
The ODSS has not been widely investigated in PN and so appraisal of its properties is limited 
and based upon studies by its authors, placing them at particular risk of bias (Merkies et al. 
2002a). The association between scores on the ODSS and other established ADL measures 
has also not been reported which challenges its validity. Despite these limitations, the ODSS 
has been used in several clinical trials and investigations and has been recommended as an 
outcome tool in trials in PN (Hagemans et al. 2005; Hughes et al. 2004; Merkies and Lauria 
2006; Merkies et al. 2003b; van Doorn and Garssen 2002).  
Two studies by the authors of the ODSS have considered the reliability, validity and 
responsiveness of the ODSS (Merkies et al. 2002a; Merkies and Schmitz 2006). The ODSS 
was reliable (inter and intra-rater intra class correlation coefficients, ICC, > 0.9) in 113 people 
with inflammatory PN and it correlated strongly with the GBS disability score (r>0.74) inferring 
validity (Merkies et al. 2002a). In the second study, the ODSS was responsive to change in 
people with PN, demonstrating significant improvements in a smaller but clinically relevant 
sample of 20 people recovering from GBS examined longitudinally over one year 
(standardised response mean, SRM= 1.2 to 1.4) (Merkies et al. 2002a; Merkies et al. 2003a). 
Indeed, it demonstrated the greatest responsiveness of all clinical measures used in this 
patient group (including hand grip strength, ten metre walk time, nine hole peg test and 
sensory sum score) (Merkies et al. 2003a).  
The ODSS has some face validity as it reflects difficulties in common ADLs such as washing, 
dressing and mobility (Merkies et al. 2002a). However, some ADLs are omitted, such as 
showering/bathing, and there is likely to be overlap between items within the ODSS as an 
inability to perform one activity (e.g. dress) limits the ability to complete others (e.g. fasten 
buttons). This overlap is common to other ADL tools and although it reflects the usual 
limitations experienced by the individual, it inflates scores (Kasner 2006).  
A limitation of the ODSS, shared by many other ADL tools, is that many items are scored from 
only two or three options and so could lack sensitivity to small but important changes in 
activities. This does not appear to be the case as scores on ODSS have been moderately and 
significantly associated with patient’s perception of change (r=0.66) (Merkies and Schmitz 
2006). Others have found that a change of one point on the GBS disability scale, which is 
somewhat similar to the ODSS, was considered to be meaningful in people with PN (Hughes 
2002c). These findings suggest that the ODSS has adequate sensitivity but its ability to 
measure changes after an exercise intervention has not been examined. Therefore, the 
properties of the ODSS were re-evaluated after its use in the study of exercise in Chapter Two. 
1.14.2. Extended Activities of Daily Living 
Although more difficult to define, extended activities of daily living (EADL), sometimes called 
instrumental ADL, include tasks which are completed less often and are not necessarily 
performed by all people, but are governed by choice and circumstance (Wade 1999). These 




 The health assessment questionnaire disability index 
The health assessment questionnaire (HAQ) was one of the first self report measures of 
functional ability and limitations (Bruce and Fries 2003; Fries et al. 1982). The HAQ disability 
index (HAQDI), a subsection of the HAQ, captures information about usual daily activities in 
the past week from eight categories which question specific EADL (e.g. grooming and 
reaching) and are scored from four levels of difficulty from zero (no difficulty) to three (unable 
to perform). The highest scored item determines the overall score for that category. The use of 
aids or adaptations increases the category score by one for scores less than two. The overall 
score is calculated as the mean of eight categories, with 25 possible scores (Bruce and Fries 
2003). A score of zero indicates little or no perceived limitation, and three indicates perceived 
maximum limitations, and an inability to perform the activities outlined. 
 Evaluation of the health assessment questionnaire disability index  
The HAQDI was originally designed as a part of a larger tool to measure limitations in people 
with arthritis. Although the HAQDI has not been used in PN, it is argued to be a generic tool by 
its authors as the constructs underpinning the items (activity limitations and dysfunction) are 
common to many other long term conditions (Bruce and Fries 2003).  
Items on the HAQDI are considered to be appropriate to indicate activity limitations in 
neurological conditions (Wade 1992a) and they question activities that are widely recognised 
to be limited in people with PN, e.g. turning taps, opening jars etc. (Bernsen et al. 2005; 
Erdmann et al. 2005; Merkies et al. 2000). These are not explicitly captured by many other 
EADL tools, supporting the inclusion of the HAQDI. It is simple, quick and straightforward to 
complete and has little burden (Wade 1992a). However, the HAQDI demonstrates a problem 
common to EADL tools as EADLs, by definition, depend upon personal preferences which vary 
between individuals. Whilst the HAQDI lacks items regarding specific hobbies and pastimes 
which reduce this limitation, this does mean that it cannot provide any information on some 
potentially important aspects of EADL. However, this limitation can be overcome if other tools 
that provide these data were used alongside the HAQDI. 
The HAQDI has demonstrated validity in people with a range of orthopaedic problems as its 
scores have correlated strongly with self reported physical functioning (r=0.7, measured on the 
Medical Outcomes Short Form 36 item questionnaire, SF-36) (Bruce and Fries 2003). 
However, its validity in PN has not been investigated. Scores on the HAQDI are reported to be 
consistent and reliable over time in a range of orthopaedic conditions (mean r=0.98 over six 
months) (Bruce and Fries 2003; Fries et al. 1982; Green et al. 2001) and the HAQ has 
demonstrated moderate responsiveness to changes in 105 people with rheumatoid arthritis 
over 15 months (Fitzpatrick et al. 1989). Others demonstrated that the HAQDI had good to 
excellent responsiveness (effect size range : 0.7 - 0.9) in 196 participants with systemic 
sclerosis who participated in a trial of a new drug (Khanna et al. 2005). These results indicate 
that the HAQDI is responsive in conditions which produce physical limitations beyond those it 
was originally designed for. Whilst this adds support to its inclusion, a similar performance in 
people with PN cannot be assumed.  
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Furthermore, some items on the HAQDI question ADLs (such as dressing, rising, eating and 
hygiene) leading to replication of information provided by other tools and potential item 
redundancy. An additional limitation of the HAQDI is that the scoring criteria lacks some 
sensitivity, as participants are considered more limited if they use an aid, even though they 
could depend on the aid considerably less than on previous testing. This difference, although 
small, could be clinically significant for some respondents but is not able to be reflected by the 
HAQDI. This may reduce its responsiveness. As the HAQDI has not been used or evaluated in 
PN previously, its performance was re-examined after its use in Chapter Two.  
1.15.  Specific components of ADL 
1.15.1. Mobility  
Mobility comprises a number of ways of moving, including changing and maintenance of body 
position, walking long and short distances on different surfaces, moving around with and 
without equipment and moving effectively in normal surroundings (World Health Organisation 
2001). Mobility is considered by many to be a key daily function (Chiou and Burnett 1985) and 
is affected in 7% (of 42) to 26% (of 40) of people at least two years after GBS (Dornonville de 
la Cour and Jakobsen 2005; Forsberg et al. 2004). In one study of people with chronic 
inflammatory PN, 80% (of 24) reported difficulty walking and climbing stairs (Erdmann et al. 
2005).  
As participants included in the studies in this thesis were required to be ambulant for at least 
part of the day (except for participants in the investigation of the Overall Neuropathy 
Limitations Scale in Chapter Three), only tools measuring ambulant ability were appropriate. 
Video and motion analysis, which measures kinematic and kinetic parameters of gait, were not 
considered for use in this thesis as studies did not specifically target gait, these data do not 
necessarily reflect usual functioning in the community and have limited clinical relevance 
(Pearson et al. 2004).  
Several of the tools already considered in this chapter measure self reported mobility, notably 
the ODSS and HAQDI. Therefore, no extra mobility questionnaires were selected to measure 
mobility in the study of exercise in Chapter Two. However, timed walking tests were used 
alongside these tools in Chapter Two to provide objective data on parameters of gait. 
Three tools, the physiological cost index (PCI) (MacGregor 1979), modified PCI (mPCI) and 
Walk-12 (Hobart et al. 2003) which measure aspects of walking and mobility were evaluated 
and developed in Chapter Four, and so are not described here. 
 Ten metre walk test 
Timed tests are one of the most common tools used to indicate mobility (Dittmar and Gresham 
1997). In the ten metre walk test participants walk in a straight line along a level surface at 
their preferred walking pace (preferred pace ten metre walk test) or as fast (fast ten metre walk 
test) as safely possible whilst being timed. The time taken at a preferred pace is strongly 
associated with cadence, stride length, balance, reported mobility, lower limb strength and has 
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discriminated between the use of aids in a range of patient groups including people after 
stroke and the elderly (Bohannon 1997a; Bohannon and Andrews 1990; Rossier and Wade 
2001; Wolfson et al. 1990). The preferred pace ten metre walk test also demonstrated 
excellent test re-test reliability when measured twice, one week apart (ICC= 0.93) in one study 
of 46 people with a range of neurological conditions (Rossier and Wade 2001).  
The preferred pace ten metre walk test has been used in several studies to describe 
functioning in people with inflammatory PN (Erdmann et al. 2005; Forsberg et al. 2004) and it 
has been recommended as an outcome tool in clinical trials in PN by expert consensus 
(Merkies and Lauria 2006). However, only one study has examined the validity of the ten 
metre walk test in people with PN. In a small study of 11 people with CIDP, ten metre walk test 
times had a strong correlation with balance scores (r=0.76) and moderate associations with 
self reported motor functioning (r= 0.55) (Erdmann et al. 2005). Whilst this suggests that the 
ten metre walk test is valid for PN, the small sample considerably limits the strength of this 
conclusion. 
Both fast and preferred pace ten metre walks appear highly responsive to changes in clinical 
status in other neurological conditions (standardised response mean, SRM= 0.92 and 0.83 
respectively) (Salbach et al. 2001). However, one study of 20 people after GBS (n=7) or with 
CIDP (n=13) demonstrated that the preferred pace ten metre walking time was poorly 
responsive to clinical changes which occurred over 12 months (SRM=0.38) (Merkies et al. 
2003a). This could be caused by a ceiling effect on the preferred pace test which has been 
reported by others (Wade 1992c) and implies the test is not responsive for more able 
participants. However, this ceiling effect could be reduced if participants walk as fast as 
possible (fast ten metre walk), although this has not been investigated.  
A disadvantage of both versions of the ten metre walk tests is that they cannot provide any 
information about other aspects of mobility that occur in the community such as walking on 
uneven surfaces or climbing steps. Consequently, despite correlating with cadence and other 
parameters of gait, they reveal little about the quality and efficiency of usual walking 
(Bohannon 1997a; Rossier and Wade 2001). However, these areas of functioning are 
measured by other ADL and EADL tools which have been pre-selected for the study of 
exercise in Chapter Two. Therefore, both preferred pace and fast ten metre walk tests were 
selected for use in studies in this thesis. 
1.16.  Participation 
Participation is defined as an individual’s involvement in a life situation or role (World Health 
Organisation 2001) and includes performance of hobbies, employment and fulfilment of family 
responsibilities. Participation restrictions are therefore influenced by personal and 
environmental factors. The absence of in depth studies of participation in PN makes it unclear 
which aspects are the most pertinent and so which participation tools are the most appropriate. 




1.16.1. The Medical Outcomes Survey Short-Form 36 item questionnaire 
The Short Form 36 item questionnaire (SF-36) is a simple self administered questionnaire, 
developed from the Medical Outcomes Survey in North America (Ware and Sherbourne 1992). 
It is considered to measure aspects of health related participation, health related quality of life 
or general health status (Merkies et al. 2002c; Salter et al. 2005c; Schepers et al. 2007). The 
SF-36 (UK, version 1) comprises eight health related subscales including: physical functioning 
(10 items), role limitations due to emotional (three items) and physical (four items) problems, 
energy and vitality (four items), pain (two items), mental health (five items), social functioning 
(two items) and general health (five items) and takes less than ten minutes to complete (Ware 
and Sherborne 1992). Answers are transformed, using a scoring algorithm, to produce raw 
scores from zero (poor health status) to 100 (good health status) for each subscale (Ware and 
Sherbourne 1992). A ninth scale, health transition, asks participants to rate their health in 
comparison to one year ago. All other scales require respondents to base their answer upon 
current health or over the previous month. This SF-36 is most commonly administered as a 
self completed questionnaire, but can also be completed by an interviewer, over the telephone, 
via post or by proxy (Salter et al. 2005c). 
Raw scores can be summarised in two categories; the physical (PCS) and mental (MCS) 
component summary scores (Ware and Kosinski 2003) which are interpreted in relation to 
“norm” based scoring derived from the general population in 1998 so that the score would 
equal 50 in a healthy population (Ware and Kosinski 2003). A score below 50 indicates poorer 
health related status, a score greater than 50 indicates better than normal status (Ware and 
Kosinski 2003).  
1.16.2. The functional limitations profile 
The functional limitations profile (FLP) (Patrick and Peach 1989) measures the respondent’s 
perception of health related functioning. It consists of 136 weighted items which are summed 
into an overall percentage score, ranging from zero (no limitations) to 100% (maximum 
limitation). It is considered to be a participation tool, although some items consider other 
activities such as eating and drinking (Salter et al. 2005c; Schepers et al. 2007). The FLP is 
administered as an interview questionnaire and takes up to 30 minutes to complete (Damiano 
et al. 1999). It contains 12 subscales: ambulation, mobility, body care and movement, 
household management, recreation and pastimes, social interaction, alertness, emotion, sleep 
and rest, eating, communication and work. In addition to an overall score, physical and 
psychosocial subscales are also calculated. 
1.16.3. Rotterdam handicap scale 
The Rotterdam handicap scale (RHS) was designed to measure restrictions to participation 
reported by people with inflammatory PN (Merkies et al. 2002b). It was initially developed by a 
group of neurologists and items were refined following interviews with 12 PN patients and a 
paper survey of 38 PN patients (Merkies et al. 2002b). It comprises nine items with five 
possible answers and takes less than four minutes to complete (Merkies et al. 2002b). The 
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items investigate transport and occupation, indoor and outdoor mobility, kitchen tasks, indoor 
and outdoor domestic tasks, and indoor and outdoor leisure activities (Merkies et al. 2002b). 
The RHS is administered by an interviewer and the respondent indicates their level of 
independence in each task, ranging from one, unable, to four, totally independent (where 0 is 
not applicable). The total score is calculated by summing all the responses, and ranges from 
nine (maximal limitations) to 36 (no limitations).  
 
1.16.4. Evaluation of outcome tools to measure participation 
 Advantages 
The SF-36 is used widely and has the advantage that scores can be seen in context to 
normative data for healthy people, indicated by values at the 50
th
 centile, as normality does not 
always equate to a maximal score on every subscale (Ware and Kosinski 2003). This means 
scores are interpretable and can be easily communicated. The SF-36 is reliable in a range of 
patient groups and over several months (median correlation coefficient from 14 studies= 0.8) 
(Ware and Kosinski 2003) and in neurological and neuromuscular conditions including stroke, 
MS and amytrophic lateral sclerosis (ALS) (Anderson et al. 1996; Bourke et al. 2004; Freeman 
et al. 1996; Hobart et al. 2001; Hobart et al. 2002). The properties of the SF-36 have been 
investigated in 114 participants with inflammatory PN (Merkies et al. 2002c). Scores were 
significantly lower than normal population values and physical scales of the SF-36 correlated 
strongly with strength (MRC sumscore), and activity limitations measured by the GBS disability 
score, supporting its validity (Merkies et al. 2002c). The SF-36 was internally consistent 
(Cronbach’s α ranged from 0.7 to 1) (Merkies et al. 2002c) and summary scores detected 
changes in clinical status when re-measured in 20 PN patients undergoing treatment or 
recovery over one year (Merkies et al. 2002c). The responsiveness of all subscales, except 
pain and health perception, was also excellent (SRM >0.8) (Merkies et al. 2002c). However, 
differences between changes from treatment, during recovery and those after an exercise 
intervention may differ meaning similar responsiveness cannot be assumed in the exercise 
study (Chapter Two). 
Although the FLP is less widely used than the SF-36, it has been shown to be appropriate to 
measure functioning in other neurological conditions (MS) (Hutchinson and Hutchinson 1995). 
The full FLP has been used to describe function after GBS (Bernsen et al. 1997) but has not 
been used to measure changes. It provides a richness and depth of data to allow description 
of a wide range of areas (e.g. social interaction and emotion) which are not measured by other 
tools, albeit with considerable respondent and administrator burden. Acceptable test re-test 
reliability has been shown in a range of conditions including ALS and MS (Damiano et al. 
1999; Hutchinson and Hutchinson 1995). It has demonstrated concurrent validity in 122 people 
with stroke, correlating significantly (r > 0.56) with other tools which measure community 
reintegration (Trigg and Wood 2003) and scores were responsive to changes in the functioning 
of 20 people with MS over six months (Hutchinson and Hutchinson 1995). 
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The RHS has been recommended by experts in PN for clinical trials (Merkies and Lauria 2006) 
and it has face validity as it contains items about return to work, socialising and hobbies which 
are known to be restricted in people with PN (Merkies et al. 2002b). It demonstrated 
acceptable inter-rater and test re-test reliability (r=0.93 and 0.98 respectively) in 113 people 
after GBS or with CIDP over 12 months, scores were also significantly associated with the 
modified Rankin scale (r=0.76, n=113) and could discriminate between groups with different 
severities of PN (Merkies et al. 2002b). Scores on the RHS were responsive (SRM= 0.8) to 
change in 20 patients recovering from GBS or undergoing treatment for CIDP (Merkies et al. 
2002b). The RHS has also been used to measure changes after an exercise intervention, 
reflecting significant improvements in 20 people after GBS or with CIDP after 12 weeks of 
aerobic training (Garssen et al. 2004), which suggests it is appropriate to detect changes in the 
study of exercise in Chapter Two.  
 Disadvantages 
Participation, by its nature, is influenced by the individual thus it is unlikely that any standard 
outcome tool will be able to capture all aspects comprehensively. Indeed, the SF-36 measures 
several areas which are unrelated to participation although it has been considered to indicate 
participation in PN by others (Ware and Sherbourne 1992; Ware and Sherborne 1992; White 
et al. 2007a). Items on the FLP and SF-36 clearly capture data regarding activity limitations 
and impairments, including continence and pain. Similarly, some items on the RHS measure 
independence in ADL (e.g. dressing) in addition to participation. However, their use may still 
be appropriate as other items do assess definite aspects of participation (e.g. hobbies and 
employment).  
Unlike the RHS, the FLP has considerable administrator and respondent burden (Lohr et al. 
1996). Several sections of the FLP are likely to be unaffected in people with PN beyond the 
acute illness in GBS (e.g. alertness) and are not appropriate for chronic inflammatory PN, 
increasing item redundancy. The FLP has not been evaluated in PN and so its validity, 
reliability and responsiveness in this group cannot be assumed. Although the SF-36 is quicker 
to complete than the FLP, it requires considerable time to calculate subscale and component 
summary scores, increasing administrator burden. There are also limitations of the PCS and 
MCS scores as changes on a single domain/subscale can be missed because physical 
components are negatively weighted on the mental summary scale and vice versa. This 
means that isolated improvement in physical or mental function alone could cause apparent 
worsening of the other summary score (Simon et al. 1998), reducing validity and 
responsiveness. It is also unclear if the assumptions required to generate the component 
scores (e.g. acceptable floor and ceiling effects) are satisfied in PN (Hobart et al. 2001). In 
light of this shortcoming, use of both summary and sub scale components of the SF-36 is 
recommended (Hobart et al. 2001; McHorney 1998). 
In conclusion, whilst some of the tools that were pre-selected for the study of exercise in 
Chapter Two have been evaluated and used in people with PN, many have not and, in 
particular, their ability to measure change after an exercise intervention has not been 
60 
 
established. Therefore, their performance was re-evaluated after their use in Chapter Two. 




Table 1-1 Tools selected for the exercise study (Chapter 2)  
Construct Selected tools 










Fixed dynamometry (knee extensors) 
 
 
Fatigue severity scale (FSS) 
 
Hospital anxiety and depression questionnaire (HADS),  
Beck Depression Inventory (BDI) 
 
Activity limitations:  
ADL 
 
Overall disability sum score (ODSS) 
EADL 
 
Health assessment questionnaire disability index 
(HAQDI) 




Ten metre walk test (preferred pace and fast as 
possible) 
 
Participation restrictions Rotterdam Handicap Scale,  
Functional Limitations Profile,  




1.17.  Chapter Conclusion 
This chapter outlined the clinical features and common problems experienced by people with 
inflammatory PN. These include muscle weakness, difficulty walking and completing daily 
activities, and persistent feelings of fatigue. There is limited evidence evaluating exercise in 
people with PN. Studies in other patient groups indicate that many of these problems could be 
helped by exercise but only if people with PN can exercise effectively and find an exercise 
programme practical. Therefore, the first aim of this thesis was to evaluate the practicality and 
possible effects of a community based exercise intervention for people after GBS and with 
CIDP. This study is presented in Chapter Two. 
Severe experienced fatigue reduces physical functioning and adds to activity limitations in 
people with PN. Some reports show that fatigue is reduced after exercise interventions but the 
mechanism by which regular exercise reduces fatigue is not known (Garssen et al. 2004; 
Garssen et al. 2005a; Pitetti et al. 1993). If the factors that contribute to experienced fatigue 
could be elucidated, targeted interventions, such as exercise, could be developed to reduce 
the severity and effects of experienced fatigue in people with PN. Therefore, the second aim of 
this thesis was to describe and investigate the nature of experienced and physiological fatigue 
in people with inflammatory PN. This investigation is presented in Chapters Five and Six. 
This thesis required a range of outcome tools to describe functioning and evaluate change. 
The outcome tools used in this thesis have been critically evaluated in this chapter. Some 
have previously had their properties established in people with PN, but the majority have not. 
After use in the exercise study (Chapter Two), three tools (ODSS, Physiological Cost Index 
and Walk-12) were refined and re-investigated in greater detail in order to determine their 
suitability for future studies of exercise in people with PN (Chapters Three and Four).  
A summary of the key conclusions and areas for future work are presented in Chapter Seven.
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Chapter 2. An investigation of exercise in 
inflammatory peripheral neuropathy 
2.1. Summary 
The aim of the study in this chapter was to investigate the practicality of a 12 week community 
based unsupervised exercise programme for the management of activity limitation and wider 
health in people several years after Guillain-Barré Syndrome (GBS) or with stable Chronic 
Inflammatory Demyelinating Polyradiculoneuropathy (CIDP).   
Sixteen people with GBS (n=10) or CIDP (n=6) and 10 healthy sedentary volunteers undertook 
a thrice weekly exercise programme comprising aerobic, strengthening and functional 
exercises for 12 weeks in their local community. Adherence and practicality of the programme 
were measured using exercise diaries and from participant report. All participants were 
assessed at baseline and after the intervention (12 weeks); PN participants were also 
assessed six months after completing the intervention. Changes in activity limitations from 
baseline were measured using the Overall Disability Sum Score (ODSS). Secondary outcomes 
of wider health status, participation and extended activities of living were measured using the 
Short-Form 36 questionnaire (SF-36), Functional Limitations Profile (FLP), Rotterdam 
Handicap Scale (RHS) and Health Assessment Disability Index (HAQDI) whilst experienced 
fatigue was measured using the Fatigue Severity Scale (FSS). 
Fourteen of 16 PN participants and 8 out of 10 healthy people completed the intervention. 
Reasons for not completing the programme were not related to exercise. Ten PN participants 
stated that they continued to exercise six months after the intervention. There were significant 
improvements in activity limitations after the intervention (mean change in ODSS scores: -1; 
95% Confidence Interval (CI): 0 to-1.5) and at six months (mean change: -1; 95% CI:-0.5 to -
1.5; p≤ 0.05). Wider health status and participation were significantly improved after the 
intervention in PN participants (mean change, 95% CI; SF-36 Physical Component Score 
(PCS): 5.8, 2.2 to 9.4; FLP: -4.9, -0.8 to -8.15; RHS: 1, 0 to -2.5 all at p≤ 0.05) but the HAQDI 
was not significantly different from baseline (-0.6, -0.07 to 0.32). The FSS demonstrated a 
significant improvement in fatigue (mean change: -0.6, 95% CI: -0.17 to -1.2) and the SF-36 
PCS remained significantly improved at six months. Healthy participants demonstrated 
significantly reduced fatigue (FSS mean change: -0.6, 95% CI: -0.2 to -1.2) after the 
intervention but no other outcomes were significantly different from baseline.  
The findings demonstrated that individually prescribed community based exercise was 
practical and well tolerated. Due to the absence of a non-exercising patient control group and 
rater blinding, the results must be interpreted with appropriate caution. Although the changes 
observed could not be confidently attributed to exercise, they suggest that the intervention 
reduced activity limitations for participants with inflammatory PN.  
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The study in this chapter has been published and is appended to this thesis:  
Graham, R.C., Hughes, R.A.C, White, C.M. A prospective study of physiotherapist prescribed 






Residual signs and symptoms of weakness, altered sensation, pain and fatigue contribute to 
persistent activity limitations, altered social status and reduced independence for between 20 
to 80% of people after GBS or with CIDP (Bernsen et al. 1997; Bersano et al. 2005; Forsberg 
et al. 2004; Gorson et al. 1997; Lennon et al. 1993; Merkies et al. 1999). Such chronic 
disablement can result in a sedentary lifestyle, leading to increased health risks such as 
obesity, cardiovascular disease and poor mental health (McDonald 2002; Santiago and Coyle 
2004).  
Narrative and systematic reviews of the current evidence in other neurological conditions have 
concluded that regular exercise reduces activity limitations, maximises functioning and 
promotes independence, as discussed in Section 1.9.2 in Chapter One (McDonald 2002; 
Smidt et al. 2005; Teixeira-Salmela et al. 1999; White et al. 2004). A panel of invited exercise 
experts and the American Heart Association also state that exercise improves general health, 
well-being and reduces the health risks associated with inactivity (Kesaniemi et al. 2001). 
These benefits might also occur in people with activity limitations due to inflammatory PN if 
they can exercise safely and effectively.  
However, potential barriers to exercising for people with PN include the sequelae of GBS or 
CIDP, such as fatigue, pain, altered proprioception and sensation, muscle weakness and the 
risk of injury (described in Section 1.5 of Chapter One). Some people with persistent activity 
limitations do not exercise regularly as they find it difficult and cannot access appropriate 
support (Rimmer et al. 2004; Rimmer 2005b). These factors may deter people with PN from 
either commencing or continuing with an exercise programme despite the likely health 
benefits. Although some of these factors have been addressed by supervised exercise 
programmes at centralised locations, exercise based in the community is more acceptable as 
participants are free to choose the location and time that they exercise, promoting adherence 
(Ashworth et al. 2005). Difficulties accessing transport experienced by some people with 
inflammatory PN would also make attendance at a centre based programmes difficult and so 
reduce participation (Merkies et al. 2002b).  
White et al. (2004a) found three controlled studies investigating exercise in people with PN 
that conformed to the majority of the inclusion criteria for their systematic review (Lindeman et 
al. 1995; Richardson et al. 2001; Ruhland 1997). They found evidence of low to moderate 
quality to support the effectiveness of progressive resistance training to increase strength in 
trained muscles (Lindeman et al. 1995; Ruhland 1997; White et al. 2007a) but there was 
insufficient evidence to judge the effect of aerobic training or to evaluate the effect of exercise 
on activity limitations. All studies in the review were at high risk of bias due to inadequate or 
unclear randomisation and allocation concealment, and lack of rater or participant blinding. 
Although White et al. (2007a) stated in their review “...exercise programmes aimed at 
strengthening muscles are feasible in people with peripheral neuropathy..." (p9), this statement 
was based upon evidence from a small number of people with different types of PN and did 
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not consider the possible complications of undertaking aerobic, or a combination of aerobic 
and strengthening training, nor if exercise was supervised or not. Two uncontrolled studies in 
PN, not included in the review, reported that exercise improved fatigue and cardiovascular 
fitness, but these results could not be directly attributed to exercise due to limitations in their 
design (Garssen et al. 2004; Pitetti et al. 1993). 
The deficits in the current evidence base indicate that high quality randomised controlled trials 
are needed to demonstrate the effect of exercise in PN (White et al. 2007a). However, it is not 
known how many participants would be needed to provide sufficient statistical power and the 
low prevalence of GBS and stable CIDP makes recruitment of enough local prospective 
participants unlikely. Whilst other designs, such as a delayed intervention or cross over trial 
may overcome some of the complications of recruitment, the nature of the design would 
prevent long term measurements of effects attributable to the intervention (Sim and Wright 
2000). These limitations indicate that a multi-centred, potentially international, trial would be 
required to recruit sufficient participants. This is outside the scope of this thesis. However, the 
ability of people with PN to exercise safely and effectively without supervision has not been 
established and data are needed to inform the design of a future trial. Therefore, the study in 
this chapter investigated the practicality (defined as the ability to achieve independent exercise 
in the community) and potential benefits of an unsupervised community based programme for 
people with inflammatory PN. These data were also used to ascertain the suitability of 
outcome tools for other studies in this thesis and will provide data to inform a future controlled 
trial.   
2.3. Aims and Objective 
The objective of the investigation was to evaluate the practicality and possible effects of a 
community based exercise intervention for people after GBS or with CIDP. 
The specific aims were:  
1. to establish the practicality of a 12 week, community based exercise programme for people 
with stable motor PN, either at least 12 months after GBS or with CIDP that has been stable 
for more than six months,  
2. to describe and evaluate any changes in activity limitation, participation and functioning of 





A prospective, longitudinal quasi-experimental design was utilised to achieve the aims of this 
investigation (Sim and Wright 2000). Participants with inflammatory PN were recruited in 
response to advertisements on the Guillain-Barré Syndrome support group website 
(www.gbs.org.uk) and magazine (‘Reaching Out’), and from the outpatient Peripheral Nerve 
clinic at Guy’s Hospital, London. Volunteers were eligible for inclusion if they were at least 12 
months after the nadir of GBS, or had stable CIDP with no self reported change in symptoms 
or medication in the previous six months. A steering committee (Appendix One) initially 
developed the design of the trial, selected outcome tools and exercise frequency. The Guillain-
Barré Syndrome support group (GBSSG) provided funding for equipment and participant travel 
expenses. 
A non-matched control group of healthy, sedentary participants from staff and students of 
King’s College London was recruited by email advertisement. These participants had no health 
problems but had not taken part in regular exercise for at least six months. They were included 
to provide normative values for comparison to PN participants, and to establish that the 
prescribed intensity and type of exercise was practical and effective in a healthy population. 
History taking, clinical examination and a resting electrocardiogram were performed to ensure 
that all participants conformed to the inclusion criteria in Table 2-1, and had no complications 
(including autonomic dysfunction in people with PN) that could affect their safety when 
undergoing an exercise test or exercising in the community (Fletcher et al. 2001).  
Medical screening by a neurologist confirmed diagnoses based upon published criteria 
(Asbury and Cornblath 1990; Hughes et al. 2001; Joint task force of the EFNS and the PNS 
2005; Nicolas et al. 2002). 
Participants were assessed by a chartered and HPC registered physiotherapist (the author) to 
identify impairments, functioning and any risks of musculoskeletal injury when exercising. 
Participants with PN were provided with orthotics, if indicated, to ensure safe exercise. 
Practical concerns including the ease of exercise in a home or gym environment were 
discussed, and appropriate equipment was obtained to facilitate effective and safe exercise if 
necessary.  
All participants gave written informed consent and ethical approval was granted from Guy’s 
Hospital and King’s College London research ethics committees in accordance with the 1964 
Declaration of Helsinki. 
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Table 2-1 Inclusion and exclusion criteria  
Inclusion criteria Exclusion criteria 
Aged over 18 years Any cardiovascular, orthopaedic or other 
neurological condition which may affect the 
safety of exercise and outcome 
Willing to exercise thrice weekly for 
approximately one hour per session for three 
months 
Pregnant women or those who think they 
might be or plan to become pregnant 
Good command of the written and spoken 
English language. 
Current regular immunoglobulin or plasma 
exchange treatment 
*A confirmed diagnosis of stable motor 
peripheral neuropathy including GBS at least 
one year after nadir and stable CIDP (defined 
as no change in self reported disability, 
symptoms or medication for the previous 6 
months). 
 
* these criteria were not applicable for healthy participants. 
 
2.4.1. Sample size 
Data were not available to calculate the sample size needed for this study. However, the 
sample size was informed by a previous study of a combined exercise intervention undertaken 
in a similar patient group which included 14 PN participants, suggesting that this number would 
be the minimum needed for the current study (Ruhland 1997). The size of the sample was also 
influenced by the availability of suitable participants who could travel to London for testing 
during the study period.  
2.4.2. Measurement 
A wide range of outcome tools were used to measure different aspects of functioning in this 
patient group. This attempted to ensure all pertinent changes which might be elicited by the 
intervention were adequately reflected. These tools have been described in Chapter One. 
All participants attended for two baseline measures of outcome, approximately one month 
apart, before beginning the exercise programme. This was to allow familiarisation with testing 
procedures and to provide data to establish pre-intervention stability. All participants were 
asked to continue their usual activities between baseline assessments.  
All measures were repeated at halfway (18 sessions, six weeks) and on completion of the 
programme (36 sessions, 12 weeks) in both groups. People with PN were also re-tested six 
months after completing the programme.  
With the exception of activity limitations, participation restrictions and disease specific outcome 
tools, healthy participants completed the same assessment and exercise programme as PN 
participants.  
All measurements took place in a quiet and comfortable room. Participants were instructed not 
to eat for two hours before the assessment and to wear loose clothing and appropriate 
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footwear, ideally trainers. All questionnaires were administered in a random order before 
completing any physical measurements in attempt to standardise arousal. The order of 
physical tests was kept the same on each testing occasion, with the exercise test being 
conducted last to minimise the effect of fatigue. All data were collected by a single unblinded 
rater (the author). 
Baseline measurements and findings from the subjective and objective physiotherapy 
assessment were used to inform the design of the exercise programme, which was tailored to 
each participant’s ability and personal goals. All participants completed aerobic and strength 
training with individual functional exercises (described on page 74). The programmes of the 
healthy participants were designed to be similar to PN participants. 
2.4.3. Assessment of practicality and acceptability of the programme 
The practicality and acceptability of the exercise programme were assessed by counting the 
number of responses to recruitment adverts, by monitoring participant report and exercise 
adherence from exercise diaries.  
The participant and investigator maintained regular telephone contact throughout the duration 
of the programme, to investigate and address any practical issues. Participants were asked if 
they had encountered any difficulties with the exercise programme, or had experienced any 
unwanted or unpleasant side effects during telephone conversations and reassessment visits. 
Participants were not directly questioned about the presence or absence of specific, named 
problems to avoid biasing their report (Ruhland 1997), but they were instructed to report any 
concerns to the investigator. These were noted and appropriate advice and adaptations made.  
Participants were asked to record information after every exercise session in an exercise diary 
to monitor exercise adherence. Heart rate monitors which recorded the time, date, heart rate 
and duration of exercise were provided to all participants to judge adherence to the aerobic 
exercise component of the programme (as described in Section 2.4.6). These data were 
downloaded by the investigator during and on completion of the intervention.  
Semi structured, informal interviews were used by the investigator to ascertain the views of the 
participants about each component of the programme and their overall appraisal of the 
intervention on completion of the programme. These were also repeated at six months in PN 
participants. Participants were asked open ended questions about how practical they found 
each aspect of the exercise programme and any differences they had noticed since exercising. 
They were asked one closed question about how they felt relative to baseline (better, worse or 
the same). At six months, questions regarding the effectiveness of the programme were 
replaced with open questions regarding continued exercise. An extra question regarding 
changes in health since completion of the programme was also included. 
2.4.4. Primary outcome tool 
The primary outcome was alteration in activity limitations which was measured using the total 
score on the disease specific overall disability sum score (ODSS) questionnaire (Merkies et al. 
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2002a) (Page 51). Upper and lower limb scores were considered separately in addition to 
evaluation of the total scores. 
2.4.5. Secondary outcomes 
Secondary outcomes aimed to measure a range of parameters including participation, mental 
health, fatigue and extended activities of daily living (EADLs). Other measures were also used 
to assess walking ability, knee extensor strength, cardiovascular fitness and general activity 
levels. 
 Extended Activities of Daily Living 
Extended ADLs were measured using the Health Assessment Questionnaire Disability Index 
(HAQDI, Page 53) (Bruce and Fries 2003). This questionnaire has eight categories which 
measure the respondent’s perception of difficulty and assistance needed to complete a range 
of ADL and EADLs.  
 Participation  
Changes in scores on the SF-36 questionnaire subscales and physical and mental component 
summary scores, Rotterdam handicap scale (RHS) and functional limitations profile (FLP) 
were used to evaluate alterations in participation and wider health status (Hutchinson and 
Hutchinson 1995; Merkies et al. 2002b; Merkies et al. 2002c; Ware and Sherbourne 1992). As 
noted in Chapter One (Page 56), these tools also measure other aspects of functioning in 
addition to participation, which was considered when interpreting the results.  
 Experienced fatigue and mood 
Fatigue was measured on the fatigue severity scale questionnaire (FSS, Page 46) (Krupp et 
al. 1989; Merkies et al. 1999). The Hospital Anxiety and Depression scale (HADS, Page 49) 
was used to measure anxiety and depression, and the severity of depression was measured 
with the Beck depression inventory (BDI, Page 49) (Beck et al. 1996; Zigmond and Snaith 
1983).  
 Walking 
The walking speed of all participants was assessed by measuring the time taken to walk ten 
metres, both at a preferred pace and as fast as safely possible (Salbach et al. 2001; van Loo 
et al. 2003) as discussed on Page 55. 
The physiological demand or energy cost of comfortable walking was measured using the 
physiological cost index (PCI) (MacGregor 1979; MacGregor 1981) and modified PCI (mPCI). 
The properties of the PCI and mPCI were investigated in Chapter Four (Page 143).  
Participants were fitted with heart rate monitors (Polar, Finland) and rested in sitting until their 
heart rate had reached steady state (Corry et al. 1996; Ijzerman and Nene 2002). Steady state 
heart rate was attained when readings of heart rate taken one minute apart were within five 
beats of each other (Bailey and Ratcliffe 1995). Participants then walked at their comfortable 
pace around a 20 metre figure of ‘8’ track. Heart rate was recorded at the end of each minute. 
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Participants continued walking for at least four minutes and until heart rate had reached steady 
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PCI=physiological cost index, mPCI= modified physiological cost index, HR= heart rate 
 
 Strength 
Peak isometric linear knee extension force (Newtons) was measured in both legs using fixed 
dynamometry (discussed on Page 45). Both legs were tested in a random order on each 
occasion. These data were re-measured on completion of the programme and at six months 
(in PN participants). 
The testing position and a more detailed method are presented in Appendix Two. In brief, 
participants were positioned in sitting with the knee flexed to 90
o 
 and a padded cuff connected 
to a strain gauge was positioned above the medial and lateral malleoli. Participants were 
instructed to straighten their knee maximally and given vigorous, standardised verbal 
encouragement throughout (McNair et al. 1996; van der Ploeg and Oosterhuis 1991). If force 
production continued to increase on the third contraction, more measurements were taken until 
force did not increase further to ensure adequate familiarisation.  
To inform the design of each individual’s exercise programme, isometric muscle strength was 
measured using a hand held dynamometer and graded using the MRC score in the following 
pairs of muscles: shoulder abductors, elbow flexors, wrist extensors, hip flexors and ankle 
dorsiflexors using hand held dynamometry (Andrews et al. 1996; Medical Research Council 
1976). Hand grip was measured using a hydraulic hand grip dynamometer (Jamar, LaFayetter, 
Indiana, USA). If participants were unable to securely hold the Jamar dynamometer, an 
inflatable pressure device was substituted (KCI Mediscus, UK). These data were only used in 
addition to physiotherapy assessment findings to identify muscles suitable for training and so 
are not presented here. 
 
 Exercise testing 
Healthy and PN participants completed a symptom-limited graded exercise test on an upright 
bicycle ergometer (Monark 818E, Monark, Sweden) at each measurement session, to 
establish peak exercising heart rate. This was used to calculate the exercise intensity for the 
aerobic component of the exercise programme. Peak and total workload (Watts) produced 
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during the exercise test were also recorded to assess the effectiveness of the aerobic training 
component of the intervention.  
Cycle based exercise testing was used in preference to other forms of exercise, such as 
treadmill or arm ergometry, to standardise testing and because it was suitable for all 
participants as it minimised difficulties with balance or hand grip (American College of Sports 
Medicine 1995). 
Before starting the test, participants rested for ten minutes. Measurements of heart rate using 
a heart rate monitor (Polar, Finland) and blood pressure were recorded using an electronic 
sphygmomanometer (Omron, HEM-757) (American College of Sports Medicine 1995).  
After resting, participants were seated comfortably on the exercise bike and the seat and 
pedals were adjusted to allow 5 to 10
o
 of knee flexion when the foot was at the lowest point 
and to ensure that the foot remained in contact with the pedal. The foot was secured onto the 
pedal using a toe strap and extra Velcro straps if necessary.  
All participants were instructed to maintain a loose grip on the handle bars and completed 
three minutes of cycling against no resistance prior to beginning the test (American College of 
Sports Medicine 1995). Participants cycled at a constant rate of 60 revolutions per minute 
throughout the warm up and test. This was shown on a digital display mounted on the 
handlebars. On completion of the warm up, the workload was increased by 30 Watts every 
minute (Mullis et al. 1999). This protocol was selected as it allowed gradual increases in 
workload but did not require participants to exercise for long periods, which is recommended to 
reduce the risk of adverse events in deconditioned individuals (Pollock et al. 1998). 
Participants were encouraged to cycle for as long as they could. Blood pressure was 
measured every two minutes and heart rate was monitored continuously.  
The primary indication to end the exercise test was the participant’s desire to stop or the speed 
of cycling decreasing below 60 revolutions per minute for more than five seconds (judged by 
the investigator). Other indications to end the test included:  
 a drop in systolic blood pressure >10 mmHg despite an increase in workload, or 
values of systolic blood pressure > 220 mmHg and diastolic pressure >115 mmHg 
 pain 
 increasing nervous system symptoms (e.g. near-syncope, dizziness), 
 signs of poor central or peripheral perfusion (e.g. pallor)  (Gibbons et al. 2002)  
On completion of the test, participants continued cycling for three minutes to cool down, at a 
self-selected speed against no resistance (American College of Sports Medicine 1995). Heart 
rate and blood pressure was monitored after the exercise test for five minutes or until they 
returned to near pre-test values.  
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The highest level of resistance at which participants were able to complete an entire minute 
was defined as the peak workload (Watts). Additionally, the total workload (Watts) was 
calculated by summing the work done at each level of resistance.  
2.4.6. Design of the exercise programme 
The design of the exercise programme was informed by recommendations and literature for 
healthy people and those with other neurological conditions. Whilst every participant’s exercise 
programme followed a similar structure, each was individually tailored to address each 
participant’s main functional impairments and activity limitations. This was informed by 
assessment and physiotherapy examination. All participants exercised in an unsupervised 
community setting, either at home or at their local gym. Each exercise session was designed 
to take approximately one hour to complete. This duration appears common in exercise 
programmes and is considered practical for most individuals to undertake regularly (American 
College of Sports Medicine 1995). 
As the programme was unsupervised, participants could choose the time and day that they 
exercised, but were advised to leave at least 24 hours between each session. They were 
instructed to avoid alcohol and large meals before exercising, to drink water throughout the 
exercise session and to postpone exercising if they were unwell (American College of Sports 
Medicine 1995). Participants were also instructed to cease exercise if they had any pain or 
practical concerns and to contact the investigator with any queries or problems.  
At each session, participants wore a heart rate monitor to guide the intensity of warm up, 
aerobic training and warm down. The heart rate monitor also recorded and stored details of the 
time, date, duration of exercise and heart rate during each exercise session. Additionally, they 
also used the 6-20 Borg scale of perceived exertion to guide effort (American College of Sports 
Medicine 1995; Borg 1982). 
 Training frequency and duration 
Participants were asked to complete three exercise sessions every week for 12 weeks (36 
sessions). Training at this frequency has been shown to produce significant increases in 
strength and aerobic fitness in healthy adults (Haskell et al. 2007; McLester et al. 2000). This 
duration was chosen to ensure there was adequate time to demonstrate changes in strength, 
fitness and activity limitations even if some initial sessions had to be completed at a lower 
intensity as reported by others (Ruhland 1997). This duration and frequency also appeared 
feasible for participants to complete in a study of exercise in 20 people with PN (Garssen et al. 
2004) and are recommended for the novice exerciser (American College of Sports Medicine 
1995; Haskell et al. 2007). 
If any exercise sessions were missed, participants were encouraged to try to incorporate extra 
sessions within the 12 week period but additional sessions were added at the end of the 
programme if necessary.  
 Warm up 
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A ten minute warm up, working below 60% of peak heart rate, determined from the exercise 
test or working at an intensity of “very light (9)” to “fairly light (11)” on the Borg scale, was 
performed at the start of exercise session (Borg 1982). A warm up of this nature is 
recommended to reduce the risk of injury (American College of Sports Medicine 1995; Fradkin 
et al. 2006). 
The type of exercise modality (e.g. walking, cycling) for the warm up and aerobic training was 
chosen by the participant and physiotherapist (the investigator) after consideration of practical 
issues. 
Participants progressed directly from the warm up to the aerobic exercise component of the 
programme. 
 Aerobic training 
Each participant exercised for 20 minutes at an intensity of 60-85% of peak heart rate which is 
recommended to improve cardiovascular fitness (American College of Sports Medicine 1995; 
Haskell et al. 2007). Upper and lower limits of heart rate during the aerobic exercise were pre-
programmed into heart rate monitors, which also stored heart rate and duration of exercise. 
Participants used the monitors to guide the intensity of exercise and were advised how to 
increase or decrease heart rate to remain within their training zone. Participants could also use 
the Borg scale to guide exertion, working between 12 and 16, which is reported to be 
approximately equivalent to 60-89% of maximum heart rate for healthy individuals, although 
this has not been established in PN (American College of Sports Medicine 1995; Fletcher et al. 
2001).  
If participants were initially unable to exercise continuously for 20 minutes, the duration of 
exercise was increased incrementally over several exercise sessions. 
 Strengthening Exercise 
After completing the aerobic component of the programme, participants performed several 
isometric strengthening exercises.  
Resisted maximal isometric contractions were used as a static contraction was easy for 
participants to replicate safely without supervision, limited the risk of injury and indicated the 
largest strength gains as participants were tested isometrically (Aitkens et al. 1993; Khouw and 
Herbert 1998; McGlynn 1972). Participants held each contraction for ten seconds which is 
reported to be a sufficient duration to strengthen muscles, if frequency and intensity are 
adequate (Agre et al. 1997; Bandy and Hanten 1993; Khouw and Herbert 1998; Kubo et al. 
2001; Weir et al. 1995). They were instructed to breathe regularly throughout to limit rises in 
blood pressure (O'Connor et al. 1989). 
Strength exercises were targeted at weaker muscles identified by dynamometry and 
physiotherapy assessment. For participants exercising at home these were performed against 
resistive bands (Theraband®, USA). If participants were exercising at their local gym, weight 
machines were set to provide sufficient resistance to allow isometric muscle work. Muscles 
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that were below MRC muscle score grade two (Medical Research Council 1976) were not 
targeted for specific strengthening exercises. Severely weak muscles have not shown 
increases in strength after specific training in neuromuscular disease (Lindeman et al. 1995; 
Milner-Brown and Miller 1988) and, as exercise was unsupervised and used limited 
equipment, it was not possible to directly exercise these muscles in a way that could be 
effective.  
 Number of repetitions and sets 
Participants gradually increased the number of repetitions and sets they performed under the 
instruction of the physiotherapist, as they progressed through the initial exercise sessions, 
building to a maximum of three sets of ten repetitions (Galvao and Taaffe 2004; Wolfe et al. 
2004). Eight to 12 repetitions are recommended for the novice exerciser to increase both 
muscular strength and endurance (American College of Sports Medicine 1995). This number 
of repetitions, appears practical and has been shown to increase strength (Braith et al. 1989; 
Starkey et al. 1996; Szeto et al. 1989; Weir et al. 1995). The added benefit of three compared 
to one set of repetitions remains controversial (Galvao and Taaffe 2004) but as contractions 
were isometric and did not require an increase in load, increasing the number of sets 
performed provided some feedback on progress to participants.  
 Other exercises 
Several functional exercises were also included for each participant, informed by the findings 
from their physiotherapy assessment. The types of functional exercise used included balance 
training, moving from sitting to standing from progressively lower surfaces, dynamic bilateral 
squats, bridging (lifting the pelvis whilst lying supine with legs bent) or postural exercises. 
These were included as targeted exercises have significantly improved balance in people with 
PN and significantly improved activities and performance in stroke survivors and the elderly 
(American College of Sports Medicine 1995; de Vreede et al. 2005; Eng et al. 2003; 
Richardson et al. 2001).   
 Stretches and cool down 
Each session of exercise was ended by a five minute cool down which consisted of walking or 
gentle cycling. An adequate cool down is reported to decrease muscle soreness and return 
heart rate to normal ranges, reducing the risk of cardiac complications (American College of 
Sports Medicine 1995; Fletcher et al. 2001; Reisman et al. 2005; Roberts and Wilson 1999). 
Participants were guided to work at an intensity of “very light” to “fairly light” on the 6 to 20 
Borg scale (Borg 1982). Stretches for the major muscle groups utilised in the programme 
(quadriceps femoris, hamstrings and gastrocnemius muscles) were completed to reduce the 
risk of soft tissue injuries. Stretches were held at the point of mild discomfort for a count of 15 
seconds and were repeated three times (American College of Sports Medicine 1995; Roberts 





 Normality of data 
Raw questionnaire data were assumed to be non-parametric, due to the non-linear nature of 
the scales. Transformed questionnaire and all other data were examined for normality using 
Kolomogorov Smirnov tests and examining frequency histograms. Parametric and non-
parametric statistics were then used. 
 Baseline measurement 
Differences between the two baseline measurements, assessed a month apart, in PN and 
healthy groups were examined using paired t or Wilcoxon tests. If significant within group 
differences were found, a 95% range was calculated to provide an indication of the variability 
of repeated measurements at baseline and to indicate the range that should be exceeded for a 
change in scores to indicate a genuine change in functioning (Altman 1991). It was calculated 
using:  
 y1 y295% range for change 1.96 SD     
Where: SD= standard deviation, y1=score at baseline one, y2=score at baseline two. 
 
 Differences between groups 
Differences between healthy and PN groups were examined at baseline using two tailed 
independent t and Mann Whitney tests.  
 Practicality and acceptability 
Practicality : The report of successful completion of exercise sessions by participants was 
used to judge the practicality of the programme. Any difficulties with equipment, exercises or 
with components of the programme were noted. Answers to the semi structured interview 
questions at the end of the programme and at six months were recorded with participant 
comments about how easy or difficult they found the exercises.  
Acceptability: This was ascertained by participant report throughout the programme and on the 
semi structured interview in which participants were asked to comment on the frequency, 
intensity and duration of the programme. 
 Adherence 
Exercise adherence was measured by counting completed exercise sessions detailed in 
participants’ diaries. The time to complete 36 sessions was also noted. 
Heart rate records stored on the heart rate monitor were used to judge adherence to the 
aerobic component of the programme. They were downloaded at half way and at the end of 
the programme to analyse the number of sessions completed and the time spent working 
within the heart rate training zones during the aerobic training component. 
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 Changes after the intervention 
Differences in measurements between baseline and completion of the exercise programme, 
and between baseline and six month follow up, were examined using one way repeated 
measures ANOVA or Friedman’s (non-parametric repeated measures) tests. Significant 
differences on repeated measures tests were further examined to determine the time at which 
differences occurred (between baseline and end of the programme, and baseline and six 
months) using two tailed paired t or Wilcoxon tests. No adjustments were made for multiple 
comparisons (Campbell et al. 2000; Perenger 1998).  
Confidence limits (95%) of the average (mean or median) change were calculated for all 
measures.  
Retrospective statistical power was calculated for a parametric outcome tool (the SF-36 
questionnaire physical component summary score) after exercise and at six months (Huck 
2004a). 
 Properties of outcome tools 
Floor and ceiling effects, defined as the percentage of the participants who achieve the worst 
and best possible scores respectively, were judged from baseline measurements in PN 
participants. These are recommended to be below 15% (McHorney and Tarlov 1995). 
As some data were not parametric and did not conform to a normal distribution, 
responsiveness was calculated using distribution free method of calculation (Hamilton 1991). 
This allowed comparison between all outcome tools analysed. It is calculated from:  
median change in scores
Responsiveness
Interquartile range of change

 
A higher score indicates greater responsiveness to change.  
Resonsiveness was examined for changes from baseline to 12 weeks and baseline to six 
months. The mean of the responsiveness after the intervention and at six months  was used to 
examine the overall responsiveness of each tool. 
All data were analysed using SPSS© software (SPSS Inc. version 11.5.1.). Significance for all 
tests was set at p<0.05 (two tailed).  
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2.5. Results  
2.5.1. Participants 
Forty one people responded to the adverts in the GBSSG website, ‘Reaching Out’ magazine 
and the neuromuscular clinic at Guy’s Hospital.  
Sixteen people were eligible for inclusion. Reasons for non-inclusion are listed in Table 2-2. 
Table 2-2 Reasons for non inclusion 
Reason for non-inclusion Number of people 
Lived too far away  13 (3 non-UK 
residents) 
Did not have diagnosis of 





Instability of CIDP 6 
 
Two participants in each group did not complete the programme. One PN participant changed 
medication just after starting exercise and was excluded. The second had to leave the UK for 
several months. One healthy participant left the study after halfway for personal reasons 
unconnected to exercise. The second was excluded after missing several exercise sessions 
after sustaining a minor ankle sprain unrelated to exercise. Data were analysed from 
remaining participants in each group (n=14 and n=8).  
Full six month follow-up data were available for 13 PN participants as one person was unable 
to attend for physical tests after moving away. All questionnaire and interview data were 
completed via post and over the telephone for this participant. No six month follow up was 
performed in the healthy group. 
Two PN participants were provided with flexible bilateral ankle foot orthoses (Bioskin Trilok, 
Cropper Medical Incorporated, USA) after initial assessment. Participant characteristics are 
displayed in Table 2-3.   
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Table 2-3 Characteristics of participants who completed the exercise programme 
 Peripheral neuropathy group 
(n=14, 4 females) 
Healthy group  
(n=8, 3 females) 
p 





Weight (Kg)  79.7 ±15.5 72.4 ±12.7 ns 
Height (metres)  168.4 ±7.6 171.9 ±10.3 ns 
Body Mass Index (kg m
-2
) 28 ±4.5 24.3 ±1.9  0.02 
Diagnosis GBS: 10, CIDP:4  
Time since diagnosis 
(years, range) 
5.9 (0.67-17.6)  
All values are mean ± SD unless otherwise stated. From GBS participants, 9 had AIDP, and 1 
had Acute Motor and Sensory Axonal Neuropathy (AMSAN). All CIDP participants had typical 
CIDP. 
 
2.5.2. Practicality, acceptability and adherence 
In the PN group, four participants exercised at their local gym and ten exercised at home. The 
aerobic and strengthening components of individual PN participants programmes are shown in 
Table 2-4 . One participant was unable to use the upright exercise bike for testing so used a 
modified recumbent cycle (Viva 2, Medimotion, UK) for exercise testing and for training at 
home. Seven healthy participants exercised using local gym facilities whilst one exercised at 
home. All healthy participants performed a range of strengthening exercises which were 
identical to those used in the PN group. Four healthy participants trained aerobically by 
walking or running, three cycled and one rowed.  
No participants left the study for reasons associated with the exercise intervention. 
Based on self report diaries, people with PN completed a mean ±SD of 37 ±3 sessions over 
3.67 ± 1.4 months. Healthy people reported completing 36 sessions ±1 during 3.5 ± 0.2 
months.  
The majority of participants did not manage to record heart rate data for all sessions 
successfully so these data could not be used to judge adherence. Session recordings were 
also sometimes affected by interference from heart rate monitors used by other exercisers and 
electrical equipment in several participants who exercised in the gym. Therefore, adherence 
was based upon self report alone. All participants reported they were able to complete 20 
minutes of aerobic training and three sets of ten repetitions of strengthening exercises by four 
weeks after commencement of exercise.  
One PN participant chose to perform the aerobic and strengthening components on different 
days because of time restrictions. All other participants completed the entire programme on the 
same day, reporting it to take about one hour.  
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Table 2-4 Training methods for PN participants 
Participant 
number 
Aerobic exercise Strengthening exercises 
1 Cycling Knee extensors & flexors, ankle dorsiflexors 
2 Cycling Knee extensors & flexors, ankle dorsiflexors 
3 Cycling Knee extensors & flexors 
4 Walking Knee extensors & flexors, shoulder abductors 
5 Cycling Knee extensors & flexors 
6 Walking, stair climbing Knee extensors & flexors, elbow flexors, ankle 
dorsiflexors 
7 Walking Knee extensors & flexors, hand grip 
8 Walking Knee extensors & flexors, ankle dorsiflexors 
9 Cycling Knee extensors & flexors, ankle dorsiflexors, 
elbow flexors 
10 Walking Knee extensors & flexors, ankle dorsiflexors 
11 Cycling* Knee extensors & flexors 
12 Cycling, exercise in water Knee extensors & flexors, elbow flexors 
13 Walking Knee extensors & flexors, elbow flexors 
14 Rowing Knee extensors & flexors, ankle dorsiflexors 
* denotes use of recumbent exercise bike for testing and training 
 
 Participant report  
After being shown their exercises, provision of equipment and an exercise booklet, all 
participants reported completing their programme with no practical difficulties. Seven PN 
participants and four healthy people reported minor muscle ache and stiffness after exercise. 
Symptoms disappeared within 48 hours and participants reported that symptoms were only 
apparent in the first half (18 sessions) of the programme. These participants also reported that 
these symptoms did not prevent normal functioning and exercise. No other symptoms or 
injuries were reported to the investigator during or after the intervention. 
On completion of the intervention, all reported that the programme was realistic and practical 
to complete. From contact with the investigator during the programme, there were no reported 
differences in practical difficulties or unwanted effects of exercise encountered by GBS or 
CIDP participants. Contact between the physiotherapist (the investigator) and participants 
occurred approximately once weekly, and became much less once participants became 
familiar with the programme. 
Several of the ten PN participants who exercised at home reported that this added flexibility to 
the programme, improving their adherence to exercise. Conversely, the four PN and seven 
healthy participants who chose to use local gym facilities said that this allowed time to exercise 
without distraction and increased their ability to exercise regularly. These PN participants 
reported that the gym equipment was straightforward to use after initial induction by gym staff 
and the author. Some participants reported that dynamic contractions for strengthening, rather 
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than isometric exercises, would allow them to judge their improvement and provide motivation. 
This indicates that the use of isometric contractions may have decreased their adherence to 
the strengthening component of the programme, although this was not reported. 
On completion of the exercise programme, all participants stated that they felt “better”, when 
asked to rate their health to pre exercise levels; common improvements stated included 
increased energy and better mood.  
At six month follow up, 11 PN participants reported feeling better than prior to starting the 
exercise programme and three felt they were the same. No-one felt worse than prior to starting 
the exercise programme. Six participants reported feeling better than when they had 
completed the programme, four felt unchanged and four felt worse.  
Ten PN participants reported continuing regular exercise at six months, from the four that did 
not, three felt worse than they did at completion of the programme. Reasons given for not 
continuing exercise were related to lack of time. Of those that continued exercising, all felt 
better than prior to starting the programme, six felt better than at the end of the programme, 
one felt worse and three reported they were unchanged. 
2.5.3. Differences between baseline measurements 
 Peripheral neuropathy group 
There were no significant differences between baseline measurements taken four weeks apart 
(data not presented) within the PN group except for a significant improvement in the scores 
from the role limitation physical (RLP) subscale of the SF-36 questionnaire (median change= 
+12.5 points, range= 0-100). The 95% range for change indicated that scores would have to 
change by more than 69 points to demonstrate an alteration beyond that attributable to 
variation between baselines. 
 Healthy group 
Healthy participants demonstrated a significant decrease in scores on the FSS at the second 
baseline, indicating less fatigue (mean decrease= 0.64 ±0.32). Calculation of the 95% range 
for change indicated that a change in the FSS scores should exceed 0.62 to indicate an 
alteration in experienced fatigue beyond baseline variation in this group. The time taken to 
walk 10 metres at a preferred pace also decreased significantly at the second baseline (7.0 
±1.1 seconds to 6.7 ±0.9 seconds, 95% range for change= 0.8 seconds) which could indicate 
increased familiarisation with the test.  
 Differences between PN and healthy groups at baseline  
The second baseline measurement values were chosen for subsequent within and between 
group comparisons. This was to minimise any learning effects as, despite familiarisation with 




There were several significant differences between healthy and PN groups at baseline. 
Participants with PN had a significantly greater body mass index (BMI) than healthy volunteers 
(participant characteristics are shown in Table 2-3). Ten had a BMI greater than 25, indicating 
they were overweight, and four of these had a BMI over 30, signifying obesity (McArdle et al. 
1996). There were no other significant differences in anthropometric variables between healthy 
and PN participants.  
Participants with PN had significantly higher levels of fatigue measured on the FSS and also 
demonstrated significantly lower energy, physical function and more pain on the SF-36 
questionnaire in comparison to healthy participants (shown on Page 86, Table 2-6).  
Participants with PN also walked more slowly on both preferred pace and fast 10 metre walk 
tests (Table 2-7, Page 88). Healthy participants reached a higher peak heart rate on the 
exercise test, although differences in workload did not reach significance between the groups 
(Table 2-7).  
2.5.4. Changes after exercise 
 Activity limitation  
Activity limitation, the primary outcome evaluated in this study, was significantly improved 
directly after exercise in the PN group, when measured on the ODSS (Figure 2-1 and Table 
2-5). Improvements in both upper and lower limb scores were evident, as shown in Table 2-5. 
 
Figure 2-1 ODSS scores in PN participants at baseline, after exercise and at six months 
















   *                        *
 
Each symbol represents one person (n=14). Dotted line indicates median score. * denotes significant 




 Extended ADL, participation and wider health status  
In PN participants, scores on the RHS, SF-36 and FLP were significantly improved after the 
intervention. Changes on the RHS and FLP are summarised in Table 2-5, alterations on the 
SF-36 are shown in Table 2-6.  
Whilst the physical subscale score on the FLP was not significantly different from baseline, 
improvements in the psychosocial and total scores reached significance. Total FLP scores 
remained significantly improved at six months, but RHS scores were not significantly different 
from baseline at six months. 
Extended activities of daily living, measured on the Health Assessment Questionnaire 
Disability Index (HAQDI), were not significantly improved after the intervention or at six 
months, as shown in Table 2-5. Scores on HAQDI were low at baseline, indicating minimal 
activity limitations. 
 
Table 2-5 Changes in activity limitation, EADL and participation restrictions in PN participants after 
exercise and at six months 
Measure Baseline Change after 
exercise  
p Change at 6 months p 
ODSS 3 (0-7) -1 (0 to -1.5)* 0.02 -1 (-0.5 to -1.5)* 0.008 
ODSS UL 1 (0-3) -1 (0 to -1.5)* 0.02 0 (0.5 to -0.5) ns 
ODSS LL 1 (0-4) -0.5 (0 to -2)* 0.03 0.5 (0.5 to -1) ns 
FLP Total 9.9 ±8 -4.9 (-0.8 to -8.15)* 0.02 -4.1 (0.32 to7.7)* 0.03 
FLP physical 12.5 ±11.3 -5.3 (-0.4 to 10.9) ns -4.5 (-0.2 to 9.1) ns 
FLP 
psychosocial 
8.6 ±7.2 -5 (-1.4 to 8.3)* 0.05 -3.4 (-0.2 to 9.1) ns 
HAQDI 0.25 (0-2.1) -0.6 (-0.07 to 0.32) ns 0.07 (-0.19 to 0.13) ns 
RHS 33.5 (26-36) 1 (0-2.5)* 0.05 1 (-3 to 0.5) ns 
All baseline values are median (range) except for FLP scores which are mean ±SD. All 
changes after exercise and at 6 months are median change (95% CI) except for FLP, which is 
mean change (95% CI). ODSS – overall disability sum score, FLP – Functional limitations 
profile (physical and psychosocial subscales), HAQDI – Health assessment questionnaire 
disability index, RHS –Rotterdam handicap scale. * denotes significant change from baseline. 
 
After the intervention, the SF-36 PCS scores improved significantly in people with PN, and 
approached values from a healthy population (50) (Ware and Kosinski 2003). The SF-36 
subscales of physical functioning, health perception and energy and vitality subscales of the 
SF-36 were also significantly improved after the intervention in the PN group (Table 2-6). Both 
improvements on the PCS and the physical function subscale of the SF-36 were maintained at 
six months (Table 2-6) and similar changes in outcome were found both for people with CIDP 
and GBS. There were no significant changes in subscales or PCS in healthy participants. 
Health, relative to one year ago, was measured on the ninth subscale of the SF-36 (“health 
transition”). After the intervention, the PN participants reported health was significantly better 
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than one year previously, but this was not maintained at six months. After the programme, five 
healthy people also reported improved health on this subscale but changes in this group were 
not significant. The perceived change in health for healthy and PN participants is shown in 
Figure 2-2.  
 
Figure 2-2 Perceived change in health, measured with the SF-36, in healthy and PN participants from 
baseline to after exercise and in PN participants from baseline to follow up at six months. 
 
 
 Changes in experienced fatigue and mood 
Changes in experienced fatigue and mood after the intervention in healthy and PN participants 
are shown in Table 2-6 (Page 86). After the programme both groups reported significantly 
improved feelings of fatigue. Experienced fatigue also remained significantly improved from 
baseline at six months in PN participants. This was echoed by significant increases in the 
energy and vitality subscale on the SF-36 questionnaire after the intervention in people with 
PN although this was not maintained at six months (p=0.06). 
As there were significant differences between baseline measurements of fatigue for healthy 
volunteers, it was calculated that scores would have to demonstrate a change greater than 
0.62 (95% range for change), despite significant improvements, to indicate an alteration in 
fatigue beyond the variation seen at baseline. This was seen in six of eight healthy people 
after the exercise intervention. 
Overall median anxiety levels were classified as normal throughout the study using cut off 
values for healthy subjects in the PN group, but would have been classified as mild anxiety if 























PN at six months
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Healthy participants demonstrated minimal levels of anxiety and depression throughout the 
study. At baseline, two PN participants demonstrated severe anxiety, which improved to 
moderate levels on completion of the programme. Similarly, median depression scores were 
within the normal range in the PN group, but one person with PN demonstrated severe 
depression on both the BDI and HADS depression subscale. After the intervention this 
decreased to moderate levels (Beck et al. 1996; Snaith and Zigmond 1994). As shown in Table 
2-6, anxiety and depression were significantly improved after the intervention in the PN group, 
although significant improvements in depression scores were not maintained at six months. 
 Changes in strength 
All healthy and PN participants trained the knee extensor muscles. In the PN group, mean 
linear isometric force values were somewhat lower than those found in healthy subjects in this 
study and reported by others (mean isometric force in dominant leg : 407 N and non dominant 
leg: 403 N) (Bohannon 1997b). However, the healthy and PN groups were not matched for age 
or gender in this study, and differences in the method of testing between the current study and 
Bohannon (1997) limits the validity of these comparisons. Baseline values and changes in 
isometric strength in this muscle group after the intervention and at six months are shown in 
Table 2-7 (Page 88). 
After exercise, isometric strength in both legs was increased, this reached significance in the 
right leg of PN participants (mean percentage change: 13 ±46%) but not in the left (7.7 ±39%). 
At six months, the isometric muscle strength of the knee extensors was not significantly 
different from baseline. Healthy volunteers increased knee extensor strength significantly in 
both legs after the intervention (right= 16 ±7%, left= 18 ±14%) indicating that the training 





Table 2-6 Changes in participation, mood and fatigue from baseline to 12 weeks in healthy and PN participants and from baseline to 6 months in PN group. 
PN Healthy 
Measure Baseline  Change after 
exercise (n=14)  
p Change at 6 
months (n=14) 





70 (15-90)δ 10 (5 to17.5)* 0.003 10 (2.5 to 17.5)* 0.02 95 (80 -100) 1.88 (-7.5 to 0) ns 
RLP 100 (0-100) 0 (-25 to 33) ns 0 (-25 to 25) ns 93.8 (50-100) -6.3 (-50 to 0) ns 
RLM 100 (0-100) 12.5 (0 to 33) ns 0 (0 to 25) ns 100 (100-100) -1.4 (-5.6 to 25) ns 
Social function 94.4 (55.5-100) 0 (-5 to11.1) ns 0 (-5.6 to 11.1) ns 94.5 (66.7-100) 4.2 (-5.6 to 16.7) ns 
Mental health 82 (20-100) 4 (0 to 16) ns 4 (0 to 14) ns 79.5 (52-92) 4.5 (0 to 10) ns 
Energy and vitality 60 (15-95)† 12.5 (2.5 to 22.5)* 0.02 5 (5 to 15) ns 73.8 (50-90) 3.1 (-5 to 10) ns 
Pain 72.8 (44.4-100)δ 11.1 (0 to 16.7) ns 5.6 (0 to 16.7) ns 91.7 (77.8-100) -1.4 (-5.6 to 5.6) ns 
Health perception 53.5 (30-82) 12 (6 to 19)* 0.002 11 (0 to 18.5) ns 76.8 (57-95) -4.4 (-15 to 5) ns 
PCS 44.3 ±6.9δ 5.8 (2.2 to 9.4)* 0.004 4.3 (1.5 to 7.4)* 0.01 56.9 (50.8-60.3) -1.8 (-6.4 to 2.2) ns 
MCS 52.5 ±11 2.3 (-3.8 to 8.3) ns 0.9 (-5.4 to 7.2) ns 53.8 (40.6-59.3) 2.1 (-7.9 to 3.4) ns 
FSS 4.6 (1.5-6.11)† -0.6 (-0.17 to -1.2)* 0.009 -0.6 (-0.2 to -1.45)* 0.01 3.3 (2.7-3.7) -0.6 (-0.2 to -1.2)* 0.04 
HADS Anxiety 6 (2-16) -2 (-0.5 to -3.5)* 0.02 -2 (0 to -4.5)* 0.04 4 (0-9) 0.25 (-1.5 to 1) ns 
HADS Depression 1.5 (0-16) -1 (-0.5 to -3)* 0.04 -0.5 (0 to -1.5) ns 1 (0-7) -0.13 (-1 to 1) ns 
BDI 3 (0-25) -2.5 (0 to -6.5)* 0.04 -0.51 (-4.5 to 3) ns 0 (0-12) 0.5 (-3.5 to 4) ns 
Baseline scores are all median (range) except for the SF-36 Physical Component Summary scores (PCS) and Mental Component Summary scores (MCS) which 
are mean ±SD. Changes after exercise and six months are all median (95% CI) except PCS and MCS which are mean (95% CI). A negative change indicates 
improvement on the FSS, HADS and BDI. A positive change indicates improvement from baseline for all other tools. RLP – role limitation physical, RLM – role 




 Changes in cardiovascular fitness and walking  
Peak heart rate, workload on exercise testing, PCI, mPCI and ten metre walk times, before 
and after the exercise intervention and at six month follow up are displayed in Table 2-7.  
There were no significant changes in the performance of healthy volunteers on any of these 
outcomes. In PN participants, total work done during the exercise test increased significantly 
from baseline to after the intervention. Increases in peak workload produced on the exercise 
test approached significance in the PN group (p=0.06) but improvements in workload were not 
significantly different from baseline at six months.  
Participants with PN had a significant reduction in their energy cost of walking measured by 
the mPCI, which was maintained at six months, although PCI and ten metre walk times were 
not significantly different from baseline at any point. 
 Statistical Power 
Changes on the SF-36 PCS after exercise were used to calculate retrospective power as the 
primary outcome, the ODSS, was not parametric. The power of the study was 0.87 (two tailed 
p=0.05). This decreased to 0.64 at six months.  
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Table 2-7 Changes in cardiovascular parameters, knee extensor strength, activity levels and walking ability in PN and healthy participants 
PN Healthy 
Measure Baseline  Change after 
exercise (n=14) 
p Change after 6 
months (n=13) 
p Baseline  Change after 
exercise (n=8) 
p 
Right knee extensors (N)  304±138.7   
(98-541) 
38 (4 to 69)* 0.03 37 (-23 to 93) ns 374.2 (242-511) 54 (35 to 73)* <0.001 
Left knee extensors (N)  297.4± 98.3 
(97-517) 
23 (-5 to 51) ns 12.2 (-42 to 66) ns 341.9 (194-439) 64 (19 to 110)* 0.01 
Resting heart rate (beats min
-1
) 75±15 (57-88) -6 (-12 to 1) ns -3 (-14 to 1) ns 70±7.2 (55-79) -2 (-6 to 1) ns 


















-0.12 (-0.01 to -0.2)* 0.04 0.16 (0.6 to 0.26)* 0.01 1.3±0.32 (1-2) -0.05 (-1.5 to 0.05) ns 
Fast 10 m walk test (s) 6.5±2.2 (4-
12.6)† 
0.4 (-0.4 to 0.53) ns -0.04 (-0.5 to 0.5) ns 4.7±1 (3.6-6.4) 0.08 (-0.5 to 0.68) ns 
Preferred pace 10 m walk test (s) 9±2.5 (6.1-16)† 0.4 (-0.1 to 0.8) ns -0.05 (-0.5 to 0.6) ns 6.7±0.1 (5.5-7.8) 0.025 (-0.5 to 0.5) ns 
Peak workload (Watts) 150±235 (60-
300) 
14 (0 to 28)* 0.06 7 (-6 to 20) ns 188±53 (90-240) 11 (-7 to 30) ns 
Total workload (Watts) 375±306 (34-
1350) 
136 (13 to 137)* 0.03 4 (-96 to 104) ns 627±302 (135-
1000) 
35 (-92 to 163) ns 
* indicates significant difference from baseline. All baseline values are means ±SD (range); change scores are mean change (95% CI). † denotes significant 
difference between PN and healthy participants at baseline at p<0.05, δ at p<0.01. 
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2.5.5. Properties of outcome tools 
The floor and ceiling effects and responsiveness for outcome tools which demonstrated a 
significant difference after the intervention are presented in Table 2-8 (Page 90). The 
appropriateness, suitability and burden of tools are considered in greater depth in the 
discussion (Section 2.6.4, Page 98).  
 Primary outcome tool 
Total ODSS scores had a floor (maximum limitations) or ceiling (no limitations) effect in 3 
participants (3/14; 21%) which exceeds recommended values (<15%) (McHorney 1998). A 
ceiling effect on the lower limb section was apparent as six participants (6/14; 43%) scored 
zero on the lower limb section, indicating no activity limitations, despite reporting reduced 
physical functioning and difficulties with ambulation on other tools. This indicates that the 
ODSS may not be a suitable indicator of limitations affecting mobility. After exercise, the 
responsiveness of the ODSS was low (SRM: 0.34) but increased at six months (SRM: 1.4).  
 Secondary outcome tools 
Over 15% of scores on the Beck depression inventory were at the floor of the scale in PN 
participants (McHorney 1998). The HADS had acceptable floor and ceiling effects (Table 2-8) 
but was observed to have some items that, whilst representing depression, could also 
correspond to limitations in physical functioning, reducing face validity.   
Despite demonstrating a significant improvement after intervention, the FLP psychosocial 
component had a considerable ceiling effect (21%). Neither the HAQDI nor the physical 
component of the FLP demonstrated significant changes in physical functioning after the 
intervention despite other tools (SF-36) indicating significant improvements. The FLP also 
caused considerable respondent and administrator burden, taking approximately 25 minutes to 
complete and ten minutes to score. 
The health perception and physical functioning subscale scores on the SF-36 with the HADS 
anxiety subscale demonstrated the largest responsiveness after exercise (all SRMs exceeded 
0.6). These scales were also quick and easy to complete, but transformation of the SF-36 raw 




Table 2-8 Floor and ceiling effects and responsiveness for outcome tools that demonstrated a significant improvement after exercise in PN participants 
Measure Range of scores at 
baseline 





six months  
Overall mean 
responsiveness  
ODSS 0 to 7 3 (21) 0.34 1.4 0.87 
SF-36 Physical function  15 to 90 0 0.68 0.66 0.67 
SF-36 Mental health  20 to 100 1 (7) 0.6 0.28 0.44 
SF-36 Energy and vitality  15 to 95 0 0.59 0.25 0.42 
SF-36 Health perception  30 to 82 0 1.59 0.78 1.19 
Rotterdam Handicap Scale  25 to 36 2 (14) 0.6 0.6 0.6 
HADS Anxiety 2 to 16 0 0.77 0.9 0.84 
HADS Depression 0 to 16 1 (7) 0.17 0.3 0.24 
Beck Depression inventory 0 to 25 3 (21) 0 0.3 0.15 
Fatigue severity scale 1.56 to 6.11 0 0.5 0.38 0.44 
PCS  33.6 to 54 0 0.51 0.67 0.54 
FLP Psychosocial component 0 to 22 3 (21) 0.28 0.46 0.74 
ODSS - Overall Disability Sum Score, HADS – Hospital Anxiety and depression questionnaire, PCS – physical component summary score from SF-36, MCS – 





This investigation was the first study to establish the practicality of a 12 week community 
based exercise intervention for people after GBS or with CIDP and to identify possible changes 
in impairments, activities and participation after the intervention, fulfilling the first aim of this 
thesis. The PN volunteers in this study complained of persistent impairments and chronic 
activity limitations which were refractory to curative medical treatment. For such individuals, 
self-management by regular exercise may be attractive if it could be shown to be practical and 
beneficial. Indeed, 41 people volunteered to participate in the trial and many more people 
contacted the investigator to convey their enthusiasm and support for the investigation, despite 
knowing they were not eligible for inclusion. Only two PN participants did not complete the 
programme, for reasons beyond their control (change in drug treatment and leaving the UK). 
Although based upon self report, which is liable to bias and inaccuracies in recall, adherence 
to the programme appeared good. Despite this flaw and other limitations in the design of the 
investigation, the response to the call for participants and the subsequent study findings 
suggest that many people with PN perceive exercise to make a valuable contribution to 
recovery and health maintenance.  
The majority of healthy volunteers and people with PN reported successfully completing the 
exercise programme, and being able to exercise independently without sustaining injuries 
either at home or at a local gym. Significant improvements in activity limitations, experienced 
fatigue, anxiety and aspects of participation were apparent after the intervention in PN 
participants and were maintained at six months.  
The findings of this study should be viewed with caution as there were several significant 
limitations in its design. These limitations are discussed in Section 2.6.5 but include the 
absence of a non-exercising PN control group, small sample and lack of rater blinding. 
Consequently, improvements in functioning seen after the intervention cannot confidently be 
attributed to the exercise intervention itself. Despite these limitations, the results indicate that a 
physiotherapist prescribed community based exercise intervention was practical for people 
with PN and these data support and inform further investigation of exercise in this patient 
group. 
2.6.1. Practicality and adherence 
All volunteers were able to exercise in an unsupervised community setting following clinical 
assessment and equipment provision by a physiotherapist. Many potential participants who 
contacted the investigator did not conform to the inclusion criteria of living within reasonable 
travelling time to the research site (13 from 41) and so could not be included. Therefore, 
achieving satisfactory recruitment and retention of willing participants for a future randomised 
controlled trial is likely to require a multi-centred national or international trial design. 
Two participants in each group left the study for reasons which were not directly influenced by 
exercise. This was identical to the attrition reported from a supervised training intervention in 
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people with CIDP or after GBS (Garssen et al. 2004). No injuries or unwanted effects related to 
the programme that necessitated missing exercise sessions were reported, although this relied 
upon participants mentioning difficulties to the assessor. After initial instruction and provision of 
a booklet detailing their exercises, all participants reported that the programme was realistic 
and practical. However, this and the report of adherence, were likely to be biased by a desire 
to please the investigator which limits confidence in these findings. These effects could be 
ameliorated by using an independent rater in future work.  
After completion of the exercise programme, PN participants reported improvements in energy, 
fitness and confidence to perform activities of daily living during an informal interview. Ten 
participants stated that they continued to exercise at six months, which may confer long term 
health benefits. The most commonly reported unwanted effects of the exercise programme 
were transient and mild muscle and joint ache, usually on the day after exercise, which did not 
limit usual activities or exercise. This suggests that the intervention was well tolerated. 
Although these findings would be fortified if detailed symptoms had been explicitly and more 
rigorously monitored, the presence of specific side effects of exercise were not sought overtly, 
as it was considered that this would influence the participant’s report (Ruhland 1997). The side 
effects reported here are similar to those described by 18 people with CIDP or after GBS after 
completing 12 weeks of supervised aerobic training and in 14 participants with chronic PN 
after a combined training programme (Garssen et al. 2006a; Ruhland 1997).  
Informal exit interviews also revealed that participants found the exercise equipment to be 
uncomplicated and the exercises straightforward to complete. There were no reported injuries 
linked to exercise and the positive comments from PN participants suggested that they found 
the intervention to be acceptable and practical. The competence of people with inflammatory 
PN to exercise in an unsupervised community setting has not been reported previously. 
However, over 40% (of 42) of people one year after GBS have not returned to their pre-morbid 
leisure activities, including sports, indicating that they struggle to recommence physical 
activities (Bernsen et al. 2002). Although no studies have identified reasons for reduced 
participation in physical activities in PN, several common causes for people with a range of 
disabilities have been identified. These include inadequate or unsuitable equipment, emotional 
and psychological barriers and a lack of knowledge by some fitness professionals (Rimmer et 
al. 2004). Indeed, some people with PN are likely to encounter difficulty when using 
conventional exercise equipment (e.g. a treadmill) due to impaired balance, reduced sensation 
and strength, resulting in exercise being perceived as difficult, unpleasant and potentially 
hazardous. This was exemplified in this study by one participant who could not use the 
standard exercise bike and who required specialised equipment.  
Adherence was only able to be judged from participant report in exercise diaries as several PN 
and healthy participants struggled to consistently record their heart rate using the monitors 
during their exercise sessions. Consequently these data were unreliable and were not used. 
The difficulty in recording heart rate appeared to be because heart rate was displayed 
continuously and so participants forgot to press the record button. In addition, the stop 
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(recording) button was situated on the outer side of the watch and was often pressed 
accidentally. Some recordings from participants who exercised in a gym were also affected by 
interference from other machines. Although exercise diaries are a common method of 
reporting adherence in exercise studies, they introduce bias as self-report is affected by 
inaccurate recall, the desire to please the investigator and often results in over-estimation of 
exercise behaviours (Jakicic et al. 1998; Tudor-Locke and Myers 2001).  
Although it is acknowledged that the accuracy of self report is limited, adherence in this study 
appeared good as the majority of participants reported completing the programme within the 
allocated time. These findings are similar to previous community based studies in 
neuromuscular disease (Agre et al. 1997; Kilmer et al. 1994; Wright et al. 1996) although 
factors affecting practicality were not reported in several (Aitkens et al. 1993; Chetlin et al. 
2004; Lindeman et al. 1995; Pitetti et al. 1993).  
Three PN participants and one healthy volunteer took longer to complete the 36 sessions than 
the recommended three month time period. Reasons for missing exercise sessions were often 
factors limiting opportunities to exercise including increased work demands, getting married 
and moving house. These issues are a common challenge to maintaining regular exercise for 
most people (Martin and Dubbert 1985) but this could indicate that the training frequency of 
the intervention was impractical for people with PN. However, these factors are more easily 
accommodated by an independent community based exercise programme as participants 
could choose when to exercise. Community based programmes have been shown to increase 
adherence (completed exercise sessions : 68%) in comparison to centre based exercise (36%) 
in older adults, supporting the design of the programme used in the current study (Ashworth et 
al. 2005). 
The continuation of regular exercise is vital to gain sustained health benefits and so the 
maintenance of exercise could be used as a measure of the success of an intervention to 
promote good health (Dishman 1990). In the current study, six months after completing the 
programme, ten PN participants (from 14) reported maintaining aerobic, strengthening and/or 
functional exercises at a similar intensity and duration to the prescribed programme. This 
continuance of exercise suggests that the majority of PN participants considered the 
intervention to be worth continuing and that the components of the original programme were 
acceptable and practical. This result is also supported by the study by Garssen et al. (2005) in 
which ten from 18 PN participants reported continuance of exercise two years after a 12 week 
supervised exercise programme.  
2.6.2. Baseline stability 
Two baseline measurements, taken one month apart before beginning the exercise 
programme, familiarised volunteers with testing procedures and provided data to evaluate the 
stability of their condition. This duration was chosen after consultation with the GBS support 
group as the steering committee anticipated that a pre intervention period of 12 weeks may 
deter potential volunteers from participation, reducing recruitment. However, it is recognised 
that one month was too short to act as a pre-intervention control period.  
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All PN participants were screened by a neurologist to ensure their neuropathy was stable. 
Despite this, in the PN group, there was a significant improvement between baselines on one 
subscale of the SF-36 questionnaire (role limitation physical, RLP) with two PN participants 
demonstrating large increases in their scores (increasing by 75 and 100 points) at the second 
baseline measurement. A true change in neurological stability is unlikely as neither reported 
any significant change in health status on questioning or on any other outcome tools. The 
apparent improvement on the RLP subscale scores could be caused by a learning effect as 
the overall variance of scores was somewhat decreased on the second measurement, 
indicating familiarisation (Bouchet et al. 1996). Participants may have altered their answers on 
the second measurement session due to the Hawthorne effect as, by being involved in 
research, they were the focus of special attention (Bouchet et al. 1996). This effect has been 
shown to produce significant changes in scores on the SF-36 questionnaire in healthy people, 
including in the RLP subscale (Bouchet et al. 1996).  
Healthy volunteers did not demonstrate significant differences on the SF-36 questionnaire 
between baseline measurements in this study but significant improvements in fatigue and the 
time taken to walk ten metres were evident at the second baseline. This may also be attributed 
to the Hawthorne and learning effects.  
In future studies, the impact of these effects on the results could be minimised or eliminated by 
greater participant familiarisation with the outcome measures and the inclusion of a non 
exercising control group. 
2.6.3. Overall changes in outcomes after the exercise intervention 
The results demonstrate that there was a significant reduction in activity limitations 
experienced by people with PN following the exercise intervention. However, limitations in the 
design of the study meant that there was risk of selection, measurement and exposure bias 
and the lack of a PN control group meant that changes after the intervention could not be 
attributed to the exercise programme.  
 Activity limitations  
The primary outcome tool, the ODSS, demonstrated a median improvement of 0.5 after the 
intervention and the upper and lower limb ODSS subscale scores also demonstrated 
significant improvements. The total ODSS score remained significantly improved from baseline 
at six months (median change: 1, range: -3 to 1), but subscale scores did not.  
An overall change of 0.5 on a very similar scale to the ODSS (GBS disability scale) has been 
proposed as worthwhile to PN patients, suggesting the improvement seen in this study is 
clinically meaningful (Hughes et al. 2001). 
A ceiling effect was apparent on the total ODSS as three from 14 scores (21%) were at the 
ceiling of the scale. Six from 14 scores (43%) were at the ceiling of the lower limb subscale 
which indicates that further important changes in functioning were not effectively 
demonstrated. This limitation, and the properties of other outcome tools, is discussed further in 
Section 2.6.4 (Page 98). 
95 
 
 Participation and EADL 
Participants with PN reported large, significant improvements in physical function (PF) and 
physical component summary (PCS) scores on the SF-36 (PF: mean change; 95% CI: 10, 5 to 
17.5; PCS: 5.8; 2.2 to 9.4). This is an important finding as it meant that PCS scores were 
within healthy population derived values after the intervention (Ware and Kosinski 2003) and 
these changes were maintained at six months. Garssen et al. (2004) reported similar 
improvements in PCS scores after a supervised aerobic exercise intervention in 20 people with 
CIDP or after GBS, although in Garssen et al.’s work (2005a), these changes were not 
maintained at follow-up despite reports of continuing exercise. This may have resulted from the 
longer (two year) follow-up period used (Garssen et al. 2005a). Alternatively, the maintained 
improvement in the current study may be due to inclusion of combination of strength, aerobic 
and functional training, or to improved coping and symptom control which is produced by 
community based exercise (Alderson et al. 1999). 
A significant improvement in the total FLP score indicated that PN participants perceived fewer 
restrictions after the intervention (FLP mean change, 95% CI: -4.9, -0.8 to -8.15). Suprisingly, 
this significant improvement occurred despite no significant change on the physical subscale 
of the FLP. There were also no significant improvements in scores on the HAQDI, a measure 
of EADL. This was also initially surprising as several other tools which measured physical 
function and participation demonstrated significant improvements. However, at baseline 
several PN participants were at the ceiling of HAQDI (n=6) and FLP physical subscale (n=3), 
indicating maximal functioning, so scores could not reflect further improvement. These findings 
indicate that these tools are not appropriate to capture participation in PN.  
 Experienced fatigue and mood  
Experienced fatigue is a common, persistent symptom and contributes to reduced activity in 
inflammatory PN (Lennon et al. 1993; Merkies et al. 1999). After the intervention, the PN group 
demonstrated a significantly reduced severity of fatigue measured on the FSS (FSS mean 
change, 95% CI; H: -0.6, -0.2 to -1.2; PN: -0.6, -0.17 to -1.2) and these improvements were 
maintained at six months. Healthy participants also reported significantly reduced fatigue after 
the intervention but as fatigue was also significantly reduced between baseline measurements 
in this group, the significance of this findings is unclear (FSS mean change, 95%: -0.6, -0.2 to -
1.2). There was also a significant increase in energy and vitality measured on the SF-36 in the 
PN group (mean change, 95% CI: 12.5, 2.5 to 22.5). Similar findings have been reported in 18 
volunteers after GBS and with CIDP who completed a 12 week exercise programme although 
fatigue scores demonstrated a larger improvement than those seen here (mean decrease of 
FSS scores: 1.3, SD: 1.9) (Garssen et al. 2004; Garssen et al. 2005a). This is likely to be 
because participants in their study were specifically selected to have severe fatigue (FSS 
scores greater than 5). The reduction in experienced fatigue after the intervention cannot be 
attributed to exercise as neither Garssen et al. (2004) nor the current study included a non-
exercising control group. However, these findings suggest that factors which were improved by 
an exercise intervention could be associated with the severity of fatigue. Future work to 
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investigate these factors could provide a mechanism for understanding and managing 
experienced fatigue in people with PN and is presented in Chapters Five and Six. 
There was a significant improvement in anxiety scores on the HADS after the intervention 
(mean change, 95% CI:-2, -0.5 to -3.5) which was maintained at six months. Anxiety has been 
reported to adversely affect activities and quality of life in people with PN (Lennon et al. 1993). 
After the intervention, several PN participants also commented that they felt less nervous 
when performing physical activities of daily living. Although a reduction in anxiety could be 
attributed to improved confidence after contact with the investigator, it is possible that the 
exercise intervention improved physical functioning and mental health via psychological and 
biological interactions (Weyerer and Kupfer 1994).  
Average depression scores on the BDI and HADS were also reduced after the intervention 
(mean change, 95% CI; HADS: -1, -0.5 to -3; BDI: -2.5, 0 to -6.5), but were not significantly 
different from baseline at six months. This finding is supported by other studies in PN (Garssen 
et al. 2004; Garssen et al. 2005a), but has little significance as the majority of participants had 
scores that fell within normal limits.  
 Muscle strength, walking and cardiovascular fitness  
There were modest, significant improvements in the strength of the knee extensors after the 
intervention (+13%) in the PN group, which were trained by all volunteers, but these changes 
were not sustained at six months. The increase in strength in healthy participants was also 
significant (+16%), indicating the training stimulus was appropriate to elicit changes in muscle 
performance. Importantly, the results of this study show no evidence over-work weakness in 
the PN group, suggesting that unsupervised isometric strength training was practical and not 
detrimental. 
These findings are similar to reported increases in strength, ranging from 7% to 60%, after 
targeted training in people with neuromuscular diseases, including PN (Agre et al. 1997; 
Aitkens et al. 1993; Chetlin et al. 2004; Garssen et al. 2004; Lindeman et al. 1995; Milner-
Brown and Miller 1988). In a study in inflammatory PN, Garssen et al. (2005b) reported that 
strength remained improved up to two years after exercise training, unlike results at six months 
in the current study. This may be explained by the isokinetic strength training that they used, 
which may be more closely related to functional muscle performance than the isometric 
training used here. Isometric contractions were selected for testing in the current study as they 
were used during training and the use of the same muscle action to that used in training is 
reported to demonstrate the greatest strength changes when testing (Khouw and Herbert 
1998; McGlynn 1972). Muscles were trained isometrically for reasons of safety as it was 
anticipated that people with PN who had reduced proprioception and muscle weakness risked 
injury performing unsupervised dynamic strengthening exercises. 
Some reports suggest that impairments in muscle strength and endurance cause activity 
limitations for people with inflammatory PN (Merkies et al. 2003b) whilst others have argued 
that these physical impairments have only a weak contribution to performance (Bussmann et 
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al. 2007). In this study, the maintenance of improved activity limitations at six months despite 
strength returning to near baseline levels suggest that strength may have little impact on 
perceived activity limitations. Similarly, times to complete the ten metre walk tests did not 
change significantly after the intervention or at six months despite alterations in reported 
walking ability on the ODSS and items on the SF-36. This indicates that the speed of walking 
measured over short distances, as in these tests, does not greatly influence daily activities in 
PN participants and that other tools to assess mobility are required.  
However, there were significant improvements on the mPCI that were sustained at six months 
(mean change, 95% CI: -0.12, -0.01 to -0.2). This indicates that the aspects measured by the 
mPCI and which influence walking efficiency were changed after the intervention. Wide 
variability on scores on the PCI meant that this measure showed no significant improvement. 
Participants with PN produced a significantly greater total workload during exercise testing 
(mean increase=+36%) after the intervention than before. They could cycle for longer and this 
suggests improved aerobic endurance. However, alterations in total workload after training in 
healthy volunteers were much smaller and did not reach significance (mean increase=+6%). 
Changes in peak workload during exercise testing after the intervention were small in the 
healthy group, but improvements approached significance in PN participants (+9%, p=0.06). 
Other reports have described much larger increases in peak workload (+29%) after supervised 
aerobic training in people with PN (Garssen et al. 2004; Pitetti et al. 1993). This could imply 
that the aerobic training stimulus in the current study was insufficient to produce tangible 
changes in cardiovascular fitness. 
However, on closer scrutiny, there was a wide variance in peak and total workload values from 
exercise testing. This was most marked in the healthy group but was also apparent in PN 
participants. This indicated that some individuals improved whilst others did not change from 
baseline, suggesting that they did not adhere to the aerobic training component of the 
programme. Better monitoring of the aerobic component of the programme would have 
provided more objective data on training intensity and adherence, but this was not possible 
due to problems with the heart rate monitoring equipment (discussed in Section 2.6.1). If more 
robust and reliable equipment could be used in future studies, it would allow these data to be 
collected whilst still facilitating participants to exercise independently in the community.  
It is also likely that, as many participants trained by walking or running and not using a cycle, 
improvements in training specific aerobic fitness were not apparent on cycle ergometer testing. 
This is a limitation of cycle based exercise testing as participant’s performance may be 
influenced by factors other than aerobic function such as leg strength and coordination 
(American College of Sports Medicine 1995) but cycle based exercise testing was used in this 
study as many people with PN have difficulties with balance. In future, estimation of aerobic 
fitness could be measured directly during a participant’s preferred training activity using 
calorimetry or a more functional exercise test protocol. Participants could also be restricted to 
one aerobic training modality as others have done (Garssen et al., 2004).  
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2.6.4. Properties of outcome tools 
 Primary outcome tool - The Overall Disability Sum Score 
The ODSS was quick and straightforward to complete and appeared to capture aspects of 
functioning that were relevant to people with PN. It demonstrated a ceiling effect at baseline as 
three from 13 (21%) participants scored zero, indicating no activity limitations (McHorney 
1998). On the lower limb section, six from 13 PN participants (46%) scored zero, despite 
indicating limitations in mobility on other questionnaires. The omission of items which measure 
more minor limitations in mobility, such as running, suggests that the ODSS is not sufficiently 
sensitive to measure the presence of, and alterations in, these limitations which may still be of 
great importance to participants. Further work is therefore necessary to evaluate other tools in 
PN or to reduce the ceiling effect of the ODSS whilst maintaining its other properties; a new 
version of the ODSS, the Overall Neuropathy Limitations Scale, ONLS, is considered in 
Chapter Three.  
 Secondary outcome tools 
Of the secondary outcome tools assessed, the SF-36 questionnaire physical function, health 
perception subscales and PCS subscales and the HADS anxiety scale were most responsive 
after exercise (Table 2-8), and had floor and ceiling effects within published recommendations 
(McHorney 1998).  
Whilst the HADS anxiety had good face validity, one item on the HADS depression scale could 
be confused with physical limitations (“I feel slowed down all the time...”).This may account for 
the small but significant improvement seen on the HADS depression scale after the 
intervention (mean change, 95% CI: -1, -0.5 to -3), despite no significant changes in 
depression measured by the BDI.  As average depression scores were within normal limits, 
these findings indicate that depression is not an important outcome in a future trial of exercise 
in PN but, if it is to be measured, other tools which do not contain physical items should be 
considered.  
The FSS had little burden and reflected moderate to severe levels of experienced fatigue in 
PN participants, indicating it is a useful tool in this patient group and supporting the findings of 
others (Merkies et al. 1999). Although the FSS reflected significant alterations in experienced 
fatigue after the intervention, it was only moderately responsive (overall responsiveness= 0.4) 
which suggests that other fatigue tools could be considered in future work. 
The RHS demonstrated face validity, acceptable floor and ceiling effects, was moderately 
responsive to changes after the intervention (overall repsonsiveness= 0.6) and had little 
burden. This suggests that the RHS and SF-36 (discussed above) are suitable and appropriate 
in PN. 
Several tools did not appear appropriate for use in this type of intervention in PN. Scores on 
the HAQDI were unchanged after the intervention despite similar tools measuring significant 
improvements (for example, aspects of the SF-36 and FLP). It is possible that the specific 
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aspects of EADL measured by the HAQDI were unchanged or that the HAQDI was insensitive 
to change in people with PN after the exercise intervention. This suggests that another EADL 
tool should be investigated for future use.  
Although the total FLP scores demonstrated significant improvements after the intervention 
(Table 2-5), the physical subscale did not, despite other tools reflecting significant activity 
limitations. The FLP also produced a considerable burden as it took up to 25 minutes to 
complete. Taken together, these limitations deters from its use in future studies. 
The ten metre walk tests (preferred pace and as fast as possible) were not responsive to 
change after the intervention, despite significant improvements in self reported walking ability 
on other tools. Although this highlights the difference between self report and objective 
measurement, it suggests that walking speed did not reflect wider mobility in PN participants. 
The mPCI demonstrated significant improvements after the intervention and so it may be an 
appropriate tool to measure walking ability for people with PN. However, its validity and 
reliability must be investigated before it can be considered for use. This investigation and other 
studies of outcome tools to indicate walking ability is described in Chapter Four.  
Based on the findings from this investigation, recommendations of outcome tools for use in 
future studies of exercise in PN are presented in Table 2-9. 
Table 2-9 Recommended outcome tools based on their performance in this study 
Recommended  Not recommended 
SF-36 subscales -  
 Physical Function 
 Health perception 
 Physical Component 
Summary 
Beck Depression Inventory 
Rotterdam Handicap Scale Health assessment questionnaire 
disability index 
Hospital Anxiety and Depression 
Scale 
Functional limitations profile 
Fatigue Severity Scale 10 metre walk tests 












2.6.5. Limitations of this study and implications for future work 
In addition to the limitations already discussed, there were a number of limitations which are 
considered in greater depth here. 
 Absence of a PN control group 
The prospective cohort study design was chosen to fulfil the first aim of the study by 
establishing the practicality of exercise for PN and factors affecting recruitment to a RCT. Both 
GBS and CIDP are rare (Hughes and Rees 1997; Lunn et al. 1999) and finding volunteers with 
stable disease, no disqualifying medical conditions and who could travel to London was 
difficult. A non exercising control group was not included as it was anticipated that the relative 
scarcity of people with PN who could attend for testing and met the inclusion criteria would 
prevent recruitment of sufficient participants within a reasonable timescale. This concern was 
justified in part, as although many people contacted the investigator, only 40% were eligible to 
participate. Furthermore, randomisation to a non-exercising control group is likely to have been 
unacceptable for some volunteers, which would have increased withdrawal from an already 
limited target population. Steps were taken to strengthen the design, despite the absence of a 
control group. The possibility of spontaneous recovery was minimised by selecting participants 
with clinically stable PN and including a short pre-intervention baseline period. Nonetheless, 
the inclusion of a control group undertaking a non-exercise based intervention would have 
allowed observation of the extent to which spontaneous recovery and other uncontrolled 
factors contributed to the results.  
However, it is recognised that complex interventions are difficult to control as several factors 
including contact with a medical professional, desire to please the investigator and 
expectations of improvement by study volunteers influence self report and performance 
adequately (Hawe et al. 2004). Whilst the placebo effect is often beneficial (Bouchet et al. 
1996), the use of realistic placebo groups in exercise interventions is difficult, not least 
because the benefits of exercise are widely documented and participants expect improvement 
(O'Halloran et al. 2002). It is also difficult to blind participants to a participatory investigation 
such as exercise and blinding does not reflect the usual clinical situation. In order to provide a 
true control for the current study, a non-exercising PN group should have undertaken an 
ethical placebo intervention which provided comparable contact with the investigator and 
elicited similar expectations of improvement as an exercise intervention. A controlled 
intervention of this nature does not exist. Others have used relaxation or cognitive behavioural 
therapy as a control in other patient groups (Bateman et al. 2001; Ridsdale et al. 2004) but 
they do not elicit similar participant expectations to exercise. The range and duration of 
symptoms demonstrated by PN participants in this study also indicate that it may not be 
possible to match control and intervention groups, limiting the usefulness of group comparison. 
A delayed intervention control group would have strengthened the design but was not included 
as the time for recruitment was not known before commencing this study. Although this would 
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not exclude some limitations, such as patient expectations and lack of participant blinding, it 
would have provided some certainty that improvements were not due to spontaneous recovery.  
 Restricted sample  
The results of this study are based upon a small number of self-selected PN participants which 
reduced the validity of the results. As inflammatory PN is relatively rare, a larger target 
population could be accessed by utilising a multi-centre trial design in future work but would 
require rigorous standardisation of testing procedures to ensure parity between centres. 
A large trial of this nature may also aid recruitment of sufficient participants to allow diagnostic 
sub-group analysis. Although people with CIDP report many similar problems to those with 
GBS, it may not be legitimate to group these conditions together. Visual inspection of the data 
revealed little difference in outcomes between conditions in the current study, but analysis of 
sub-groups was not possible due to the small sample.  
 Nature of the data  
Whilst participants completed a battery of outcome tools, very little qualitative data were 
collected. This meant the participant’s perceptions of the intervention and the factors which 
were of importance to them could not be determined. In particular, this limited the 
understanding of reasons affecting adherence to the programme, potential changes in health 
behaviours and their beliefs about exercise. This could be remedied in future work by adopting 
a mixed methods approach and using qualitative techniques, such as interviews, alongside 
quantitative measurement.  
 Absence of blinding 
The expectations of the assessor in this study are likely to have biased results. Recollection of 
previous performance by the assessor would predominantly affect impairment measurements 
which they recorded. Their expectations may also bias tools administered by interview such as 
the RHS and ODSS. The likelihood of the assessor recollecting previous results was limited as 
much as possible by ensuring all data were entered within 24 hours of assessment, and not 
examined prior to the next assessment visit (at least one month later). Standardised protocols 
and instructions were adhered to throughout to minimise the likelihood that the assessor could 
influence performance by providing different encouragement. Many other outcome tools were 
questionnaires completed independently by the participant, so are unlikely to be affected by 
assessor bias, but a future study should utilise a blinded assessor to eliminate this source of 
bias. However, participants were not able to be blinded, thus their expectations of 




The aim of this study was to investigate the practicality of a 12 week community based 
unsupervised exercise programme and its potential effect upon activity limitation and wider 
health in people after GBS or with stable CIDP. The results showed that an individually tailored 
combined exercise programme was practical and well tolerated in people with inflammatory 
PN and that they could exercise safely, without supervision, in their local community. 
Following the intervention, PN participants had significantly improved physical functioning and 
decreased activity limitations. Other persistent symptoms, including fatigue and anxiety, which 
contribute to persistent disablement, were also significantly reduced. Many significant 
improvements were maintained at six months and the majority of PN volunteers reported 
continuing to exercise. Whilst this is based on self report, it suggests that the intervention 
produced important changes in health behaviour that could potentially reduce risks of 
secondary health problems in this patient group (McDonald 2002).  
There were several limitations of this study including the absence of a non-exercising control 
group and lack of blinding. Consequently, the changes observed could not be attributed to the 
effect of the exercise intervention. The sample was also small reducing its external validity and 
preventing sub-group analysis. Despite its limitations, this study offers evidence to support the 
use of exercise in people with inflammatory PN but, perhaps more importantly, provides data to 
inform the design of a larger controlled trial. 
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Chapter 3. A new measure of activities for 
people with peripheral neuropathy – the 
overall neuropathy limitations scale 
3.1. Summary 
In this Chapter, the modification and evaluation of a disease specific measure of activity 
limitation for people with peripheral neuropathies (PN) is presented. The modified scale, the 
Overall Neuropathy Limitations Scale (ONLS), was derived from an existing scale, the Overall 
Disability Sum Score (ODSS), to overcome the ceiling effect that was apparent on the lower 
limb subscale when the ODSS was utilised in the exercise intervention study in Chapter Two.  
The validity and reliability of the ONLS were examined in 100 participants (49 females, mean 
age (SD): 58 (15.1), with a wider range of PN than originally investigated for the ODSS 
(CIDP=41, PDN=15, GBS=12, CIAP=12, Other neuropathies=20). Its responsiveness was 
measured using 24 measurements from 19 participants over one year. The reliability and 
validity of the ONLS as an observed measure was also evaluated using four raters (two 
neurologists, two physiotherapists) in 35 participants.  
The ONLS and ODSS demonstrated similar inter-rater reliability (ICC: 0.97). There were fewer 
scores at the ceiling of the ONLS lower limb subscale (n=8) than on the ODSS (n=13), 
indicating that the changes made to produce the ONLS had reduced a potential ceiling effect. 
Both the ONLS and ODSS had concurrent validity as they were significantly and moderately 
associated with the SF-36 and Rotterdam Handicap Scale (RHS) (both r>0.6, p<0.05). The 
ONLS was more closely associated with scores on a 12 item mobility questionnaire (Walk-12) 
than the ODSS, suggesting it was more able to measure mobility problems (ONLS: r=0.65, 
ODSS: r=0.43, both p<0.05). However, the ONLS demonstrated somewhat lower 
responsiveness than the ODSS (ONLS: Standardised Response Mean (SRM), 95% 
confidence limits =0.76, 0.67 to 0.81; ODSS: SRM=0.88, 0.88 to 0.95). Whilst there were not 
significant changes in activity limitations between repeated measurements according to either 
scale and the sample was small, the reduced responsiveness of the ONLS was probably due 
to the two activities added to the lower limb section.  
The ONLS demonstrated greater face validity, had fewer scores at the ceiling of the scale and 
was more able to reflect mobility problems for participants with PN, but it was somewhat less 
responsive than the ODSS. Further work should re-examine the responsiveness of the ONLS 
in a larger sample of participants undergoing larger changes in clinical status. However, future 
work could also develop new measures of activity limitations and/or evaluate other activity 
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Outcome tools which measure common, daily difficulties are necessary to evaluate status, 
guide treatment and determine rehabilitation goals (Chiou and Burnett 1985; Hobart et al. 
1996). Alterations in activity limitations reflect changes which are of importance to the 
individual, and are thus considered to be most appropriate to describe the effects of 
rehabilitative interventions, including exercise (Wade 2003). However, few outcome measures 
commonly used in PN assess activity limitations, despite only 40% or less of the variance in 
functional status being explained by alterations in more frequently measured aspects of 
functioning such as strength and sensation (Molenaar et al. 1995; Molenaar et al. 1999).  
There are a number of outcome tools which may be appropriate to indicate activity limitations 
in people with PN. However, several are not suitable as they do not capture the range of 
common activity limitations experienced in PN, have some redundant items and are likely to 
demonstrate a ceiling effect. One tool, the overall disability sum score (ODSS) was specifically 
designed to assess activity limitations in people with inflammatory PN (Merkies et al. 2002a). It 
was reported to be valid and reliable and was used as the primary outcome of activities in 
Chapter Two (Merkies et al. 2002a). The ODSS was originally derived from a scale which 
assessed activity limitations in multiple sclerosis, the Guy’s neurological disability scale 
(Sharrack and Hughes 1999). It consists of a checklist for interviewing people, with a focus 
upon upper and lower limb functions (presented in Chapter One, Pages 51 to 53). Upper limb 
activities are scored from a maximum of five, and lower limb from a maximum of seven, which 
can be summed to produce a total ODSS score out of 12. A maximum overall score of 12, and 
subsection scores of five or seven indicate an inability to produce purposeful movement in 
both the upper and lower limbs and the upper or lower limbs respectively. Zero indicates no 
activity limitations in everyday activities.  
The published properties of the ODSS were critically discussed in Chapter One (Page 51). 
Scores on the ODSS showed a significant improvement after the exercise intervention in 
Chapter Two. However, the ODSS demonstrated a ceiling effect at baseline in Chapter Two as 
three participants (from 14; 21%) scored zero, indicating no activity limitations, despite 
reporting problems on similar outcome tools. Scores on several tools such as the physical 
function (PF) subscale of the SF-36 questionnaire (median score at baseline: 85, range: 85-
90) significantly improved after the intervention whereas scores on the ODSS remained at zero 
and thus the ODSS was unable to measure small but potentially significant improvements. 
These findings suggest that the ODSS might not be appropriate to measure changes after 
interventions in more able people with inflammatory PN. 
On closer examination, the ceiling effect observed on the ODSS in Chapter Two appeared 
attributable to scores on the lower limb subscale. The ODSS does not fully represent lower 
limb limitations as it does not examine limitations such as difficulties in climbing stairs or 
running. One year after GBS, 18% (from 79) to 24% (from 42) of people were unable to run 
(Forsberg et al. 2004; Rees et al. 1998) and, in a small survey of 12 people with CIDP, ten 
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stated they struggled to climb stairs (Erdmann et al. 2005). However, rehabilitation, including 
exercise interventions, may improve these activities (Aitkens et al. 1993; Garssen et al. 2004; 
Lindeman et al. 1995) and so tools to capture these data are required. Furthermore, the 
properties of the ODSS have only been examined in GBS, CIDP and PDN which limits its 
clinical usefulness for other forms of PN. 
As the ODSS has demonstrated reliability, responsiveness and concurrent validity in people 
with GBS, CIDP and PDN (Merkies et al. 2002a; Merkies et al. 2003a) and has been used to 
assess activity limitations in clinical trials and investigations (Hughes et al. 2004; Merkies et al. 
2003a), it was anticipated that the modification of the ODSS could address the ceiling effect 
whilst maintaining its other properties. Therefore, the ODSS was modified to capture difficulties 
with running and climbing stairs with an aim to reduce the ceiling effect seen in Chapter Two. 
This new scale was called the Overall Neuropathy Limitations Scale (ONLS) and is shown on 
Page 107. The ODSS item “Does the patient have difficulty walking?” has been altered to 
“Does the patient have difficulty running, walking or climbing stairs?” on the ONLS. Therefore 
to score zero on the lower limb section of the ONLS, indicating no activity limitations, the 
respondent must report no difficulty running or climbing stairs, in addition to no difficulty 
walking.  
An observed version of the ONLS, scored by clinicians watching participants perform the tasks 
outlined on the ONLS, was also designed for use in people with language or communication 
difficulties.  
3.3. Aim  
The aim of this study was to investigate the reliability, validity and responsiveness of the new 




3.3.1. Overall Neuropathy Limitations Scale (ONLS) 
 
Overall Neuropathy Limitations Scale (ONLS) 
Instructions :  The examiner should question and observe the patient in order to determine the answers to the following 
 Questions. .Note should be made of any other disorder other than peripheral neuropathy which limits function at the foot of the page. 
 
ARM SCALE   
Does the patient have any symptoms in their hands or arms e.g. tingling, numbness or weakness? 
 Yes           No  (if “no”, please go to “legs” section) 
 
Is the patient affected in their ability to:                                          Not affected      Affected but not             Prevented 
                                                                                                                                              prevented 
Wash and brush their hair         
 
Turn a key in a lock           
 
Use a knife and fork together (or spoon, if knife and fork not used)        
 
Do or undo buttons or zips          
 
Dress the upper part of their body excluding buttons or zips       
 
If all these functions are prevented can the patient 
make purposeful movements with their hands or arms? Yes  No  Not applicable  
 
Arm Grade  
0 = Normal 
1= Minor symptoms in one or both arms but not affecting any of the functions listed SCORE=_____  
2= Disability in one or both arms affecting but not preventing any of the functions listed 
3= Disability in one or both arms preventing at least one but not all functions listed 
4= Disability in both arms  preventing all functions listed but purposeful movement still possible 
5= Disability in both arms preventing all purposeful movements 
 
LEG SCALE  
      Yes                   No         Not Applicable 
Does the patient have difficulty running or climbing stairs?                                                                 
 
Does the patient have difficulty with walking?        
 
Does their gait look abnormal?        
 
How do they mobilise for about 10 metres (i.e. 33 feet)? 
     Without aid          
     With one stick or crutch or holding to someone’s arm       
     With two sticks or crutches or one stick or  
     crutch holding onto someone’s arm or frame       
     With a wheelchair        
 
If they use a wheelchair, can they stand and walk 1 metre 
with the help of one person?        
 
If they cannot walk as above are they able to make some purposeful 
movements of their legs e.g. reposition legs in bed?        
Does the patient use ankle-foot orthoses/braces ?(please circle)      
      If yes: (please circle) right/left 
Leg grade 
0= Walking/climbing stairs/running not affected 
1= Walking/climbing stairs/running is affected, but gait does not look abnormal  SCORE=_____  
2= Walks independently but gait looks abnormal 
3= Requires unilateral support to walk 10 metres (stick, single crutch, one arm)  
4= Requires bilateral support to walk 10 metres (sticks, crutches, crutch and arm, frame) 
5= Requires wheelchair to travel 10 metres but able to stand and walk 1 metre with the help of one person 
6= Restricted to wheelchair, unable to stand and walk 1 metre with the help of one person, but able to make  
some purposeful leg movements 
7= Restricted to wheelchair or bed most of the day, unable to make any purposeful movements of the legs  
 
Overall Neuropathy Limitation Scale = arm scale (range 0-5) + leg scale (range 0-7);  
[range: 0 (no disability) to 12 (maximum disability)]                                                 TOTAL SCORE=_____ 
Is there any disorder, other than peripheral neuropathy, which affects the above functions    Yes  No    




3.4.1. Design and participants 
A cross sectional design was used to investigate reliability and validity of the ONLS (Sim and 
Wright 2000). Participants with any form of PN were recruited from the Peripheral Nerve clinic 
and inpatient neurology ward at Guy’s and King’s College Hospitals, London. With permission 
from the local ethics committee and after informed consent was given, 35 people were filmed 
performing the tasks involved on the ONLS in addition to completing the ONLS, ODSS and 
several other questionnaires(detailed below). 
With audit committee approval, the ONLS questionnaire was then audited in 65 more people 
attending the Peripheral Nerve clinic at Guy’s Hospital. The ONLS interview was administered 
and scored according to the instructions in Appendix Three. 
 Sample Size 
The estimate of the sample needed to investigate the properties of the ONLS was informed by 
Merkies et al. (2002b) who recruited 113 participants when initially evaluating the ODSS.  
 Face validity 
Sixteen neurologists were shown the ODSS and ONLS and asked to anonymously complete a 
short questionnaire. They were asked which questionnaire they preferred (ODSS or ONLS), if 
they would be interested in using the ONLS in clinical practice and how well they considered 
the ONLS captured common problems in people with PN (very well, well, not very well, not at 
all).  
 Concurrent validity 
The ODSS, ONLS interview and observed measures were administered by a physiotherapist 
(the author) or consultant neurologist (Professor R.A.C. Hughes). All questionnaires were 
completed in random order.  
Scores on the ONLS interview and the observed version were compared to several other self 
report tools. These were the ODSS, SF-36 questionnaire, the Rotterdam handicap scale 
(discussed in Chapter One) and the Walk-12 (described and evaluated in Chapter Four) to 
investigate concurrent validity (Hamilton 1991; Hobart et al. 2003; Merkies et al. 2002b; 
Merkies et al. 2002c). Associations between scores on the ONLS, ODSS and these tools were 
examined separately in people with GBS, CIDP and other PN, to identify if either outcome tool 
remained similarly valid in wider forms of PN.  
Measurements from routine clinical assessment were also collected. These comprised the 
time taken to walk ten metres as fast as safely possible (described in Chapter One, Page 55) 
(van Loo et al. 2003) and the isometric strength of the following pairs of muscles graded from a 
maximum of 70 by an expert neurologist (Professor R.A.C. Hughes) using the Medical 
Research Council (MRC, Page 45) sum score (Kleyweg et al. 1991; Medical Research Council 
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1976): shoulder abductors, elbow flexors, wrist extensors, first dorsal interossei, hip flexors, 
knee extensors and ankle dorsiflexors. 
3.4.2. Hypotheses 
It was hypothesised that: 
H1: ONLS scores would demonstrate significant and strong associations with the ODSS and 
physical function subscale on the SF-36, 
H2: ONLS or ODSS scores would not correlate strongly with the mental health and role 
limitation due to emotional problems subscales on the SF-36 questionnaire, 
H3: ONLS scores would demonstrate significant and strong associations with the Walk-12 and 
ODSS scores would not, as the ONLS is more sensitive to lower limb limitations 
Null hypothesis (H0): there would be no significant association between the ONLS, ODSS or 
SF-36 and, that associations between the ONLS and Walk-12 would be similar to those 
between the ODSS and Walk-12. 
and 
H4: scores from the ONLS administered as an observed measure, would correlate less 
strongly with data collection tools based upon participant report, compared to scores from the 
ONLS applied as a questionnaire. 
Null hypothesis(H0): scores from the ONLS administered as an observed measure would 
demonstrate similar correlations with data collection tools based upon participant report, to 
scores from the ONLS applied as a questionnaire. 
Correlation coefficients were judged to be small/low (0.1-0.3), moderate (0.3-0.6) or 
large/strong (>0.6) according to published criteria (Cohen 1977). 
3.4.3. Reliability 
 Inter-rater reliability 
In 20 participants, two raters completed the ONLS interview on the same occasion.  
Film footage of 35 people performing the tasks on the ONLS was scored independently by four 
raters, two consultant neurologists (Professor R.A.C. Hughes, Dr Paul Holmes) and two senior 
physiotherapists (Dr Claire White and the author). 
 Intra-rater reliability 
Video footage of ten people performing the activities described on the ONLS was re-scored by 
one rater (the author) three months after the first assessment. 
3.4.4. Responsiveness 
A longitudinal design was utilised to assess responsiveness (Sim and Wright 2000). Repeated 
measurements of the ONLS interview and ODSS were collected over one year from 19 
participants. Five participants were re-assessed on a third occasion, producing 24 repeated 
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ODSS and ONLS scores. Seventeen participants also rated their abilities relative to their 
previous assessment on a global rating scale (worse, same, better). These participants (n=17) 
were re-filmed and scored by one rater (the author) to determine the responsiveness of the 
ONLS as an observed measure. It was anticipated that all participants would undergo some 
change in their status over this time as they attended hospital for follow up and treatment. 
3.4.5. Analysis 
The distribution of scores on the ONLS and ODSS was examined to determine floor and 
ceiling effects. Differences between scores from the ONLS interview, ODSS and observation 
of the tasks outlined on the ONLS were examined using the Friedman (non parametric 
repeated measures) test.  
Associations between age and gender with ONLS and ODSS scores were investigated by 
examining scatter plots and calculating Spearman’s rank correlation coefficients.  
 Validity 
Responses from neurologists were examined to judge the face validity of the ONLS. 
Concurrent validity was investigated with Spearman’s rank correlation coefficients between the 
ONLS, observed ONLS and the ODSS scores, and subscales on the SF-36, the MRC sum 
score, Walk-12 questionnaire, Rotterdam handicap scale and ten metre walk time. These were 
repeated for two diagnostic subgroups, people with GBS and CIDP and those with other forms 
of PN. Correlation coefficients were compared to test the hypotheses listed on Page 109.  
 Reliability 
Agreement between two raters completing the ONLS interview and the ODSS, and between 
four raters assessing the observed ONLS, was measured by counting the number of cases 
when raters disagreed. 
An ICC between two raters’ scores on the ONLS and ODSS were calculated using a one-way 
random effects model to allow direct comparison with previous reports of reliability of the 
ODSS questionnaire (Merkies et al. 2002a) and as values were identical to non-parametric 
weighted Kappa tests. Similarly, a two way random effects ICC was also calculated between 
the scores of four raters on the ONLS administered as an observed tool (Weir 2005). 
Significance was set at p<0.05 for all tests. 
 Responsiveness 
Twenty four repeated measurements (n=19) on the ONLS and ODSS, and from 17 participants 
who were reassessed by one rater (the author) on the observed ONLS were tested using a 
two tailed Wilcoxon test to determine significant changes in scores.  
As the data were assumed to be non-parametric, responsiveness was initially assessed using 
the median change in scores and the inter quartile range (Hamilton 1991). However, the 
median change on the ONLS, ODSS and the observed ONLS was zero, despite some 
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changes of 1 or 2 points. Therefore, responsiveness was estimated using the standardised 
response mean (SRM):  
Absolute mean change in score
SRM
SD of mean change in score

 
A measure was considered to have good responsiveness if the SRM exceeded 0.8; moderate 
responsiveness was indicated by values from 0.5-0.8 (Cohen 1977).  
The participant’s perception of change in their abilities since their last measurement and any 
alteration in ODSS and ONLS scores was examined heuristically in 17 participants by counting 
the number of cases in which the direction of change in scores agreed with the individual’s 




3.5.1. Participants  
One hundred participants, including four inpatients, were recruited. Their characteristics are 
shown in Table 3-1. 
 
Table 3-1 Participant characteristics. 
Participant characteristics n=100 
Gender (n) Male 51 
 Female 49 
Mean Age, SD; range 
(years)  
58  15.1; 19.7–83.1  
Median ONLS scores, 
range  
4 0-12 
Median ONLS Obs, 
range (n=35) 
4 0-11.5 
Median ODSS scores, 
range 
4 0-12 





Observed ONLS scores (ONLS Obs) are median score and range for four raters. PDN - 
Paraproteinaemic demyelinating neuropathy; CIAP - Chronic Idiopathic Axonal 
Polyneuropathy. Other neuropathies included: Charcot-Marie-Tooth disease: 9, sensory 
multiple mononeuropathy: 5, mild generalised neuropathy: 3, vasculitic neuropathy: 2, 
idiopathic radiculomyelopathy: 1.  
 
There were no significant associations between ONLS or ODSS scores and age or gender 
(r<0.3). There were no significant differences between scores on the ONLS, observed ONLS 
and ODSS (Friedman test, p=0.12). 
3.5.2. Floor and ceiling effects 
Two (2%) of the total scores (sum of lower and upper limb sections) on the ONLS and three 
(3%) on the ODSS were at the floor (highest available score, indicating maximal activity 
limitations) or ceiling (zero, indicating no activity limitations) of the scale. When lower limb 
section scores were examined, five participants scored zero (ceiling) on the lower limb section 
of the ODSS, indicating no activity limitations, but scored one, indicating some activity 






Figure 3-1 Scatter plot to show relationship between ONLS and ODSS lower limb scores.  
 
Lines at each point (sunflowers) represent multiple cases (n=100). 
 
3.5.3. Validity  
 Face validity 
All consultant neurologists (n=16) independently preferred the ONLS to the ODSS and 
considered it appropriate for use in clinical practice. All considered the ONLS superior to the 
ODSS, 12 stated they would be interested in using the ONLS in their clinical practice and all 
reported that the ONLS reflected common activity limitations experienced by people with PN 
well (n=13) or very well (n=3).  
 Concurrent validity 
There were no significant differences between the ONLS interview, observed ONLS and 
ODSS scores.  
The ONLS questionnaire correlated closely with the ODSS (r=0.97, p<0.001) as hypothesised 
(H1). The observed ONLS also correlated significantly with the standard ONLS (r=0.86, 
p<0.001) but was somewhat less strongly associated with the ODSS (r=0.81, p<0.001). 
Correlations between the ONLS and ODSS, and ONLS and ONLS observed are shown in 





Figure 3-2 Scatter plot to show correlation 
























Lines at each point denote multiple cases 
(sunflowers), r = Spearman’s rank  correlation 
coefficient. 
Figure 3-3 Scatter plot to show correlation 


























The ONLS and ODSS had similar, moderate and significant correlations with the SF-36 
physical function subscale (r>0.6) and strong associations with the RHS (r>0.75) shown in 
Table 3-2. As hypothesised (H2), the ONLS (questionnaire and observed measure) did not 
correlate strongly with mental health or role limitation due to emotional problems subscale 
scores on the SF-36 (r<0.4). The associations between these measures and the ODSS were 
also weak (r<0.4). 
The ONLS and ODSS demonstrated similar correlations with measures of strength and 
walking speed (MRC sum score, both ONLS and ODSS r=0.6, and ten metre walk times: 
ONLS r=0.58; ODSS r=0.54) whilst the ONLS had a somewhat stronger association with the 
Walk-12 questionnaire than the ODSS (ONLS: r= 0.65, 95% CI: 0.48 to 0.77, ODSS: r=0.43, 
95% CI: 0.21 to 0.61). Scores from the ONLS administered as an observed measure also 
demonstrated slightly weaker associations with the SF-36 physical function and Rotterdam 
handicap scales than the ONLS questionnaire, as predicted (r=0.67 and 0.63 respectively). 








n=35 for Observed and interview ONLS 
115 
 
Table 3-2 Scores and Spearman's rank correlations for the ONLS, observed ONLS and ODSS. 
  Spearman’s rank correlation coefficients (r) 




39 (0-80) -0.65 <0.01 -0.63 <0.01 -0.66 <0.01 
Mental health 72 (24-96) -0.24 ns -0.23 ns -0.24 ns 





70 (0-100) -0.013 ns -0.09 ns -0.004 ns 
PCS 35.6 ±11 -0.55 <0.01 -0.54 <0.01 -0.56 <0.01 
MCS 50 ±11 0.01 ns 0.01 ns 0.03 ns 




0.58 <0.01 0.38 0.05 0.54 <0.01 
MRC Score 
(n=97) 
62 (16-70) -0.62 <0.01 -0.72 <0.01 -0.6 <0.01 
Walk-12 
(n=65) 




30 (9-36) -0.77 <0.01 -0.67 <0.01 -0.77 <0.01 
n=35 unless otherwise stated, n=35 for all observed ONLS (ONLS Obs) correlations. Scores 
are median (range) except for physical and mental component summary scores (PCS and 
MCS) which are mean ±SD. 
 
The ONLS and ODSS correlated strongly with each other in people with GBS and CIDP 
(r=0.98, n=54) and in those with other neuropathies (r=0.96, n=46). The scores on the ONLS 
from observation were similarly associated with other parameters and the ONLS questionnaire 
when examined in people with GBS or CIDP (r=0.87) and other PN (r=0.84). 
The ONLS and ODSS also had similar associations with many of the other clinical measures in 
different forms of PN (Table 3-3). However, associations between the role limitation physical 
subscale of the SF-36 and the ONLS and ODSS were strong and statistically significant in 
people with GBS and CIDP (r=0.65, p<0.01), but weak and non significant in those with other 
PN (ONLS: r=0.09; ODSS r=0.04, both p>0.05). Strength measured using the MRC sum score 
also had weaker associations with ONLS and ODSS scores (r=0.35; p<0.01) in people with 




Table 3-3 Association between ONLS and ODSS scores and measures of health status and participation 
for people with GBS or CIDP and other PN. 
Spearman’s rank correlations (r) 
  ONLS p ODSS P 
GBS and 
CIDP 
SF-36 : Physical Function -0.72 <0.01 -0.8 <0.01 
Mental health -0.41 ns -0.42 ns 
Role limitation due to 
emotional problems 
-0.35 ns -0.35 ns 
 Role limitation due to 
physical problems 
-0.65 <0.01 -0.65 <0.01 
 MRC (n=50) -0.87 <0.01 -0.87 <0.01 
 10 m walk time (n=37) 0.54 <0.01 0.53 <0.01 
 RHS  -0.82 <0.01 0.85 <0.01 
Other PN  SF-36 : Physical Function -0.65 <0.01 0.59 0.01 
Mental health 0.02 ns 0.17 ns 
 Role limitation due to 
emotional problems  
0.29 ns 0.34 ns 
 Role limitation due to 
physical problems 
-0.09 ns -0.04 ns 
 MRC (n=47) -0.38 <0.01 -0.38 <0.01 
 10 m walk time (n=33) 0.68 <0.01 0.63 <0.01 
RHS  -0.81 <0.01 -0.83 <0.01 
n=17 for GBS and CIDP and n=18 for other PN unless otherwise stated. Ten metre walk times 
are measured in seconds. RHS- Rotterdam handicap scale. 
 
3.5.4. Reliability 
There was near perfect agreement between two independent raters who administered the 
ONLS and ODSS (ICC=0.97 for both). They agreed 19 times out of 20 on the interview ONLS 
and 18 times out of 20 on the ODSS. 
On the observed ONLS, four different raters agreed in 18 cases from 35 (ICC=0.97). There 
were no significant differences between individual raters’ scores. In the 17 cases where all 
raters did not agree, three raters agreed on nine cases and two raters agreed on the remaining 
eight cases.  
Within professions, there were ten cases in which the scores between the consultant 
neurologists did not agree and eight cases where the scores between physiotherapists 
disagreed. Physiotherapists’ and consultants’ scores did not agree in eight cases.  
There was perfect intra-rater agreement between the scores of one rater (the author) when 
film footage of ten participants performing the tasks outlined on the ONLS was rescored three 
months later. 
When the median scores from four raters on the observed ONLS were compared with those 
from interview (n=35), 23 readings were within one point of each other. Nine individuals 
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reported greater activity limitations than were identified from observation of performance of the 
tasks on the ONLS, and three reported fewer activity limitations than were judged from 
observation. 
3.5.5. Responsiveness 
There were no significant differences between 24 repeated measurements on the ODSS and 
ONLS. Both tools measured similar changes after a mean of 31 weeks between 
measurements (range: three days to 52 weeks) as shown in Table 3-4. 
The SRM of the ONLS questionnaire was 0.76 (95% confidence limits calculated using a 
‘bootstrap’ technique
2
= 0.67 to 0.81) and the ODSS was 0.88 (0.8 to 0.95) (Efron 1979). The 
SRM for ONLS scores from observation was 0.83 (0.22 to 0.95). 
When 17 participants were asked to identify any change in their abilities compared to previous 
measurements, seven patients felt they had deteriorated, five felt they had not changed since 
the previous measurement and five felt better. The ONLS scores detected these changes in 
only two cases and the ODSS in four cases. The median ONLS and ODSS scores on 
repeated measurements are shown in Table 3-4. 
Table 3-4 Median scores for repeated measurements on the ODSS and ONLS. 
 ONLS ONLS Obs ODSS 
Measurement one 4 (1-7) 4 (1-6) 3.5 (1-7) 
Measurement two  4 (1-6) 3.5 (1-5.5) 4 (1-6) 
All values are median (range) for 24 repeated measurements on ONLS and ODSS and 17 
measurements for the ONLS Obs. 17 from 24 participants were asked to rate the change in 
their health. 
 
                                               
2




The ONLS was derived from the ODSS to overcome a ceiling effect apparent on the lower limb 
scale in Chapter Two by including questions about running and climbing stairs. This study 
investigated the reliability, validity and responsiveness of the ONLS and the ODSS in people 
with PN.  
The results demonstrated that the ONLS had similar reliability to the ODSS. However, the 
ONLS had better face validity and had a somewhat stronger association with mobility scores, 
measured by the Walk-12 questionnaire, than the ODSS suggesting improved sensitivity to 
mobility problems. The ONLS also had fewer scores at the ceiling (scoring zero) of the lower 
limb section (n=8, 8%) when compared to the ODSS (n=13, 13%) although both the ODSS 
and ONLS had scores within the recommended limits for floor and ceiling effects (McHorney 
1998). The changes made to develop the ONLS also provided greater face validity; the ONLS 
has since been used as an outcome tool in a European randomised controlled trial of 
methotrexate in CIDP (RMC trial group 2009). However, the changes made to the ONLS 
appeared to somewhat reduce its responsiveness when compared to the ODSS (SRM: ONLS: 
0.76; ODSS: 0.88), although the responsiveness of the ONLS was still considered moderate 
according to published criteria (Cohen, 1977). 
Whilst the ODSS and ONLS could be considered to be representative indicators of ADL 
(Dittmar and Gresham 1997), a potential limitation of both scales is that they only comprise a 
restricted number of questions about common ADL which may not capture an individual’s 
specific problems. There are several tools which specifically question mobility, including the 
Walk-12 investigated in Chapter Four. However, adapting the ODSS to include mobility items 
was considered preferable to using an additional tool to avoid increasing respondent burden, 
unless specific evaluation of mobility was required.  
The suitability of the ONLS to measure activity limitations was supported by reports that 
climbing stairs is difficult for many people with PN, indicating it is an important activity to 
assess as it affects functioning both in the home and workplace (Erdmann et al. 2005). 
Similarly limitations in the ability to run are reported by over 24% (from 42) of people several 
years after GBS and could contribute to the reduction in leisure activities and sports reported 
after PN, indicating that assessing this ability is also important (Forsberg et al. 2004). The 
ability of the ONLS to measure these aspects of mobility was demonstrated in this study as 
ONLS scores were significantly and strongly associated with scores on the Walk-12 
questionnaire (r=0.65) (Table 3-2). 
This study utilised participants with a wider range of PN than those in the Merkies et al.‘s 
(1999) original study of the ODSS. This aimed to increase the external validity of the findings 
and thus the clinical usefulness of both the ODSS and ONLS. The ONLS and ODSS 
demonstrated similar associations in people with GBS and CIDP and those with other PN on 
several clinical measures. However, the ONLS and ODSS did not correlate significantly with 
the SF-36 role limitation physical (RLP) subscale in neuropathies other than GBS and CIDP 
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(SF-36 RLP, r<0.1). Both were also less strongly associated with strength (MRC sum score, 
r<0.4; Table 3-3) in participants with other PN. Although these results should be viewed with 
caution because of the relatively small size of the subgroups, they suggest that people with 
GBS and CIDP are limited in a slightly different way to people with other PN. This finding also 
indicates that that the tools used in inflammatory PN cannot always be assumed to be similarly 
valid in other PN. Consequently, the ONLS and ODSS should be used with appropriate 
caution in PNs other than GBS and CIDP until their properties have been investigated further. 
The ONLS demonstrated slightly less responsiveness to change than the ODSS when 
evaluated from 24 repeated measurements of 19 individuals (SRM ONLS: 0.76; ODSS: 0.88). 
This finding is likely to be due to differences in scoring; a zero score on the ONLS lower limb 
scale requires no problems with running, walking or stair climbing whilst a zero score on the 
ODSS only requires no difficulty walking. This small difference makes it more difficult to 
improve from one to zero on the ONLS. Whilst the addition of these extra activities increased 
the validity of the ONLS, it appears to have reduced its responsiveness and so somewhat 
decreased its suitability to measure changes after treatment or interventions. This is a 
limitation which is common to many traditionally developed outcome tools, even when they are 
adapted, but may be remedied by newer, statistically orientated approaches to outcome tool 
development such as Rasch analysis (discussed on Page 123).  
Interestingly, changes in the ODSS and ONLS scores did not concur with the participant’s 
perception of change in their abilities (worse, same, better) in the majority of cases (ONLS: 2 
from 17 cases; ODSS: 4 from 17 cases). This could be because the activities measured by the 
ONLS or ODSS did not examine areas that were important to participants. It is perhaps more 
likely that because responsiveness in this study was assessed in a small sample of outpatients 
who experienced relatively minor improvements and deteriorations in their clinical status, it 
was more difficult to detect an overall response. As participants were not undergoing large 
changes in their activities, they may have based their perception of change upon factors which 
are not measured on the ONLS or ODSS, including general and mental health. Others have 
reported greater agreement (r=0.67) between ODSS scores and the participant’s perception of 
change from 201 repeated measurements taken over one year in participants who were 
undergoing substantial changes in their functioning (Merkies and Schmitz 2006). Large 
responsiveness (SRM >1) of the ODSS was also found (Merkies and Schmitz 2006). These 
participants were receiving treatment for CIDP or were recovering from GBS, and thus 
experienced larger improvements than participants in the current study, which is likely to 
influence the level of responsiveness. 
Although the ONLS demonstrated moderate responsiveness, the somewhat stronger 
responsiveness seen on the ODSS deters from using the ONLS to measure change in future 
work (Cohen 1977). If the ONLS is to be used in future studies, its responsiveness would need 
to be re-examined in a larger group of people with PN who are experiencing changes in their 
activities to determine if it is able to measure change. 
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 Observation of activities 
The observed ONLS was designed to allow raters to observe participant activities, rather than 
ask people about how they would usually perform the tasks outlined by the questionnaire. An 
observed scale may be useful if an individual has difficulty communicating or there are other 
factors which may unduly influence the accuracy of their report. However, observation of 
performance may not be practical in a clinical environment and differences between the clinical 
and home setting may result in different levels of performance. This was shown by the less 
than perfect agreement between scores obtained by the questionnaire and observed ratings of 
people completing the tasks on the ONLS. This is consistent with report and performance of 
activities being influenced by factors in addition to physical capacity, including environmental 
and contextual aspects, motivation and personal variables (Schwartz and Spranger 1999; 
Wade 2001; World Health Organisation 2001). These results also indicate that the 
questionnaire and observed versions of the ONLS are not interchangeable. 
The observed ONLS is complicated by the need for standardised equipment and by reduced 
inter-rater reliability. The reduced reliability seen in this study (17 from 35 cases were not 
agreed by all four raters) is likely to be because the observed score is dependent upon the 
rater’s subjective opinion of the quality of the performance of the tasks and raters were not 
provided with formal training regarding the scoring of the observed ONLS. Whilst training is 
recommended to optimise the reliability of outcome measurement, it significantly increases 
administrator burden (Ottenbacher et al. 1996). Inter-rater reliability may have also been 
reduced in this study as participants were filmed and so raters could not adjust their position to 
obtain a clearer view of the tasks being performed.  
In light of these limitations, the questionnaire version of the ONLS should be used in 
preference to the observed ONLS. As relatively few people with PN had difficulty completing 
the questionnaire ONLS in this study, the value of further work to refine the observed version 
of the ONLS is unclear. If an observed outcome tool was required, further work including 
formal assessor training and re-investigation of the reliability of the observed ONLS in a range 
of patients with PN would be needed. Alternatively, future work could seek to investigate the 
suitability of other tools based on observation or proxy report, such as the Frenchay Activities 
Index, for people with PN (Tooth et al. 2003). 
3.6.1. Limitations 
The conclusions from this study are limited by a number of factors. Both the ONLS and ODSS 
questionnaires are based upon respondent’s report, and so may be affected by a range of 
personal, social and environmental factors, a desire to please the rater and by phenomena 
including response shift. Response shift (also discussed in Chapter One, Page 44) occurs 
when an individual recalibrates their perceptions and standards to accommodate to changes in 
their health and affects the accuracy of report (Spranger and Schwartz, 1999). These factors 
are inherent to all tools which rely upon participant report but should be considered when 
viewing the data they yield. 
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The ONLS and ODSS were developed without direct involvement of PN patients. This means 
that the items, whilst generic, may not be the most appropriate or relevant to this patient group. 
Whilst this is a limitation common to many tools, patient and public involvement (PPI) would 
allow new tools to be developed that reflect the key issues faced by people with PN and 
increase their suitability for research and clinical use (INVOLVE 2012).  
The small sample utilised in some sub group analyses, such as the estimation of 
responsiveness and measurement of validity in different diagnostic groups, reduced the 
external validity of the findings. As the raters were the authors of the ONLS, their expectations 
are likely to have introduced bias in the collection and interpretation of data. The assessment 
of face validity is also likely to be biased as it was based upon the answers of neurologists 
whose opinions may be influenced by a desire to please the authors of the ONLS. Although 
this is a limitation of the evaluation of many published outcome tools, it suggests that 




This study modified the ODSS to produce the ONLS outcome tool to measure common activity 
limitations experienced by people with PN. Both were evaluated in a wide range of PN. The 
ONLS correlated well with the ODSS, retaining the simplicity of this tool whilst improving its 
ability to measure minor lower limb limitations. This also reduced the number of scores at the 
ceiling of the scale. This provided the ONLS with better face validity, supporting its use over 
the ODSS. The ONLS also demonstrated a strong association with the Walk-12, indicating it 
was able to better reflect aspects of mobility than the ODSS. However, the ODSS 
demonstrated a slightly higher level of responsiveness than the ONLS which deters from using 
the ONLS to measure change. Further work is necessary to re-examine the responsiveness of 
the ONLS in a larger sample undergoing greater changes in their functioning before it can be 
used in clinical settings, as it appears that the improved ability to measure mobility problems 
gained by refining the lower limb criteria has inadvertently reduced its ability to reflect change. 
Despite several similar strength correlations with the SF-36 and its subscales and other tools 
in all participants, the ONLS and ODSS were only significantly associated with the role 
limitation physical subscale of the SF-36 in GBS and CIDP and not in other PN. Although this 
may be an artefact of the sample size, this indicates that people with different PN may be 
affected somewhat differently and that similar validity of the ODSS and ONLS cannot be 
assumed in all types of PN.  
The ONLS observed scale developed here could be used as an alternate measure of activity 
limitations in people with PN, but is only recommended if the ONLS questionnaire cannot be 
used. Scores between observed and questionnaire versions are not interchangeable, which 
confirms that self report is influenced by a range of factors not captured by observation.  
The ONLS now requires independent evaluation in other patient settings in comparison to 
other validated ADL tools and in different groups of PN. Future work should also seek to 
develop new measures of activity limitations and/or evaluate other activity limitation tools to 




3.8. Postscript: developments since 2009 
In 2011, Van Nes et al. published a patient based linear scale of activity limitations for people 
with PN, developed using Rasch analysis (Bond and Fox 2007; van Nes et al. 2011). This was 
developed to overcome limitations in the existing tools measuring activity limitations in people 
with PN which are based upon expert consensus (van Nes et al. 2011). Traditional outcome 
tools require respondents to complete all items, even if some are irrelevant and assume that 
all items are equally weighted. Rasch developed tools use the probability of a specified 
response to eliminate redundant items and provide a true unidimensional, linear scale. Items 
on the new tool for people with PN, called the Rasch built Overall Disability Scale (R-ODS) 
were derived from the International Classification of Functioning, literature search and patient 
interviews. Respondents indicated if they had no difficulty (2), some difficulty (1) or were 
unable to do (0) a range of activities including eating, brushing their teeth and turning a key in 
a lock. These initial questionnaires were sent to people with a clinically stable immune 
mediated polyneuropathy who also completed the ODSS. Two hundred and ninety four people 
returned the questionnaires (GBS;174, CIDP:80, Monoclonal gammonopathy: 40). Rasch 
analysis of their responses refined the original 146 items to 24 which formed the R-ODS. 
Scores from the R-ODS had acceptable ceiling effects (5.8%), correlated strongly with the 
ODSS (r=0.85) and appeared reliable (ICC >0.9). Items derived from Rasch analysis which 
appear on the R-ODS, but are not measured on the ODSS, include the ability to run and climb 
stairs which further supports their inclusion in the ONLS. Whilst the R-ODS has more items 
than both the ODSS and ONLS it is still likely to have an acceptable burden. The R-ODS has 
advantages over the ONLS and ODSS as it is able to measure a wider range of activities, has 
fewer redundant items and demonstrates similar validity and reliability. The performance of the 
R-ODS now requires independent evaluation in patient groups outside the Netherlands and its 
responsiveness must be established if it is to be used to indicate change. 
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Chapter 4. Measurement of mobility in 
people with peripheral neuropathy 
4.1. Summary 
Many people with inflammatory peripheral neuropathies (PN) experience difficulty with 
mobilising. In this Chapter, the properties of three different outcome tools were investigated to 
determine if they were suitable to reflect aspects of ambulant mobility in people with PN.  
Study One: The Walk-12 measures an individual’s perception of their mobility and was 
investigated in a prospective study of 65 patients with PN. The Walk-12 was valid as it 
demonstrated several strong correlations with other tools (r= 0.72 with SF-36 Physical 
component summary score and r= 0.86 with SF-36 Social Function score, all n=15; r=0.77 with 
ONLS lower limb subscale, n=50) and was internally consistent (Cronbach’s alpha α=0.96, 
n=61) and reliable (test re-test reliability ICC=0.96, n=12). Although originally designed for 
people with multiple sclerosis (MS), this study indicated that the Walk-12 could be used to 
measure self-reported wider mobility in ambulant people with PN if its responsiveness can be 
established.  
Studies Two and Three: The physiological cost index (PCI), was originally designed as a 
quick and low technology measure of the energy used whilst walking. However, the optimal 
dimensions of the track used to measure the PCI and the properties of the PCI in PN have not 
been determined. In Study Two, PCI values in 40 healthy participants measured on two 
differently shaped tracks were compared. The results showed that a 20 metre figure of 8 track 
facilitated a faster self-selected walking speed than a 12 metre figure of 8 track (mean ±SD 
self-selected walking speed on 20 m track= 70.7 ± 13 metres min
-1
; 12 m track= 63.2 ± 12 
metres min
-1
). Studies Two and Three also examined the validity of the PCI and compared 
results to a new adaptation of the PCI, the mPCI using energy cost (EO2) as a criterion 
measure of the energy used whilst walking. Responsiveness of the mPCI and PCI was 
assessed using changes in 14 PN participants from the exercise intervention in Chapter Two. 
The results showed that the PCI had limited validity (correlations with EO2 were r= 0.03 and r= 
0.21 in healthy and PN participants respectively) and demonstrated large variability on 
repeated measurements. The mPCI showed greater validity than the PCI in both healthy and 
PN participants as correlations with EO2 were somewhat stronger (r= 0.34 and r= 0.87 in 
healthy and PN participants respectively) and discriminated between participants who walked 
independently and those who used walking aids. It also had better responsiveness than the 
PCI (mPCI: SRM: 0.62, PCI: 0.27). 
Further work is necessary to confirm the properties of the Walk-12 in inpatients with PN, 
assess its responsiveness and determine the test re-test reliability and responsiveness of the 
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mPCI in a larger sample of people with PN. However, both are promising tools to measure 
meaningful aspects of mobility in people with inflammatory PN.  
The studies in this chapter have been published and full papers are appended to this thesis:  
Graham, R.C., Smith, N.S., White, C.M. The reliability and validity of the physiological cost 
index of walking in health participants when walking on two tracks. Arch Phys Med Rehab 
2005 Vol. 86, p. 2041-2046 
Graham, R.C., Smith, N.S. White, C.M. An investigation of the physiological cost index of 
walking. Abstract, International Society for Posture and Gait Research proceedings. Gait and 
Posture. 2005 Vol. 21, S1; S147 
Graham, R.C., Smith, N.S. White, C.M. The reliability and validity of the physiological cost 
index on two different tracks. Abstract Clin Rehabil 2005 Vol. 19, p 576 -577 
Graham, R.C., Hughes, R.A.C. Clinimetric properties of a walking scale in peripheral 





Mobility describes a number of ways of moving including walking, changing positions and 
moving effectively in normal surroundings (World Health Organisation 2001). Normal mobility 
is a complex activity. It depends upon an integrated nervous system to provide sufficient motor 
drive and sensory feedback to allow smooth progress of the body through space, using the 
smallest amount of energy possible (Prince et al. 1997; Waters and Mulroy 1999). Difficulty 
mobilising is a significant feature of many neurological conditions, including PN, and so is a 
frequent focus of rehabilitation (Lord et al. 1992; Pearson et al. 2004).  
As discussed in Chapter One, the majority of people with inflammatory PN will maintain or 
regain the ability to walk but will have some residual difficulties. Common persistent mobility 
problems in PN include reduced walking speed, difficulty running, and difficulty walking long 
distances and outside (Busse et al. 2006; Erdmann et al. 2005; Forsberg et al. 2004; Forsberg 
et al. 2005; Lennon et al. 1993). In one small survey, 80% (of 12 people) with CIDP reported 
difficulty climbing stairs and running whilst almost a quarter (24% of 42) of people after GBS 
remained unable to run several years after nadir (Erdmann et al. 2005; Forsberg et al. 2004).  
4.2.1. Measuring mobility 
A person’s ability to ambulate influences their capacity to perform simple activities of daily 
living and to interact within the wider community (Chiou and Burnett 1985; Lord et al. 2004). 
Changes in mobility often indicate disease progression or improvement in response to a range 
of treatments, including rehabilitation, yet there is no standard way of measuring an 
individual’s usual ambulation (Pearson et al. 2004).  
The time taken to walk a specified distance (often ten metres) is a commonly used indicator of 
mobility. As reported in Chapter One, ten metre walk times are considered reliable and 
responsive in people with a range of neurological conditions, including PN (Merkies et al. 
2003a; Rossier and Wade 2001; Salbach et al. 2001; van Loo et al. 2003). However, the ten 
metre walk times of PN participants were not significantly different from baseline after the 
exercise intervention (Chapter Two) despite significant improvement in reported physical 
functioning. Whilst this may indicate that mobility was not affected by the intervention, it could 
also be because an assessment of walking speed over a short distance in a safe, well lit, 
standard environment does not reflect usual walking performance (Thies et al. 2005). This 
indicates that other tools that directly measure aspects of a participant’s usual mobility should 
be considered for people with PN.  
 Measurement of self-reported mobility 
In contrast to objective measurement of walking, self-reported mobility indicates perceived 
functioning in a respondent’s usual environment. It is already measured by some activity and 
participation tools in PN (e.g. the Overall Disability Sum Score, ODSS, and Rotterdam 
Handicap Scale, RHS) (Merkies et al. 2002a; Merkies et al. 2002b) but items typically focus 
upon the assistance or aids required to walk and do not question other aspects of mobility 
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such as effort and quality of walking. Whilst these features are beyond the scope of a global 
activities of daily living scale (ADL) they may influence mobility in the community and 
independence and so warrant measurement (Lord et al. 2004; Rossier and Wade 2001; 
Shumway-Cook et al. 2002).  
One tool that reflects wider aspects of mobility is the multiple sclerosis walking scale (MSWS-
12 or Walk-12). This self completed questionnaire was designed to capture aspects of mobility 
reported by people with MS (Hobart et al. 2003). The Walk-12 contains items about stairs, 
indoor and outdoor mobility and it also questions distance and the effort of walking. It does not 
measure non-ambulant mobility (such as turning in bed) which are unaffected in the majority of 
people beyond the acute illness or with a chronic PN (Forsberg et al. 2004). The Walk-12 has 
12 items scored on a five point Likert scale and is reported to be quick and easy to complete 
(Hobart et al. 2003). Since the development of the Walk-12, its properties have been evaluated 
in 120 people with a range of neurological conditions and shown to be acceptable, valid and 
reliable (Holland et al. 2006). This supports its use in PN, although it was not responsive to 
changes after rehabilitation in people with spinal cord injury (Holland et al. 2006). Despite 
being developed for people with MS, all items also appear suitable to capture common mobility 
limitations in PN including stair climbing, walking on uneven surfaces and running. Therefore, 
the validity, reliability and responsiveness of the Walk-12 in people with PN were investigated 
in Study One in this Chapter.  
 Measurement of the energy used when walking 
People with PN often have decreased muscle strength, poor balance, reduced sensation 
and/or reduced aerobic fitness which increases the energy used when mobilising (Mueller et 
al. 1994; Pearson et al. 2004; Thoumie and Mevellec 2002). These increased energy demands 
can reduce walking distance or prevent walking in some environments, which indicates that 
measurement of energy use is warranted in this patient group (Boyd et al. 1999; Brehm et al. 
2006; Waters and Mulroy 1999). Energy usage can be measured most accurately by direct or 
indirect calorimetry. However, both systems are expensive, cumbersome and are not available 
in the majority of clinical settings. The Physiological Cost Index (PCI) and modified PCI (mPCI) 
are low technology, low cost alternatives which could be used to measure the energy used 
whilst walking in people with PN if their validity, reliability and responsiveness can be 
established (MacGregor 1979). Therefore, Studies Two and Three in this chapter investigated 
the properties of the PCI and mPCI as potentially cheap and simple alternative measurements 
of energy use when walking in healthy and PN participants.  
4.3. Objective  
The overall objective of the studies in this Chapter was to examine the validity, reliability and 
responsiveness of the Walk-12, PCI and mPCI outcome tools as measures of mobility in 
people with PN. 
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4.4. Study One - The validity and reliability of the Walk-12 
questionnaire for people with peripheral neuropathy 
4.4.1. Aim 
The aim of this study was to investigate the validity and reliability of the Walk-12 to measure 
self reported mobility in people with PN. 
4.4.2. Background 
The MS walking scale, renamed the Walk-12, questions self-perceived mobility (Hobart et al. 
2003). The Walk-12 is completed by the respondent. It has 12 items which are answered using 
a Likert scale (1-5, shown overleaf). It contains items which question mobility activities 
including walking, running and stair climbing. Overall scores are calculated using the equation: 
Total score minimum score (12)
Walk 12 score x100
Maximum score possible 12
 
   
 
 
A higher score indicates greater limitation in mobility and walking ability (Hobart et al. 2003; 
Holland et al. 2006). 
The Walk-12 measures the respondent’s perceived limitations of their mobility due to their 
condition and was generated for people with MS from patient interview, literature review and 
expert opinion (Hobart et al. 2003). It has demonstrated excellent internal consistency 
(Cronbach’s α= 0.97) and test re-test reliability (ICC=0.94) in over 400 people with MS (Hobart 
et al. 2003). It was also valid and internally consistent in two hospital based samples (n=132) 
and responsive to change after treatment (effect size=0.93) (Hobart et al. 2003).The internal 
consistency, validity and responsiveness of the Walk-12 were independently confirmed in 
community based participants and outpatients with MS (McGuigan and Hutchinson 2004) and 
have been investigated in 120 inpatients after spinal cord injury (SCI) and stroke (Holland et al. 
2006). In these groups, the Walk-12 was broadly appropriate, internally consistent and 
responsive although responsiveness was less in spinal cord injured participants and test re-
test reliability was not assessed (Holland et al. 2006).  
There are no validated measures of self-reported mobility used in PN currently despite these 
data being useful in increasing understanding of functioning. Although PN and MS are very 
different, the similarities of activity limitation and favourable properties of the Walk-12 in other 
neurological groups indicate that it deserves consideration in PN. The items on the Walk-12 
are generic functions, irrespective of neurological diagnosis, further supporting its evaluation in 
PN. It also has good face validity, as it examines limitations in mobility which many people with 
PN clinically report as troublesome. It also provides indications of usual functioning in the 
community, which are not captured by objective, clinically based measurements. 
 Outline of the Walk-12 questionnaire 
The Walk-12 questionnaire, given to participants, is shown overleaf.  
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Walking Scale Questionnaire (Walk-12) 
These questions ask about limitations to your walking due to peripheral neuropathy during the 
past 2 weeks 
For each statement please circle the one number that best describes your degree of limitation. 
Please answer all questions even if some seem rather similar to others, or seem irrelevant to 
you. If you cannot walk at all please tick this box □ 
 
In the past 2 weeks how 
much has your peripheral 
neuropathy… 
Not at all  A little Moderately Quite a 
bit 
Extremely 
Limited your ability to walk? 1 2 3 4 5 
Limited your ability to run? 1 2 3 4 5 
Limited your ability to climb 
up or down stairs? 
1 2 3 4 5 
Made standing when doing 
things more difficult? 
1 2 3 4 5 
Limited your balance when 
standing or walking? 
1 2 3 4 5 
Limited how far you are 
able to walk? 
1 2 3 4 5 
Increased the effort needed 
for you to walk? 
1 2 3 4 5 
Made it necessary for you 
to use support when 
walking indoors e.g. holding 
on to furniture, using a stick 
etc.? 
1 2 3 4 5 
Made it necessary for you 
to use support when 
walking outdoors e.g. using 
a stick or frame etc.? 
1 2 3 4 5 
Slowed down your walking? 1 2 3 4 5 
Affected how smoothly you 
walk? 
1 2 3 4 5 
Made you concentrate on 
your walking? 
1 2 3 4 5 
 
Please check you have circled one number for each question. 
Please hand this to the doctor at the start of your consultation. 
Thank you for completing this questionnaire. 





A cross-sectional design was used to investigate the concurrent validity, internal consistency 
and test re-test reliability of the Walk-12 in people with PN (Sim and Wright 2000).  
Fifteen volunteers with inflammatory PN were initially recruited from the Peripheral Nerve clinic 
at Guy’s Hospital, London, and from a volunteer database of participants from previous 
research at King’s College London (Group One). Local ethical approval was granted by Guy’s 
and St Thomas’s Hospital research ethics committee and participants gave informed consent. 
All attended King’s College London for testing on one occasion. A subgroup of 12 participants 
returned for re-measurement one week later.  
After initial investigation in this group (Group one), the Walk-12 was incorporated into routine 
clinical assessment of outpatients attending the Peripheral Nerve clinic at Guy’s Hospital. With 
local audit committee approval, the properties of the Walk-12 were examined in 50 patients 
attending the clinic (Group two). All participants had a secured diagnosis of PN and were 
ambulant for at least some part of the day.  
 Measurement 
 Group One 
All participants (n=15) completed the Walk-12, SF-36, ODSS and RHS questionnaires in a 
quiet room (Merkies et al. 2002a; Merkies et al. 2002b; Merkies et al. 2002c). The times taken 
to walk ten metres at both preferred and fast pace were recorded (Merkies et al. 2003a; van 
Loo et al. 2003). The MRC sum score was used to grade muscle strength (Kleyweg et al. 
1991). All data were collected by a chartered physiotherapist (the author) who was 
experienced in grading muscle strength and data collection in this patient group. 
 Group Two 
All participants (n=50) completed the Walk-12, ODSS and ONLS questionnaires. Muscle 
strength was measured using an adapted form of the MRC sum score, expanded to include 
the first dorsal interosseous muscles and scored from a maximum of 70 by an expert 
neurologist (Professor R.A.C. Hughes). Participants were timed as they walked ten metres, as 
fast as they safely could (van Loo et al. 2003). The ODSS, ONLS, MRC sum score and timed 
ten metre walk were recorded during routine clinical examination by a consultant neurologist 
whilst the Walk-12 was completed by the patient in the waiting area prior to consultation.  
4.4.4. Analysis 
Any uncompleted items on the Walk-12 were replaced by the mean of that individual’s 
completed items (Hobart et al. 2003). If less than 50% of items (six items) were completed, the 
individual’s data were excluded (Hobart et al. 2003). The Walk-12 was transformed to a 0-100 
scale as shown on Page 128. 
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The ceiling (zero, indicating no limitations) and floor effects (100, indicating maximal 
limitations) for total Walk-12 scores were examined and the mean score on each item was 
calculated.  
Raw questionnaire data were assumed to be non-parametric due to the ordinal nature of the 
scales. Transformed questionnaire and all other data were investigated for normality using 
Kolomogorov Smirnov tests and by examining frequency histograms. Parametric or non-
parametric statistics were then used as appropriate. 
 Validity 
The concurrent validity of the Walk-12 was investigated by measuring associations with other 
outcome tools.  
In Group one (n=15), Pearson’s or Spearman’s rank correlation coefficients between the Walk-
12 and values from the SF-36, ODSS and ten metre walk times were calculated. It was 
hypothesised that: 
H1: Convergent validity: Walk-12 scores would be strongly and significantly associated with the 
SF-36 physical function (PF) subscale and the physical component summary score (PCS). 
H2: Discriminant validity: associations between Walk-12 scores, mental health (MH) subscale 
and mental component summary scores (MCS) of the SF-36 would be weak and considerably 
lower than the associations between the Walk-12 and PF and PCS. 
In group 2 (n=50), Spearman’s rank correlation coefficients were calculated between the Walk-
12, the upper, lower limb section and total scores on the ONLS and ODSS, the expanded 
MRC sum score and ten metre walk times. It was hypothesised that: 
H3: Convergent validity: ONLS lower limb scores and the Walk-12 would be strongly and 
significantly associated. 
H4: Discriminant validity: associations between the Walk-12 and the upper limb scores on the 
ONLS and ODSS would be weak and considerably smaller than the associations between the 
lower limb scores and Walk-12. 
The null hypothesis for both groups was: 
H0: There would be no significant associations between Walk-12 scores and scores on the SF-
36 nor between the Walk-12 and ONLS upper limb scores. 
Correlation coefficients were compared to test these hypotheses and were judged to be 
low/weak (r=0.1-0.3), moderate (r=0.3-0.6) or large/strong (r>0.6) according to published 
criteria (Cohen 1977). 
Divergent validity was assessed by examining the ability of scores on the Walk-12 to 
discriminate between participants who used walking aids and those who did not using an 




The internal consistency of the scale was assessed using Cronbach’s α (alpha) reliability 
coefficient (Huck 2004b). A high value of α (usually greater than 0.7) indicated that the scale 
had good internal consistency and that all items assessed the same construct (Huck 2004b). 
The test re-test reliability of the Walk-12 was assessed by comparing two repeated 
measurements in 12 participants in group one, recorded one week apart. Agreement between 
repeated measurements was examined using a two way fixed intra class correlation coefficient 
(Weir 2005) and by calculating the standard error of the measurement (SEm) from: 
m wSE MS  
where MSw – mean squares of within subject variability (Weir 2005). 
 
The SEm provides an index of reliability, but is independent of between subject variability (Weir 
2005).   




Participant characteristics and mean Walk-12 scores are shown in Table 4-1. Sixty one from 65 
participants fully completed the Walk-12. Missing data were able to be substituted by the 
average score reported by remaining participants in all cases as respondents only omitted one 
item.  
Table 4-1 Participant characteristics for groups 1 and 2 
Participant characteristics  Group 1 (n=15) Group 2 (n=50) 
Mean age, years  50.7 ±11 (25-70) 57.7 ±15.5 (20-84)  
Gender 11 male, 4 female 27 males, 23 females 
Diagnosis GBS:7, CIDP:6, MMN:1, 
PDN:1 
GBS:11, CIDP:20, CIAP:4, 
PDN:6, Other:9 
Walk-12 scores  37.5 ±22.6 (0-69) 48.3 ±33 (0-100) 
Age and Walk-12 scores displayed as mean ±SD (range). Other neuropathies in group two 
included: vasculitic neuropathy: 3, CMT: 3, sensory multiple mononeuropathy: 2, idiopathic 
radiculomyelopathy: 1. A higher Walk 12 score indicated greater limitations. 
 
 Description of mobility reported by people with PN 
The mean score on each question on the Walk-12 for all participants (n=65) is shown in Figure 
4-1. Participants with PN reported limitations on all items on the Walk-12. As can be seen in 
Figure 4-1, they reported most difficulty with running, walking longer distances, smooth walking 
and walking quickly and required increased concentration and effort while walking.  
The Walk-12 questionnaire had excellent internal consistency (Cronbach’s α=0.96, n=61). 
There were no significant associations between age and Walk-12 scores in the entire cohort 
(r=0.03, n=65). 
 Group One 
Participants in Group one completed all items on the Walk-12 (Table 4-1). Whilst two (13.3%) 
participants scored zero (indicating no limitations), no one scored at the floor of the scale (100, 
indicating maximum limitations). 
 Validity 
Correlations between the Walk-12 and other questionnaire scores are shown in Table 4-2.  
As predicted in H1, the Walk-12 demonstrated convergent validity as scores were strongly and 
significantly associated with physical function and performance measured on the SF-36 PF 
and PCS. Furthermore, correlations with the SF-36 MH and MCS scores, also shown in Table 
5-2, were weak and not statistically significant, showing discriminant validity.  
 Reliability 
Test re-test reliability was assessed on a sub group of 12 participants (10 males) who 


















































similar between session one (31.2 ±26.3) and session two (29.5 ±24) and the test re-test 
reliability was high (ICC=0.96, SEm=5).  
 
Figure 4-1 Chart to show mean scores on each question of the Walk-12. 
 
 
Error bars show the standard error of the mean for each item. Mean scores for each item are 
shown in italics. Numbers under x axis denote the number of participants who reported 
maximal limitations (5) on each item. 
 
 Group Two  
Forty-six from 50 patients completed all Walk-12 items appropriately. Four patients missed out 
one item. Eight patients (16%) scored zero on the Walk-12 and two (4%) scored 100. Mean 
Walk-12 scores, MRC sum score, ten metre walk times and scores on the ODSS and ONLS 
are displayed in Table 4-2. 
 Validity  
As predicted by H3, the Walk-12 correlated significantly and most strongly with the ONLS lower 
limb scores (Table 4-2), demonstrating convergent validity. Walk-12 scores also demonstrated 
moderate significant associations with ten metre walk times and the total ONLS. Only a weak 
correlation was seen between the ODSS lower limb score and the Walk-12.  
Divergent validity was demonstrated as correlations with the upper limb scores on the ONLS 
































































































































Walk-12 could discriminate between patients who used walking aids (mean ±SD: 63.3 ±14.4, 
n=21) and those who did not (27.2 ±22.7; n=44 p<0.001).  
 
Table 4-2 Walk-12 scores, and correlations with the ODSS, Rotterdam handicap scale and SF-36 
questionnaire subscales. 
 Group 1 n=15 Score Correlation coefficient 
(r) 
p  
Walk-12  37.5 ±22.6 (0-68.7) - - 
SF-36: PCS 45.1 ±10.3 (28.5-58) -0.72* 0.003 
MCS 57.4 ±4.9 (48.2-63.2) -0.4 ns 
PF 75 (30-100) -0.82* 0.001 
RLP 100 (0-100) -0.42 ns 
RLM 100 (100-100) - - 
Social function 55.6 (0-100) -0.86* <0.001 
MH 88 (64-100) -0.45 ns 
Energy and vitality 60 (20-95) -0.64* 0.01 
Pain 77.8 (33.3-100) -0.71* 0.003 
Health perception 72 (25-92) -0.65* 0.009 
Health transition 50 (0-100) -0.5 0.06 
ODSS 2 (0-5) 0.81* 0.001 
Rotterdam handicap scale 35 (22-36) 0.6* 0.03 
Group 2 n=50    
Walk-12  48.3 ±33 (0-100) - - 
ONLS upper limb 2 (0-4) 0.30* 0.05 
ONLS lower limb 2 (0-5) 0.77* <0.001 
ONLS total 4 (0-9) 0.67* <0.001 
ODSS upper limb 2 (0.4) 0.31* 0.02 
ODSS lower limb 2 (0-5) 0.36* 0.01 
ODSS total 4 (0-9) 0.36* 0.01 
MRC sum score n=49 64 ±7.9 (32-70) -0.28* 0.05 
Ten metre walk time (seconds) 
n=42 
9.8 ± 6.7 (4.6-40) 0.63* 0.001 
All values are medians (range) except for the Walk-12, MRC sum score, PCS, MCS and 10 
metre walk time which are mean ±SD (range). All correlations were calculated using 
Spearman’s rank except for correlations between the MRC, PCS, MCS, 10 metre walk test and 
Walk-12 scores which are Pearson’s correlations. A higher score indicates greater restriction in 
activities on all scales. * denotes a significant correlation with the Walk-12 at p<0.05.  
PCS- Physical component summary score, MCS- Mental component summary score, PF- 
physical function, RLP – role limitation physical, RLM – Role limitation due to emotional 






The aim of this study was to investigate the suitability, internal consistency, test re-test 
reliability and validity of the Walk-12 questionnaire in people with PN (Hobart et al. 2003). The 
results show that people with PN reported most difficulty running and moderate difficulty 
walking smoothly, walking over longer distances, walking at a faster speed. Participants also 
reported that they required greater concentration when walking. 
The Walk-12 was quick and straightforward to complete. Only four participants omitted one 
item from the Walk-12, and total scores for all participants were able to be calculated by 
adjusting for missing items. Ten participants (from 65) had scores at the ceiling of the range, 
indicating no reported limitations in mobility. Two participants scored at the floor of the scale 
(indicating maximum limitations in mobility). These levels indicate that Walk-12 was largely 
well targeted to the level of self-reported mobility for the majority of people with PN in this 
sample. Cronbach’s alpha was high (0.96) indicating that the Walk-12 measured a single 
consistent construct in people with PN, and that it was reasonable to score the Walk-12 by 
summing all items (Huck 2004b).  
 Validity 
The magnitude and pattern of correlation with other data collection tools provide support for 
the validity of the Walk-12 in the study sample. As predicted, the Walk-12 correlated strongly 
with indicators of reported physical function and lower limb functional ability, but weakly with 
reported mental health and upper limb function (shown in Table 4-2). Similar findings have 
been reported in people with MS (Hobart et al. 2003). Participants who used walking aids had 
significantly higher scores on the Walk-12 than those who did not, indicating that the scale 
could discriminate between these two states.  
The Walk-12 correlated strongly and significantly with lower limb scores on the ONLS scale 
(r=0.77) but had only a weak, albeit significant association with lower limb scores on the ODSS 
(r=0.36). This was anticipated as, although the ODSS and ONLS differ on only one item in the 
lower limb category, the ONLS was specifically designed to be more sensitive to the presence 
of minor lower limb restrictions (as described in Chapter Three) and included some similar 
activities to the Walk-12.  
Of all the outcome tools that correlated with the Walk-12, the social function subscale scores 
of the SF-36 demonstrated the strongest association, accounting for 74% of its variance (r=-
0.86). As items on the Walk-12 do not directly question social functioning, this strong 
association indicates that the Walk-12 reflected the influence of mobility upon social 
participation. This enhances its clinical usefulness.  
From data routinely collected in the host outpatient clinic (MRC sum score, ten metre walk 
time, ODSS and ONLS) the strongest association with scores on the Walk-12 was with the 
lower limb section of the ONLS. However, this only explained 59% (r=0.77) of the variance of 
the Walk-12, indicating that the Walk-12 could add valuable information to assessment for 
people with PN in clinical and research settings. 
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The composition of the sample did not allow comparison of the validity of the Walk-12 between 
GBS and CIDP and other PN as the majority of participants had either a diagnosis of GBS or 
CIDP (77%; n=50). All participants in this study were also outpatients. Consequently, the 
properties of the Walk-12 require further evaluation if it is to be used in inpatients or in other 
PN. Others have noted that there is considerable floor effect (scores indicating maximal 
limitations) on the Walk-12 in inpatients after stroke, spinal cord injury or with MS, although 
this was not evident at discharge (Holland et al. 2006). This implies that the Walk-12 might not 
be suitable for people with PN who experience severe mobility limitations, those during the 
acute phase of GBS or an exacerbation of CIDP when inpatient rehabilitation is required. In 
these situations, other tools which measure more severe limitations including reduced bed 
mobility and transfers would be more appropriate. 
 Reliability 
Test re-test reliability of the Walk-12 was high (ICC= 0.96), but this should be viewed with 
some caution as the sample in which it was measured was small (n=12), comprising only 
those participants able to return for reassessment, which reduced its external validity. 
4.4.7. Limitations of the study 
The findings of this investigation are limited by a number of factors. As the study was not blind, 
the expectations of the investigator could influence results although this was minimised by 
participants completing questionnaires independently. The nature of the study sample restricts 
the external validity of the findings as the majority of people had GBS or CIDP, were 
outpatients and had to be ambulant for at least some part of the day. This means that the 
results cannot be automatically applied to other forms of PN and the Walk-12 cannot be 
assumed to be suitable for people with PN who experience severe mobility limitations or those 
during the acute phase of GBS or an exacerbation of CIDP when inpatient rehabilitation is 
required. The responsiveness of the Walk-12 was not examined, nor were its properties 
compared to other mobility tools. However, this investigation demonstrated that the Walk-12 
was a valid and reliable indicator of perceived mobility in ambulant outpatients with 
inflammatory PN, and is worthy of further investigation to determine its responsiveness and 
establish its properties in a wider range of PN. 
4.4.8. Conclusion 
The Walk-12 was a useful, valid and reliable measurement tool for assessment of perceived 
ambulatory mobility in this study. It was quick and easy to complete and includes items that 
assess aspects of mobility that people with PN perceive as problematic and that are not 
captured by other disease specific outcome tools. These aspects include running, walking long 
distances, concentration and the effort of walking. Interestingly, the Walk-12 was strongly 
associated with social functioning measured on the SF-36, indicating that it reflected some of 
the potential effects of mobility limitations. The Walk-12 also demonstrated internal 
consistency and test re-test reliability in participants. These findings show that the data yielded 
by the Walk-12 provide an important insight into mobility and functioning, and support its use in 
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people with PN. Whilst the Walk-12 was a valid indicator of perceived mobility in people with 
PN, there may be other mobility tools which perform equally well or better, and so future 
studies could compare the performance of the Walk-12 to other mobility tools. Further work is 
also necessary to examine the properties of the Walk-12 in inpatient and community settings, 
in a wider range of PN and to determine its responsiveness. Future studies could also seek to 
develop a new tool based on the mobility problems reported by people with PN. Items could be 
generated from qualitative enquiry and patient involvement to ensure that the most relevant 
and pertinent aspects of mobility for people with PN are captured comprehensively.  
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4.5.  Investigation of the properties of the original and modified 
physiological cost index of walking in healthy and peripheral 
neuropathy participants 
4.5.1. Background 
Gait abnormalities can result in elevated energy expenditure when walking and affect the 
ability of individuals to function in the community (Boyd et al. 1999). Common impairments 
experienced by people with PN can make walking more effortful (Forsberg et al. 2004; Mueller 
et al. 1994) and the scores obtained on the Walk-12 from participants in Study One indicated 
that an increased feeling of effort negatively affected their perceived walking ability (Page 
134). Therefore, as measurement of the energy used when walking is likely to be important 
when assessing functioning in people with PN, a valid, reliable and responsive tool is required. 
The physiological cost index (PCI) was originally devised by MacGregor (MacGregor 1979) to 
indicate the energy expenditure (Tofts et al. 1998) or energy cost or effort of walking (Taylor et 
al. 1999). It was based upon the assumption that oxygen consumption and heart rate have a 
linear relationship at submaximal levels (McArdle et al. 1996). Thus the energy cost of walking 
can be indicated by measuring the change in heart rate whilst walking and walking speed 





Working HR Resting HR (Beats min )
PCI (Beats m )






  (MacGregor 1979) 
PCI= physiological cost index, HR=heart rate 
 
Values from healthy individuals range from 0.11 to 0.55 beats m
-1
, with a higher value 
indicating greater energy cost (MacGregor 1979).  
Minimal equipment is used to administer the PCI; consequently it has been proposed as a 
practical, low-cost, low technology alternative to cumbersome and expensive gas and 
calorimetric analysis equipment, which may not be available in clinical settings (Harvey et al. 
1998).  
Two criteria must be fulfilled in order to assess the PCI accurately. Firstly, a steady state heart 
rate should be reached during both the resting and walking period (Nene 1993). This is usually 
attained within four minutes, providing noise and distractions are minimised (Corry et al. 1996; 
Ijzerman and Nene 2002). Secondly, participants must walk at their usual, comfortable pace 
whilst the components of the PCI are measured (MacGregor 1979; Rose et al. 1991). This 
preferred pace of walking has been found to be surprisingly reproducible on level surfaces 
(MacGregor 1979).  
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4.5.2. Properties of the PCI 
The PCI has been previously used in healthy people, amputees and spinal cord injured 
patients to describe and evaluate the effects of assistive equipment and interventions, 
including exercise, upon the energy demands of walking (Bowen et al. 1998; Boyd et al. 1999; 
Burridge and McLellan 2000; Harvey et al. 1998; Hood et al. 2002; Ijzerman et al. 1999; Macko 
et al. 1997; Rose et al. 1991; Taylor et al. 1999; Tofts et al. 1998). However, no studies have 
used the PCI in people with PN. 
 Validity  




) is a standard, criterion measure of the energy 
used while walking and has been used to evaluate the validity of the PCI by others (Bowen et 
al. 1998; Boyd et al. 1999; Ijzerman and Nene 2002). Values of EO2 are calculated from 




Oxygen consumption, VO (ml kg min )
EO (ml kg metre )






Oxygen consumption is measured whilst walking using portable indirect calorimetric systems. 
One system, the Metamax (Cortex, Metamax 3B, Biophysik, Leipzig, Germany) is lightweight, 
comfortable and provides real time readings of heart rate and VO2 via telemetry.  The validity 
and reliability of this system to measure VO2 at heart rates analogous to those attained when 
walking is presented in Appendix Four. 
Despite widespread use in a range of patient groups, the validity of PCI scores to indicate the 
energy cost of walking has not been widely investigated. The PCI could be valid in PN as 
common impairments which produce difficulties in walking increase energy demands that 
should be measured by the PCI (MacGregor, 1979). However, the validity could be dependent 
upon the patient group it is used in. Minimal association between PCI and EO2 has been 
reported in 20 healthy participants and 17 people with mid thoracic spinal cord injury (r=0.2) 
(Hood et al. 2002). Others have reported moderate correlations in small studies of children 
with cerebral palsy (r=0.5; n= 17) (Bowen et al. 1998; Ijzerman et al. 1999). Bowen et al. 
(1998) also reported PCI scores could not discriminate between five healthy and five children 
with cerebral palsy, implying poor divergent validity, although this could equally be an artefact 
of the small sample size. Nonetheless, these findings suggest that the validity of the PCI 
cannot be assumed for people with PN. 
The validity and reliability of the PCI relies upon a preferred walking speed being attained 
consistently throughout the test. In a clinical environment, participants are likely to walk around 
a track of known distance. However, the distance walked in a straight line and the numbers of 
changes in direction are likely to influence the pace of walking, challenging validity. Some 
studies have used short walking track designs of 12 metres or less (Boyd et al. 1999; Burridge 
and McLellan 2000; Ladouceur and Barbeau 2000; Sienko Thomas et al. 1996; Taylor et al. 
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1999), often using several repetitions on a straight track (Burridge and McLellan 2000; 
Ladouceur and Barbeau 2000; Sienko Thomas et al. 1996; Taylor et al. 1999). However, a 
track with tight turns or arcs may prevent attainment of preferred walking pace, reducing speed 
and thus increasing PCI scores if heart rate remains unchanged. Other authors have used 
longer, straight or oval designs (Boyd et al. 1999; MacGregor 1981) but no standard track has 
been identified for reliable and valid measurement of the PCI.   
 Reliability 
Several studies investigating the PCI report it has poor reliability. Large variability of repeated 
scores has been shown in children with cerebral palsy and healthy participants (repeated 
values varied by >20%) (Bowen et al. 1998; Boyd et al. 1999; Ijzerman and Nene 2002). 
Similarly, reduced test retest reliability meant that the smallest detectable difference exceeded 
40% in people with paraplegia and healthy participants (Hood et al. 2002; Ijzerman et al. 1999) 
and over 60% in children with cerebral palsy (Ijzerman and Nene 2002).  
This inconsistency of repeated measurements has led to doubts regarding the clinical 
usefulness of the PCI (Bowen et al. 1998; Boyd et al. 1999; Ijzerman and Nene 2002). 
Variability in resting heart rate has a significant impact on the PCI’s test re-test reliability 
(Ijzerman et al. 1999; Ijzerman and Nene 2002) but was included in the PCI equation to correct 
for variation in cardiovascular fitness between individuals. However, resting heart rate could be 
omitted from the PCI equation to improve reliability, as working heart rate is also influenced by 
cardiovascular conditioning and so can reflect differences in aerobic fitness (McArdle et al. 
1996). Thus a new measure, the modified PCI (mPCI) which excludes resting heart rate was 




Working HR (Beats min )
mPCI (Beats metre )






Large variability in repeated measurements of the PCI will affect the estimation of 
responsiveness. Several studies have calculated the smallest difference required to exceed 
the inherent variability in repeated measurements of PCI scores, and thus indicate a true 
alteration in walking ability. The magnitude of change required ranges from 20% to over 80% 
of the original PCI score in healthy people and participants with limitations (Bailey and Ratcliffe 
1995; Bowen et al. 1998; Butler et al. 1984; Hood et al. 2002; Ijzerman et al. 1999; Nene 
1993). This is considered unacceptable by many (Boyd et al. 1999; Hood et al. 2002; Ijzerman 
et al. 1999) as changes after interventions, such as exercise, are unlikely to exceed the 
measurement error and so cannot be reflected by the PCI. Consequently it is important to 







The objective of the two studies in this section was to investigate the properties of the PCI and 
mPCI in healthy and PN participants.  
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4.6. Study Two – An investigation of the inter and intra-rater 
reliability and validity of the original and modified physiological 
cost index in healthy participants when walking on two tracks. 
4.6.1. Background 
Few studies have investigated the reliability of the PCI and only three studies have 
investigated its validity, finding equivocal results (Bowen et al. 1998; Hood et al. 2002; 
Ijzerman et al. 1999). In addition to variations in heart rate, walking speeds can vary and affect 
the reliability and validity of PCI and mPCI scores in response to differing track dimensions. 
Despite use of the PCI in a range of environments and patient groups, no one track shape has 
been advocated for use. Therefore, the reliability and validity of the PCI and mPCI 
measurements from different track shapes requires investigation to determine their suitability. 
4.6.2. Aims 
The aims of this study were to: 
1. investigate the inter and intra-rater reliability and validity of the physiological cost index 
(PCI) and modified PCI (mPCI) measurements in healthy participants. 
2. establish a standardised track that participants would walk upon whilst the PCI and mPCI 
are measured.  
4.6.3. Method 
A cross-sectional design was utilised to achieve the aims of this investigation (Sim and Wright 
2000). Forty healthy participants were recruited from the staff and students of King’s College 
London from email advertisement, following local ethical approval. All gave informed consent 
to take part and fulfilled the criteria listed in Table 4-3.  
 
Table 4-3 Inclusion and exclusion criteria for healthy volunteers 
Inclusion criteria Exclusion criteria 
Ambulant Neurological condition 
Good command of the English 
language 
Current diagnosis or a history of significant muscle, bone or 
joint pathology 
 Respiratory disease 
Cardiovascular pathology or medication which would cause 
an atypical cardiac response to gentle walking 
Recent injury to lower limbs or spine 
 
Participants were instructed to avoid eating for at least two hours prior to the test, and to wear 




Participants wore the Metamax system and a heart rate monitor (described in Appendix Four) 
and, after familiarisation, were asked to walk around two differently shaped tracks, marked on 
the floor, (Figure 4-2) at their normal, comfortable walking pace. The validity and reliability of 
the Metamax system at heart rates analogus to walking were established prior to use 
(Appendix Four). 
One track measured 20 metres in circumference, the other 12 metres, and both had a ‘figure 
of 8’ shape. In addition to length, the main difference between the tracks was that the shorter, 
12 m track had tighter turns at either end (radii were 1.5m and 0.33m for 20 m and 12 m tracks 
respectively) and required a period of walking in a straight line prior to each turn. The longer 
track line curved gradually and required minimal periods of walking in a straight line. These 
track designs were chosen as they were likely to fit into most clinical environments and their 
shape meant that an equal number of turns were made in each direction, more closely 
mimicking functional walking. Participants practised walking on both tracks for several minutes, 
whilst wearing the gas measurement system before testing. 
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Figure 4-2 Diagram of two tracks for PCI and mPCI measurement. 
 
Circumferences: 20 metres for the blue track and 12 metres for the pink track. Radii of the turn 
on each track are shown. 
 
 Measurement of the PCI and mPCI 
After familiarisation, participants sat quietly for at least four minutes and until their heart rate 
reached a steady state (resting heart rate, RHR). Steady state resting or working heart rate 
was attained when heart rate readings taken one minute apart were within five beats of each 
other (Bailey and Ratcliffe 1995). Once RHR was at steady state, participants began walking 
around a randomly assigned track at their preferred walking pace. Real time recordings of 
heart rate (beats min
-1




) were made via the telemetry system of the 
Metamax system throughout the resting and walking periods. Participants walked until steady 
state walking heart rate was reached and they had walked for at least four minutes (Corry et 
al. 1996; Ijzerman and Nene 2002). The time and distance walked was recorded and the 
participant returned to sitting. Values of speed (metres min
-1







) and mPCI (beats metre
-1
) were calculated by one observer, after each 
walk. 
All participants were assessed twice on both tracks by one observer (N. Smith, physiotherapy 
student during summer studentship) to evaluate intra-rater reliability. Thirteen volunteers were 
assessed a further time on each track by another observer (the author). The PCI and mPCI 
values between raters for this subgroup, were compared to establish inter-rater reliability. In 
between walks, participants sat for at least four minutes until steady state heart rate was 
reached before starting to walk on the next track. The order for all walks was randomised prior 
to commencement to eliminate order effects. 
4.6.4. Analysis 
The physiological cost index (PCI, beats m
-1
) modified PCI (mPCI, beats m
-1










Reliability of the PCI and mPCI was determined in several ways (Rankin and Stokes 1998). 
Two way fixed intra class correlation coefficients (ICC) were calculated between PCI scores 
obtained by the same observer (NS) on the same track. Two way random ICC were used to 
examine the inter-rater reliability on both tracks (Weir 2005). The standard error of the 
measurement (SEm) was also calculated for repeated measurements of the PCI and mPCI.  
The smallest detectable difference (SDD) was expressed as a percentage of the mean PCI 
and mPCI scores for 12 and 20 metre tracks, in order to allow comparison between the two 
tracks. 
Bland Altman plots were used to visually examine agreement throughout the range of the PCI 
and mPCI and 95% limits of agreement for intra and inter-rater reliability were calculated using 
the following formula: 
(x y) (x y)95% Limits of agreement Mean 1.96 x SD    
where x = measurement 1 for intra-rater reliability, or the mean of measurements 1 and 2 by 
one rater (NS) for inter-rater reliability, y = measurement 2, or measurement 1 by a different 
rater (the author) (Altman and Bland 1983). 
 
 Differences between tracks 
Paired t tests (two tailed, assuming unequal variance) were used to ascertain differences in 
PCI, mPCI, speed, EO2 and VO2 on each track. Differences between resting and working heart 
rates and VO2 were also examined using paired t tests. A repeated measures ANOVA was 
used to investigate systematic differences in PCI and mPCI scores on different tracks and in 
the order of measurement. 
 Validity 
To investigate the validity of the PCI and mPCI, Pearson correlation coefficients (r) were used 
to examine the association between PCI, mPCI and EO2 and between change in heart rate, 
speed and VO2. Stepwise linear regression analysis was performed for the mean of PCI and 
mPCI scores from each track. Factors with p <0.05 were included in the model and removed if 
p>0.1. 
All statistics were calculated using SPSS© software (version 11.5.1). 
Significance was set at p<0.05 for all tests. All values shown are presented as mean ± 





40 healthy people (15 males, 25 females) were recruited. Participant variables are displayed in 
Table 4-4. 
 
Table 4-4 Anthropometric data for healthy volunteers 
(n=40)  Range 
Age (years) 34.5 ±12.6 21-65.9 
Height (m) 1.69 ±0.09 1.53-1.96 
Weight (kg) 68.6 ±11.4 50-99 
Leg length (m) 0.89 ±0.05 0.78-1.05 
All values are mean ±SD. Leg length was measured from the anterior superior iliac spine to the medial 
malleolus. 
 
The order of testing had no effect on PCI scores (repeated measures ANOVA, p=0.28). 
Oxygen consumption values were similar for both tracks and within the range validated for the 
Metamax in Appendix Four (Table 4-5). 
 
Table 4-5 Scores of PCI, mPCI, VO2, EO2 and components of the PCI for 20 metre and 12 metre tracks 
Measure 20 metre track 12 metre track p 
PCI (beats m
-1
) 0.30 ± 0.1 (0.13-0.49) 0.34 ± 0.1 (0.14-0.6)* <0.01 
Modified PCI (beats m
-1
) 1.36 ± 0.28 (0.85–2.4) 1.53 ± 0.3 (0.98-2.5)* <0.01 




72 ± 8 72 ± 9 ns 
Working HR (beats min
-1
) 93 ± 11† 94 ± 12† ns 






11.23 ± 2.2† 11.36 ± 2.2† ns 






0.16 ± 0.02 0.18 ± 0.02* <0.01 
Speed (m min
-1
) 70.73 ±12.9 63.24 ± 11.7* <0.01 
Values are mean ±SD (range). * denotes significant difference between tracks, † denotes significant 
difference from resting values. 
 
 Reliability 
The intra and inter-rater reliability of the mPCI was much greater than the PCI (Table 4-6). The 
Bland-Altman plot (Figure 4-3) shows the variation in repeated PCI scores on both tracks. The 
95% limits of agreement for the mPCI indicated less variability in repeated measurements by 
the same and different raters when compared to the PCI (Table 4-6). The SDD was also larger 
for the PCI, and on the 12 metre track (Table 4-6). 
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Table 4-6 Reliability of the PCI and mPCI for 20 and 12 m tracks 
 PCI mPCI 
Track 20 metre 12 metre 20 metre 12 metre 
Intra-rater reliability (n=40)     
ICC 0.72 0.79 0.96 0.94 
SEm  for one rater  0.16 0.21 0.16 0.21 
SDD (%) 52 61 11.5 13.5 
95% limits of agreement -0.25 to 0.2 -0.14 to 0.18 -0.15 to 0.17 -0.22 to 0.19 
Inter-rater reliability (n=13)      
ICC  0.76 0.85 0.81 0.74 
SEm  for two raters 0.23 0.21 0.34 0.51 
SDD (%) 76 63 25 33 
95% limits of agreement -0.23 to 0.18 -0.2 to 0.2 -0.3 to 0.39 -0.6 to 0.47 




 Differences in PCI and mPCI between tracks 
Paired t tests demonstrated that both the mean PCI and mPCI scores were significantly higher 
on the 12 metre track (Table 4-5). Participants also walked significantly more slowly and had a 




 Determinants of PCI and mPCI 
The components used to calculate the PCI (working and resting heart rate, speed), calculated 
from linear regression, strongly predicted PCI (r
2
 =0.96 and 0.90 for 20 and 12 metre tracks 
respectively). Similarly, the components used to calculate the mPCI (working heart rate and 
speed of walking) accounted for over 90% of the variation in mPCI scores (r
2
= 0.93 and 0.94 
for 20 and 12 metre tracks). 
 Validity 
The assumption underpinning the PCI and mPCI that heart rate and VO2 have a linear 
relationship was largely satisfied as the association between working heart rate and VO2 was 
significant on both tracks (20 m: r=0.37; 12 m: r=0.43) (Cohen 1977; MacGregor 1979). There 
were also significant but somewhat weaker associations between working heart rate and the 
speed of walking on both tracks (20 m: r=0.34; 12 m: r=0.33).  
The PCI and mPCI scores were significantly different when measured on different walking 
tracks (Table 4-5). No significant correlations between PCI and the criterion measure, EO2, 
were seen on either track (Figure 4-4) but there was a significant but weak correlation between 




Figure 4-4 Scatter plot to show relationship between energy cost and PCI 
 
 









The first aim of this study was to examine the reliability and validity of the PCI and mPCI in 
healthy participants when walking on two different tracks. Values for both the PCI and mPCI 
were higher and values for walking speed were significantly lower on the 12 metre walking 
track when compared to the 20 metre. These data indicated that the PCI and mPCI 
discriminated between the different tracks, implying divergent validity, but also showed that the 
track design used to measure the PCI or mPCI influenced the results. 
A significant finding was that the PCI did not correlate with the standard measure of energy 
cost, EO2, on either track and repeated measurements had large variability, indicating poor 
criterion validity and reliability in healthy participants. The mPCI, developed and tested for the 
first time in this study, was more reliable and did demonstrate a significant, although not strong 
association with EO2, so was a more valid measure of the energy cost of walking in this cohort. 
 Reliability 
In healthy participants, repeated measurements of mPCI and PCI taken by the same and by 
different raters on the same day were largely similar and levels of reliability were analogous to 
the findings of others in healthy people (ICC= 0.74) (Hood et al. 2002). However, despite 
moderate ICCs for PCI and mPCI values (ICCs>0.72), there was a large variability between 
repeated PCI measurements. As shown in Table 4-6, a change exceeding 50% of the mean 
PCI score would be necessary to be sure that an alteration in PCI score was not attributable to 
measurement error. If the PCI was measured by two raters, an alteration in score of over 60% 
of the mean PCI score would be needed, although this was derived from a small sample 
measured by both raters (n=13). Others have reported similar findings in healthy participants 
(Hood et al., 2002). However, changes of 8% to 31% in PCI scores have been claimed to 
indicate a genuine alteration in walking ability in some studies (Burridge and McLellan 2000; 
Steven et al. 1983; Taylor et al. 1999). The results of this study suggest these interpretations 
are erroneous as this magnitude of change falls within the range of measurement error 
reported here and by others (Bowen et al. 1998; Butler et al. 1984; Hood et al. 2002; Ijzerman 
et al. 1999; Ijzerman and Nene 2002). Although the large measurement error seen here might 
not be replicated in patient groups, it is equally possible that some patient groups may 
demonstrate even greater variation in repeated PCI measurements. However, a limitation of 
this study is that serial measurements were taken on the same day, so cannot be used to 
judge the test re-test reliability of the PCI or mPCI over a longer and perhaps more clinically 
relevant period.  
The reduced reliability of the PCI was primarily attributable to the variability of resting heart 
rate. Resting heart rate was taken after at least four minutes of rest and was at steady state. 
Despite these precautions, resting heart rate can vary by approximately 7% within the same 
participant when tested on the same day (McCrory et al. 1998). The mPCI, calculated without 
resting heart rate, had considerably less variability between repeated measurements which 
meant it had to alter by much less than the PCI to reflect a genuine change in walking (12.5% 
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when measured by one rater and 29% for two raters). This supports the use and further 
evaluation of the mPCI in future work. 
 Track design 
The current literature does not recommend a standardised track shape or size for 
measurement of the PCI. The second aim of this study was to investigate two different track 
designs. These were selected as their dimensions were practical for most clinical 
environments. The results show that PCI and mPCI scores from both tracks demonstrated 
similar levels of validity and reliability, but it was apparent that the choice of walking track 
influenced PCI or mPCI scores by affecting the speed of walking. Although the PCI values 
from healthy participants were similar to those reported elsewhere (Bailey and Ratcliffe 1995; 
Ijzerman and Nene 2002; Nene 1993; Steven et al. 1983) and volunteers walked within the 
range of customary walking speeds (Waters and Mulroy 1999), they had significantly higher 
values of PCI, mPCI and EO2 on the 12 metre track. Whilst values of PCI from the 20 metre 
track remained within the 99% confidence intervals calculated in MacGregor’s (1979) original 
study (0.11-0.55), PCI scores from the 12 metre track exceeded these values. The higher 
values of PCI, mPCI and EO2 were attributable to a significantly slower walking pace on the 12 
metre track in the absence of a decrease in working heart rate. This appears to be an effect of 
the track shape. The smaller radius of turn and requirement for more turns on the 12 metre 
track decreased preferred walking speed. In the absence of decreased working heart rate or 
VO2, this produced higher values of PCI, mPCI and EO2. 
This finding indicates that the same track size and shape should be used when taking serial 
measurements, but does not indicate one design’s superiority over the other. As the 12 metre 
track limited walking speed, the 20 metre track would perhaps be more sensitive to 
improvements in walking speed brought about after rehabilitation or exercise training as it 
facilitated a faster preferred walking speed. Other track designs could be equally appropriate 
or superior to those tested here and could be investigated in future work. However, from these 
results, the 20 metre track is recommended for use in future work as it allowed a faster walking 
speed.  
 Validity of the PCI and mPCI as measures of the energy cost of walking. 
In this study, the PCI did not demonstrate validity in healthy participants as there were no 
significant correlations between PCI and EO2 on either track (Figure 4-4). This is supported by 
the findings of others in healthy participants (Hood et al. 2002). The mPCI did demonstrate a 
significant, although only moderate association with EO2 on both tracks, implying greater 
validity (Figure 5-6). As the only difference between the mPCI and PCI is the inclusion of 
resting heart rate, this finding shows that the variability in resting heart rate (discussed 
previously) is the likely cause of the poor association between PCI and EO2. Despite poor 
criterion validity, the PCI demonstrated divergent validity, as did the mPCI, as the scores were 
significantly different between 12 and 20 metre track designs (Table 4-5).  
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The relationship between the PCI, mPCI and EO2 is influenced by the relationship between 
walking speed and heart rate. In the calculation of PCI, it is assumed that walking speed and 
working heart rate have a co-dependent relationship. If walking speed decreased, heart rate 
would be expected to decrease, causing the PCI and mPCI to remain constant. In this study, 
the association between walking speed and working heart rate was weak (r< 0.35), showing 
this was not the case.This may be because there were a range of preferred walking speeds 
which were attained for a similar working heart rate in healthy people. If this is the case, 
changes in speed with no change in heart rate would cause variations in PCI and mPCI 
scores, despite no alteration in the energy used, thereby reducing their validity. Consequently, 
these results indicate that the PCI and mPCI are not likely to be suitable measures of the 
energy cost of walking in healthy participants. 
However, the PCI and mPCI may have a more direct relationship with the energy cost of 
walking in people who have difficulty ambulating as this increases the stress on the 
cardiovascular system, resulting in a greater elevation of working heart rate (MacGregor 
1979). Higher working heart rates will also decrease the impact of variability in resting heart 
rate upon PCI scores, thereby increasing the reliability of the PCI. Reports of mean walking 
heart rates (144 beats min
-1
) from adults with lower limb impairments (Ijzerman et al. 1999) are 
almost 40% greater than those seen in healthy participants in this study (93 and 94 beats min
-1
 
for 20 m and 12 m tracks respectively). Therefore, the PCI and mPCI could be valid indicators 
of the energy cost of walking in people who have conditions which produce walking difficulties, 




This cross sectional study demonstrated that the PCI has unacceptably large variability 
between repeated measurements which makes it unreliable in healthy people. The PCI scores 
also did not correlate with the criterion measure of energy cost (EO2), so cannot be considered 
a valid indicator of energy usage in healthy people. The variability in scores were attributable 
to alterations in resting heart rate, therefore a new tool, the mPCI, which excludes resting heart 
rate was evaluated for the first time here. It had greater reliability than the PCI, with the 
smallest detectable difference of the mPCI required to demonstrate a change in walking ability 
being approximately 12% if a single rater was used (20 metre track; Table 4-6, Page 148). The 
mPCI also demonstrated a weak but significant association with energy cost, inferring some 
validity. 
When participants walked on the 12 metre track they demonstrated significantly higher PCI 
and mPCI scores, largely as a result of reduced walking speed. Although the 12 metre track 
was similarly valid and reliable, the 20 metre track is preferred for measurement of the PCI and 
mPCI, as it allowed a faster walking pace and so would be more able to detect changes after 
interventions which increase walking speed.  
Despite the findings of poor reliability and validity in this study, the PCI may still be a valid 
indicator of energy cost for some patient groups where gait abnormalities are likely to have a 
greater energy demand of walking than people with no gait problems. The consequent larger 
increases in heart rate when walking would reduce the impact of variability in resting heart rate 
upon PCI.  
A new tool, the mPCI, developed in this study also warrants further investigation in patient 
groups as it was reliable and more valid than the PCI. Further work is now needed to 
investigate the suitability of both these tools in people with PN. 
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4.7. Study Three - An investigation of the reliability and validity of 
the original and modified physiological cost index in people with 
peripheral neuropathies 
4.7.1. Background 
In Study Two, the validity and reliability of the PCI and mPCI were examined in healthy 
participants on two different walking tracks and recommendations about their evaluation in 
people with PN were given. Despite poor reliability and validity in healthy participants, the PCI 
and mPCI may still be suitable for clinical populations that experience difficulty walking due to 
their greater energy demands which cause larger changes in heart rate. Therefore, the 
properties of the PCI and mPCI require investigation in people with PN.  
4.7.2. Aim 
The aim of this study was to investigate the test re-test reliability, validity and responsiveness 
of the PCI and mPCI in people with PN. 
4.7.3. Method 
Group One: Fourteen people with PN volunteered to participate in this cross-sectional study, 
(these subjects also participated in the study of fatigue displayed in Chapters Five and Six). 
Their data were used to determine the validity of the PCI and mPCI.  
Of these 14 participants, seven participants were tested twice, one week apart to examine test 
re-test reliability.  
Group Two: The responsiveness of the PCI and mPCI was ascertained by examining the 
change from the second baseline, pre-exercise measurements to values after the exercise 
intervention in 14 PN participants from the prospective, uncontrolled study presented in 
Chapter Two.  
Excepting the diagnosis of a PN, all participants conformed to the inclusion criteria detailed in 
Table 4-3, Page 143. Ethical approval was obtained from Guy’s Research Ethics Committee 
and participants gave informed consent. 
Participants were asked to avoid caffeine for 12 hours prior to testing, not to eat two hours 
prior to testing and to wear comfortable clothing and shoes for each session. 
The method of measurement of the PCI, mPCI and energy cost has been previously detailed 
(Study Two). Participants walked on the 20 m track as shown in Figure 4-2.  




), the standard measure of energy expenditure when walking, the 
mPCI and the PCI were calculated in Group One participants as described previously (Pages 
139 and 140). 
All participants completed the overall disability sum score (ODSS) (Merkies et al. 2002a), 
Rotterdam handicap scale (RHS), (Merkies et al. 2002b) and the SF-36 questionnaires (SF-
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36) (Merkies et al. 2002c; Ware and Sherbourne 1992). These questionnaires were described 
in Chapter One. 
4.7.4. Analysis 
Data were checked for normality using Kolomogorov Smirnov tests. Parametric statistics were 
then used accordingly. 
 Validity (Group One) 
Pearson correlation coefficients (r) were used to examine the association between the PCI, 
mPCI and the standard measure of energy cost of walking, EO2. Associations between heart 
rate, speed and VO2 were also examined to test the assumptions underlying the PCI and 
mPCI in this patient group. 
The divergent validity of the PCI and mPCI was examined using two tailed independent t tests, 
assuming unequal variance, between scores from people with PN and data from healthy 
participants described in Study Two. 
 Reliability (Group One) 
The test re-test reliability of the PCI and mPCI was estimated using 95% limits of agreement 
(Altman and Bland 1983). The variability of repeated PCI and mPCI scores and EO2 was 
examined using the standard error of measurement (SEm), and calculating the smallest 
detectable difference (SDD), as shown in Study Two (Page 131). 
 Responsiveness (Group Two) 
The standardised response mean (SRM) was calculated using changes in PCI and mPCI 
scores from baseline to after the exercise intervention (Chapter Two), using: 
Mean change in scores
SRM
SD of change in scores
  
SRM: standardised response mean, SD: standard deviation. 
 





All participants reached a steady state heart rate required for accurate measurement of the 
PCI. Participant details are shown in Table 4-7. 









) were within the range previously validated for the Metamax (Appendix Four). 
 
Table 4-7 Participant characteristics 






Age (years) 50.7±11.5 (25-70) 50.3±6.1 (42-60) 52.4 ±13.6 (28-74) 
Weight (Kg) 86.8±14.5 81.2±12.1 79.7±15.5 
Height (metres) 1.74±6.7 1.73±4.3 168.4±7.6 
BMI (kg m
-2
) 28.2 ±5 27.1 ±3.5 28 ±4.5 
Diagnosis 6 GBS, 6 CIDP, 1 
MMN, 1 PDN 
3 GBS, 3 CIDP, 1 
MMN 
10 GBS, 4 CIDP 
Overall disability sum 
score (0-12) 
2 (0-5) 2 (0-5) 3 (0-7) 
Rotterdam handicap 
score (9-36) 
35 (22-36) 35 (30-36) 33.5 (26-36) 
Physical function score 
from SF-36 (0-100) 
75 (20-100) 75 (50-100) 70 (15-90) 
PCI (beats m
-1
) 0.37 ±0.12 (0.18-
0.59) 
0.36 ±0.14 0.35 ±0.13 
mPCI (beats m
-1
) 1.6 ±0.42 (1.2.-2.6)† 1.46 ±0.15 1.66 ±0.6 






0.19 ±0.06† 0.19 ±0.03 - 




79 ±13 79 ±12 75±15 




100 ±14 100 ±14 96±15 
Walking speed (m min
-1
) 62.7 ±14.2 69.2 ±12.6 61 ±11 
All values are mean ±SD or mean ±SD (range) except for ODSS, RHS and SF-36 data which 
are median (range). † demonstrates significant differences between PN and healthy 
participants (from Study Two, n=40 mPCI (mean±SD)= 1.36± 0.28 beats m
-1







 Validity (Group One) 
One participant was noted to have a very high resting steady state heart rate (108 beats min
-1
), 




). This individual’s results 
were excluded from analysis, as the cause of this anomaly could not be ascertained. 
Therefore, analysis of the validity of the PCI and mPCI was performed on data from 13 
participants. Working heart rate and VO2 were moderately and significantly correlated (r=0.58) 
but the correlation between PCI and EO2 was weak and not statistically significant (Figure 4-6). 
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However, the mPCI strongly and significantly correlated with EO2 (r=0.87, p <0.001). This is 
shown in Figure 4-7. 
Two participants had considerably higher values of mPCI and EO2 as can be seen in Figure 
4-7. This was likely to be because they demonstrated the slowest walking pace (45 m min
-1
 
and 37.5 m min
-1
). When these participants were excluded from analysis the correlation 
between mPCI and EO2 was no longer significant (r=0.35, p=0.3).  
Figure 4-6 Scatter plot to show the relationship between energy cost and PCI in PN participants (n=13) 
PCI (beats m-1)





























Figure 4-7 Scatter plot to show relationship between the mPCI and energy cost in PN participants (n=13). 
Modified PCI (beats m
-1
)




























 Divergent validity 
Values of PCI from PN participants in this study were not statistically different to healthy data 
from Study Two, despite significantly higher values of EO2 in the PN group. However, mPCI 
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values were significantly higher in PN participants when compared to healthy volunteers. The 
change in heart rate from resting to walking was the same for PN and healthy groups (21 
beats min
-1
) but PN participants exhibited somewhat higher working and resting heart rates 
and a slower walking pace (Figure 4-8). However, these differences did not reach significance. 
  
Figure 4-8 Mean resting and working heart rate and walking speed for healthy and PN participants.  
 
Error bars denote one standard error. 
 
 Reliability 
Test re-test reliability was assessed on a subgroup of seven PN participants, who completed a 
second walk exactly one week after their initial assessment session. The values of PCI, heart 
rate, walking speed and EO2 are shown in Table 4-8. 
Table 4-8 PCI and mPCI scores, and walking speed and energy consumption on two occasions. 






) 0.36 ±0.14 0.29 ±0.08 
Modified PCI (beats m
-1
) 1.46 ±0.15 1.5 ±0.3 
Resting heart rate (beats min
-1
) 79 ±12 79 ±7 
Working heart rate (beats min
-1
) 100 ±14 100 ±12 
Speed of walking (m min
-1
) 69.2 ±12.6 68 ±16.5 




) 0.19 ±0.03 0.18 ±0.05 
All values are mean ±SD. 
 
There was no significant difference between PCI scores at measurement one and two, 



















































session. The 95% limits of agreement were large (-0.14 to 0.28) and the SEm was 0.087 beats 
m
-1
. Therefore, the smallest detectable difference for repeated PCI measurements indicated 
that scores would have to exceed a change of 74% of the mean PCI score (SDD=0.24 beats 
m
-1
) to be confident of detecting a change in the energy cost of walking beyond measurement 
error. 
The mPCI had narrower 95% limits of agreement (-0.54 to 0.46) and the SEm was 0.19 beats 
m
-1
. This indicated that a change in mPCI scores exceeding 35.5% of the mean mPCI scores 
was required to demonstrate a change in walking ability beyond measurement error. This was 
similar to the SDD of EO2 (34%). 
 Responsiveness (Group Two)  
The change in PCI and mPCI scores after the exercise intervention undertaken in Chapter 
Two was used to calculate the responsiveness of the PCI and mPCI. These changes and the 
SRM for both outcome tools are shown in Table 4-9. 
 
Table 4-9 Responsiveness and change in PCI, mPCI, heart rate and walking speed. 
n=14 Change after exercise SRM 
PCI (beats m
-1
) -0.03 (-0.08 to 0.03) 0.27 
mPCI (beats m
-1
) -0.12 (0.01 to 0.24)* 0.62 
Resting heart rate (beats min
-1
) -6 (-12 to -1) - 
Working heart rate (beats min
-1
) -3 (-8 to 3) - 
Walking speed (metres min
-1
) 4.5 (0.5 to 2.5) - 
Values are mean change (95% confidence limits). * denotes significant difference from pre 
exercise, baseline measurements at p<0.05. 
 
As reported in Chapter Two, the PCI scores were not significantly different from baseline after 
the exercise intervention, but the mPCI scores were significantly improved (p=0.04). The 
responsiveness of the PCI was poor (SRM: 0.27) but the mPCI had moderate responsiveness 




The PCI and mPCI were developed to indicate the energy cost of walking when indirect 
calorimetry systems were not available. The current study fulfilled its aims as it investigated 
the reliability, validity and responsiveness of the PCI and mPCI in people with PN. The range 
of PCI values was similar to that reported in other patient groups (0.38 to 0.4 beats m
-1
) 
(Steven et al. 1983; Tofts et al. 1998). They were higher than scores in healthy people (0.11 to 
0.51) (MacGregor 1981) but were generally lower than reports in people with more severe 
activity limitations with MS, spinal cord injuries and after stroke (0.59 to 1.3 beats m
-1
), 
suggesting that the values are representative of the energy demands of walking in people with 
impairments (Burridge and McLellan 2000; Hood et al. 2002; Taylor et al. 1999).  
 Validity 
 Validity of the PCI 
The poor association between PCI and EO2 and the absence of a significant difference 
between PCI scores of healthy and PN participants in this study demonstrates that the PCI 
was not a valid measure of the energy demands of walking for participants with PN. Others 
have reported a similarly weak relationship between EO2 and PCI in people with spinal cord 
injuries (r=0.14) (Hood et al. 2002) but a moderate, significant association between PCI and 
EO2 is reported in children with cerebral palsy (r=0.5) and has been assumed by others who 
use the PCI (Bowen et al. 1998; Burridge and McLellan 2000; Tofts et al. 1998).  
The PCI has been reported to be able to discriminate between the use of different walking aids 
and interventions in people after stroke, with arthritis and with paraplegia (Burridge and 
McLellan 2000; Harvey et al. 1998; Steven et al. 1983; Taylor et al. 1999) but the PCI scores 
in this study were not significantly different from those obtained from healthy people in Study 
Two, despite observed differences in heart rate and a significant difference in EO2. However, 
as median scores on the ODSS indicated only mild or moderate activity limitations, it is 
possible that the PCI could demonstrate validity if tested in a larger number of more affected 
participants. Nonetheless, the results of this study show that the PCI was not a valid indicator 
of the energy cost of walking in participants with PN. 
 Validity of the mPCI 
The mPCI strongly correlated with EO2 (r= 0.87) demonstrating it was a valid indicator of the 
energy cost of walking in PN participants. Values of mPCI were significantly higher in PN 
participants, indicating that the mPCI also had divergent validity. These findings show that, 
despite the small sample, the number of participants included in the study were sufficient to 
allow some significant relationships to be identified. However, two participants who 
demonstrated considerably greater activity limitations than the majority of other volunteers 
(ODSS: 4 and 5) walked very slowly, producing high values of EO2 and mPCI, thus 
strengthening their statistical association (Huck 2004b). When they were excluded, the 
correlation between EO2 and mPCI was no longer statistically significant, although this is likely 
to be caused by the consequent reduction in sample size (Huck 2004b). Despite these 
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limitations, the results support further investigation of the mPCI in a larger and more diverse 
group of PN participants to establish its validity as an indicator of the energy cost of walking. 
 Reliability 
The reliability of PCI and mPCI was examined using two measurements, recorded one week 
apart, in seven clinically stable PN participants.  
 Reliability of the PCI 
The reliability of the PCI was poor, as 95% limits of agreement were large and of similar 
magnitude to the mean PCI score (-0.14-0.28). A non-significant reduction in PCI scores from 
the first to the second measurement was also observed (Table 4-6). As EO2 differed by only 




), the reduction in PCI scores was unlikely to be attributable to increased 
familiarisation with the test protocol. However, both resting and working heart rates were less 
variable on the second testing session, indicating a possible familiarisation effect.  
The variability between repeated PCI scores indicated that scores would have to change by 
74% (SDD) of the mean PCI to be confident of a change in walking ability beyond 
measurement error. A change of this magnitude has not been reported after intervention in any 
study. This provides a strong argument that the PCI is not reliable to indicate the energy cost 
of walking in people with PN. 
 Reliability of the mPCI 
The mPCI was somewhat more reliable, as values varied less on repeated measurements 
(95% limits of agreement: -0.54-0.46). The SDD was also considerably smaller than that of the 
PCI (35.5% of the mean mPCI) and similar to the SDD of the standard measure of energy 
cost, EO2 (34%). These findings indicate that the mPCI is less variable and thus more a 
reliable indicator of the energy cost of walking than the PCI in people with PN but are limited 
by the small sample, especially as only seven participants were used to determine the SDD. 
Further work is now needed to establish the reliability of the mPCI in a larger and more diverse 
sample and over longer, more clinically relevant time periods. 
 Responsiveness 
After an exercise intervention (Chapter Two), PCI scores remained similar to baseline values 
and demonstrated poor responsiveness (SRM= 0.27). Although it is possible that the energy 
cost of walking was not improved after the intervention, decreases in heart rates and a 
significant increase in walking speed were observed (Table 4-9), suggesting this was not the 
case. Values of mPCI were significantly reduced after the intervention (by 7.5%) and 
demonstrated moderate responsiveness (SRM= 0.62) (Cohen 1977; Smithson 2000), although 
the improvement in mPCI scores did not exceed the SDD (35.5%). However, these findings 
are limited as the SDD was calculated from only seven PN participants and so cannot be 
applied to a wider population. Further investigation should seek to determine the SDD in a 
larger number of participants and to examine the responsiveness of the mPCI after exercise 




The assumptions underlying the PCI were met in this study as working heart rate was 
significantly associated with energy consumption during walking. However, this study shows 
that the PCI was not valid, reliable, or responsive when used in people with PN. This was 
primarily due to large variability in resting heart rate which was also observed in healthy 
participants in Study Two.  
However, an alternative tool, the mPCI, calculated without resting heart rate demonstrated 
reliability between repeated measurements and could discriminate between healthy people in 
Study Two and PN participants. It also correlated with the criterion measure of energy cost in 
the PN group and was responsive to improvements in the energy cost of walking after a 12 
week exercise intervention. These results suggest that the mPCI is a promising tool to indicate 
the energy cost of walking in people with PN. 
However, the findings of this study are limited by the relatively small sample and lack of rater 
blinding which reduces their external validity. Furthermore, a disadvantage of both the mPCI 
and PCI is that they were designed to provide data about participants’ performance in a 
laboratory setting and so have limited validity to usual mobility in the community. Although this 
could be addressed by measuring the PCI and mPCI in community settings, uncontrolled 
variables such as noise, distractions and other people are likely to influence heart rate, walking 
speed and so affect scores.  
Further work is needed to confirm these findings and to establish the properties of the mPCI in 
a larger group of people with PN. However, these results provide some support for the use of 
the mPCI as a preferable measure of the energy cost of walking to the PCI in people with PN. 
 164 
 
4.8. Chapter Discussion and Conclusion 
Mobility has great importance to the individual and is a vital function for most daily activities 
(Chiou and Burnett 1985; Lord et al. 2004). People with PN often have difficulty with aspects of 
mobility, including walking, running and climbing stairs, yet there are no validated outcome 
tools to reflect aspects of mobility in this specific patient group (Erdmann et al. 2005; Forsberg 
et al. 2004). This chapter contains three studies which investigated different aspects of 
measurement of ambulant mobility. As each study has its own discussion and conclusion, only 
the main points are considered in this section. However, all three studies share some 
limitations which are discussed here before the results of each study are summarised.  
Each study is somewhat limited by the size and nature of the sample used as all participants 
had to travel to London to be tested. This unintentionally excluded people with PN who had 
more severe activity limitations and could not access transport, thus biasing the sample. All 
participants were recruited as they were ambulant; this was necessary for measurement of the 
Walk-12, PCI and mPCI as, in their current form, these tools are not suitable for those who 
cannot walk. However, some people with PN are unable to walk, and so the external validity of 
these findings is limited. The size of the sample also limits the external validity of the findings 
to the PN population, particularly those studies which contained subgroups of few participants 
(e.g. the study of test re-test reliability in Study Three). This limitation was predominantly due 
to difficulties with recruiting participants who were able to re-attend for testing, and could be 
remedied in future studies by using multiple testing sites. Despite these limitations, the findings 
of these studies provide several conclusions and identify areas for further work in people with 
PN. 
The Walk-12 mobility questionnaire appeared appropriate to use in people with PN as it 
demonstrated some validity, reliability and little burden with only a small floor and ceiling effect. 
Whilst the Walk-12 assessed aspects of self-reported mobility not questioned on other tools, it 
may not capture all the mobility problems experienced by people with PN and is not suitable 
for people who cannot walk. Further work is therefore necessary to identify and develop new 
tools for people with PN which can be used in non-ambulant patients, examine the properties 
of the Walk-12 in comparison to other tools and to establish its responsiveness. Its properties 
should also be evaluated in inpatients and in a broader range of PN to determine if it can be 
used in these groups.  
A longer, 20 metre track was preferred to a 12 metre track when measuring the PCI and mPCI 
as it facilitated a faster preferred walking speed. However, further work could investigate if 
other track designs are superior. The PCI was not valid in healthy or PN participants as it did 
not correlate with EO2, the criterion measure of energy cost and repeated measurements were 
not reliable. However, the mPCI was reliable, demonstrated acceptable validity in people with 
PN and captured a significant change after an exercise intervention. These findings require 
confirmation in a larger and more diverse group of PN participants, suggest that the mPCI is a 
promising and appropriate tool to indicate the energy cost of walking in people with PN. 
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Chapter 5. An investigation of experienced 
fatigue in people with peripheral 
neuropathies 
5.1. Summary 
The study in this chapter investigated the feelings of fatigue experienced by people with 
inflammatory PN (defined as experienced fatigue) and examined potential contributors to 
experienced fatigue. Thirteen participants with peripheral Neuropathies (PN) and 13 healthy 
participants completed tools which measured experienced fatigue (Fatigue Severity Scale, 
FSS, Fatigue Impact Scale, FIS, and revised Piper Fatigue Scale, PFS) activity limitations 
(Overall Neuropathy Limitations Scale, ONLS) participation, mobility and mood. Perceived 
exertion during fatiguing exercise was measured using the Borg Scale. Resting heart rate, 
activity levels over five days and the energy cost (EO2) of walking were also assessed.  
Experienced fatigue was significantly greater for people with PN (mean ±SD: FSS: 4 ±1.8; FIS: 
22.6 ±21; PFS: 2.7 ±2.1) than healthy people (FSS: 2.3±0.8; FIS : 6.8 ±6.9; PFS: 1.22 ±1.1) on 
all three questionnaires and greater fatigue was significantly associated with greater activity 
limitations, poorer mobility and depressed mood (all r>0.6). Ten PN participants noted that 
exercise worsened their experienced fatigue, and eight stated that severe experienced fatigue 
was a persistent and troublesome symptom. Participants with PN had higher resting heart 
rates (RHR) (mean±SD: PN: 79 ±14, H: 72 ±8 beats per minute) and were significantly less 
active (activity counts over five days: PN: 1151 ±339; H: 1489 ±408 counts) than healthy 
controls. However, the severity of experienced fatigue was not significantly associated with 
heart rate or activity levels. Five out of 8 PN participants who stated that fatigue was a 
persistent problem did not complete the fatiguing exercise protocol and there was a general 
trend for PN participants to report greater perceived exertion throughout the fatiguing exercise 
in comparison to healthy volunteers, although this did not reach significance.  
The results of this study are limited due to the small self-selected sample and the inclusion of 
people with a range of PN. Nevertheless, they show that participants with PN experienced 
significantly greater fatigue than healthy volunteers and that this was significantly associated 
with greater activity limitations, reduced participation, depressed mood and poorer health 
status. Whilst this cannot explain the mechanisms underpinning experienced fatigue, 
participants with PN were less fit and less active which suggest that these factors could 
influence the severity of experienced fatigue. Further work is now needed to confirm these 
results in a larger sample of people with PN, to re-examine the potential contribution of fitness, 
energy cost and activity levels to experienced fatigue and to consider the impact of other 
factors, not investigated here, which may also contribute to experienced fatigue. 
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This work has been presented at the World Congress in Physical Therapy 2007 and its 
abstract has been published:  
Graham, R.C., White, C.M. Fatigue report, activity, cardiovascular fitness and energy cost in 




The term fatigue is commonly used by patients and clinicians to describe feelings of tiredness, 
lack of energy and lassitude (Krupp and Pollina 1996). Experienced fatigue is a multi-
dimensional, individual experience, and to be aware of some experienced fatigue is likely to be 
normal (Friedberg and Jason 1998). However, a feeling of persistent and severe experienced 
fatigue is a common symptom reported by people with neurological conditions, including PN, 
and contributes to functional limitations (Iriarte et al. 2000; Kalkman et al. 2005; Lennon et al. 
1993; Lou et al. 2003; Merkies et al. 1999; Taylor et al. 2000).  
Reports indicate that up to 80% (from 113) of people after GBS, with CIDP or 
Paraproteinaemic Demyelinating Neuropathy (PDN) complain of severe experienced fatigue 
several years after the onset of their neuropathy and that many consider it one of their three 
most limiting symptoms (Merkies et al. 1999). Severe experienced fatigue also has a negative 
effect upon health perception, activities and leisure pursuits in PN, and can be apparent 
despite otherwise good clinical recovery (Garssen et al. 2006c; Merkies et al. 1999). Little is 
known about the nature of fatigue experienced by people with CIDP or PDN. After GBS, 
experienced fatigue is independent of both the subtype of GBS and antecedent infection, but is 
more common in women and those over 50 years (Burrows and Cuetter 1990; Garssen et al. 
2006c; Merkies et al. 1999). At present the nature and mechanism behind experienced fatigue 
in PN are unclear and therefore it is not possible to identify interventions which may reduce its 
severity and functional consequences.  
The second aim of this thesis was to investigate and describe the nature of fatigue in people 
with inflammatory PN. Experienced fatigue was investigated in the study described in this 
chapter whilst the physical factors which could contribute to experienced fatigue by reducing 
the force generating capacity of a muscle (physiological fatigue) are considered in Chapter Six 
(Bigland-Ritchie 1981; Gandevia 2001). 
5.2.1. Operational definitions of fatigue 
For clarity, operational definitions of components of fatigue used in this thesis are provided 
both here and on Page 41.  
Experienced fatigue is defined as: “Feelings of fatigue, tiredness, lassitude and/or lack of 
energy” (Sharpe and Wilks 2002). 
It is recognised that to have some experienced fatigue is likely to be normal. Severe 
experienced fatigue is considered to be abnormal and is defined here as: “an excessive, 
abnormal feeling of tiredness or lack of energy which is not relieved by rest” (Krupp and Pollina 
1996; Piper et al. 1989). 
5.2.2. Potential causes of severe experienced fatigue 
Many factors may contribute to the severe experienced fatigue reported by people with 
inflammatory PN. These include factors that may produce physiological fatigue which are 
investigated in Chapter Six (Bigland-Ritchie 1981; Gandevia 2001). Likely factors considered 
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here were identified from the limited evidence in PN and from evidence in other neurological 
conditions and chronic fatigue syndrome (CFS). 
5.2.3. Mood 
The relationship between severe experienced fatigue and mood or well-being is likely to be 
complex. Severe experienced fatigue in otherwise healthy people can be caused by 
psychiatric disorders, most commonly depression (Skapinakis et al. 2000). Conversely, well-
being could be adversely affected by severe experienced fatigue (Buchwald et al. 1997) and 
severe experienced fatigue is a common symptom of physical disease (Guelfi et al. 2004).  
The relationship between well-being and severe experienced fatigue in PN is unclear. Garssen 
et al. (2004) initially reported that people with PN and severe experienced fatigue had normal 
levels of anxiety and depression and no other studies have examined this relationship. Their 
later RCT investigated the effect of anti-depressant medications upon experienced fatigue in 
74 people with inflammatory PN, inferring that low mood was related to more severe fatigue 
(Garssen et al. 2006b). However, their finding that there was no significant difference in 
experienced fatigue scores between participants receiving anti-depressants or placebo 
indicates that this was unlikely to be the case (Garssen et al. 2006b).  
In the study presented in Chapter Two, the severity of experienced fatigue, anxiety and 
depression was significantly improved after the exercise intervention. Garssen et al. (2004) 
also found that the severity of experienced fatigue was significantly reduced and anxiety and 
depression were significantly improved after 12 weeks of supervised aerobic training in 20 
people with inflammatory PN. These findings suggest that the factors which influence 
experienced fatigue may also affect anxiety and depression or that they directly influence each 
other. Therefore, investigation of the possible relationship between anxiety, depression and 
experienced fatigue in people with PN is warranted.  
 Activity, energy expenditure and cardiovascular fitness  
The findings of reduced experienced fatigue after exercise interventions in Chapter Two and 
the work of others (Garssen et al. 2004) indicate that the factors improved by exercise 
interventions may directly affect the severity of experienced fatigue. Whilst other factors, 
including the effect of time and attention from the investigator may be responsible for some of 
the observed changes in these uncontrolled cohort studies, the results in Chapter Two and 
Garssen et al. (2004) indicate that activity, fitness and increased energy demands may be 
associated with the severity of experienced fatigue in PN and require further investigation.  
Physical deconditioning is thought to contribute to both severe experienced and physiological 
fatigue in people with CFS (Gibson et al. 1993). Some authors suggest that cardiovascular 
deconditioning elevates feelings of perceived exertion, and may increase the severity of 
experienced and physiological fatigue (Ohashi et al. 2002; Sharpe and Wilks 2002; Vercoulen 
et al. 1997). This is proposed to lead people with CFS to avoid exertion and activity which 
further reduces cardiovascular fitness and leads to greater feelings of exertion when 
undertaking even simple activities (Sharpe and Wilks 2002). Whilst this theory is not fully 
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tested and CFS has many differences from PN, it is possible that the model suggested in CFS 
could potentially explain the severe experienced fatigue in people with PN.  
No studies have examined the relationship between general activity levels, energy use, fitness 
and experienced fatigue in people with PN. These factors require investigation as if they are 
found to be associated with experienced fatigue then targeted interventions, including 
exercise, could be developed to reduce experienced fatigue.  
5.2.4. Aims 
The aims of the study in this chapter were to: 
1. describe the nature and severity of experienced fatigue in people with PN in comparison to 
healthy volunteers, 
2. investigate the relationships between experienced fatigue, activity levels, perceived 
exertion, cardiovascular conditioning, activity limitations and health status in people with PN 




People with a confirmed diagnosis of GBS, CIDP or PDN were recruited from the Peripheral 
Nerve clinic at Guy’s Hospital, London to participate in this cross-sectional study. All diagnoses 
were secured upon standard criteria (Asbury and Cornblath 1990; Cornblath 1990; Hadden et 
al. 2005; Hughes et al. 2001). Healthy participants who did not complain of severe 
experienced fatigue were recruited via adverts from staff and students at King’s College 
London.  
A general health questionnaire, the GHQ-28, was used to screen for severe depression in all 
potential participants (Goldberg and Williams 1988). It is a 28 item questionnaire which 
measures non-psychotic psychiatric disturbance (Goldberg et al. 1997). It has demonstrated 
high test retest reliability (Pearson’s correlation coefficients: 0.85 to 0.9) and internal 
consistency (Cronbach’s α :0.86) in neurological conditions (Gibbons et al. 2004; Goldberg 
and Williams 1988). Subscale scores can be used alone or as part of the total tool (Goldberg 
et al. 1997). In this study the depression subscale was chosen to screen for inclusion as items 
were distinct from physical function, unlike other commonly used tools which measure 
depression. Respondents completed each item, from four possible answers, which was scored 
on a zero to two modified Likert scale. The maximum score of two indicates greatest severity, 
and a minimum score of zero represents no problem / no alteration from normal. If the score 
on the depression subscale exceeded zero, the individual was excluded from participation 
according to the exclusion criteria below. 
Local ethical approval was given and all participants gave informed written consent. All 
participants met the criteria detailed in Table 5-1. 
 
Table 5-1 Inclusion and exclusion criteria 
Inclusion criteria Exclusion criteria 
Over 18 and under 80 years old Electrical or metal implants e.g. pacemakers, metal 
joint replacements. 
Good command of the English 
language. 
Current diagnosis or treatment for muscle, nerve, 
bone or cardiovascular pathology or depression or 
other psychiatric disorder. 
Diagnosis of chronic fatigue syndrome or other 
known cause of fatigue. 
Pregnant or lactating women. 
 
Before attending, all volunteers were asked if they had experienced problematic or severe 
fatigue in the last six months according to the definition: “an excessive, abnormal feeling of 




If healthy people reported severe fatigue, they were excluded.  
All participants were tested on two occasions one week apart. A battery of questionnaires 
(shown below) was completed prior to physical measurements and all testing took place in a 
quiet room. The order that questionnaires were given to the participant was randomised.  
 
Table 5-2 Questionnaires used to measure experienced fatigue and other aspects of functioining 
Questionnaires 
Fatigue Severity Scale 
Revised Piper Fatigue Scale 
Fatigue Impact Scale 
Hospital Anxiety and Depression Scale 
SF-36 
ONLS* 
Rotterdam Handicap Scale* 
Walk-12* 
*denotes those questionnaires completed by PN participants only; all others were completed 
by PN and Healthy participants. 
5.3.1. Assessment of experienced fatigue 
Experienced fatigue was assessed using three questionnaires, the fatigue severity (FSS), 
fatigue impact (FIS) and revised Piper fatigue scales (PFS) (Fisk et al. 1994; Krupp et al. 1989; 
Piper et al. 1998). These scales were described and evaluated in Chapter One (Page 46 and 
47).  
5.3.2. Measurements of energy cost, cardiovascular fitness and activity 
levels 
These tests were conducted after the questionnaires were completed. 
 Assessment of the energy cost of walking 




) was measured in PN participants using 
indirect calorimetry, as shown in Studies Two and Three of Chapter Four (Page 139). Values 
of EO2 when walking around a 20 metre figure of “8” track were compared to age and gender 
matched healthy data (n=12, 4 females, mean age: 48.5 ±8.3 years) collected as part of a 
larger data set in Study Two in Chapter Four. 
5.3.3. Cardiovascular fitness 
Values of resting heart rate were used to indicate cardiovascular conditioning (McArdle et al. 
1996). Despite intra individual variability, the resting heart rate of a group of participants is 
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reproducible (McCrory et al. 1997). Heart rate was measured using a heart rate monitor (Polar, 
Finland) in all participants after sitting quietly for at least four minutes (Corry et al. 1996; 
Ijzerman and Nene 2002).  
5.3.4. Activity monitoring 
After the first measurement session all participants were given an activity monitor (Actigraph: 
model AM 71624 2.2, MTI USA) to wear for one week during waking hours. The Actigraph is 
an uniaxial accelerometer which measures vertical displacement, weighs 43 grams, and 
measures accelerations from 0.05 to 2 G (G: gravitational acceleration; 1 G= 9.8 metres 
second
-2
), recording ten samples per second, which are summed for each minute epoch. It 
measures frequencies between 0.25 to 2.5 Hertz, which is the common frequency range of 
human movement (Warms 2006). Each displacement within these parameters is counted, 
recorded and stored in the Actigraph as activity counts. 
Whilst direct or indirect calorimetry are considered to be the criterion method for measuring 
energy use (McArdle et al. 1996), the equipment required makes them impractical to use for 
measuring energy use outside a laboratory so they cannot provide data about usual activity 
levels. The MTI Actigraph activity monitor was selected to be used as, unlike questionnaires, it 
provides objective information regarding the intensity or frequency of movement (Warms 
2006). Whilst observation of activity by a trained observer provides a large amount of data 
regarding activity duration, frequency and intensity, it was impractical (Warms 2006). The 
Actigraph is practical to wear, being worn at waist height during waking hours and only 
removed for bathing, although participants must remember to wear the monitors regularly. The 
Actigraph was preferred to a pedometer as it can only measure the steps taken and has been 
shown to underestimate physical activity by up to 48% (Leenders et al. 2001). Activity counts 
have demonstrated strong associations with double labelled water uptake (r=0.71), and so are 
a valid indicator of activity (Bouten et al. 1996). Counts from the Actigraph are strongly 
associated with steady state oxygen consumption and activity report in healthy people and 
have been used in neurological conditions, suggesting they may be appropriate for people with 
PN (Busse et al. 2004; Freedson et al. 1998; Munneke et al. 2001; Sirard et al. 2000; Sisto et 
al. 1998). Activity counts have discriminated between people with chronic fatigue syndrome 
and people with MS, indicating divergent validity (Vercoulen et al. 1997) and have 
demonstrated acceptable test re-test reliability in eight people with Parkinson’s disease (ICCs 
>0.76) when measured one week apart (White et al. 2007b). 
However, activity monitors may overestimate the energy used in low intensity activities and 
under estimate high intensity activities if activity counts are used to calculate energy 
expenditure (Warms 2006). This is because the equation used to transform activity counts to 
energy is inexact (Warms 2006). This suggests that values of energy expenditure should not 
be calculated from activity counts. However, it is reasonable to compare activity counts 
between groups or before and after an intervention in the same group. Therefore, the 
cumulative mean activity count per day over five days (counts) was collected and compared to 
healthy data in this study. 
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5.3.5. Perceived exertion  
The six to 20 Borg scale was used to measure perceived exertion (Borg 1970; Borg 1982) in 
healthy and PN participants during fatiguing exercise which is fully described in protocol A in 
Chapter Six (Page 201).  
Before testing, the structure of the Borg scale was explained to the participants and the verbal 
anchors on the scale were highlighted. Participants performed up to eight sets of ten isometric 
contractions of the knee extensors at 50% MVC force. Single isometric contractions were 
repeated at intervals during a ten minute recovery period. After each set of ten repetitions and 
after each single isometric contraction during the recovery period, participants were presented 
with a large card displaying the Borg and asked to state a number that corresponded to how 
hard they felt they were working at that point (Borg 1970). A higher number denoted increased 
perceived exertion. Participants were asked to base their response upon their overall feelings 
of exertion, including muscle fatigue and experienced effort (Pandolf 1982).  
The Borg scale was used by participants in the exercise investigation in Chapter Two and 
appeared appropriate and easily understood. It is argued to have similar meaning to all 
participants (Dawes et al. 2005). The scale is reliable over time and is widely used to grade 
perceived exertion, although it has not been evaluated in PN (Borg 1970; Carton and Rhodes 
1985; Cook et al. 2002; Dawes et al. 2005; Lagally and Costigan 2004). Whilst the validity of 
the Borg scale has been challenged in some patient groups, its widespread use, ease of 
application and reported reliability supported its use in this study (Sharpe et al. 2002).  
5.3.6. Sample size 
Many of the parameters used in this study to describe the profile of experienced fatigue have 
not been used in people with PN previously. However, two calculations of sample size were 
used to provide an indication of the number of participants required to demonstrate a 
significant difference to healthy participants in FSS questionnaire scores and fatigue index 
during a sustained MVC over 60 seconds (measured in Chapter Six). 
Merkies et al. (1999) reported mean ±SD scores on the FSS of 5.6  ±1.4 for PN and 2.9 ±1.1 
for healthy participants. From these values, it was calculated that five participants in each 
group would be necessary to demonstrate a significant difference between healthy and PN 
groups for a power of 0.8 and significance level of 95% (two tailed).  
Milner Brown et al. (1989) measured the decrease in force over an isometric 60 second 
contraction in 20 healthy participants and 15 people with a range of neuropathies. A fatigue 
index (the final force at the end of the 60 second contraction expressed as a percentage of 
initial force) was calculated for healthy (mean±SD 46% ±15) and neuropathy participants (62% 
±17). For a power of 0.8 and a significance level of 95% (two tailed) it was estimated that 16 
participants in each group were necessary.  





Fatigue questionnaires were examined using Kolmogorov Smirnov tests and frequency 
histograms were drawn for inspection for normality of distribution. Paired t tests (two tailed, 
assuming unequal variance) were used to indicate if fatigue scores changed significantly from 
measurement one to two. 
Two tailed independent t tests were used to identify significant differences between healthy 
and PN groups for the mean scores on all fatigue and SF-36 questionnaires, activity counts, 
resting heart rate and values of EO2.  
For the PN group, associations between the fatigue questionnaire scores, ONLS and 
Rotterdam handicap scale were measured using Spearman’s rank correlations. Similarly, the 
association between anxiety and depression, SF-36 subscales, perceived exertion (total sum 
of Borg scores), activity counts, resting heart rate and EO2 with fatigue questionnaire scores 
were examined using Pearson’s correlation coefficients. The size of correlation coefficients 
were judged to be small/low (0.1-0.3), moderate (0.3-0.6) or large/strong (>0.6) according to 
published criteria (Cohen 1977). 
A Kruskal-Wallis test was used to examine differences in the Borg scores of healthy and PN 
participants during exercise and recovery.  
Differences between PN participants who complained of severe experienced fatigue (PNF), 
and those who did not (PNN), were examined using Mann-Whitney U tests as small numbers 
meant the data were not normally distributed.  
Significance was set at p<0.05 for all tests. All data were analysed using SPSS© software 





Fifteen volunteers with PN conformed to the inclusion criteria and were recruited. However, 
one participant could not tolerate the physiological fatigue tests and one other was unable to 
return for the second testing visit. Therefore, 13 PN participants (four females) with PN and 13 
healthy volunteers (seven females) were compared. Four PN participants had completed the 
exercise programme in Chapter Two at least six months prior to their participation in this study. 
Participant characteristics are shown in Table 5-3.  
 
Table 5-3 Participant characteristics  
 PN (n=13) Healthy (n=13) p  
Age, years (±SD; range) 51.9 (±11; 27.8-69.7) 44.8 (±13.8; 23-65) ns 
Weight, Kg  84.4 ±18 73.6 ±16.8 ns 
Height, metres  1.73 ±0.84 1.71 ±0.09 ns 
BMI, Kg m
-2
 28 ±5.8 25 ±4.7 ns 
Diagnosis GBS: 4, CIDP: 7, MMN: 1, PDN: 1 
 
- 
Mean time since 
diagnosis, (SD; range) 
9 years, 9 months (±9 months; 1 year-29 years) 
 
- 
SF-36 PCS 42.4 ±9.6 57.5 ±3.2* <0.001 
SF-36 MCS 57.6 ±5.3 54.4 ±4 ns 
Walking Scale (Walk-12) 32 (±21) - - 
ONLS 4 (0-5) - - 
Rotterdam Handicap 
scale 
33 (22-36) - 
- 
HADS Anxiety 2.5 (0-8) - - 
HADS Depression 1.5 (0-8) - - 
All GBS had AIDP, all CIDP participants had the typical form.* denotes significant difference between 
healthy and PN groups. All values are mean ±SD except the ONLS, RHS and HADS which are median 
(range). SF-36 PCS – Physical component summary score, MCS – mental component summary score, 
HADS – Hospital anxiety and depression scale. 
 
5.4.2. Fatigue report 
Fatigue questionnaire scores were normally distributed in healthy and PN groups 
(Kolmogorov-Smirnov test, p=0.2) thus parametric statistical tests were used. There were no 
significant differences within groups between scores on the first and second visit for all fatigue 
scales. Therefore, the mean of fatigue questionnaires scores from both visits were used for all 
comparisons. 
Mean fatigue scores for each questionnaire are shown in Table 5-4. Overall scores on the PFS 
were classed as mild for both groups, but affective and sensory subscales indicated moderate 
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fatigue in PN participants (Piper et al. 1998). Healthy fatigue scores were all within normal 
limits. 
Participants with PN had significantly more severe experienced fatigue than healthy volunteers 
on the PFS, FIS and FSS. Physical and behavioural subscale scores on the FIS were also 
significantly higher in PN participants, indicating greater experienced fatigue.  
 
Table 5-4 Fatigue questionnaire scores for PN and healthy participants. 
Measure PN  Range Healthy  Range p 
FSS Total 4 ±1.8 1-6.4 2.3 ±0.8 1-4.1* 0.005 
FIS Total 22.6 ±21.6 0.5-72 6.8 ±6.9 0-20* 0.02 
PFS Total 2.7 ±2.1 0-6.2 1.22 ±1.1 0-3.2* 0.04 
FIS cognitive  3.7 ±4 0-12.5 2.5 ±2.9 0-8 ns 
FIS physical 10.3 ±8.6 0-25 1.23 ±1.6 0-5* 0.001 
FIS social 10.8 ±12 0-36.5 3.2 ±3.2 0-11* 0.04 
PFS behavioural 2.3 ±2.6 0-6.8 0.26 ±0.4 0-1* 0.01 
PFS affective 3.8 ±2.4 0-7.1 1.84 ±1.8 0-4.8* 0.03 
PFS sensory 3.3 ±2.4 0-6.6 2.1 ±1.9 0-5.2 ns 
PFS cognitive 1.83 ±1.6 0-4.8 1.6 ±1.1 0-4 ns 
* denotes significant difference between healthy and PN participants. All scores are mean ±SD. FSS - 
fatigue severity scale, FIS – fatigue impact scale, PFS – Piper fatigue scale. 
 
In the PN group, fatigue severity was not correlated with age (r<0.3), and females had similar, 
or slightly lower scores on the FSS (2.8 ±2), FIS (22.6 ±33) and PFS (1.7 ±3) than men (FSS: 
4.55±1.5; FIS: 22.6 ±17; PFS: 3.2 ±1.6).  
Participants with CIDP demonstrated significantly more severe experienced fatigue than those 
after GBS. Overall fatigue scores for people with CIDP and after GBS are shown in Table 5-5. 
 
Table 5-5 Fatigue questionnaire scores of participants with GBS and CIDP. 
 GBS (n=4) CIDP (n=7) p 
FSS Total 1.7 (1.2-3.9) 5 (3.7-5.9)* 0.01 
FIS Total 3.5 (0.5-20) 27 (5-72)* 0.05 
PFS Total 0.5 (0-2) 4 (0.3-6)* 0.003 
* denotes significant difference between people after GBS and with CIDP. All values are median (range). 
 
On the FSS, seven PN participants rated fatigue to be one of their three most disabling 
symptoms and ten noted that exercise exacerbated their experienced fatigue. 
Scores on all fatigue scales correlated strongly and significantly with each other in PN 
participants (r>0.7) but there were no significant associations between fatigue scales for 
healthy volunteers (r<0.3).  
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5.4.3. Experienced fatigue 
In the PN group, eight participants reported that severe experienced fatigue was a significant 
and consistent problem during at least the last six months (PNF). The remainder of PN 
participants did not report persistent severe fatigue (PNN). No healthy volunteers reported 
severe experienced fatigue. 
When compared, PNF participants displayed significantly higher scores on all fatigue scales, 
including cognitive subscales. These are shown in Table 5-7, overleaf. 
The PN participants who reported severe persistent fatigue were slightly younger than those 
that did not, and reported significantly lower energy and vitality, reduced social functioning and 
poorer general health perception on the SF-36 questionnaire (Table 5-8). Although not 
statistically significant, PNF participants had higher activity limitations, measured by the ONLS. 
5.4.4. Associations between experienced fatigue report, activity limitations 
and mental health in PN participants 
Activity limitation, measured on the ONLS, mobility and depression scores were positively and 
significantly associated with experienced fatigue measured by the FIS and PFS in people with 
PN. These associations and those with the HADS and RHS are shown in Table 5-6 . 
 
Table 5-6 Associations between activity limitations, participation, mobility and experienced fatigue. 
 FSS FIS PFS 
ONLS 0.5 0.66* 0.69* 
RHS 0.34 0.43 0.3 
Walk-12 0.52 0.8* 0.73* 
HADS Anxiety 0.47 0.51 0.42 
HADS Depression 0.7* 0.9* 0.8* 
All correlations are Spearman’s ranks except those between the fatigue scales and the Walk-12, which 
were analysed using Pearson’s correlation. * denotes a significant correlation at p<0.05. 
 
 
The association between scores on the fatigue scales and SF-36 questionnaire for PN 
participants are displayed in Table 5-8. The severity of reported experienced fatigue correlated 
most strongly and negatively with the energy and vitality and social function subscales on the 
SF-36. Pain, physical function and general health perception were also significantly and 







Table 5-7 Participant characteristics, fatigue report and other questionnaire scores for PNN 
and PNF participants. 
 PNN (n=5) PNF (n=8) P 
Age (years) 57 (49-70) 49 (28-62) - 
BMI (Kg m
-2
) 31 (21-40) 26 (23-34) - 
Diagnosis 3 GBS, 2 CIDP 5 CIDP, 1 PDN, 1 
GBS, 1 MMN 
- 
FSS 2.7 (1-5.1) 4.6 (1.9-6.3)* 0.05 
FIS Total 8.2 (0-17) 29.5 (0-76)* 0.01 
PFS Total 1.2 (0-2.3) 3.6 (0.2-6)* 0.007 
FIS cognitive  0.4 (0-1) 6 (0-15)* 0.006 
FIS physical 4.8 (0-11) 15 (0-24)* 0.05 
FIS social 3 (0-7) 16.9 (0-41)* 0.02 
PFS behavioural 0.26 (0-1.2) 3.9 (0-7.5)* 0.01 
PFS affective 2.1 (0-4.4) 4.6 (0.2-7)* 0.02 
PFS sensory 1.7 (0-3.8) 3.9 (0-6)* 0.02 
PFS cognitive 0.83 (0-2) 2.7 (0-4.5)* 0.03 
ONLS 2 (1-4) 4 (0-5) ns 
HADS Anxiety 1 (0-5) 3 (0-8) ns 
HADS depression 1 (0-1) 2 (0-8) ns 
Rotterdam handicap scale 33 (26-36) 33.5 (22-36) ns 
SF-36:    
Physical function 66 ±19 62 ±25 ns 
Role limitation physical 80 ±4.7 68 ±40 ns 
Role limitation mental 100 ±0 100 ±0 - 
Social function 95.6 ±10 81 ±15 0.07 
Mental health 90.4 ±4.6 79.4 ±14 ns 
Pain 77.8 ±11 60 ±23 ns 
Energy and vitality 79 ±16 44.3 ±16* 0.006 
General health perception 80 ±9 45 ±16.3* 0.001 
Walking scale (Walk-12) 24 ±5 37 ±26 ns 
* denotes significant difference between PN participants who reported severe experienced fatigue (PNF) 
and those who did not (PNN). All values are median (range) except SF-36 summary and subscale scores 




Table 5-8 Associations between SF-36 subscales and fatigue questionnaires for PN participants. 
















0.4 0.6* 0.45 0.5 0.6* 0.66* 0.58 0.45 0.39 0.37 
SF-36 Social 
function 
0.67* 0.9* 0.72* 0.86* 0.76* 0.91* 0.84* 0.63* 0.63* 0.63* 
SF-36 Mental 
health 
0.44 0.78* 0.59 0.77* 0.76* 0.74* 0.57 0.55 0.4 0.7* 
Sf-36 energy 
and vitality 
0.86* 0.82* 0.9* 0.88* 0.77* 0.76* 0.82* 0.86* 0.88* 0.3* 




0.56 0.62* 0.68* 0.75* 0.53 0.65* 0.52 0.63* 0.5 0.54 
* denotes a significant association at p<0.05. All values are Pearson’s correlation coefficients and were negative (i.e. increased fatigue scores were associated with 
poorer health status on the SF-36) There were no significant associations between any fatigue scale and physical role limitation, mental role limitation, or change in 
health subscales (data not shown). 
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5.4.5. Energy demands of walking  
One PN participant was uncomfortable whilst wearing the face mask used to measure EO2, 
therefore the oxygen cost of walking was examined in 12 PN participants. These data were 
compared to values from 12 healthy gender and age matched participants from Chapter Four. 
Participant characteristics and values of EO2 are shown in Table 5-9. 
There was no significant difference in the energy cost of walking between PN and healthy 
participants (Table 5-9).  However, as people with PN were significantly heavier than healthy, 




Oxygen Consumption (VO ml min )
EO (ml m )






This revealed that PN participants used significantly more energy whilst walking than healthy 
participants (Table 5-9).  
 
Table 5-9 Healthy and PN participant characteristics for the energy cost of walking. 
 Healthy (n=12) PN (n=12) P 
Age, years  48.5 ±8.3 52.1 (11.5) ns 
Height (metres) 1.66 ±0.09 1.73 ±0.9 ns 
Weight (Kg) 68.9 ±11.5 84.4 ±18* 0.01 
BMI (Kg m
-2
) 25 ±3.2 28.4 ±6.4 ns 









) 11.1 ±2.3 16.5 ±7* 0.02 
Resting heart rate (beats min
-1
) 72 ±8 79 ±14
#
 0.04 
Activity levels (counts) 1489 ±408 1151 ±339* 0.03 
*denotes significant difference between healthy and PN groups. 
# 
denotes n=11 resting heart rate 
measurements in the PN group as one PN participant’s heart rate readings were faulty. All are expressed 
as mean ±SD. Healthy data are from 12 age matched participants who participated in a previous study 
(described in Chapter Four). 
 
There were no significant differences in EO2 (normalised to body weight) between PNF and 
PNN participants (Table 5-10) although the size of each group was small.  
 
Table 5-10 Differences in EO2, resting heart rate and activity in PNF and PNN participants 
 PNF (n=8) PNN (n=4) P 




) 0.21 ±0.07 0.18 ±0.04 ns 
Resting heart rate (beats min
-1
) 78 ±11 72 ±9 
#
 ns 
Activity levels (counts) 1132 ±340 1181 ±375 ns 
#
 n=3 as readings of one PNN participant’s resting heart rate were faulty so was excluded from 
comparison.  
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Values of EO2 were not significantly correlated with fatigue scores on any of the questionnaires 
in PN participants (r<0.3). 
5.4.6. Resting heart rate 
The mean resting heart rate of PN participants was significantly higher than age matched 
healthy people (Table 5-9). The PNF group also had somewhat higher resting heart rates than 
PNN groups, but the difference was not significant (Table 5-10). Resting heart rate was not 
significantly associated with experienced fatigue measured on the FSS, FIS and PFS 
questionnaires for PN participants (r<0.1). 
5.4.7. Activity counts 
Activity counts for PN and healthy participants are shown in Table 5-9 and for PNF and PNN 
participants in Table 5-10. Participants with PN had significantly lower activity counts over five 
days than healthy volunteers. There were no significant differences in activity levels between 
PNF and PNN participants.  
The mean activity counts of PN participants did not significantly or strongly correlate with 
scores on the FSS and PFS questionnaires (r<0.3), but had a moderate, positive association 
which reached significance with scores on the FIS (r=0.56, p=0.048). In healthy people, there 
were no significant associations between scores on the fatigue questionnaires and activity 
levels. 
5.4.8. Perceived exertion during fatiguing contractions 
Borg scores for healthy and PN participants are displayed in Figure 5-1.  
Participants with PN had slightly increased feelings of exertion earlier in the fatigue protocol 
when compared to healthy people, but differences were not statistically significant. They 
recovered slightly more slowly. Five PNF participants stopped the fatigue protocol; three as 
they reported they were too tired to continue, and two as they were unable to continue to 
produce adequate force (as shown in Chapter Six). All PN participants who did not complete 
all repetitions were assumed to have a maximum Borg score (20) after the point at which they 
stopped. 
There were no significant differences in perceived exertion between PNF and PNN 
participants. The sum of all Borg scores during the fatiguing exercise did not correlate with 
scores on any fatigue questionnaires in PN or healthy participants (r<0.5). It also did not have 
any significant associations with EO2 or resting heart rate (r<0.5). 
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Figure 5-1 Median scores of perceived exertion during 80 intermittent voluntary contractions at 50% MVC 
and during recovery for healthy and PN participants. 
After set / recovery time






































































Error bars denote 25th and 75th centiles for the median Borg score. The size of the PN group as the 
fatigue protocol progresses is also shown, as five PNF participants did not complete the entire protocol. 
All participants in both groups (n=13) completed the recovery contractions. There were no significant 
differences between PN and healthy groups. 
 
 
  183 
5.5. Discussion 
The aim of this study was to describe the nature and severity of experienced fatigue in people 
with PN in comparison to healthy volunteers and investigate the relationships between 
experienced fatigue and selected aspects of functioning. This is the first investigation of the 
relationship between activity levels, fitness, perceived exertion, anxiety, depression and 
experienced fatigue in people with PN and demonstrated that PN participants experienced 
significantly more severe fatigue than healthy volunteers. Whilst the findings of this study 
cannot elucidate the causes of experienced fatigue and its effect upon aspects of functioning 
in people with PN, the severity of experienced fatigue was significantly associated with 
decreased social function, lower mood, poorer general health perception, reduced activity 
levels and poorer perceived mobility (all r>0.6). When compared to healthy, age matched 
volunteers, people with PN had significantly higher resting heart rates, weighed more and were 
less active. Ten (from 13) PN participants noted that exercise increased the severity of their 
experienced fatigue.  
5.5.1. Description of experienced fatigue 
This study showed that severe experienced fatigue was significantly and moderately 
associated with persistent activity limitations and reduced health related functioning (r>0.6 for 
all correlations). This has been reported by others in PN (Merkies et al. 1999). The scores on 
the fatigue questionnaires indicated that PN participants found that experienced fatigue had 
the greatest impact upon social and physical activities. Contrary to the findings of Garssen et 
al (2006), the severity of experienced fatigue was similar between men and women, was not 
increased with age and was somewhat greater in participants with CIDP when compared to 
those after GBS, although this may be an artefact of the sample size and composition.  
5.5.2. Possible contributors to experienced fatigue  
 Mood  
Poorer mood and well-being, measured on the HADS and SF-36 were significantly associated 
with increased experienced fatigue in PN participants (all r>0.7) which is supported by the 
findings of others in people after GBS and with CIDP (Merkies et al. 1999). In the current 
study, fatigue and depression scores measured on the HADS had a significant and strong 
association with each other (r>0.7). This could suggest that more severe experienced fatigue 
was a symptom of depression or alternatively, that it precipitated feelings of low mood. 
Psychological factors and experienced fatigue have been shown to be linked in other 
neurological patient groups including MS (Iriarte et al. 2000; Strober and Arnett 2005), 
although not by others in PN (Garssen et al. 2004) and anti-depressants were ineffective in 
reducing the severity of fatigue in people with PN (Garssen et al. 2006b). It seems most likely 
that, as all participants were screened to exclude severe depression (using the GHQ-28), and 
did not demonstrate abnormal depression scores on the HADS, the significant and strong 
association between depression and fatigue scores could be because they share some 
common symptoms. However, the findings of this study are limited as only anxiety and 
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depression were specifically examined. Other factors which may influence both well-being and 
experienced fatigue such as sleep disturbances and beliefs about fatigue, not investigated 
here, could be responsible and should be examined in future work to determine any 
associations with experienced fatigue in people with PN. 
 Activity levels, perceived exertion, energy cost and cardiovascular fitness  
Cumulative activity levels were significantly lower in PN participants than healthy volunteers 
and were moderately and significantly associated with severity of experienced fatigue on one 
questionnaire (r=-0.56). However, this study cannot identify if people with PN have reduced 
their activity levels because of an increased severity of fatigue or if reduced activity has 
precipitated increased experienced fatigue.  
People with PN had significantly higher resting heart rates than age and gender matched 
healthy volunteers and those PN participants that reported persistent severe fatigue (PNF, 
n=8) had somewhat higher resting heart rates than those who did not (PNN) (PNF mean 
resting heart rate: 78 ±11 beatsmin
-1
; PNN: 72 ± 9 beatsmin
-1
). Despite significant differences 
in resting heart rate and experienced fatigue between healthy and PN groups, resting heart 
rate and experienced fatigue were not associated in people with PN (r<0.1) which suggests 
that cardiovascular fitness did not influence fatigue in participants with PN. However, although 
heart rate is commonly used and valid to indicate cardiovascular conditioning, it is not as 
sensitive as other tools such as peak oxygen consumption (VO2 max) recorded during 
exercise (McArdle et al. 1996). Heart rate also varies at rest (as shown in Study Two of 
Chapter Four), which might reduce the size of any statistical association. The small sample 
may have also limited the strength and significance of associations and so cardiovascular 
fitness cannot be confidently excluded as a potential contributor to the severity of experienced 
fatigue. 
Similarly, associations between EO2 and the severity of experienced fatigue were weak and 
not significant (r<0.3) and there were no significant differences in normalised EO2 between 
participants with PN and age and gender matched healthy participants. This is in contrast to 
the findings of a small study of 14 people with post polio syndrome (Brehm et al. 2006) who 
found that people with post polio syndrome used significantly more energy when walking than 
healthy participants, and that the energy cost of walking was strongly and significantly 
associated with reduced lower limb muscle strength (r=0.84, p<0.001). Although the results of 
the current study suggest that an increased energy cost of walking was not a contributor to the 
severity of experienced fatigue, people with PN were significantly heavier than age and gender 
matched healthy controls which may have skewed the results. Further work is therefore 
needed to compare the energy cost of walking between people with PN and healthy 
participants who are also matched for weight.  
During the fatiguing exercise test, there was a trend for PN participants to report higher levels 
of perceived exertion earlier than healthy volunteers, although this did not reach significance. 
Reduced cardiovascular fitness, and/or an increased sensitivity to exertion may be responsible 
for this tendency. An elevated perception of exertion may be a regulatory, learnt protective 
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response in people with CFS (Noakes et al. 2004; Noakes et al. 2005) and may be a 
mechanism to avoid overwork, limit feelings of fatigue and to allow continued functioning after 
exertion (Noakes et al. 2004; Noakes et al. 2005). However, avoidance of activity and exercise 
in this way is thought to further reduce fitness and worsen symptoms in people with CFS 
(Sharpe, 2002). An altered perception of exertion may also explain the failure to complete 
fatiguing exercise in five PN participants who complained of severe fatigue (PNF) due to 
feelings of tiredness and fatigue. Three of these five PNF participants were able to maintain 
the force required by the test, despite stopping the test because they were exhausted. In 
addition to an altered perception of exertion, early cessation of fatiguing exercise could be 
reinforced by an expectation of increased severity of experienced fatigue after exercise, such 
as that reported by ten PN participants in this study on the FSS questionnaire.  
Despite trends in some measures, PN participants who complained of severe experienced 
fatigue (PNF group) did not demonstrate significant differences from non-fatigued PN 
participants (PNN) in most measures of participation and activity limitations. This is likely to be 
attributable to the very small size of these subgroups. There were also no significant 
differences between PNF and PNN groups in activity levels, the energy cost of walking and 
resting heart rates. However, trends of increased resting heart rate, elevated energy cost and 
reduced activity levels were observed in the PNF group, implying that they might contribute to 
more severe experienced fatigue. These findings suggest that future work should utilise a 
larger sample and specifically select a greater number of PN participants with severe 
experienced fatigue.This would allow comparison between non-fatigued and fatigued PN 
volunteers, to determine if the trends seen in the current study would be replicated and reach 
statistical significance. 
Taken together, the findings from this study indicate that experienced fatigue is significantly 
associated with reduced participation, poorer mood, reduced activity levels and greater activity 
limitations. The results also suggest that reduced fitness and activity levels could contribute to, 
or are affected by, severe experienced fatigue in PN participants. Reported reductions in the 
severity of experienced fatigue and improvements in activity and fitness after exercise 
interventions in people with PN support this suggestion, although these changes could not be 
directly attributed to exercise due to the uncontrolled, unblinded designs (Garssen et al., 2004; 
Chapter Two).  
 Other contributors to experienced fatigue 
As this investigation only assessed some of the possible causes of fatigue, other factors which 
were not considered here could contribute to the severity of experienced fatigue in people with 
PN. In addition to increased physiological fatigue, examined in Chapter Six, factors such as 
increased immune activation could also be involved in experienced fatigue in people with 
CIDP, as it has been associated with reported fatigue in other chronic, immune mediated 
neurological conditions (Iriarte, Subira, & Castro 2000). In addition, significantly lower levels of 
hypocretin, a neuropeptide associated with narcolepsy and excessive daytime sleepiness, 
have been shown in 65% of 18 GBS patients during the acute illness (Kanbayashi et al. 2002; 
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Nishino et al. 2003). However, this finding has not been replicated and is based on a small 
number of patients, and may not persist beyond the acute stage of GBS. Nonetheless, both 
immunoactivation and hypocretin levels could be considered in addition to examination of a 
range of psychological factors, sleep patterns and peak VO2 during exercise testing for future 
investigations of experienced fatigue in people with PN.  
5.6. Limitations 
The findings of this study are limited by several factors. The target sample size of 16 
participants in the PN group was not reached, reducing statistical power and external validity. 
Whilst this may be because potential PN participants did not perceive fatigue as an important 
problem, it could equally be because travel to London for testing was difficult or that the 
inclusion criteria and nature of the physiological fatigue tests (Chapter Six) meant potential 
subjects, particularly those with severe experienced fatigue, were unwilling or unable to 
participate. This reduces the external validity of the results, as does the relatively narrow range 
of PN studied. There was considerable variability in scores on several measures in the PN 
group which, whilst increasing external validity, made statistical significance difficult to achieve 
on some tests. Lack of assessor blinding may also bias measurements. This could be 
addressed in future work by using a blinded assessor. 
The nature of experienced fatigue reported by the PN group is also likely to be influenced by 
the fatigue questionnaires used in this study. As they were not designed to measure fatigue in 
this patient group, they may be unable to fully reflect the nature and severity of experienced 
fatigue experienced by people with PN, restricting our understanding of their experienced 
fatigue. Future work could seek to develop new tools for people with PN, using patient 
involvement to develop items from qualitative enquiry. However, the tools selected for the 
current study are well used and validated in other neurological conditions and alternative 
methods of examining fatigue, such as qualitative enquiry, would not allow direct comparison 
of the nature and severity of experienced fatigue between healthy and PN participants and so 
would not fulfil the aims of this study.  
Another limitation is that all participants were volunteers and so could be considered to have 
an atypical interest in fatigue. Healthy participants were screened to exclude those who stated 
that they experienced severe fatigue, so they may have under reported fatigue on the 
questionnaires to please the investigator. Conversely, PN participants who initially stated that 
they had severe experienced fatigue may have felt compelled to indicate more severe levels of 
fatigue on questionnaires. However, the levels of fatigue experienced by PN participants in this 
study (mean FSS score: 4; range:1 to 6.4, where 7 = most severe fatigue) were less severe 
than reported by Merkies et al. (1999) and Garssen et al. (2004) levels (FSS= 5.6 to 6.1) 
suggesting this was not the case.  
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5.7. Conclusions 
This is the first study to describe several aspects of the nature of experienced fatigue in people 
with PN. Whilst its findings are limited by aspects of the design and sample size, the results 
provided some important data about the nature of experienced fatigue in this patient group. 
Participants with PN reported a significantly greater severity of experienced fatigue than 
healthy volunteers. This fatigue was associated with increased activity limitations, decreased 
social function, poorer general health perception and poorer perceived mobility.  
The results were unable to identify other clear factors which influenced the severity of 
experienced fatigue. However, the results suggest that a combination of factors could 
contribute to or are affected by, the severity of experienced fatigue. These include decreased 
cardiovascular fitness and reduced daily activity levels which were all significantly different to 
those in healthy participants. It is not known whether these factors are a result of, or play a 
part in increasing activity limitations and poorer health status which were significantly 
associated with an increased severity of experienced fatigue. It is also unclear whether these 
factors initiated worsened experienced fatigue or if severe experienced fatigue reduced 
functioning in these areas, although this could be elucidated in a future longitudinal study. 
Other areas not considered in this study including immune system activation, sleep 
disturbance and psychological factors now warrant investigation as they could contribute to 
experienced fatigue in people with PN.  
Further work is also necessary to address the limitations of this study and to confirm the 




Chapter 6. An investigation of physiological 
fatigue in people with peripheral 
neuropathies 
6.1. Summary 
Physiological factors, including poor muscle activation and reduced muscular endurance may 
contribute to severe experienced fatigue in people with PN and were investigated in this 
chapter. 
The physiological fatigue profile of the knee extensors of 13 people with peripheral 
neuropathies (PN) (4 females; Mean age: 51± 2; years; Diagnosis: 7 CIDP, 4 GBS, 2 other) 
and 13 healthy participants (7 females; Mean age: 44.8 ± 14 years) was compared. 
Measurements included the voluntary activation, surface EMG, strength, response and 
recovery from i) Protocol A, intermittent isometric voluntary contractions (up to 80 repetitions at 
50% MVC) and ii) Protocol B, a 60 second sustained isometric MVC and intermittent electrical 
stimulation of the knee extensors. 
Apart from significant muscle weakness in people with PN (H Mean ±SD: 7.5 ±2.2 N Kg
-1
 ;  
PN: 5.4 ±2 N Kg
-1
) there were no significant differences in any measurements between healthy 
and PN groups including voluntary activation (H: 85 ±10%; PN: 92 ±7%), changes in surface 
EMG, delayed low frequency recovery and force decline during a sustained contraction (H:59 
± 18%; PN: 60 ±14%). In addition, there was no significant difference between PN participants 
who complained of severe experienced fatigue (PNF) and those who did not (PNN).  
Five of eight PNF participants were unable to complete all voluntary repetitions during protocol 
A. However, there were no significant differences in their voluntary activation, recovery or 
performance to other PN participants during Protocol B. 
When these results were considered with those from Chapter Five, experienced fatigue in the 
PN group was not associated with any measures of physiological fatigue including reduced 
muscular endurance or voluntary activation. Although cardiovascular fitness and knee 
extensor strength were signficantly reduced compared to healthy people, these factors were 
not significantly associated with experienced fatigue in people with PN. Therefore, further 
investigation of factors affecting experienced fatigue is warranted in a larger number of people 
with PN. Further work is also necessary to investigate physiological fatigue after more 
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People with PN often complain of severe experienced fatigue after exertion or exercise, 
suggesting that altered physical or physiological factors influence experienced fatigue 
(Garssen et al. 2004; Merkies et al. 1999).  
Physiological fatigue is defined as: “a reduction in the ability of a muscle to maintain or 
produce force” (Bigland-Ritchie 1981; Gandevia 2001). It may be produced by changes in the 
central and peripheral nervous systems, or within the muscle itself. To experience some 
physiological fatigue during physical exertion is considered normal (Bigland-Ritchie 1981; 
Gandevia 2001), but abnormal physiological fatigue could elicit severe experienced fatigue, 
reduce function and limit performance if already weakened muscles further decrease their 
force output during or after activities.  
Many people with weakened muscles may use near maximal forces to perform activities of 
daily living (ADLs), thus even small decrements in force could severely increase the effort 
required to perform simple ADLs and so hinder functioning (Milner-Brown and Miller 1989; 
Shumway-Cook et al. 2002). Reductions in the force generating capacity of some muscles 
could also require patients to perform compensatory movements to complete activities of daily 
living, increasing energy expenditure (Waters and Mulroy 1999), which may add to the severity 
of experienced fatigue and perceived exertion. Therefore, investigation of physiological fatigue 
is needed to determine if people with PN experience an earlier onset, greater severity or 
longer lasting physiological fatigue when compared to healthy volunteers. 
There are a number of factors that could alter the physiological fatigue profile in people with 
inflammatory PN. These are discussed in more detail in Section 6.2.2 (Page 192) and include 
changes in voluntary activation, nerve and neuromuscular propagation and alterations in the 
muscle and its metabolism. These aspects have been investigated in several different patient 
groups, but studies in PN are inconclusive. Reduced voluntary activation and altered muscle 
fatigability have been shown to produce abnormal physiological fatigue in people with enlarged 
motor units after polio (Allen et al. 1994; Allen et al. 2004). Whilst there are clear differences 
between the pathophysiology of polio and PN, enlarged motor units may be present in over 
half of people with inflammatory PN which suggests that people with PN could also have an 
altered physiological fatigue profile (Dornonville de la Cour et al. 2005).  
In PN, two studies reported reduced muscular endurance during a sustained isometric 
contraction of the knee extensors and ankle dorsiflexors in people with PN (n=15, 10 with PN, 
n=5 with other neuromuscular disorders) and CMT (n=29) when compared to healthy 
participants (Lindeman et al. 1999; Milner-Brown and Miller 1989). Similarly, in 15 people with 
neurogenic weakness including PN, the fatigability of the knee extensors was significantly 
greater than healthy participants and was strongly related to muscle strength (r=-0.88) 
indicating that the changes producing muscle weakness may also increase physiological 
fatigue (Milner-Brown and Miller 1989). In contrast, others have shown significantly greater 
muscular endurance of the ankle dorsiflexors in 40 people after GBS during repeated 
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isokinetic contractions, compared to healthy participants, despite significant weakness 
(Dornonville de la Cour and Jakobsen 2005). Increased muscular endurance has also been 
reported in the knee extensors and dorsiflexors of people with diabetic neuropathy (Andersen 
1998). Whilst the reason for this is unclear, it could be because the remaining innervated 
muscle fibres have to work harder to compensate for overall muscle weakness during daily 
activities and so become more resistant to fatigue.  
In addition to their contradictory findings, the clinical relevance of these studies is limited as 
none measured or detailed the relationship between experienced and physiological fatigue. 
However, two studies have investigated the association between experienced fatigue and 
factors which may contribute to abnormal physiological fatigue including nerve conduction 
velocities, muscle endurance and voluntary activation in people after GBS or with CIDP 
(Garssen et al. 2005b; Garssen et al. 2006a). One study found narrower nerve conduction 
velocity distributions in 15 people with PN (GBS: n=13, CIDP n=2) who complained of severe 
experienced fatigue in comparison to healthy controls, but conduction velocities were not 
significantly associated with the severity of experienced fatigue (Garssen et al. 2006a). In the 
second study, physiological fatigue during a sustained MVC of the biceps brachii in 10 people 
after GBS did correlate significantly with experienced fatigue (r=0.66, p=0.04), but was not 
different to healthy participants (Garssen et al. 2005b). Whilst methodological differences, 
such as the muscle tested and the method of fatiguing it may account for these somewhat 
conflicting results, they indicate that further investigation of physiological and experienced 
fatigue is needed to determine if there is a relationship between them in people with PN. 
A limitation of several studies of fatigue is that they have reduced relevance to everyday 
function as they utilised sustained contractions to elicit physiological fatigue. This type of 
contraction is not as common as a sub-maximal intermittent contraction when undertaking 
activities of daily living such as climbing stairs and walking (Garssen et al. 2005b; Lindeman et 
al. 1999; Milner-Brown et al. 1986). Furthermore, upper limb or smaller muscles were often 
tested despite the fatigue profile of these muscles being likely to have a very limited impact 
upon daily performance or experienced fatigue when compared to larger weight bearing 
muscles, such as those used when walking. Weakness brought about by abnormal 
physiological fatigue in these muscles could influence the severity of experienced fatigue as 
individuals have to work harder and utilise compensations which necessitate greater energy 
and effort (Gandevia 2001).Therefore, measurement of physiological fatigue in larger and 
weight bearing muscles during more functional muscle activity is warranted in order to mimic 
physiological fatigue during everyday activities and investigate any associations with 








The aims of this study were to: 
1. describe the physiological fatigue profile of the knee extensors in people with PN in 
comparison to healthy volunteers, 
2. investigate the relationships between experienced fatigue and physiological fatigue in 
people with PN 
This investigation, with that in Chapter Five, fulfils the second aim of this thesis by determining 
the fatigue profile of people with PN. 
6.2.2. Possible causes of physiological fatigue 
The source of physiological fatigue can lie within the central or peripheral nervous system, the 
muscle under test, or at all three sites. Central factors which produce physiological fatigue 
include the ability to fully activate muscles and changes that occur in peripheral nerves in 
response to activity. These are discussed on Page 194. Peripheral factors which cause a 
reduction in force output include alterations at the neuromuscular junction and within the 
muscle and are discussed on Page 195 (Bigland-Ritchie et al. 1983; Gandevia 2001). Central 
and peripheral factors, which are intricately related to each other, can be assessed separately 
to allow dissection of the cause of physiological fatigue. A simplified summary of techniques to 












































CNS – central nervous system. Adapted from Vollestad et al. 1997. 
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6.2.3. Central factors of physiological fatigue 
 Central nervous system 
Physiological fatigue mechanisms in the central nervous system (CNS) include decreased 
voluntary activation, or increased inhibition, and alterations in discharge frequency of spinal 
motor neurones (Gandevia 2001). 
 Voluntary activation 
Voluntary activation is the ability to fully and voluntarily contract the muscle or muscles under 
test (Gandevia 2001). Decreased voluntary activation causes abnormal reductions in strength 
which appear as weakness (Gandevia 2001). Inhibition, or decreased activation, occurs after 
disuse (Duchateau and Hainaut 1998), injury (Dornonville de la Cour and Jakobsen 2005; 
Rutherford et al. 1986), if afferent proprioceptive information is impaired (Hurley et al. 1997) 
and is thought to be a protective, subconscious response to prevent injury or over work 
(Gandevia 2001; Rutherford et al. 1986). Some reports in people with neurological conditions 
show that voluntary activation is not significantly lower than healthy volunteers (Kent-Braun et 
al. 1994; White et al. 2004) whilst others demonstrate that it is significantly reduced (Gandevia 
et al. 2000). One small study has investigated the voluntary activation of the elbow flexors in 
ten people who complained of severe experienced fatigue after GBS (Garssen et al. 2005b). 
There were no significant differences in activation to healthy participants both at rest and after 
a two minute sustained contraction, indicating that voluntary activation was normal in people 
with PN, despite severe experienced fatigue (Garssen et al. 2005b). However, this study used 
a small number of participants (n=10) and only the elbow flexors were tested so the results 
cannot be generalised to other muscles or to the wider PN population. Abnormal physiological 
fatigue of a small or upper limb muscle is also less likely to markedly influence experienced 
fatigue as it may not affect daily performance. Voluntary activation of large, weight bearing 
muscle groups has not been assessed in people with inflammatory PN. If inhibition was 
present in muscles such as the knee extensors, it could elicit experienced fatigue as their 
inhibition will affect function. These deficits could contribute to more severe experienced 
fatigue but may be reduced by training (Rutherford and Jones 1986). Therefore, voluntary 
activation of the knee extensors requires assessment to see if deficits are present and to 
investigate any relationship with experienced fatigue in people with PN. 
 Peripheral nervous system 
Changes in the peripheral nervous system can affect the drive to the muscle and thus force 
production. Activity dependent conduction block (ADCB) in peripheral nerves which have been 
demyelinated could produce physiological fatigue in people with PN, which may contribute to 
experienced fatigue (Cappelen-Smith et al. 2001; Kaji et al. 2000; Kaji 2003). In demyelinated 
nerves, the conduction of nerve impulses is slowed which results in a decreased driving 
current. If this driving current cannot overcome the threshold needed to cause depolarisation, 
conduction block occurs, resulting in temporarily and rapidly reduced muscle force (Kaji et al. 
2000). Activity could elicit conduction block as a train of impulses, such as those required to 
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produce a sustained or repeated muscle contraction, can cause hyperpolarisation (Kaji et al. 
2000). This increases the threshold for depolarisation which cannot be reached by the already 
reduced driving current in demyelinated nerves (Kaji et al. 2000). Activity dependent 
conduction block has been demonstrated in hand muscles after sustained voluntary 
contractions in people with MMN and CIDP, but its functional effects, if any, are not clear. If 
present, ADCB could result in loss of force during sustained activity, impairing function and 
potentially contributing to experienced fatigue. Although the presence of ADCB was not able to 
be investigated directly in this study, ADCB would be one cause of an abnormal force decline 
seen during fatiguing exercise and could then be specifically investigated in future work. 
6.2.4. Peripheral factors of physiological fatigue 
 Neuromuscular junction 
The neuromuscular junction appears largely normal after treatment in GBS and no disorders 
are reported beyond the acute period of GBS, in CIDP or PDN (Buchwald et al. 2002; 
Cappelen-Smith et al. 2001; Kaji et al. 2000; Kaji 2003; Kiernan et al. 2002; Kimura 2001). 
Therefore, changes at the neuromuscular junction are an unlikely source of physiological 
fatigue in this patient group. For this reason, the performance of the neuromuscular junction 
was not examined in this investigation. 
 Muscle factors 
 Delayed low frequency recovery 
Alterations in sacroplasmic calcium dynamics within muscles during exercise can produce long 
lasting force reductions which are most apparent on low frequency electrical stimulation (Jones 
1996; Tupling 2004). This low frequency fatigue or delayed low frequency recovery (DLFR) 
can cause persistent physiological fatigue, lasting for several hours or even days (Westerblad 
and Allen 2002). It is caused by abnormalities in calcium ion regulation within the sacroplasmic 
reticulum which affects muscle contraction, and is exacerbated by damage to sarcomeres by 
increased oxidative stress and high calcium transients during exercise (Tupling 2004; 
Westerblad and Allen 2002). Some report that increased DLFR contributes to physiological 
fatigue in people with multiple sclerosis (MS) (Lenman et al. 1989; Ng et al. 2004) and others 
hypothese that DLFR could contribute to physiological fatigue in people with neuromuscular 
conditions, but this has not been investigated (Milner-Brown and Miller 1989). If present, 
increased DLFR would cause persistent physiological fatigue after exertion which, in turn, may 
worsen experienced fatigue in people with PN. Therefore, an investigation of DLFR is required 
to identify if abnormal levels are present in people with PN and to examine any association 
with the severity of experienced fatigue.  
 Muscle fatigability 
Muscle fibre type determines the fatigability or fatigue profile of all muscles. The fatigue profile 
of a muscle may alter in response to changes in the relative proportions of muscle fibre types 
after alterations in motor unit size or after disuse or training, but this has not been directly 
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examined in people with inflammatory PN (Duchateau et al. 1998). Findings in conditions 
affecting the central nervous system are not likely to be applicable to PN as tonal changes are 
recognised to influence muscle fatiguability (Lieber et al. 2004). However, Borg et al. (1988) 
examined muscle fibre type in 19 people after polio and found that the muscles which were 
most severely affected were markedly atrophied but retained a normal fibre type differentiation 
(Borg et al. 1988). However, in less severely affected muscles, there was a significant increase 
in the relative proportion of fatigue resistant fibres (Type I) (Borg et al. 1988). This was thought 
to be because people overused these muscles to allow continued function by compensating 
for those which were severely atrophied. Although the differences between PN and polio are 
acknowledged, these findings suggest that people with PN could have altered physiological 
fatigue in some muscles. This is supported by two studies which attributed greater muscular 
endurance of the ankle dorsiflexors and knee extensors in people after GBS to an increased 
proportion of fatigue resistant fibres (Andersen 1998; Dornonville de la Cour and Jakobsen 
2005). Conversely, compensatory reinnervation which occurs in over 60% of patients with PN 
(Dornonville de la Cour et al. 2005), disuse during the acute illness and persistent reductions 
in activity would predict increased fatigability of muscle (Duchateau and Hainaut 1998). From 
this limited and equivocal evidence, people with PN may exhibit a combination of changes 
associated with disuse and increased motor unit size which would produce greater or lesser 
physiological fatigue. Therefore, in order to describe the physiological fatigue profile of people 




A cross sectional design was chosen to address the aims of this investigation (Sim and Wright 
2000). Participants with a confirmed diagnosis of GBS, CIDP, MMN or PDN were recruited as 
described in Chapter Five. 
Participants were asked to attend Shepherd’s House, King’s College London on two 
occasions, one week apart. Participants were instructed to avoid caffeinated beverages for 12 
hours prior to testing (Spriet 1995) and not to eat a heavy meal or consume alcohol on the day 
of the test (American College of Sports Medicine 1995). Sample size was estimated from two 
studies as described in Chapter Five (Page 173). 
6.3.1. Measurement of physiological fatigue 
After completion of the questionnaires and physical tests described in Chapter Five, tests of 
physiological fatigue were performed in the knee extensor muscle group, which were tested on 
both visits. The limb to be tested, and the fatiguing protocol used (A or B) was randomly 
chosen on the first visit. The remaining protocol was performed on the same leg on the second 
visit.  
The fatigue protocols used were designed to assess different aspects of physiological fatigue 
and are described in Section 6.3.4. Protocol A comprised repeated sub maximal contractions 
of the knee extensors in attempt to mimic daily activity and test aerobic muscle metabolism 
and function. Participants completed a sustained isometric maximal contraction in Protocol B 
to assess the response to predominantly anaerobic muscle work. This was followed by 
intermittent electrical stimulation to measure muscle fatigability. 
One week was left between testing sessions to allow recovery but to minimise the chance of 
any changes in the participants’ clinical status. 
 Testing position  
Participants were comfortably seated on a Kin Com dynamometer (Chattanooga Corporation, 
USA) and firmly secured at the waist, hips and across the chest with adjustable straps (Figure 
6-2). The hips were positioned in 80
o
 flexion. The axis of the Kin Com was positioned by eye at 
the centre of rotation of the knee, which was flexed to 90
o
, and secured firmly above the 
malleoli to the lever arm via a cushioned cuff. Lever arm length (between the centre of the 
knee joint and ankle cuff) was not incorporated in force calculation, therefore linear forces 
were expressed in Newtons (N). 
The Kin-Com dynamometer has previously demonstrated test re-test reliability in 
measurements of linear isometric knee extensor muscle force (Mayhew et al. 1994). Sixteen 
repeated measurements on the Kin-Com, with known forces of 49 to 196 Newtons, were 




Two moistened, sponge covered electrodes were used to percutaneously electrically stimulate 
the knee extensors. They measured 12 cm x 7 cm, were placed proximally and distally on the 
anterolateral thigh and secured with bandages. 
6.3.2. Measurement of surface electromyography 
At each session surface electromyography (sEMG) was recorded from the rectus femoris, 
vastus medialis and vastus lateralis muscles in the tested leg. To ensure good electrode-skin 
contact, the skin was shaved if necessary, gently abraded and then cleaned with an alcoholic 
wipe (Basmajian and Deluca 1985). Once the skin was dry, two disposable, self adhesive 
EMG Ag/AgCl electrodes (recording area= 7.9 mm
2
) were placed on the muscles in the 
direction of the muscle fibres at an inter electrode distance of 20 mm (SENIAM 1999). The 
measurements of sEMG were not compared for the same participants between sessions, 
therefore the placement of electrodes was not marked on the skin. Placement positions are 
described in Table 6-1. 
 
Table 6-1 Surface EMG electrode placements 
Muscle group Position 
Rectus femoris 50% on the line from the anterior superior iliac spine to the superior 
patella. 
Vastus medialis 80% on the line between the anterior iliac spine and the joint space of 
the medial ligament 




On the anterior tibia below the tibial tuberosity. 
Adapted from the SENIAM guidelines (SENIAM 1999). 
 
All sEMG data were recorded using the Biopac, MP 100 system (Biopac Systems 
Incorporated, USA). This system has a common mode rejection ratio of 100 dB at 50 to 60Hz. 
The gain was set at x1000 to produce a range of raw EMG amplitude from ± 1 Volt (Basmajian 




Figure 6-2 Diagram to show position for testing of the knee extensors 
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 Preliminary treatment of surface EMG 
Surface EMG readings were recorded onto a personal computer via a 16 bit analogue to digital 
converter (1401, Cambridge electronic design, UK) at a frequency of 1200 Hz, and displayed 
using Signal software (version 2.13, Cambridge electronic design, UK). The DC offset was 
checked to be zero before each testing session. The root mean squared (RMS) sEMG 
amplitude was calculated over 250 milliseconds for RF, VM and VL muscles during MVC and 
50% MVC contractions.  
The RMS sEMG amplitudes during voluntary contractions for each muscle were normalised 
(nEMG) by dividing by the corresponding muscle RMS EMG from the baseline isometric MVC 
at each testing session. 
The average RMS nEMG of knee extensors was also calculated, as the contribution of the RF, 
VM and VL muscle groups could change with physiological fatigue (Akima et al. 2002). 
6.3.3. Testing procedure 
After a short warm up, consisting of several sub maximal isometric knee extensions, 
participants were asked to perform five isometric MVCs of the knee extensors, each lasting 
three seconds, to familiarise themselves with the protocol. Force was recorded on a computer 
and simultaneously displayed on a monitor next to the participant using Signal software 






 Measurement of peak force 
After a two minute rest participants performed several isometric MVCs, with 20 seconds rest 
between each contraction. Contractions were repeated until force did not increase further, and 
the peak force attained was noted.  
Each participant was verbally encouraged throughout to “push as hard as you can” on each 
contraction (McNair et al. 1996). A monitor was also used to provide visual feedback 
throughout testing. The gain of the display was changed between sessions to maximise effort 
and activation (Gandevia 2001).  
 Measurement of voluntary activation 
At both testing sessions, the ability to fully activate the knee extensors was assessed using the 
percutaneous twitch superimposition technique (Rutherford et al. 1986). This technique is 
considered reliable and sensitive if activation exceeds 40% (Herbert et al. 1997; Nørregard et 
al. 1997; Todd et al. 2004) and has been used widely in healthy subjects and a range of 
patient groups including people with post polio syndrome and MS (Horemans et al. 2004; Ng 
et al. 2004).  
Three one Hertz (Hz), 50 microseconds (µs), 400 Volt square wave impulses of 250 
milliseconds duration were applied over three seconds using an electrical stimulator (Digitimer 
D4030, Digitimer Stimulator DS7, Digitimer, UK) via the moistened, sponge covered electrodes 
placed proximally and distally on the anterolateral thigh (Rutherford et al. 1986). The current 
was increased so that at least 10% of MVC force was produced by each impulse, and the 
twitch force reached a plateau (Nørregard et al. 1997).  
Participants received three stimuli whilst at rest, and were then instructed to produce a MVC 
and “kick out as hard as possible”. Whilst participants maintained a MVC, the knee extensors 
were stimulated percutaneously so that three stimuli were coincident when force was 
maximum or near maximum. Participants were provided with visual feedback and verbal 
encouragement during each contraction to maximise activation (Gandevia 2001). Immediately 
on relaxation, three stimuli were applied to the relaxed muscle. This test was repeated three 
times.  
The greatest force at which a twitch was applied during an MVC was identified. A resolution 
which allowed sensitivity to 0.5 N was used. If a superimposed twitch was visible, calculation 






St= superimposed twitch height. Pt= resting twitch height after MVC (potentiated twitch). 
 
The potentiated twitch was consistently used as sufficient time was not available to allow rest 
between each measurement and it is likely that the superimposed twitch on near maximal 
contractions is potentiated (Folland and Williams 2007; Vandervoort et al. 1983). 
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Five participants’ voluntary activation levels (three healthy and two PN participants) were 
recalculated on two occasions to establish the ability of the rater (the author) to reliably 
calculate voluntary activation. The mean difference between repeated calculations was less 
than 1% (0.78%, range 0-1.6%). 
 Measurement of low and high frequency stimulated muscle force  
The presence of delayed low frequency recovery (DLFR, or low frequency fatigue) was 
investigated by measuring the force produced when the quadriceps was stimulated 
percutaneously at 20 Hz and 100 Hz (Jones 1996; Jones and Round 1990). A two second 
train of 100 Hz square wave (50 µs, 400 Volts) was applied via the two electrodes, positioned 
as described previously. The stimulation current was increased to produce a force of 20 to 
25% of MVC at 100 Hz stimulation and until plateau, if tolerated. This was to ensure a 
representative portion of the muscle was stimulated. A 20 Hz pulse was then applied at the 
same intensity for two seconds. The ratio of 20 Hz force to 100 Hz force was calculated at 
baseline and after fatigue Protocols A and B (Gibson et al. 1993; Jones 1996).  
6.3.4. Fatiguing protocols 
After completion of the baseline measurements described in Section 6.3.3, the knee extensors 
were fatigued in two different ways. The same leg was tested in both protocols.  
Investigations of physiological fatigue have used a range of protocols to induce muscle fatigue. 
Some have used sustained muscle contractions (Garssen et al. 2005a; Lindeman et al. 1999; 
Milner-Brown et al. 1986), or intermittent contractions (Badier et al. 1993; Lanza et al. 2004; 
Lindstrom et al. 1997), a combination of both (Schwid et al. 1999; Seghers and Spaepen 
2004), whilst others have chosen a ramped protocol which incrementally increases the force 
during intermittent contractions (Akataki et al. 2001). A ramped protocol was not utilised as it 
was anticipated that participants would require considerable familiarisation to achieve accurate 
incremental force production which in itself may elicit fatigue in some PN participants. 
Practically, it was also difficult to alter the scale of the monitor used to display the force trace 
quickly, meaning that participants would be unable to accurately obtain the required force. 
Therefore, intermittent contractions were chosen for Protocol A and a sustained contraction 
was used for Protocol B. 
 Protocol A 
This protocol was designed to assess physiological fatigue during and after voluntary repeated 
muscle contractions in an attempt to mimic functional muscle work (Vollestad 1997) and was 
adapted from others used to induce physiological fatigue in people with post polio and chronic 
fatigue syndromes (Allen et al. 1994; Lloyd et al. 1988; Rodriquez and Agre 1991). Intermittent 
contractions also ensured that blood supply was not fully occluded and that muscles could be 
assumed to be working predominantly aerobically.  
Participants performed repeated voluntary isometric knee extensions, at 50% of MVC force, 
while sEMG and force were measured continuously. Each contraction was maintained for six 
seconds, followed by four seconds rest. Ten repetitions were performed consecutively and 
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formed one set. After the tenth contraction, participants were asked to rate their perceived 
exertion using the 6-20 Borg scale (Borg 1970) (as described in Chapter Five). 
Participants were provided with continuous visual feedback to allow accurate development of 
force. A metronome was used to indicate the duration of each contraction and rest period. 
After sets one, three, five and seven participants performed an MVC. Standardised verbal 
encouragement was given throughout.  
The protocol continued until participants were unable to produce forces above 40% MVC on 
two contractions, wished to stop, or had completed eight sets (80 repetitions). 
 Recovery 
Recovery was monitored for ten minutes on completion of the protocol, by measuring the 
sEMG during 50% MVC contractions and perceived exertion at 10 seconds, 30 seconds, one 
minute, 90 seconds, two, four and ten minutes. A final MVC and 20 Hz and 100 Hz stimulation 
were also performed at ten minutes. 
 Protocol B 
Protocol B was designed to measure the physiological fatigue elicited by predominantly 
anaerobic muscle work as participants performed an isometric MVC for one minute. After ten 
minutes recovery, intermittent electrical stimulation was also used to directly estimate the 
fatigability of the knee extensors muscle group. 
 Sustained isometric contraction 
After baseline measurements, participants performed an isometric MVC of the knee extensors 
for one minute, while force and sEMG were measured. All participants were instructed to 
breathe regularly during the sustained contraction, and to relax the upper limbs to avoid large 
changes in blood pressure (O'Connor et al. 1989). Verbal encouragement was given 
throughout. A fatigue index for the change in force (FI) was calculated from (Milner-Brown and 
Miller 1989): 
Final Force (60 seconds)
Fatigue Index (%) x100
Initial Force (1 second)
 
  
    
 
The test re-test reliability of the fatigue index was investigated in one healthy and one PN 
participant from two repeated measurements, one week apart. The fatigue index varied by 3% 
in both participants (coefficient of variance: 6%). 
 Power spectra of EMG during the susta ined MVC 
The power spectra of the EMG of the RF, VM and VL muscles at the start and end of the 60 
second isometric MVC were obtained by applying a Fast Fourier Transform (size: 256) to raw 
EMG signals (James 1995). The median value of frequencies between 10 and 300 Hz were 
then calculated. The median power frequency was calculated for each muscle during the first 
and final second of the 60 second isometric MVC. The median power frequency was used in 
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preference to the mean as it is less affected by signal noise (Basmajian and Deluca 1985; 
Jurrell 1998).  
 Recovery 
A MVC was performed after 90 seconds of recovery and the force produced by low and high 
frequency stimulation was measured at ten minutes. 
 Electrically induced fatigue 
After ten minutes rest, percutaneous electrical stimulation at 40 Hz (50 µs, 400 Volt square 
wave impulses) was applied for 250 ms every second for three minutes (180 impulses) via the 
two electrodes positioned as described previously (Burke et al. 1973; Lenman et al. 1989). The 
current was adjusted so that the stimulated force was approximately 25% of MVC. This 
technique has been used previously to indicate muscular fatigue in healthy participants and 
several patient groups including people with MS and spinal cord injury (Lenman et al. 1989), 
but not in people with PN. 
Participants were instructed to relax throughout the test and to avoid tensing the leg. The 
decline in force from the first stimulation indicates the profile of muscle fibre fatigability and 
muscle metabolism. It was calculated by expressing the force produced by the 180
th
 impulse 
as a percentage of the force produced by the first. 
Measurements taken one week apart were moderately reliable in one healthy participant 
(coefficient of variance of 4%). The effect of the sustained MVC and recovery contractions 
upon the decline in force during electrically induced fatigue was investigated in one PN 
participant, who repeated the electrically induced fatigue test on a third occasion. There was a 
+6% difference in the decline in force during the electrically induced fatigue test after 
completing the sustained MVC compared to the when the test was repeated in the rested 
muscle. 









































































Peak MVC force was normalised by dividing by body weight, to account for gender differences 
between groups (Pincivero et al. 2004).  
The ratio between force and RMS nEMG of the knee extensors was calculated for baseline 
MVCs and during the 60 second sustained MVC during Protocol B. This Torque:EMG ratio 
(TER), or neuromuscular efficiency, has been shown to demonstrate differences between 
healthy and PN participants more clearly than EMG or force readings alone in previous studies 
of PN (Lindeman et al. 1999). It is calculated from (Lindeman et al. 1999): 
 1
MVC force (Newtons)
Torque : EMG ratio (N mV )
Mean RMS nEMG (RF,VM,VL) milliVolts  
 
Two tailed independent t tests assuming unequal variance were used to assess differences 
between healthy and PN participants in MVC force in the knee extensors, voluntary activation, 
RMS nEMG, TER, 20:100 Hz stimulation at baseline and after fatigue protocols, and the 
fatigue index and decline in force after intermittent electrical stimulation.  
The MVC force, RMS nEMG, TER and 20:100Hz stimulation after the fatigue protocol were 
compared to pre-fatigue values using two tailed paired t tests for each group.  
Differences in force and RMS nEMG amplitude parameters between healthy and PN groups 
during the fatigue protocols and recovery were examined using repeated measures analysis of 
variance (ANOVA).  
Differences between PN participants who reported severe experienced fatigue (PNF) and 
those who did not (PNN) were examined using descriptive statistics and Mann Whitney tests, 
as small numbers meant the data were not normally distributed.  
Associations between strength, activation and age were assessed for both groups using 
Pearson’s correlation coefficients. The association between strength, activation and fatigue 
index with experienced fatigue severity, activity limitations, participation, EO2, and resting heart 
rate (from Chapter Five) was also assessed using Spearman’s and Pearson correlation 
coefficients. The size of correlation coefficients were judged to be low/weak (0.1-0.3), 
moderate (0.3-0.6) or large/strong (>0.6) according to published criteria (Cohen 1977). 
No adjustments were made for multiple comparisons (Perenger 1998). Significance was set all 





Fifteen people with PN volunteered, but one could not tolerate electrical stimulation and one 
other could not attend both testing sessions. Therefore 13 participants (four females) with PN 
were recruited and completed all measurements. Thirteen healthy volunteers (seven females) 
were also recruited from staff and students of King’s College London. Participant 
characteristics are shown in Chapter Five in Table 5-3 on Page 175. There were no significant 
differences between healthy participants and those with PN for demographic characteristics of 
age, weight, height and BMI. 
Local ethical approval was obtained from Guy’s and King’s College London research ethics 
committees and all participants gave written informed consent. 
Eight PN participants (one female) reported levels of severe experienced fatigue that persisted 
for more than six months (PNF), the remainder (n=5, three females) did not report severe 
fatigue (PNN). 
6.4.2. Baseline measurements 
 Knee extensor force 
Knee extensor force is shown in Table 6-2. When peak linear MVC force was normalised to 
weight, healthy people were significantly stronger than PN participants. There were no 
significant differences in peak MVC knee extensor force between session one and two for PN 
or healthy groups. Interestingly, PNF participants were slightly stronger than those with no 
fatigue (PNN) but this was not statistically significant (Table 6-2). Age was not significantly or 
strongly associated with peak extensor force for either group (both r<0.4). 
 Surface EMG 
Repeated RMS nEMG measurements during MVC did not differ significantly between session 
one and session two, therefore mean values were used in all comparisons. When the sEMG 
was expressed relative to peak force produced during the initial MVC (Torque:EMG ratio, TER, 
Lindeman et al. 1999), there were no significant differences between healthy and PN 
participants, nor between PNF and PNN participants. This is shown in Table 6-2. 
 Voluntary Activation 
There was no difference in levels of voluntary activation between measurements taken one 
week apart. The mean voluntary activation of PN participants was not significantly different to 
healthy people, but was somewhat higher. There were no significant differences between PNN 
and PNF participants (Table 6-2).  
Age, gender and peak force were not significantly or strongly associated with voluntary 
activation in either group (PN: all r<0.3; Healthy: all r< 0.5).   
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Table 6-2 Strength, voluntary activation, Torque:EMG ratio and 20:100 Hz force ratio in the knee 






H vs PN 







7.5 ±2.2 5.4 ±2* 0.002 6.2 ±8 4.1 ±1.9 ns 
Strength (N) 476.4 ±122 433 ±161 ns 476 ±123 364 ±215 ns 
TER (N mV
-1
) 1.58 ±0.4 1.4 ±0.4 ns 1.5 ±0.4 1.76 ±0.9  ns 
Voluntary 
activation (%) 
85 ±10 92 ±7 ns 90.4 ±9 94 ±7 ns 
20:100 Hz 
stimulation ratio 
0.67 ±0.1 0.58 
±0.13 
ns 0.6 ±0.3 0.55 ±0.2 ns 
All values are the mean ±SD of baseline values on two occasions. TER: Torque: EMG ratio.* 
denotes significant difference at p<0.05 
 
 Low and high frequency stimulation 
There were no significant differences between baseline measurements of 20:100 Hz 
stimulated force taken one week apart in either group, suggesting that participants had 
recovered fully between each testing session. There were also no significant differences 
between PN and healthy or PNN and PNF participants (Table 6-2). 
6.4.3. Protocol A  
In Protocol A, participants performed up to 80 repetitions at 50% MVC force. All healthy 
volunteers completed all repetitions, as did eight PN participants. However, five PNF 
participants were unable to complete 80 repetitions. The number of repetitions completed in 
the PN group and the reason for stopping are shown in Figure 6-4. 
Two PN participants were stopped as they were unable to continue generating forces above 
40% of MVC, a criterion for stopping the test. One stopped after 20 repetitions and one after 
47. Three PN participants stopped as they felt too tired to continue, despite maintaining force, 
after 50, 60 and 70 repetitions.  
There were no significant differences in the mean voluntary activation and peak MVC force 
between PN participants that did complete the protocol (mean ±SD: 95.2% ±4; 4.7 N Kg
-1
 ±1.8) 
and those that did not (87% ±7.7; 6.3 N Kg
-1
 ±2).  
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Figure 6-4 Number of repetitions completed during Protocol A and reasons for non-completion. 
 
 Changes in surface EMG  
During repeated contractions at 50% MVC, a significant increase in RMS nEMG for RF, VM, 
VL and the mean nEMG was seen in healthy and PN groups. These changes were not 
significantly different between PN and healthy groups during Protocol A. Changes in RMS 
nEMG from initial MVC values during Protocol A and recovery are shown in Figure 6-5 and 
Figure 6-6 overleaf.  
The change in RMS nEMG from the first to the last completed 50% MVC during Protocol A 
was also examined to include PN participants that did not complete the entire protocol. These 
changes were not significantly different between healthy and PN groups. There was also no 
significant difference between PN participants who completed all contractions and those who 
did not, or between PNF and PNN participants.  





































































Figure 6-5 RMS nEMG during Protocol A and recovery for healthy participants  
Set number                       Recovery time (s)





































Figure 6-6 RMS nEMG during Protocol A and recovery for PN participants 
Set number                              Recovery time (s)












































contraction. * indicates a significant difference between EMG activity at 10 minutes recovery 
and the 1
st
 contraction (100%) for the RF, VL and mean EMG. The number of PN participants 
remaining during the protocol are shown. There were no significant differences between PN 
and healthy groups. Error bars denote one standard error of the mean. 
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 Changes in RMS nEMG during 50% MVCs during recovery 
During the recovery period, there were no significant differences in RMS nEMG for any 
muscles between healthy and PN participants, nor between PNF and PNN participants (Figure 
6-5 and Figure 6-6). 
After ten minutes of recovery, the RMS nEMG of the VM muscle was not significantly different 
to that during the first 50% MVC of the first set for both healthy and PN groups. However, RF, 
VL and mean RMS nEMG remained significantly elevated for both healthy and PN 
participants.  
 Changes in MVC force during fatigue and recovery 
There was a significant decrease in MVC force in both groups from baseline after the first set 
of fatiguing contractions. This was slightly larger in the PN group but not significantly different 
to healthy participants. The percentage of change in MVC force is shown for both groups in 
Figure 6-7. 
Figure 6-7 Decrease in MVC force for healthy and PN participants during Protocol A 
Set number                             Recovery Time (min)


































* denotes significant difference from baseline MVC force. Error bars denote one standard error 
of the mean. There was no significant difference between healthy and PN groups. 
 
Peak MVC force remained significantly decreased from baseline MVC after ten minutes of 
recovery in both groups (Table 6-3). There were no significant differences in changes in MVC 
force between PN participants who completed all fatiguing contractions and those who did not, 





 Changes in RMS nEMG activity during fatigue and recovery 
Both groups demonstrated significant increases in RMS nEMG from the baseline MVC to the 
MVC performed after one set of fatiguing repetitions in RF, VM and VL muscle groups 
(p<0.001). This is shown in Figure 6-8 for healthy participants and in Figure 6-9 for PN 
participants. There were no significant differences between healthy and PN groups for any 
muscle during MVCs. Similarly, the RMS nEMG for all muscles in both groups remained 
significantly higher than baseline MVC values after ten minutes of recovery. 
There were also no significant differences in RMS nEMG on the last completed MVC during 
Protocol A between PN participants that completed all repetitions and those who did not. 
 Change in 20:100 Hz stimulated force ratio  
The ratio of force produced by 20 and 100 Hz electrical stimulation was assessed at baseline 
and after ten minutes of recovery from Protocol A and is shown in Table 6.3.  
The ratio was significantly reduced from baseline in healthy and PN participants (p<0.001). 
Despite the decrease in the PN group being somewhat larger, there was no significant 
difference between groups. There were also no significant differences in the decrease in the 
20:100 Hz ratio between PNF and PNN participants. Similarly, the decrease in PN participants 
who did not complete all repetitions in Protocol A was slightly larger than other PN participants, 
but was not statistically different. 
 
Table 6-3 Change in MVC force and 20:100 Hz ratio in Protocol A 
 Change (Newtons) from baseline MVC to MVC at:  Change in 20: 
100 Hz force 
p 
 10 reps 70 reps Recovery p 
Healthy 38 ±56* 133 ±102 63 ±109* ns 0.08 ±0.09* ns 
PN 80 ±46* 136 ±57 83 ±42* 0.14 ±0.1* 
PNF 98 ±49 164 ±24 92 ±45 ns 0.16 ±0.11 ns 
PNN 55±29 114 ±69 69 ±38 0.12 ±0.09 
PN non C 98 ±63 - 89 ±44 ns 0.19 ±0.13 ns 
PN C 69 ±31 - 80 ±43 0.12 ±0.07 
* denotes within group significant difference from baseline at p<0.05 (not tested after 70 repetitions). All 
changes were negative, indicating a decline in force. PN non C- PN participants who did not complete 80 




Figure 6-8 Healthy RMS nEMG for MVC during fatigue Protocol A and after 10 minutes of recovery. 
Set number                              Recovery time (s)










































Figure 6-9 RMS nEMG for MVC for PN participants during fatigue Protocol A and after 10 minutes of 
recovery 
Set number                              Recovery time (s)











































* denotes significant difference from baseline MVC. 
  
* denotes significant difference from baseline MVC. 
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6.4.4. Protocol B  
 Changes in force and sEMG in response to a sustained isometric MVC  
Changes in force and sEMG during adn after a 60 second sustained MVC are shown in Table 
6-4.  
At the end of the isometric sustained 60 second MVC, the fatigue index of healthy and PN 
participants were similar (Table 6-4 and Figure 6-10). The fatigue index was also not 
significantly different between PNF and PNN participants.  
Figure 6-10 Change in force during a 60 second sustained MVC and MVC at 90 seconds after 
completion. 
Time (seconds)                 Recovery time (seconds)



































* denotes significant difference between initial MVC and force at 60 seconds at p<0.05 for both 
groups. Error bars denote one standard error of the mean. 
 
Correlations between initial MVC force and the fatigue index were neither strong nor significant 
for PN or healthy participants (r<0.5).  
Force in both healthy and PN participants recovered quickly as a MVC performed at 90 
seconds after completion of the sustained contraction was not significantly different to baseline 
values (Figure 6-10), although RMS nEMG remained significantly higher for both as shown in 
Figure 6-11 for healthy volunteers and Figure 6-12 for PN participants. 
Both groups demonstrated similar changes in the RMS nEMG amplitude during and after the 
60 seconds MVC (Figure 6-11 and Figure 6-12) and there were no significant differences 





Figure 6-11 Change in RMS nEMG for healthy participants during 60 second isometric contraction and 
recovery MVC at 90 seconds. 
Time (seconds)                   Recovery Time (seconds)




































* denotes significant difference at 90 seconds recovery from baseline MVC at p<0.01. Error bars denote 
one standard error of the mean. 
 
Figure 6-12 Change in RMS nEMG for PN participants during 60 second isometric contraction and 
recovery MVC at 90 seconds. 
Time (seconds)                   Recovery Time (seconds)





































* denotes significant difference at 90 seconds recovery from baseline MVC at p<0.01. Error bars denote 
one standard error of the mean. 
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 Changes in the torque:EMG ratio during a 60 second sustained MVC  
The TER was calculated for healthy and PN participants throughout the 60 second MVC and is 
shown in Figure 6-13. The TER values at 60 seconds were significantly lower than baseline for 
both groups (p<0.01, Table 6-4).  
There were no significant differences between healthy and PN groups, implying both groups 
had similar neuromuscular efficiency. Similarly, the change in TER was not significantly 
different between PNN and PNF participants. 
Figure 6-13 TER for healthy and PN groups during 60 second MVC. 
Time (seconds)










































* denotes significant difference from baseline for both groups (p<0.01). Error bars denote one 
standard error of the mean. 
 
 Changes in EMG median frequency after fatigue 
The median frequencies at the start and end of the sustained MVC are shown in Table 6-5. 
Healthy participants demonstrated a significant decrease in the median frequency of the RF 
and VM muscles after the sustained MVC. The change in frequency in the PN group was 
somewhat smaller and was not significant in any muscles after the sustained MVC. However, 
the change in median frequency was not significantly different between groups, nor between 
PNF and PNN participants.  
 Changes in the ratio of low and high frequency stimulated force after a 60 
second MVC 
Changes in the 20:100 Hz stimulated force are shown in Table 6-4. The ratio of 20:100 Hz 
stimulated force was significantly decreased from baseline in both groups, after completion of 
a 60 second sustained isometric contraction and ten minutes recovery. This change was not 
significantly different between healthy and PN groups. There was a slightly greater decline in 
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the ratio in PNF participants when compared to PNN, inferring increased DLFR, but this was 
not statistically significant. 
 Changes in force produced by intermittent electrical stimulation  
The force decline after three minutes of percutaneous intermittent stimulation is shown Table 
6-4. There was no significant difference between healthy and PN groups, nor between PNN 




Table 6-4 Changes during Protocol B 
 Fatigue Index (%) Change in TER (Newtons) Change in 20:100 Hz force Force decline after electrical 
stimulation (%) 
Healthy 59 ±18 485 ±233* 0.11 ±0.15* 63 ±11 
PN 60 ±14 374 ±134* 0.13 ±0.18* 60 ±13 
PNN 60 ±7 297 ±82 0.06 ±0.05 62 ±7 
PNF 60 ±17 421 ±143 0.17 ±0.22 59 ±16 
* denotes significant decline from baseline at p<0.05 in both groups. There were no significant differences between groups. Values are mean ± SD. 
 
 
Table 6-5 Changes in power spectra after a sustained MVC 
Initial and final median frequency, Hz (range) 
Healthy PN p PNN  PNF  p 
 Initial Final  Initial Final  Initial  Final  Initial  Final   
Rectus 
Femoris 
67 (51-86) 53 (33-81)
δ
 61 (34-85) 53 (35-74) ns 56 (34-67) 42 (35-55) 65 (47-85) 59 (48-74) ns 
Vastus 
Medialis 
60 (47-99) 44 (27-62)
 δ
 60 (43-97) 50 (31-78) ns 55 (43-66) 44 (33-66) 63 (43-98) 53 (31-77) ns 
Vastus 
Lateralis 
58 (39-84) 51 (28-84)
 
 49 (31-78) 46 (35-60) ns 50 (27-61) 43 (35-47) 49 (31-66) 47 (35-60) ns 
δ 




6.4.5. Associations between experienced fatigue, activity, fitness and 
physiological fatigue 
In PN participants, experienced fatigue measured on the FSS, FIS and PFS (from Chapter 
Five) was not associated with knee extensor strength, TER, voluntary activation, decrease in 
20:100 Hz stimulated force after a 60 second MVC or the percentage decrease in electrically 
stimulated force after three minutes of intermittent stimulation (Table 6-6). Physiological fatigue 
measures were also not significantly associated with scores on the ONLS, SF-36 and 
Rotterdam Handicap questionnaires as shown in Table 6-6.  
In healthy participants, the fatigue index during an isometric sustained MVC was significantly 
associated with increased fatigue measured on the PFS questionnaire (r=0.6) but no other 
significant associations were seen.  
 
Table 6-6 Associations between experienced and physiological fatigue, activity, activity limitations, 
participation, energy and resting heart rate for PN participants 






) 0.47 0.38 0.31 -0.16 0.44 0.08 -0.5 
Voluntary 
activation 
-0.4 -0.24 -0.24 -0.44 -0.04 0.31 0.26 
DLFR 0.12 -0.13 0.19 -0.26 0.27 0.13 -0.01 
Fatigue index (%) -0.1 -0.5 -0.4 -0.39 -0.15 -0.02 0.47 




0.01 0.06 -0.04 0.28 -0.4 -0.23 0.09 
All associations were not statistically significant at p<0.05. SF-36 PCS and MCS – SF-36 
physical and mental component summary scores, DLFR – delayed low frequency recovery 
expressed as decrease in 20:100 Hz stimulated force after 60 second sustained MVC 
(Protocol B), TER – torque:EMG ratio on baseline MVC. 
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6.4.6. Summary of physiological fatigue results 
Table 6-7 Main findings of physiological fatigue tests 
Measure Healthy vs PN PNN (n=5) vs PNF (n=8) 
Strength (N Kg
-1
) Healthy significantly stronger than PN No significant difference but PNF slightly stronger 
Activation (%) No significant difference but PN group had slightly 
higher activation 
No significant difference 
20: 100 Hz stimulation ratio No significant difference No significant difference 
TER (N mV-1) No significant difference No significant difference 
Protocol A:  All healthy completed; 5 from 13 PN (38%) did not 
complete 
All PNN completed; 5 from 8 PNF (62%) did not 
complete 
RMS nEMG during 50% MVC  No significant difference No significant difference 
MVC force during Protocol A and recovery No significant difference No significant difference 
RMS nEMG during MVC No significant difference No significant difference 
Decrease in 20:100 Hz ratio after Protocol A No significant difference No significant difference 
Protocol B :   
Force during sustained MVC No significant difference No significant difference 
RMS nEMG during sustained MVC and recovery No significant difference No significant difference 
TER No significant difference No significant difference 
Median Frequency No significant difference but healthy group had 
significant decrease in RF and VM muscles 
No significant difference 
Decrease in 20:100 Hz ratio after sustained MVC No significant difference No significant difference but somewhat greater 
decrease in PNF participants 
Force change after intermittent electrical 
stimulation 




This study described the physiological fatigue profile of the knee extensor muscles of people 
with inflammatory PN and compared findings with those from healthy volunteers. These 
aspects of fatigue have not been investigated previously in this patient group and, with the 
findings of Chapter Five, provide important indications of the potential contributors to 
experienced fatigue in PN.  
The knee extensors were selected for investigation as they are vital to the performance of 
many functional activities in ambulant individuals and so their fatigue is likely to impact greatly 
upon activities and participation. It is acknowledged that the fatigue profile of each of the four 
muscles within the quadriceps and other knee extensors may differ to each other and other 
muscles as fibre type composition varies (Milner-Brown et al. 1986). Other muscles that may 
limit ambulant mobility such as tibialis anterior, are often affected in people with PN but 
practical factors (such as equipment provision) meant that this muscle could not be tested in 
this study. Muscles used in respiration are also likely to impact upon exercise endurance and 
aerobic capacity in people with PN, and so could contribute to experienced fatigue, but again 
could not be measured for practical reasons.  
The knee extensors of PN participants were significantly weaker than those of healthy 
participants (H: 7.5 ± 2.2 N Kg
-1
 ; PN: 5.4 ± 2 N Kg
-1
), showing that they were affected by 
neuropathy or deconditioning due to disuse, but peak force was not significantly associated 
with experienced or physiological fatigue in either group. These findings agree with others who 
reported no significant associations between experienced fatigue measured on the FSS and 
MRC sum scores in 113 people with PN (Merkies et al. 1999). 
As shown in Table 6-2, participants with PN had similar levels of voluntary activation to healthy 
people (mean ±SD H: 85 ±10 %; PN: 92 ±7%). These results are also supported by Garssen et 
al. (2005b) who found no difference in voluntary activation of the biceps brachii muscle in ten 
people with severe experienced fatigue after GBS when compared to healthy volunteers. Full 
activation (100%) of the knee extensors was not expected in this study as evidence indicates 
that with greater sensitivity in testing, adults may only be able to activate the quadriceps 
femoris muscle to between 85-95% despite maximal effort (Folland and Williams 2007; Shield 
and Zhou 2004).This suggests that, despite people with PN being significantly weaker than 
healthy participants in this study, this was not attributable to an inability to fully activate the 
muscle.  
Due to the design of the study, voluntary activation was not assessed in either group after the 
fatigue protocols, as the onset of delayed low frequency recovery meant that the interpolated 
twitch height was not reliable. As a result, this investigation was unable to establish if 
reductions in voluntary activation after exertion differed significantly to that in healthy 
participants. If present, abnormally reduced activiation after exertion could cause greater 
physiological fatigue and affect experienced fatigue (Stackhouse et al. 2001; Yamada et al. 
2002). Interestingly, several healthy participants demonstrated relatively low levels of voluntary 
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activation when compared to results in other studies, although there were no significant 
differences to the PN group, and the reason for this is unclear. Methodological issues such as 
the timing of the twitch during the MVC or a non-linear relationship between voluntary force 
and interpolated twitch height could under or overestimate activation, but there is no reason to 
suggest that these factors would affect the healthy group but not PN participants (Folland and 
Williams 2007; Shield and Zhou 2004). As activation in PN participants was similar to ranges 
reported elsewhere, the somewhat lower activation in some healthy participants is more likely 
to be attributable to previous injuries or reduced motivation. Although all participants were 
screened for injury, old, benign injuries which are not apparent on screening have been shown 
to reduce voluntary activation (Rutherford et al. 1986). Alternatively, healthy participants may 
not have been as motivated as people with PN, or despite standardised protocols, the 
expectations of the investigator may have altered verbal encouragement and thus 
performance. This limitation could be partially addressed by using a blinded assessor but as 
voluntary activation requires maximal effort, individual motivation during the test would still 
affect activation.  
6.5.1. Response to voluntary intermittent muscle activity  
Protocol A assessed physiological fatigue in response to intermittent voluntary sub maximal 
isometric contractions that aimed to mimic functional muscle activity, were practical to perform 
and allowed maintenance of blood flow (Garssen et al. 2005a; Lindeman et al. 1999; Milner-
Brown et al. 1986). The choice of exercise protocol somewhat limits the external validity of 
these results as it is recognised that closed chain, dynamic exercises are more representative 
of functional activities. However, recording of accurate and comparable recordings of sEMG 
during more functional exercise would be difficult as alterations in muscle length and skin 
position would reduce the reliability of recordings.  
During Protocol A, three PN participants stopped exercising as they reported feeling fatigued 
despite minimal changes in their force production. Two further PN participants became unable 
to produce forces above 40%, a criterion for stopping the test and they expressed high 
perceived exertion on the Borg scale (17 and 19). All five participants who failed to complete 
the protocol reported problematic experienced fatigue (PNF). Nevertheless, their baseline 
measurements of strength, voluntary activation, and other physiological fatigue tests were 
similar to healthy and PN participants who completed the protocol. In addition, there was no 
difference between their performance during the sustained contraction and intermittent 
electrical stimulation in Protocol B compared with other PN and healthy participants, 
suggesting that they had normal muscle endurance and fatigability. This suggests that their 
inability to complete the fatiguing exercise was due to factors other than physiological fatigue. 
These factors could include enhanced or early perceived exertion and may be secondary to 
reduced cardiovascular fitness. Alternatively, altered perceived exertion could represent a 
learnt protective response preventing over exertion before muscular fatigue is detectable, as 
reported in CFS (Noakes et al. 2005).  
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The reduced endurance of some PN participants during intermittent voluntary contractions of 
the knee extensors contrasts with findings from one study in people a mean of seven years 
after GBS (Dornonville de la Cour and Jakobsen 2005). In their study, 40 participants after 
GBS demonstrated normal and significantly greater endurance of the wrist and ankle muscles 
respectively during isokinetic contractions when compared to healthy participants (Dornonville 
de la Cour and Jakobsen 2005). These conflicting results could be due to differences in the 
muscle groups tested or the muscle action used to elicit fatigue. Alternatively, the inclusion of 
people with other, chronic PN in addition to GBS in the current study may mean increased 
endurance in GBS participants was masked. 
Indeed, people with chronic PN could have a different fatigue profile than those after GBS as 
four of the five participants that did not complete all repetitions in Protocol A had CIDP. 
Although the small number of participants with CIDP (n=7) makes firm conclusions difficult, it is 
possible that people with CIDP experience greater or altered fatigue or have reduced tolerance 
to exercise. People with CIDP reported significantly more severe experienced fatigue in 
Chapter Five, although again these findings could be an artefact of the sample size and 
composition as they have not been found by others (Merkies et al. 1999). Boukhris et al. 
(2005) described 11 cases in which experienced fatigue was the predominant initial symptom 
of CIDP, although the frequency of fatigue as a presenting symptom of CIDP was not explored 
(Boukhris et al. 2005). However, it is possible that participants with CIDP were more sensitive 
to feelings of fatigue and exertion if they perceived that they could precipitate a worsening in 
their condition. This suggests that both experienced and physiological fatigue should be further 
investigated in sub-groups of people with different forms of PN. 
A limitation of protocol A was that all contractions were performed at a percentage of each 
individual’s maximum force (50%). Whilst this is a commonly used method of testing and 
training which allows standardisation of work load, everyday tasks demand a greater 
percentage of MVC for weaker participants than those with normal strength (Shumway-Cook 
et al. 2002). Therefore some weaker PN participants could experience greater physiological 
fatigue during daily activities which would not be detected in this study. Future studies could 
use a standard exercise intensity or fixed external load to make more realistic comparisons 
between people with weakness due to PN and healthy volunteers. Alternatively, a more 
functional fatiguing exercise (e.g. repetitive walking or stair climbing) as used by others could 
be utilised (Schwid et al. 1999). Common fatiguing activities could be identified from patient 
opinion through surveys, interviews or focus groups to increase the relevance of the 
physiological tests to every day performance in the wider patient group. Functional fatiguing 
exercises were not used the current study as it complicated force and EMG activity 
measurement and, as the response of participants to fatiguing exercise was unknown, may 
have had safety implications. 
Recovery from repeated voluntary muscle contractions has not been reported previously in 
people with PN but was similar between all participants including those who did not complete 
all contractions in Protocol A. This implies that the inability to complete all contractions during 
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Protocol A in some PN participants and the reported worsening of experienced fatigue after 
exertion (Chapter Five and Merkies et al. 1999) are unlikely to be caused by abnormal 
recovery of central and peripheral factors of physiological fatigue.  
Protocol A produced physiological fatigue in both healthy and PN groups as the final MVC 
force did not return to pre-fatigue values during the course of the test in either group (mean 
decline in strength from baseline= H: 63 ±109; PN: 83 ±42 Newtons). As discussed on Page 
190, a decline in available force after fatiguing exercise could have significant negative effects 
upon functioning in individuals who already have reduced muscle strength as it means that 
greater effort and/or the use of compensations would be required to undertake even simple 
activities. As PN participants were significantly weaker they had to utilise a greater percentage 
of their MVC force to perform activities of daily living. Further loss of strength after exertion 
could explain the increased severity of experienced fatigue after exercise which was reported 
by ten PN participants in Chapter Five.  
6.5.2. Response to a sustained contraction and intermittent electrical 
stimulation 
By measuring the response to a sustained MVC, Protocol B allowed assessment of the 
physiological fatigue of the knee extensors whilst minimising the effect of cardiovascular 
components. The decline in stimulated force after intermittent electrical stimulation allowed 
direct measurement of the fatigability of the knee extensor muscles.  
There were no significant differences between healthy and PN groups during sustained 
contractions of the knee extensors in Protocol B (Fatigue index (mean ±SD) = H:59 ±18%; 
PN:60 ±14%). These results agree with the findings of Garssen et al. (2005b) in the elbow 
flexors, who found no significant differences in force decline between healthy volunteers and 
ten people with severe experienced fatigue after GBS. However, they did find that peripheral 
fatigue of the elbow flexors developed significantly more slowly in people after GBS, 
demonstrating increased peripheral endurance in comparison to healthy participants (Garssen 
et al. 2005b). The findings from reports in other neurological conditions are equivocal. Some 
have reported a significantly greater force decline during a sustained contraction implying 
increased fatigability of the ankle dorsiflexors and knee extensors in people with 
polyneuropathies or CMT, when compared to healthy volunteers (Lindeman et al. 1999; 
Milner-Brown and Miller 1989). Conversely, in 34 diabetic patients with neuropathic symptoms, 
increased peripheral endurance was reported in the knee and ankle flexors and extensors, 
despite significantly reduced strength in comparison to healthy participants (Andersen 1998). 
They proposed that the diabetic participants had a greater proportion of fatigue resistant 
muscle fibres, but this was not measured and so could not be proven. In the current study, the 
fatiguability of the knee extensors was examined using intermittent muscle stimulation. The 
results indicated that people with PN had similar fatiguability of these muscles to healthy 
participants, despite being significantly weaker.  
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A range of factors including the muscle tested, the duration and intensity of the fatiguing 
exercise, and motivation of participants may account for some of the differences between 
studies. In particular, unlike participants in Lindeman et al’s study (1999) volunteers in the 
current study did not exercise until exhaustion. Although this may have revealed greater 
differences between groups it was not feasible for health and safety reasons as participants 
had to travel home on the same day of testing and the reaction of participants to the testing 
protocols could not be predicted. Future work could seek to test PN patients to exhaustion if 
appropriate accommodation and monitoring could be provided although the willingness of 
people with fatigue to exercise to exhaustion may impede recruitment. 
There were no differences in the recovery of healthy and PN groups after the sustained MVC 
in Protocol B. This contrasts with the only other study which examined recovery after a 
sustained 60 second MVC in people with neurogenic weakness (Milner-Brown and Miller 
1989). They reported a large, initial decline in the sEMG amplitude from the tibialis anterior 
muscle in 15 participants during recovery contractions after a sustained 60 second MVC, 
proposing that this was caused by alterations in calcium release from the sacroplasmic 
reticulum which delayed recovery (Milner-Brown and Miller 1989). However, markers of 
sacroplasmic calcium release, such as response to low frequency stimulation, were not 
measured in their study, and the range of conditions included make comparisons to other work 
difficult. The current study is the first to measure low frequency recovery in PN participants. 
Delayed low frequency recovery (DLFR) appears associated with disuse and inactivity in 
studies of healthy people (Duchateau and Hainaut 1998) but has been improved by targeted 
exercise training (Maffiuletti and Martin 2001). In the current study, there were no significant 
differences in low frequency recovery between PN and healthy groups, implying normal 
sacroplasmic reticulum functioning in PN participants, although this can only be confirmed by 
invasive measurements. Although there was a somewhat larger decrease in 20:100 Hz 
stimulated force ratio, indicating DLFR, in PNF participants when compared to PNN and 
healthy groups, this was not statistically significant. Whilst this could indicate that DLFR 
contributes to experienced fatigue in this participant subgroup the very small sample 
necessitates further study to determine if this is a factor.  
There were also no significant differences between the median frequencies of healthy and PN 
participants, or between PNF and PNN participants, at the start and end of the sustained MVC. 
This indicates that the patterns and frequency of muscle activation is largely normal and is 
similar to findings in people with post polio syndrome (Ng et al. 2004; Sharma et al. 1995). In 
healthy subjects, median power is shifted towards lower frequencies with fatigue, as larger 
motor units are recruited and motor units increase firing synchrony (Bigland-Ritchie et al. 1983; 
Westerblad and Allen 2002). The decline in the median frequency of the power spectra is also 
thought to reflect a beneficial and normal adaptation to prolonged muscle activity, as the 
slowed relaxation of muscle requires a lower frequency of stimulation to maintain force 
(Duchateau and Hainaut 1998). However, unlike healthy volunteers, the decline in median 
frequency during the MVC was not significant in PN participants in the current study. This is 
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similar to the findings of others in 86 participants with neuropathic weakness (Yaar and Niles 
1992) but the reason for this is unclear. During a sustained MVC, blood flow to the muscle is 
reduced by the contracting muscle, necessitating anaerobic respiration and slowing the 
relaxation rate of the muscle so that a lower frequency of stimulation is required to maintain 
force (Duchateau and Hainaut 1998). However, as PN participants were significantly weaker in 
the current study, it is possible that their atrophied muscles did not significantly occlude blood 
flow during the sustained MVC so that some aerobic respiration still took place in the muscles 
(Behm and St-Pierre 1998; Garssen et al. 2005b). This would minimise anaerobic respiration 
within the muscles, slow the accumulation of metabolic by-products, maintain the relaxation 
rate of the muscles and so a smaller change in frequency would be required.  
However, this finding could also be explained by changes in motor units after PN and the 
method used to measure median frequency in this study. In one study of 37 people at least 
one year after GBS, 60% had enlarged motor units as a result of compensatory reinnervation 
(Dornonville de la Cour et al. 2005). If PN participants in the current study had enlarged motor 
units, the sEMG electrodes may have recorded from fewer units and so the recruitment of 
larger motor units and increased synchrony would not be reflected in their EMG signal. This 
could result in a somewhat smaller decrease in median power frequency in people with PN 
when compared to healthy participants, as seen in this study. It is also possible that the wide 
variability of frequencies seen in the PN group in this study in concert with the small sample 
meant that the decline in median frequency did not reach statistical significance. Therefore, 
further work to examine changes in power spectra frequency after fatigue in larger and more 
homogenous PN cohort is warranted. 
This is the first study to directly investigate the fatigability of the knee extensor muscles in 
response to electrical stimulation in people with PN. The results showed that the response of 
healthy and PN, and PNN and PNF participants was not significantly different, indicating 
similar fatigability of muscles (Burke et al. 1973). This is supported by findings in affected 
muscles in people after polio (Borg et al. 1988) but contrasts with the conclusions of others in 
people with MS and older people (Ditor and Hicks 2000; Kent-Braun et al. 1997). However, the 
results cannot be directly compared to other studies as participants in this study completed the 
sustained MVC prior to measurement. This could have fatigued the knee extensors before 
being stimulated. This does not affect the comparison between healthy and PN groups in this 
study, as all participants performed the tests in the same order. However, when the 
intermittent electrical stimulation was repeated in unfatigued muscles in one PN participant, 
there was a small (6%) difference indicating that muscles began the electrical stimulation still 
somewhat fatigued. This limitation could be addressed in future studies by arrangement of an 
extra testing visit which would allow comparison between results in different patient groups. 
6.5.3. Associations between physiological and experienced fatigue and 
functioning 
The work presented here and in Chapter Five demonstrated that measures of physiological 
fatigue, including sEMG activity and voluntary activation, were not significantly associated with 
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the severity of experienced fatigue reported by participants with PN. Although the validity of 
these results is limited by a number of factors including the small, self-selected sample, 
diverse neuropathies studied and the use of non-functional fatigue tests, the similarity between 
the physiological fatigue profile of PN and healthy participants suggests that the greater 
severity of experienced fatigue reported by many people with PN is predominantly caused by 
other factors.  
The results from Chapter Five showed that an increased severity of fatigue was significantly 
associated with reduced activity levels, poorer mood, increased activity limitations and reduced 
participation. This could indicate that an increased severity of experienced fatigue is simply a 
symptom of a more severe PN. However, the lack of association between experienced fatigue 
and several other impairment measures, including muscle strength and neuromuscular fatigue 
suggests that the severity of experienced fatigue is independent of disease severity. This is 
supported by a report from 100 people at least one year after GBS in which experienced 
fatigue (measured on the FSS) was not significantly associated with the severity of symptoms 
at nadir, antecedent events or infections (Garssen et al. 2006c). However, neither Garssen et 
al. (2006) nor the current study has identified clear contributors to more severe experienced 
fatigue. 
Knee extensor strength, activity levels and resting heart rate were significantly reduced when 
compared to healthy participants (in Chapter Five) and there was a trend for people with PN to 
report greater exertion during fatiguing exercise. Although these measures were not 
individually associated with the severity of experienced fatigue, they could still influence 
experienced fatigue collectively. Decreased muscle strength and reduced cardiovascular 
fitness (as seen in the current studies when compared to healthy participants) could precipitate 
a greater perceived exertion when undertaking activities of daily living. This may lead to 
avoidance of exertion and reduced activity levels (as seen in comparison to healthy 
participants in Chapter Five). Reduced activity would further decrease cardiovascular fitness, 
increase muscle weakness and increase feelings of exertion during daily activities resulting in 
greater experienced fatigue (Sharpe and Wilks 2002). However, the sequence in which these 
factors could contribute to experienced fatigue is not clear and it is equally possible that 
greater experienced fatigue has negatively influenced these factors. Nonetheless, the findings 
of this study indicate that further investigation of activity limitations, cardiovascular fitness, 
activity levels and perceived exertion in a larger homogeneous group is warranted to 
determine if they have an association with experienced fatigue. 
6.5.4. Limitations 
In addition to limitations discussed in context throughout this section and in Chapter Five, the 
small self-selected sample who volunteered to undergo physiological fatigue tests is likely to 
have limited external validity to all people with PN. As four participants had undertaken the 
exercise programme in Chapter Three, although over six months previously, their fatigue 
profile may have been atypical of the target population. Their data may have biased results as 
experienced fatigue was significantly reduced after the exercise intervention, and so the 
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factors which may have contributed to experienced fatigue may have also been largely 
reduced. Finding PN participants that conformed to the inclusion criteria, could travel for 
testing and were happy to participate was also difficult. In addition to not meeting the required 
sample size for this study (n=16), this also meant that it was not possible to match healthy and 
PN participants, decreasing the strength of comparisons between groups.  
As discussed in Chapter Five, the investigator was not blind to diagnosis, placing the results at 
risk of bias. Although instructions and verbal encouragement were standardised to avoid bias, 
it is possible that the expectations of the investigator influenced the results. Another possible 
limitation is that it was assumed that the physiological fatigue profile of the healthy group was 
normal and so could be used to compare and identify any abnormalities in the PN group. 
However, as the fatigue protocols were adapted for this study and other investigations have 
not examined the same factors, used similar methods or have tested very different participants 
(e.g. athletes or the elderly) it is not possible to conclusively establish the normality of the 





This study was the first to investigate many aspects of physiological fatigue in people with 
inflammatory PN.  
Although these findings and those from Chapter Five require confirmation in a larger study, 
they imply that experienced fatigue in participants with PN is not associated with abnormal 
physiological fatigue of the knee extensors. Although these muscles were significantly weaker 
than healthy participants, they demonstrated similar levels of voluntary activation, fatigue and 
recovery during testing. This suggests that the factors that produced muscle weakness in 
people with PN did not precipitate an altered physiological fatigue profile. 
Interestingly, several people with PN who complained of severe experienced fatigue did not 
complete the voluntary fatigue protocol (Protocol A) despite no significant differences to other 
people with PN or healthy participants on other tests of physiological fatigue. Their early 
cessation of muscle work may be attributable to a learnt protective response to avoid over 
exertion to limit worsening of fatigue and warrants further investigation. Although not 
significantly associated with experienced fatigue, cardiovascular fitness and strength were 
significantly reduced in people with PN when compared to healthy participants. Whilst the 
relevance of this finding is unclear, it could suggest that these factors could indirectly influence 
experienced fatigue and that they should be re-examined in future work. 
It is also recommended that future studies examine the response to a functional fatiguing 
protocol (e.g. stair climbing) and utilise a larger sample to ensure adequate statistical power 
and so that comparisons between diagnostic groups in PN and between people with and 




Chapter 7. Conclusions 
7.1. Aims and Objective 
The overall objective of this thesis was to examine the role of exercise for treating people with 
PN. Two aims were developed. These were to:  
(i) Evaluate the practicality and possible effects of a community based exercise intervention for 
people at least 12 months after the nadir of GBS and with stable CIDP. 
(ii) Investigate and describe the nature of fatigue in people with inflammatory PN.  
To fulfil these aims, it was also necessary to evaluate outcome tools which could accurately 
and comprehensively describe aspects of functioning. 
7.2. Summary of findings 
Persistent problems, including weakness, altered sensation, pain and fatigue are common in 
inflammatory PN and contribute to poor health status and reduced functioning (de Jager and 
Minderhoud 1991; Lennon et al. 1993). Exercise would be an attractive self-management 
choice for many people with PN if it could be shown to be practical and beneficial to 
functioning. However, there is little evidence to support its use in people with PN (White et al. 
2007a). The prospective, uncontrolled study described in Chapter Two demonstrated that PN 
participants can undertake an individually tailored exercise intervention safely and 
independently in the community. Significant improvements in activity limitations, physical 
functioning, mood and fatigue apparent after the intervention remained significantly improved 
at six months follow up, except for depression. In addition the majority of PN participants 
reported continuing to exercise at six months. Whilst this report is likely to have been 
influenced by recall bias and the desire to please the rater, it suggests that some participants 
successfully underwent changes in their health behaviour that may reduce their risk of health 
complications associated with a sedentary lifestyle. The absence of a non-exercising patient 
control group, lack of rater blinding, reliance upon self report to indicate exercise adherence 
and the small sample of volunteers mean it is not possible to attribute the changes after the 
intervention to the intervention itself and reduces the external validity of the findings. However, 
the findings demonstrate that prescribed unsupervised community based exercise is practical 
and well tolerated by people with PN. The experience of conducting this study therefore 
informs the recommendations for a future multi-centred randomised controlled trial to evaluate 
the effects of exercise in people with inflammatory PN that is discussed below. 
During their use in Chapter Two, it became apparent that some outcome tools were not 
appropriate or responsive to measure changes after the exercise intervention. The primary 
outcome tool, the ODSS questionnaire, had a ceiling effect and so was insensitive to minor 
lower limb activity limitations such as the ability to run or climb stairs. This meant that it did not 
reflect small but potentially relevant changes in lower limb functioning. A new tool, the overall 
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neuropathy limitations scale (ONLS) was developed to address the shortcomings of the ODSS 
and was evaluated in Chapter Three. The ONLS is very similar to the ODSS but it includes an 
item regarding running and climbing stairs in addition to walking items. The clearer instructions 
and expanded lower limb criteria provide greater face validity than the ODSS and the ONLS is 
able to detect difficulties in running and stair climbing, in addition to walking, thereby reducing 
the undesirable ceiling effect of the ODSS. However, the ONLS was somewhat less 
responsive than the ODSS in the current study. Whilst this may be an artefact of the sample 
used, in terms of both size (n=17) and composition, it indicates that neither the ODSS nor 
ONLS can be currently recommended to be used to measure changes in activity limitations in 
future interventions.  
Reduced mobility due to residual deficits in inflammatory PN may be improved by exercise 
interventions (Bernsen et al. 2005; Erdmann et al. 2005; Lennon et al. 1993; Pearson et al. 
2004) but, other than the ten metre walk test which was not responsive to changes after the 
exercise intervention in Chapter Two, no outcome tools which specifically measure ambulant 
mobility have been evaluated in people with PN. Therefore, three tools were investigated in 
Chapter Four. These were the Walk-12 (a 12 item questionnaire scored on a five point Likert 
scale), and the standard and modified physiological cost index (PCI and mPCI, measured 
during walking at a preferred pace on a flat surface). The Walk-12 and mPCI were shown to be 
reliable and valid. The mPCI was also responsive to improvements after the exercise 
intervention. However, the PCI was not reliable and did not significantly correlate with the 
criterion measure of oxygen cost in healthy or PN participants, suggesting it had limited 
validity. Further work is required to establish the responsiveness of the Walk-12, to confirm the 
properties of the mPCI in a larger sample of PN participants and to determine if the Walk-12 is 
superior to other common mobility tools which are used in other conditions. Nevertheless, the 
studies in Chapter Four show that the Walk-12 and mPCI measured walking ability 
appropriately and are potentially useful tools for people with inflammatory PN, in both clinical 
and research settings. 
The second aim of this thesis was to describe the nature and possible contributors to 
experienced fatigue which is a significant problem for many people with inflammatory PN 
(Bernsen et al. 2002; Merkies et al. 1999). Studies to investigate and describe the potential 
factors which were associated with experienced fatigue in people with PN were presented in 
Chapters Five and Six. This is the first investigation of the relationship between experienced 
and physiological fatigue and wider functioning, including the energy cost of walking and 
activity levels, in people with PN. The results of this study were limited by the small, self-
selected sample but the findings confirm that people with PN exhibited greater levels of 
experienced fatigue than healthy people, which agrees with reports by others (Merkies et al. 
1999). Experienced fatigue was significantly associated with increased activity limitations, 
poorer mood, lower activity levels and reduced physical and social functioning, but the cross-
sectional design of the study meant that it was not possible to determine if these factors 
contributed to, or were the result of experienced fatigue. Measures of muscular endurance 
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(physiological fatigue) were not associated with experienced fatigue but cardiovascular fitness 
and knee extensor strength were significantly reduced when compared to healthy participants. 
Whilst these factors were not significantly associated with increased experienced fatigue their 
potential relationship with experienced fatigue in people with PN is worthy of further 
investigation. 
7.3. Clinical implications 
The findings of the fatigue and exercise studies need to be established in larger groups of 
participants in blinded and controlled trials before they can be categorically proven. However, 
in the absence of controlled clinical trials, clinical practice has to be based upon the best 
observational studies available (Evans 2003). Therefore, major implications for clinical practice 
arising from the findings of this thesis are discussed here.  
7.3.1. Exercise  
The results of the study of a community based exercise intervention indicate that a prescribed, 
combined aerobic, strength and functional exercise intervention could be offered to people with 
inflammatory PN, to facilitate safe exercise. Participants were able to exercise independently 
in the community following clinical assessment, orthotic prescription where appropriate and 
individual exercise prescription. The side effects were mild and similar to those described by 
others in 18 people with CIDP or after GBS and in 14 participants with chronic PN after 
exercise interventions (Garssen et al. 2006a; Ruhland 1997). The findings of significantly 
reduced activity limitations, improved experienced fatigue and strength support the results of 
others (Garssen et al. 2006a; Ruhland 1997), but the design of the study meant that these 
changes could not be attributed to exercise. 
The design of a suggested potential exercise programme to improve functioning and fatigue, 
informed by the exercise study is shown in Appendix Six. This programme includes aerobic 
and functional components in addition to dynamic strengthening exercises. Several of the 
outcome tools identified in this thesis could also be used to provide appropriate and suitable 
indicators of the effect of interventions in clinical practice, although it is noted that a tool’s 
performance in a group does not necessarily mean it is equally suitable for monitoring change 
in individuals (Hobart 1996). 
7.3.2. Fatigue  
This study found that experienced fatigue is a persistent and severe problem and is associated 
with increased activity limitations for many people with PN, which agrees with the findings of 
others (Merkies et al. 1999). Therefore, clinicians should be encouraged to ask patients with 
PN about the presence and nature of any fatigue and use a fatigue questionnaire in their 
clinical assessment if they suspect fatigue to be present. The fatigue impact scale (FIS) or the 
fatigue severity scale (FSS) could be used to assess experienced fatigue in a clinical setting. 
Although the FSS has been validated in PN, the FIS might describe fatigue more fully as, 
unlike the FSS, it can quantify the effect of experienced fatigue on physical, cognitive and 
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social function (Fisk et al. 1994). However, the properties of the FIS, including responsiveness, 
require investigation in people with PN.  
7.4. Implications for future research 
7.4.1. Patient and public involvement 
The absence of patient or user involvement in the design of the studies in this thesis is a key 
limitation to their findings. Patient and public (or partner) involvement (PPI) can help develop 
research priorities, generate relevant research questions and it is considered to be vital at 
each stage of research; from design to outcome dissemination, to ensure that the study 
addresses questions that are meaningful to patients and particularly for complex interventions 
such as exercise (Medical Research Council 2008). Therefore, future studies should seek to 
involve patients in all aspects of the research process at the earliest opportunity; this may 
include utilising existing patient organisations such as the Guillain Barré Syndrome Support 
Group (GBSSG) to guide research priorities, inform trial design and disseminate findings but 
could also include local patients and their carers in project steering groups and informal 
networks (INVOLVE 2012). 
7.4.2. Design of a future randomised controlled trial of exercise to 
determine the effects of exercise in people with inflammatory PN 
The design of the investigation of exercise in Chapter Two aimed to mimic a typical clinical 
exercise intervention for people with inflammatory PN but its uncontrolled, unblinded design 
and small number of participants meant that it was unable to establish the effects of the 
intervention. However, information and data from the study in Chapter Two should be used to 
design a future RCT with secure concealment of group allocation and blinded assessors to 
minimise selection and observer bias.  
 Sample 
An appropriate sample size based on a pre-determined power and level of significance to 
detect a clinically meaningful difference in the primary outcome and taking account of the 
standard deviation of the measure could be calculated from the data in Chapter Two. This is 
likely to reveal a sample size in excess of the numbers recruited in Chapter Two, therefore a 
multi-centred design is recommended. Whilst this design could facilitate recruitment of a wider 
range of PNs and include ambulant and non-ambulant participants, this would increase 
heterogeneity and necessitate a much larger sample. It may therefore be preferable to develop 
separate studies to investigate the effectiveness of exercise in different forms of PN and in 
non-ambulant participants.  
 Control 
Randomisation to a control group of usual care rather than exercise might not be acceptable to 
some potential volunteers, increasing attrition. A delayed intervention control group, whilst 
ethically acceptable given the current lack of evidence for the efficacy of exercise to reduce 
 233 
 
activity limitation in people with PN, is likely to be more acceptable to potential participants and 
so increase recruitment to the study. However, it is also likely to either significantly increase 
the length of the study or reduce the possibility for long term follow up of control and 
intervention groups. Studies investigating exercise in other conditions including stroke and 
chronic fatigue syndrome have overcome this by using control interventions such as advice 
and education or, more pragmatically, usual care (Saunders et al. 2009; Wallman et al. 2004). 
However, these are unlikely to control for the effects of the increased time and attention given 
to the experimental group, therefore an alternative intervention such as relaxation may be 
more appropriate in a future trial.  
 Intervention and outcome measurement  
The exercise programme provided to participants in Chapter Two appeared practical and well 
tolerated but did not include overt components of education or interventions to facilitate a 
change in health behaviours. Whilst beliefs about exercise and perceived barriers to physical 
activity have not been investigated in PN changing health behaviours and addressing fear 
avoidance has been purported to be a vital element of interventions to increase physical 
activity (Nijs et al. 2013). Therefore, exploration of health beliefs and addressing health 
behaviours could be included in a future exercise intervention in people with PN and could 
include aspects of motivational interviewing, cognitive behavioural based therapies, 
counselling and advice and education (Nijs et al. 2013).  
The ONLS and ODSS did not appear entirely suitable to use as a primary outcome tool in a 
future exercise trial. However, further research is needed to determine if the responsiveness of 
the ONLS is improved in a larger sample or to alter the scoring criteria so that stair climbing 
and running are scored separately. Other work should investigate if different tools (such as the 
R-ODS) demonstrate better responsiveness to the ODSS or ONLS and utilise patient views in 
tool selection to ensure that the outcomes are relevant and meaningful to the target population 
(INVOLVE 2012). In the absence of these data, the SF-36, which was responsive to changes 
after the exercise intervention and is valid in people with PN, is proposed as the primary 
outcome in a future trial of exercise (Merkies et al. 2002c). The SF-36 can provide 
comprehensive data on functioning as items cover a range of routine activities which are of 
importance to patients. Subscale scores can also be compared to normative values which 
make them easily interpretable. Secondary outcomes could include the Walk-12 and mPCI, if 
their properties can be established in further investigations, as mobility is of great importance 
to patients and prominently affected after GBS and in CIDP (Chiou and Burnett 1985; 
Erdmann et al. 2005; Forsberg et al. 2004).  
Assessment of adherence to the exercise programme should also be objectively measured, 
but methods of recording need to be simple and reliable. The heart rate monitors were not 
used reliably to record heart rate in Chapter Two whilst the activity monitors used in Chapter 
Five are reliant on the participant remembering to wear them and cannot provide direct 
indications of the intensity of exercise. As no single measure appears entirely suitable to 
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measure adherence, it is suggested that future studies use a combination of activity monitoring 
and self-report exercise diaries.  
The health beliefs and opinions about exercise of people with PN were not investigated in 
Chapter Two. A mixed methods design would allow qualitative data from a sub-set of 
participant interviews or focus groups to be generated in addition to quantitative measurement 
in a future trial of exercise. Whilst not allowing direct comparison within or between groups, 
qualitative methods provide rich contextual data that can complement quantitative outcomes 
and would inform further work and clinical practice (Sim and Wright 2000). 
The study in Chapter Two did not overtly target or measure self efficacy, described as the 
confidence someone has in their ability to perform a specific activity or alter a behaviour 
(McAuley 1993). A future study could investigate whether any changes in exercise are 
mediated by self-efficacy using qualitative methods such as interviews or measured using 
standardised tools such as the self-efficacy for exercise scale to allow statistical comparison to 
controls and to indicate the magnitude of any change (Fletcher and Banasik 2001).  
Cost effectiveness was also not measured in Chapter Two. These data would inform health 
care providers about the costs of the intervention and its relative benefit, influencing the wider, 
clinical provision of exercise for people with inflammatory PN, and so should be measured in a 
future trial. There are several measures of cost effectiveness but the Quality-Adjusted Life-
Year (QALY) is the most widely used (Roine et al. 2009). Measurement of QALYs derived from 
data obtained from participant interviews regarding overall health, social and informal service 
use and costs in a future study of exercise would also allow comparison to other interventions 
and so inform service delivery and wider health policy (Roine et al. 2009).  
7.4.3. Fatigue 
The studies in Chapters Five and Six failed to establish clear contributors to the fatigue 
experienced by people with PN. Abnormal physiological fatigue was not apparent in people 
with PN using a standardised protocol of repetitive sub-maximal voluntary isometric 
contractions. However, it is possible that this protocol may not have adequately mimicked 
functional activity and so physiological fatigue brought on by everyday functional muscle 
activity may have been missed. Future work should therefore seek to develop a functional task 
for participants to perform until fatigue, to facilitate further investigation of physiological fatigue.  
A key limitation of the work in Chapter Five was that the tools used to indicate experienced 
fatigue were not originally developed for people with PN and constrained their answers to pre-
determined categories. This may have limited their description of their fatigue and so restricted 
our understanding of this complex symptom. Future work could use qualitative methods and/or 
seek to develop new outcome tools with PPI to increase our understanding of fatigue and 
improve the available methods to capture these data.  
Although the size of the sample in the fatigue investigations in Chapters Five and Six was 
informed by other studies, the wide variability in participant characteristics which was evident 
meant that any future work should utilise a larger sample to increase external validity. Future 
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work could also examine psychological, immune and endocrine factors which may contribute 
to fatigue but which were beyond the scope of the current study.  
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Appendix 2 Method of measuring knee extensor 
force in Chapter Two 
Participants were positioned as shown in Figure 1 below. 
The seat was adjusted so that the knee was flexed to 90
o
 and they were secured with lap 
straps to provide proximal stability. A padded cuff connected to a strain gauge was positioned 
above the medial and lateral malleoli of the ankle. Participants were instructed to fold their 
arms to prevent isometric upper limb work (American College of Sports Medicine 1995). After 
a brief warm up of several sub-maximal contractions, each participant performed three 
maximal consecutive contractions (Lord et al. 1992). If force production continued to increase 
on the third contraction, more measurements were taken until force did not increase further to 
ensure adequate familiarisation. 
Participants were instructed to straighten their knee maximally and given vigorous, 
standardised verbal encouragement throughout (McNair et al. 1996; van der Ploeg and 
Oosterhuis 1991). They were provided with simultaneous visual feedback, as a small pilot 
study, confirmed by the work of others (Ogiwara et al. 1991), demonstrated greater force 
production in three out of four healthy participants when they could see their progress (410.5 
±80.9 Newtons) in comparison to when they could not (394.3 ±64.1 Newtons). The linear force 
produced was amplified (x 25), passed through an analogue to digital converter (1401, 
Cambridge Electronic Design) and displayed visually using Signal software (Signal version 2.1 
Cambridge Electronic Design).  
Figure 1 Position for isometric knee extension testing using fixed dynamometry 
 
Folded Arms
Lap strap to stabilise hip
Knee flexion 90°






Appendix 3 Instructions for scoring the Overall 
Neuropathy Limitations Scale (ONLS) 
 Introduction 
This questionnaire should be administered in a comfortable and quiet room. The patient should 
sit.  
Start by saying “I would like to ask you about some activities you may do every day. This is to 
help us understand any difficulties you might have. Please answer each question as accurately 
as you can and ask me to repeat a question or slow down if you do not understand”. 
Encourage the patient to answer all the questions themselves. A carer, relative or friend may 
help if the patient is unsure or has communication difficulties. If the patient does not 
understand, change the question to, “Do you have difficulty doing - activity x - ?”. Give 
clear instructions and, if necessary, demonstrate the task required. Ask about the tasks in 
relation to their usual activity at present. If their condition has changed recently, ask them to 
base their answers on the last 24 hours. 
In judging whether tasks are prevented, allow aids, but not aid from another person. 
This questionnaire assesses the limitations whatever the medical reason. If the patient has 
other conditions which cause limitations, this is recorded in the last question. 
 Upper limb items 
Ask about the upper limbs first.  
Does the patient have any symptoms in their hands or arms e.g. tingling or weakness? 
Ask: Do you have any tingling, numbness, pain or weakness in your hands or arms? 
Include all symptoms that are attributable to peripheral nerve conditions, including carpal 
tunnel syndrome and neuropathic pain. Do not include symptoms not due to peripheral nerve 
disease e.g. arthritis, but if such symptoms affect function, check the ‘yes’ box at the foot of the 
page.  
Washing and brushing hair 
Ask: Is your ability to wash and brush your hair affected? 
If the patient considers themselves to be affected, ask: Are you able to wash and brush 
your hair? 
If they cannot wash and brush their hair the task is prevented. Only being able to do one or the 
other is not sufficient, and the task should be considered prevented. If a patient does not 
usually wash or brush their hair, they should be asked if they think they could, if required. If 
there is doubt, ask the patient to mime the tasks. 
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Turning a key in the lock 
Ask: Is your ability to turn a key in a lock affected? 
If the patient considers themselves to be affected, ask: Are you able to turn a key in a lock? 
Ask the patient to consider a lock they commonly use at home e.g. their front door. To 
complete the activity successfully they must be able to turn the lock sufficiently to unlock or 
lock a door. If they can complete the activity but have difficulty, the task is affected. If they are 
unable to turn a key in the lock with either or both hands, the activity is considered prevented. 
If a key turner is used the task should be considered affected. If the patient cannot turn the key 
in the lock even when using a key turner the task is considered prevented.  
Using a knife and fork together (or spoon if knife and fork are not usually used) 
Ask: Is your ability to use a knife and fork (or spoon) together affected? 
If the patient considers themselves to be affected they should be asked: Are you able to use 
a knife and fork (or spoon) together? 
If patients do not use a knife and fork, their usual eating implements should be substituted 
(e.g. chopsticks).The task is considered as affected if the patient can use cutlery to eat their 
food but has difficulty. The activity is prevented if the patient cannot use their cutlery to eat. If 
adapted cutlery is used the task should be considered affected. If the patient cannot use a 
knife and fork (or spoon) even when using adapted cutlery, the task is prevented.  
Do or undo buttons or zips 
Ask: Is your ability to do and undo all your buttons and zips affected? 
If the patient considers themselves to be affected they should be asked: Are you able to do 
and undo all your buttons and zips? 
They must be able to fasten and unfasten all buttons and zips without difficulty to be 
considered unaffected. If the patient can do and undo all buttons and zips but has difficulty, 
they should be considered as affected in this task. If they are not able to do and undo all zips 
and buttons, the activity is considered as prevented. If button hooks and adapted zips are used 
the task should be considered affected. If the patient cannot fasten or unfasten buttons or zips 
even when using button hooks or adapted zips the task is prevented. 
Dress the upper part of their body excluding buttons or zip. 
Ask: Is your ability to dress the upper half of your body (e.g. putting on a T-shirt or jumper) 
affected? 
If the patient considers themselves to be affected, ask: Are you able to dress the upper half 
of your body? 
If they can manage to dress but find it difficult, the activity is affected, if they are unable to 
dress the upper part of the body the task is considered prevented. This activity does not 




Ask: Can you move either hand or arm at all? 
If necessary, ask the patient to show you the movement. Score “yes” if any voluntary 
movement is observed. Only assess this if all four tasks are prevented. If the patient is not 
prevented in all the previous tasks, the “not applicable” box should be checked.  
ARM GRADE: Work out the score from the answers to the questions using the scoring criteria.  
 Lower limb items 
Does the patient have difficulty running or climbing stairs? 
Ask: Do you have difficulty running or climbing stairs? 
If they do have difficulty, ask: Are you able to run or climb stairs? 
They should be considered to have difficulty with running and climbing stairs if they have 
difficulty with either. If the patient is not accustomed to running or does not know if running is 
affected, rely on the answer about stair climbing. 
Does the patient have difficulty with walking? 
Ask: Do you have difficulty walking? 
Difficulty walking may include pain, difficulty walking longer distances, fatigue or unsteadiness. 
Does their gait look abnormal? 
Ask the patient to walk or mobilise over at least 10 metres at their preferred pace and with their 
preferred aid. Abnormalities may include altered speed or cadence, foot drop, Trendelenberg 
type gait, limp, unsteadiness, or inability to maintain a straight direction of movement.  
How do they mobilise for 10 metres? 
Ask: Would you usually need a walking aid or someone to help you to walk about 10 metres/33 
feet? 
If the patient uses different aids depending upon the environment they are in, they should be 
asked which aid they usually use for this distance. If still unsure, the aid used during 
observation of the last item should be taken. Moderate assistance from one person holding the 
patient’s arm or hand is considered as unilateral support. 
Wheelchair users 
If a patient needs a wheelchair to mobilise 10 metres the next two items should be assessed. 
Can they stand and walk 1 metre with the help of one person? 
Ask: Can you stand up and walk about 1 metre if one person helps you? 
This can be answered by the patient or their carer. If the answer is unclear, observe the task. If 




If they cannot walk are they able to make some purposeful movements with their legs? 
This should only be assessed if unable to walk 1 metre with the help of one person.  
Ask: Can you move either leg or foot at all? 
If necessary, ask the patient to show you the movement. Score “yes” if any voluntary 
movement is observed. 
Does the patient use ankle foot orthoses or braces? 
Please circle any devices the patient usually wears and the side on which they are usually 
worn. 
LEG GRADE: Work out the score from the answers to the questions using the scoring criteria 
Is there any disorder, other than peripheral neuropathy, which affects the above functions?   
If the patient does not have any other disorders affecting the upper or lower limb, the ‘no’ box 
should be checked. 
TOTAL SCORE: Add the arm and leg scores and record the total (out of 12) 
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Appendix 4 Validity and Reliability of the Cortex 
Metamax Indirect calorimetry system 
 Background 
The properties of the MetaMax system have not been investigated at work rates analogous to 
walking. In order to have confidence in the measurement of the criterion indicator of energy 
cost for the studies in Chapter Four, its validity and reliability must be confirmed. 
 Aim 
The aim of this study was to determine the validity and reliability of measurements of oxygen 
consumption by the Metamax indirect calorimetry system at heart rates analogous to those 
attained whilst walking.  
 Method 
Four healthy participants with no cardiovascular, respiratory, neurological or musculoskeletal 
conditions were recruited to this cross sectional study and consented to complete two sub 
maximal exercise tests at least 24 hours apart. The testing protocol was designed to allow 
measurement of heart rates similar to those that may be reached during walking in healthy 
volunteers and in people with difficulties walking. Participants were asked to avoid strenuous 
exercise and to refrain from eating for at least two hours before testing. 
Participants were fitted with a heart rate monitor (Polar, Finland) and Cortex Metamax 3B 
(Biophysik, Leipzig, Germany) gas measurement system, consisting of a snug fitting face 
mask and lightweight (weighing approximately 200 grams) telemetric recording device, worn 
over the shoulders, shown in Figure 2. 
Values of VO2 from the Metamax were compared to a static system consisting of Servomex 
fast response oxygen and carbon dioxide analysers, (series 1400; Servomex, Jarvis Brook, 
Sussex, UK) a dry gas meter (Harvard Apparatus, Kent, UK), mixing chamber, mouthpiece 
and nose clip. The gases were dried using anhydrous calcium sulphate before analysis. 
Participants performed a sub maximal exercise test on a recumbent bicycle ergometer whilst 
measurements were taken using a heart rate monitor and either the Metamax or Servomex 
system. Participants were instructed to pedal at 60 revolutions per minute in time with an 
electronic metronome. Each participant exercised at two stages (50 and 100 Watts) for four 
minutes, after an initial resting period and warm up (two minutes duration at 25 Watts). A brief 
warm down concluded the test. The test was repeated using the alternate system (Metamax or 
Servomex) at least 24 hours after the initial session. Experimental conditions were kept as 
consistent as possible across the two testing sessions.  
On the Servomex system, the volume and percentage of oxygen (O2) and carbon dioxide 
(CO2) in expired gas were manually recorded every 30 seconds, along with heart rate. Data 
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from the Metamax were displayed on a laptop computer using Metasoft software (version 
1.11.5, Cortex, Germany) which provided breath by breath analysis of VO2 and heart rate. 
Figure 2 Diagram to show the Metamax system 
 
 
After testing, oxygen uptake at standard temperature, pressure and dry conditions (STPD) was 
calculated for data obtained from the Servomex using the following equations: 
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The Metasoft software does not display values of expired O2 or CO2, therefore it was not 
possible to manually calculate VO2. However, VO2 in ambient conditions is calculated by the 
Metamax system using: 
 2 I 2 E 2VO  (ATPS) = (FO  x VI) - (F O  x VE)  
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   
Where VO2=oxygen consumption, ml min
-1
; ATPS = ambient temperature pressure and saturation; VI = 
volume of inspired air, ml; FIO2  = Fraction of inspired oxygen, (0.209); FEO2 = Fraction of expired 
oxygen; FIN2 = Fraction of inspired nitrogen, (0.79 in room air); FEN2 = Fraction of expired nitrogen; PB = 
Barometric pressure, mmHg; PH2O = saturation of water in room air (room temperature x room humidity, 
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mmHg for Servomex, Pascals for Metamax), mmHg; Tr = Room temperature (centigrade), Tb = 
expiratory gas temperature (Kelvin). 
 





 for both systems. 
 Calibration 
Both systems were calibrated before every test session. 
The Metamax was calibrated according to the manufacturer’s instructions, using room air and 
O2 and CO2 concentrations of 17% and 5% respectively. The accuracy of O2 and CO2 
measurements by the Metamax were also checked with 100% nitrogen and room air. 
The Servomex gas analysers were zeroed manually using 100% nitrogen, then calibrated with 
known concentrations of O2 (13.69%) and CO2 (5.03%), before confirming values of room air. 
Volume measurement for both systems was calibrated using three and one litre gas syringes.  
 Data treatment 
Metamax: Raw breath by breath values for VO2 from the Metamax system were averaged 
over the fourth minute for each stage, to ensure participants had reached steady state 
(Wasserman et al. 1999). Heart rate was recorded from the fourth minute for each stage. 
Servomex: Values for volume and heart rate were recorded from the fourth minute from each 
stage. Values for O2 and CO2 were measured exactly one minute later, to allow for the time lag 
caused by mixing of the gases in the mixing box.  
 Analysis 
Due to the small sample size, descriptive statistics were primarily used to describe differences 
in VO2 data. However, a paired, two tailed t-test was used to determine any systematic 
differences in VO2 between readings from the Servomex and Metamax (significance set at 
p<0.05). 
Bland Altman techniques were used to examine agreement between the two systems (Altman 
and Bland 1983). Limits of agreement were calculated using the following formula: 
(x y) (x y)95% Limits of agreement Mean 1.796 x SD    
where x = Metamax measurement y = Servomex measurement (Altman and Bland 1983). As the sample 




Four healthy participants (three males) completed testing on two occasions (mean age: 37 ±6 
years; weight: 73.3 ±6.7 Kg). 
 Calibration 
Values of O2 and CO2 recorded by the Metamax in room air and with 100% nitrogen were 
reliable (coefficient of variation: <1% for all readings before and after exercise). Thirty repeated 
readings of volumes by the Metamax from three (mean: 3.01 ±0.04 Litres) and one litre (1.05 
±0.04) gas syringes and by the Servomex (2.9 ±0.08; 0.98 ±0.1) were also accurate and 
reliable. 
 Validity 
There were no significant differences in VO2 readings from the Servomex and Metamax 
systems. The 95% limits of agreement indicated that measurements on the different systems 




, Table 7-1). 
 
Table 7-1 VO2 and heart rate measurements at rest and during exercise on Servomex and Metamax 
systems 






















Rest 3.46 ±0.33 71 ±6 3.03 ±1.28 77 ±14 
50 Watts 12.1 ±0.81 103 ±16 11.17 ±2.6 105 ±16 
100 Watts 18.9 ±1.54 125 ±22 17.3 ±4.03 129 ±23 
All values are mean ±SD.  
Heart rates were broadly similar during tests, indicating that participants were working 
equivalently when being measured by both systems (Table 7-1).The mean difference between 




) and was equivalent to 9.3% of the overall 
mean VO2 value. The greatest difference between measurements was at rest, where mean 




The advent of telemetric indirect calorimetry systems allows participants to move freely while 
data are collected. In addition to increased flexibility, the Metamax system facilitates 
monitoring of participants in situations akin to those experienced in daily living, including 
walking. No studies have examined the validity of the VO2 readings produced by the Metamax 
at heart rates similar to those attained whilst walking. In this study, conditions were controlled 
to produce values of VO2 in four healthy volunteers similar to those reported during 









) (Ijzerman et al. 1999; Waters and Mulroy 1999) to allow validation of the 
Metamax system. 
The Metamax appeared valid as there were no systematic differences in VO2 values between 
the Metamax and the standard Servomex system. Oxygen consumption values varied by a 
mean of 9.3% overall when measured on the Metamax and Servomex. However, day to day 
variation in VO2 may account for over 4% of the inconsistency seen between the repeated 
measurements (Becque et al. 1993). If day to day differences were assumed to contribute 4% 
variability to the VO2 values in this study, the Metamax VO2 measurements would be within 




) of the Servomex values. Although small, this variability should be 
considered when interpreting results of oxygen cost. 
A significant limitation of this investigation is the small sample used as only four, healthy 
participants were included. This considerably limits the external validity of these findings. As 
heart rate ranges were similar to those reported during walking, the conclusion that the 
Metamax system appears valid to measure VO2 within the heart rate range investigated in this 
study (77 to 129 beats min
-1









may be legitimate.  
 Conclusion 
Measurements of VO2 recorded by the Metamax appear to have acceptable validity for the 
range likely to be obtained while walking, although the small sample size limits the strength of 
this study. Values varied by over 9% between Metamax and Servomex systems, indicating 
that there is not complete agreement between the two systems. Although this could be 
attributable to day to day variation in energy consumption as heart rate values were not 
identical on subsequent testing sessions, it should be considered when viewing data from the 
Metamax system. 
Although future work should be undertaken to conclusively establish the validity and reliability 
of the system using a larger number of participants, from these results it appears reasonable 





Appendix 5 Test re-test reliability of the Kin Com 
Dynamometer 
 Method 
The Kin Com dynamometer lever arm was set at 0
o
, parallel to the floor. Known weights (5 Kg, 
10 Kg, 20 Kg) were applied to the load cell attachment. Linear force readings were displayed 
in Volts using Signal software (version 2.13, Cambridge electronic design, UK). These 
measurements were repeated on 16 separate occasions over three months. 
The linearity of repeated measurements over time and with increasing weights were examined 
using a line graph. The number of Volts per Newton at each weight was calculated for all 
repeated readings (48 values). The coefficient of variance and Pearson correlation coefficients 
between repeated readings were also calculated.  
 Results 
The Kin Com demonstrated linearly increased force readings with increased weight. Sixteen 
repeated measurements are shown in Figure 3. 
Figure 3 Repeated measurements of known weights on the Kin Com 
 
One volt was found to equal a mean of 422.56 ±12 Newtons.  
The coefficient of variance was less than 3% (2.83%) and the Pearson’s correlation between 
repeated readings was almost perfect (r=0.999). A limitation of this study was that heavier 


































Appendix 6 The design of a potential exercise 
programme for people with peripheral 
neuropathies 
 Assessment 
Medical tests should exclude cardiac or respiratory problems, including unmanaged autonomic 
dysfunction, which might worsen on exercise. Other assessments should identify potential 
risks of musculoskeletal injury including unsupported joints or compensatory movement 
patterns due to weakened muscles. Orthotic provision may be necessary to support joints at 
risk of damage during sustained activity. 
Measurement of muscle strength using fixed dynamometry will identify weaker muscles which 
may be strengthened to facilitate aerobic exercise and function. 
The level of functional aerobic fitness of the patient should be ascertained to provide a 
baseline level at which the programme can start. A conventional exercise test, using a cycle 
ergometer or treadmill, may provide indications of endurance and peak exercising heart rate to 
inform the exercise intervention. However, a test of this nature may be limited by factors other 
than aerobic fitness (e.g. muscle strength, perceived exertion) and may also exacerbate 
subjective fatigue, discouraging the participant. As an alternative, a functional exercise 
tolerance test, such as the six minute walk test, may also indicate peak exercising heart rate 
and provide qualitative data regarding exertion during functional exercise. Careful questioning 
may also provide information on current levels of exercise tolerance which will inform the 
design of the aerobic component of an exercise programme.  
Outcome tools including the ONLS, mPCI, and Walk-12 which were evaluated and developed 
in this thesis could be used to assess activity limitations and mobility. Other instruments 
including the SF-36, FIS and HADS could also be used to indicate participation, subjective 
fatigue and mood.  
 Goal setting and progression 
It is vital that the design of the exercise programme considers the aims and goals of the patient 
in order to promote adherence and compliance. The initial exercise sessions should also begin 
at an intensity level achievable by the participant.  
Gradual increases in the duration and / or intensity of aerobic exercise (grading) are 
recommended for participants who cannot exercise for 20 minutes. Advice on pacing of 
exercise and rest could also help to limit fatigue and increase activity. This is particularly 
important for severely fatigued individuals. By minimising the exacerbation of fatigue related to 




 Compliance and adherence 
Exercise should be unsupervised and based in the community to provide flexibility, increase 
adherence and to encourage participants to develop independent and long lasting health 
behaviours (Ashworth et al. 2005).  
Participants should be informed about the normal feelings to be expected when exercising, 
including the mild muscle ache experienced by half of participants in the exercise study in 
Chapter Two. 
Heart rate monitors could be used to provide feedback on the intensity of exercise whilst 
completing the aerobic component of the programme. In addition to providing feedback, heart 
rate monitors may reduce the focus upon feelings of exertion and effort (Moss-Morris et al. 
2005). However, simple models should be used to avoid lost data as in Chapter Two. 
Adherence to the programme can be judged by asking participants to note details of each 
exercise session in an exercise diary, by regular contact with the health professional and from 
the memory of heart rate monitors. If available, activity monitors (detailed in Chapter Five) 
could be worn throughout the initial weeks of the programme to ascertain adherence. 
 Exercise programme design 
 Frequency of exercise 
Three exercise sessions should be completed every week to produce changes in fitness and 
strength. This is based upon recommendations by exercise authorities (American College of 
Sports Medicine 1995; Fletcher et al. 2001) and as this frequency was reported to be practical 
in the exercise study in this thesis.  
 Warm up 
At the start of every exercise session, a ten minute warm up is recommended at approximately 
60% of peak or age predicted heart rate (American College of Sports Medicine 1995). The 
duration of warm up may be gradually increased over successive exercise sessions if patients 
were initially unable to exercise for ten minutes. 
 Aerobic training  
This should proceed directly from the warm up. Heart rates between 60 to 85% of peak heart 
rate should be reached during this component of the programme. If a baseline exercise test 
was not undertaken, maximum heart rate can be predicted from the age of the participant 
using (American College of Sports Medicine 1995): 
Maximum heart rate (beats min
-1
) = 220 - age 
The duration of aerobic exercise could be calculated from the level of exercise tolerance 
reported by the patient and from exercise testing. The duration of exercise should be 
increased slowly over successive exercise sessions, depending upon participant feedback and 
heart rate recordings. 
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Increases of one minute at each session have been used by others in fatigued participants 
(Fulcher and White 1997) and may be used in people with PN. If participants complain of 
worsening of fatigue symptoms, the duration of aerobic exercise should be maintained at the 
current level for one week, before continuing to progress (Fulcher and White 1997). The 
modality of training should be determined by the patient and physiotherapist to promote 
adherence whilst ensuring exercise is safe and effective. These modalities could include static 
cycling, walking or swimming. 
 Other exercises 
Exercises to improve muscle performance should be included in the programme to strengthen 
weak muscles or if reduced muscular endurance appears to limit function or aerobic exercise 
(Brill et al. 2000; Clark et al. 1996). Ideally, these exercises should be completed directly after 
the aerobic component to eliminate the need for an additional warm up period. However, in 
participants for whom fatigue is problematic, the exercise programme could be paced so these 
exercises are undertaken after a period of rest and an additional warm up.  
The number of sets and repetitions should be increased gradually, monitoring for signs of 
increased subjective fatigue and muscle ache. A maximum of three sets of ten repetitions 
appeared practical in people with PN in Chapter Two, and is recognised to provide an 
adequate strengthening stimulus (American College of Sports Medicine 1995; Galvao and 
Taaffe 2004; Wolfe et al. 2004). A limitation of the exercise study in Chapter Two was that 
participants only completed isometric contractions for reasons of safety. However, dynamic 
strength training is likely to have greater benefit to function, provide greater feedback to 
participants on progress and has been shown to increase strength in other studies (Lindeman 
et al. 1995; Ruhland 1997). However, as training is unsupervised, the health professional must 
be confident in the participant’s ability to control a dynamic contraction throughout the range. 
Otherwise, isometric contractions could be used.  
Functional exercises to improve posture, function and balance should be included to improve 
performance (de Vreede et al. 2005; Eng et al. 2003; Richardson et al. 2001). These should be 
informed by the findings of the initial assessment but may include postural and balance 
exercises. 
 Cool down 
A five minute cool down is recommended to allow heart rate to return to resting levels (Fletcher 
et al. 2001). This should be followed by stretches of the major muscle groups exercised which 
may include quadriceps femoris, hamstrings and calf muscles. 
 Continuation of the programme 
The exercise programme could be continued indefinitely. Regular re-measurement within the 
first months of exercise will guide the development of the exercise programme, identify 
problems and provide encouraging feedback for the participant. As the individual’s ability to 
exercise increases, the health professional may advise the individual to begin other forms of 
exercise, and support return to, or uptake of specific leisure pursuits to maintain interest and 
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enjoyment. Contact with the health professional should become less frequent as the 
participant becomes more confident and familiar with exercise. However, intermittent follow up 
may be helpful to monitor progress and judge outcome. This can be agreed between the 
health professional and participant. 
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